[{"to": "156", "prefix": "                Both CYP1A2 and CYP2D6 are responsible for ", "from": "147", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "duloxetine", "suffix": " metabolism.\n\n               \n               \n              "}, {"to": "812", "prefix": "CYP1A2\n\n                     \n                        When ", "from": "803", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "duloxetine", "suffix": " 60  mg was co-administered with fluvoxamine 100  mg, a potent"}, {"to": "925", "prefix": " ", "from": "916", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "duloxetine", "suffix": " AUC was increased approximately 6-fold, the Cmax was increa"}, {"to": "1019", "prefix": "imately 6-fold, the Cmax was increased about 2.5-fold, and ", "from": "1010", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "duloxetine", "suffix": " t1"}, {"to": "1507", "prefix": "               \n                        Concomitant use of ", "from": "1498", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "duloxetine", "suffix": " "}, {"to": "1603", "prefix": " increased the concentration of ", "from": "1594", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "duloxetine", "suffix": " AUC by about 60%, and greater degrees of inhibition are exp"}, {"to": "2149", "prefix": "    \n                        Concomitant administration of ", "from": "2140", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "duloxetine", "suffix": " 40  mg twice daily with fluvoxamine 100  mg, a potent CYP1A2 "}, {"to": "2306", "prefix": " resulted in a 6-fold increase in ", "from": "2297", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "duloxetine", "suffix": " AUC and Cmax.\n\n                     \n                     \n"}, {"to": "3260", "prefix": " under steady state conditions with ", "from": "3251", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "duloxetine", "suffix": " 60 or 120  mg once daily for up to 14 days in healthy subjec"}, {"to": "3577", "prefix": " for both R- and S-warfarin were not altered by ", "from": "3568", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "duloxetine", "suffix": ". Because of the potential effect of duloxetine on platelets"}, {"to": "3624", "prefix": " altered by duloxetine. Because of the potential effect of ", "from": "3615", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "duloxetine", "suffix": " on platelets, patients receiving warfarin therapy should be"}, {"to": "3720", "prefix": "eiving warfarin therapy should be carefully monitored when ", "from": "3711", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "duloxetine", "suffix": " is initiated or discontinued [see Warnings and Precautions "}, {"to": "4073", "prefix": "\n                        Under steady-state conditions for ", "from": "4064", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "duloxetine", "suffix": " "}, {"to": "4160", "prefix": ", the pharmacokinetics of ", "from": "4151", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "duloxetine", "suffix": " were not affected by co-administration.\n\n                  "}, {"to": "4486", "prefix": "\n                        Under steady-state conditions for ", "from": "4477", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "duloxetine", "suffix": " "}, {"to": "4560", "prefix": ", the pharmacokinetics of ", "from": "4551", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "duloxetine", "suffix": " were not affected by co-administration.\n\n                  "}, {"to": "5328", "prefix": " the gastrointestinal pH may lead to an earlier release of ", "from": "5319", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "duloxetine", "suffix": ". However, co-administration of CYMBALTA with aluminum- and "}, {"to": "5517", "prefix": "tidine, had no significant effect on the rate or extent of ", "from": "5508", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "duloxetine", "suffix": " absorption after administration of a 40  mg oral dose. It is"}, {"to": "5669", "prefix": "ncomitant administration of proton pump inhibitors affects ", "from": "5660", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "duloxetine", "suffix": " absorption [see Warnings and Precautions "}, {"to": "6068", "prefix": "        In vitro drug interaction studies demonstrate that ", "from": "6059", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "duloxetine", "suffix": " does not induce CYP1A2 activity. Therefore, an increase in "}, {"to": "6314", "prefix": "ugh clinical studies of induction have not been performed. ", "from": "6305", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "Duloxetine", "suffix": " is an inhibitor of the CYP1A2 isoform in in vitro studies, "}, {"to": "6539", "prefix": " when co-administered with ", "from": "6530", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "duloxetine", "suffix": " "}, {"to": "6830", "prefix": "d by CYP2D6\n\n                     \n                        ", "from": "6821", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "Duloxetine", "suffix": " is a moderate inhibitor of CYP2D6. When duloxetine was admi"}, {"to": "6881", "prefix": "        Duloxetine is a moderate inhibitor of CYP2D6. When ", "from": "6872", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "duloxetine", "suffix": " was administered "}, {"to": "7402", "prefix": "              Results of in vitro studies demonstrate that ", "from": "7393", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "duloxetine", "suffix": " does not inhibit activity. In a clinical study, the pharmac"}, {"to": "7552", "prefix": "in, a CYP2C9 substrate, were not significantly affected by ", "from": "7543", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "duloxetine", "suffix": " [see Drug Interactions "}, {"to": "7898", "prefix": "              Results of in vitro studies demonstrate that ", "from": "7889", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "duloxetine", "suffix": " does not inhibit or induce CYP3A activity. Therefore, an in"}, {"to": "8496", "prefix": "              Results of in vitro studies demonstrate that ", "from": "8487", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "duloxetine", "suffix": " does not inhibit CYP2C19 activity at therapeutic concentrat"}, {"to": "10887", "prefix": "ein\n\n                     \n                        Because ", "from": "10878", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "duloxetine", "suffix": " is highly bound to plasma protein, administration of CYMBAL"}, {"to": "11155", "prefix": "ulting in adverse reactions. However, co-administration of ", "from": "11146", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "duloxetine", "suffix": " "}, {"to": "441", "prefix": "                  Potent inhibitors of CYP2D6 may increase ", "from": "434", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C058218", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "CYMBALTA", "suffix": " concentrations "}, {"to": "500", "prefix": ".\n\n                           ", "from": "493", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C058218", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "CYMBALTA", "suffix": " is a moderate inhibitor of CYP2D6 "}, {"to": "4874", "prefix": "ric Acidity\n\n                     \n                        ", "from": "4867", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C058218", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "CYMBALTA", "suffix": " has an enteric coating that resists dissolution until reach"}, {"to": "5044", "prefix": " where the pH exceeds 5.5. In extremely acidic conditions, ", "from": "5037", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C058218", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "CYMBALTA", "suffix": ", unprotected by the enteric coating, may undergo hydrolysis"}, {"to": "5159", "prefix": "o hydrolysis to form naphthol. Caution is advised in using ", "from": "5152", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C058218", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "CYMBALTA", "suffix": " in patients with conditions that may slow gastric emptying "}, {"to": "5368", "prefix": "rlier release of duloxetine. However, co-administration of ", "from": "5361", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C058218", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "CYMBALTA", "suffix": " with aluminum- and magnesium-containing antacids "}, {"to": "5438", "prefix": " or ", "from": "5431", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C058218", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "CYMBALTA", "suffix": " with famotidine, had no significant effect on the rate or e"}, {"to": "9729", "prefix": "lcohol\n\n                     \n                        When ", "from": "9722", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C058218", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "CYMBALTA", "suffix": " and ethanol were administered several hours apart so that p"}, {"to": "9840", "prefix": " apart so that peak concentrations of each would coincide, ", "from": "9833", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C058218", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "CYMBALTA", "suffix": " did not increase the impairment of mental and motor skills "}, {"to": "9959", "prefix": " skills caused by alcohol.\n\n                        In the ", "from": "9952", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C058218", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "CYMBALTA", "suffix": " clinical trials database, three CYMBALTA-treated patients h"}, {"to": "10000", "prefix": "           In the CYMBALTA clinical trials database, three ", "from": "9993", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C058218", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "CYMBALTA", "suffix": "-treated patients had liver injury as manifested by ALT and "}, {"to": "10949", "prefix": "etine is highly bound to plasma protein, administration of ", "from": "10942", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C058218", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "CYMBALTA", "suffix": " to a patient taking another drug that is highly protein bou"}, {"to": "855", "prefix": "            When duloxetine 60  mg was co-administered with ", "from": "845", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "fluvoxamine", "suffix": " 100  mg, a potent CYP1A2 inhibitor, to male subjects "}, {"to": "2184", "prefix": "mitant administration of duloxetine 40  mg twice daily with ", "from": "2174", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "fluvoxamine", "suffix": " 100  mg, a potent CYP1A2 inhibitor, to CYP2D6 poor metaboliz"}, {"to": "1122", "prefix": "3-fold. Other drugs that inhibit CYP1A2 metabolism include ", "from": "1113", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002927", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "cimetidine", "suffix": " and quinolone antimicrobials such as ciprofloxacin and enox"}, {"to": "1173", "prefix": "sm include cimetidine and quinolone antimicrobials such as ", "from": "1161", "name": "Ciprofloxacin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2551", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "ciprofloxacin", "suffix": " and enoxacin [see Warnings and Precautions "}, {"to": "1186", "prefix": "ine and quinolone antimicrobials such as ciprofloxacin and ", "from": "1179", "name": "Enoxacin", "fullId": "http://purl.bioontology.org/ontology/MESH/D015365", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "enoxacin", "suffix": " [see Warnings and Precautions "}, {"to": "1542", "prefix": " with ", "from": "1533", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "paroxetine", "suffix": " "}, {"to": "1700", "prefix": "er degrees of inhibition are expected with higher doses of ", "from": "1691", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "paroxetine", "suffix": ". Similar effects would be expected with other potent CYP2D6"}, {"to": "1789", "prefix": "e.g., ", "from": "1780", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "fluoxetine", "suffix": ", quinidine"}, {"to": "1800", "prefix": "e.g., fluoxetine, ", "from": "1792", "name": "Quinidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9068", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "quinidine", "suffix": ""}, {"to": "2564", "prefix": "e.g., NSAIDs, ", "from": "2558", "name": "Aspirin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1191", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "Aspirin", "suffix": ", and Warfarin"}, {"to": "2982", "prefix": "leeding have also shown that concurrent use of an NSAID or ", "from": "2976", "name": "Aspirin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1191", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "aspirin", "suffix": " may potentiate this risk of bleeding. Altered anticoagulant"}, {"to": "2578", "prefix": "e.g., NSAIDs, Aspirin, and ", "from": "2571", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "Warfarin", "suffix": ""}, {"to": "3154", "prefix": "been reported when SSRIs or SNRIs are co-administered with ", "from": "3147", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "warfarin", "suffix": ". Concomitant administration of warfarin "}, {"to": "3194", "prefix": "-administered with warfarin. Concomitant administration of ", "from": "3187", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "warfarin", "suffix": " "}, {"to": "3441", "prefix": ". The total ", "from": "3434", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "warfarin", "suffix": " "}, {"to": "3546", "prefix": " for both R- and S-", "from": "3539", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "warfarin", "suffix": " were not altered by duloxetine. Because of the potential ef"}, {"to": "3666", "prefix": "tial effect of duloxetine on platelets, patients receiving ", "from": "3659", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "warfarin", "suffix": " therapy should be carefully monitored when duloxetine is in"}, {"to": "7485", "prefix": "t activity. In a clinical study, the pharmacokinetics of S-", "from": "7478", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "warfarin", "suffix": ", a CYP2C9 substrate, were not significantly affected by dul"}, {"to": "11184", "prefix": " with ", "from": "11177", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "warfarin", "suffix": " "}, {"to": "11334", "prefix": "R and in the pharmacokinetics of either total S-or total R-", "from": "11327", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "warfarin", "suffix": " "}, {"to": "2636", "prefix": "\n\n                     \n                        ", "from": "2628", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "Serotonin", "suffix": " release by platelets plays an important role in hemostasis."}, {"to": "2860", "prefix": "tion between use of psychotropic drugs that interfere with ", "from": "2852", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "serotonin", "suffix": " reuptake and the occurrence of upper gastrointestinal bleed"}, {"to": "3981", "prefix": "           \n                     \n                     7.5 ", "from": "3973", "name": "Lorazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6470", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "Lorazepam", "suffix": "\n\n                     \n                        Under steady"}, {"to": "4106", "prefix": " and ", "from": "4098", "name": "Lorazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6470", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "lorazepam", "suffix": " "}, {"to": "4394", "prefix": "           \n                     \n                     7.6 ", "from": "4386", "name": "Temazepam", "fullId": "http://purl.bioontology.org/ontology/MESH/D013693", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "Temazepam", "suffix": "\n\n                     \n                        Under steady"}, {"to": "4512", "prefix": " and ", "from": "4504", "name": "Temazepam", "fullId": "http://purl.bioontology.org/ontology/MESH/D013693", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "temazepam", "suffix": " "}, {"to": "5454", "prefix": " or CYMBALTA with ", "from": "5445", "name": "Famotidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4278", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "famotidine", "suffix": ", had no significant effect on the rate or extent of duloxet"}, {"to": "6183", "prefix": "e.g., ", "from": "6172", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10438", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "theophylline", "suffix": ", caffeine"}, {"to": "6464", "prefix": " increase in ", "from": "6453", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10438", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "theophylline", "suffix": " AUC was 7% "}, {"to": "6193", "prefix": "e.g., theophylline, ", "from": "6186", "name": "Caffeine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002110", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "caffeine", "suffix": ""}, {"to": "6986", "prefix": " in conjunction with a single 50  mg dose of ", "from": "6976", "name": "Desipramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003891", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "desipramine", "suffix": ", a CYP2D6 substrate, the AUC of desipramine increased 3-fol"}, {"to": "7030", "prefix": " 50  mg dose of desipramine, a CYP2D6 substrate, the AUC of ", "from": "7020", "name": "Desipramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003891", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "desipramine", "suffix": " increased 3-fold [see Warnings and Precautions "}, {"to": "9741", "prefix": "                \n                        When CYMBALTA and ", "from": "9735", "name": "Ethanol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/448", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "ethanol", "suffix": " were administered several hours apart so that peak concentr"}, {"to": "10150", "prefix": "ns, with evidence of obstruction. Substantial intercurrent ", "from": "10144", "name": "Ethanol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/448", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "ethanol", "suffix": " use was present in each of these cases, and this may have c"}, {"to": "81", "prefix": "ractions\n\n\n\n\n\nDrugs Highly Bound to Plasma Protein\nBecause ", "from": "72", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " is highly bound to plasma protein "}, {"to": "191", "prefix": ", administration of ", "from": "182", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " to a patient taking another drug that is highly protein bou"}, {"to": "426", "prefix": "versely, adverse effects could result from displacement of ", "from": "417", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " by other highly bound drugs.CLINICAL PHARMACOLOGY, Pharmaco"}, {"to": "525", "prefix": ", administration of ", "from": "516", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " to a patient taking another drug that is highly protein bou"}, {"to": "760", "prefix": "versely, adverse effects could result from displacement of ", "from": "751", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " by other highly bound drugs.Warfarin"}, {"to": "915", "prefix": "ding times or upon the pharmacokinetics of R-warfarin when ", "from": "906", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " "}, {"to": "1063", "prefix": "or 2 weeks with warfarin. Although the coadministration of ", "from": "1054", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " did decrease the subjects"}, {"to": "1333", "prefix": "uggest no adjustments in warfarin dosage are required when ", "from": "1324", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " is administered to patients stabilized on warfarin, such pa"}, {"to": "1628", "prefix": "ngle oral 5 mg dose of haloperidol was coadministered with ", "from": "1619", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " "}, {"to": "1994", "prefix": "here were no changes in the pharmacokinetic parameters for ", "from": "1985", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": ". Dosage adjustment of haloperidol may be necessary when coa"}, {"to": "2081", "prefix": "t of haloperidol may be necessary when coadministered with ", "from": "2072", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": ".Lorazepam"}, {"to": "2132", "prefix": " and ", "from": "2123", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " "}, {"to": "2480", "prefix": "Although ", "from": "2471", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " did not potentiate the cognitive and psychomotor effects of"}, {"to": "2619", "prefix": "n experiments with normal subjects, the concomitant use of ", "from": "2610", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " and alcohol in depressed patients is not advised.Buspirone"}, {"to": "2809", "prefix": " with ", "from": "2800", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " "}, {"to": "3162", "prefix": "es of buspirone, slight increases in AUC were observed for ", "from": "3153", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " "}, {"to": "3257", "prefix": ". Subjects receiving ", "from": "3248", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " 250 mg BID and buspirone 5 mg BID experienced lightheadedne"}, {"to": "3844", "prefix": "es of buspirone, slight increases in AUC were observed for ", "from": "3835", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " "}, {"to": "3939", "prefix": ". Subjects receiving ", "from": "3930", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " 250 mg BID and buspirone 5 mg BID experienced lightheadedne"}, {"to": "4370", "prefix": "NDICATIONS, WARNINGS, and PRECAUTIONS: Pharmacokinetics of ", "from": "4361", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "Nefazodone", "suffix": " in "}, {"to": "4579", "prefix": " and ", "from": "4570", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " "}, {"to": "4812", "prefix": "there were no changes in the pharmacokinetic parameters of ", "from": "4803", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " or HO-NEF; however, the mean AUC levels of the nefazodone m"}, {"to": "4870", "prefix": " nefazodone or HO-NEF; however, the mean AUC levels of the ", "from": "4861", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " metabolites mCPP and triazole-dione increased by 3- to 6-fo"}, {"to": "4993", "prefix": "o 6-fold and 1.3-fold, respectively. When a 200 mg dose of ", "from": "4984", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " was administered to subjects who had been receiving fluoxet"}, {"to": "5286", "prefix": " mCPP levels. Patients who are switched from fluoxetine to ", "from": "5277", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " without an adequate washout period may experience similar t"}, {"to": "5479", "prefix": "e minimized by allowing a washout period before initiating ", "from": "5470", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " therapy and by reducing the initial dose of nefazodone. Bec"}, {"to": "5534", "prefix": "ing nefazodone therapy and by reducing the initial dose of ", "from": "5525", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": ". Because of the long half-life of fluoxetine and its metabo"}, {"to": "5795", "prefix": "Pretreatment for 7 days with 200 mg BID of ", "from": "5786", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " had no effect on the pharmacokinetics of a single 300 mg or"}, {"to": "6120", "prefix": "e possibility of a clinically significant interaction with ", "from": "6111", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " when phenytoin is dosed chronically. However, no change in "}, {"to": "6358", "prefix": "When ", "from": "6349", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " "}, {"to": "6593", "prefix": "ine. There were also no changes in the pharmacokinetics of ", "from": "6584", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " or its triazole-dione metabolite, but the AUC and C max of "}, {"to": "6781", "prefix": "of HO-NEF decreased by 19%.  No changes in doses of either ", "from": "6772", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " or desipramine are necessary when the two drugs are given c"}, {"to": "7067", "prefix": "of HO-NEF decreased by 19%.  No changes in doses of either ", "from": "7058", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " or desipramine are necessary when the two drugs are given c"}, {"to": "7283", "prefix": "In 13 healthy subjects the coadministration of ", "from": "7274", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " "}, {"to": "7520", "prefix": "es in the steady-state pharmacokinetics of either lithium, ", "from": "7511", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": ", or its metabolite HO-NEF; however, there were small decrea"}, {"to": "7643", "prefix": "decreases in the steady-state plasma concentrations of two ", "from": "7634", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " metabolites, mCPP and triazole-dione, which are considered "}, {"to": "7802", "prefix": "ance. Therefore, no dosage adjustment of either lithium or ", "from": "7793", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " is required when they are coadministered.Carbamazepine"}, {"to": "7892", "prefix": "The coadministration of ", "from": "7883", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " "}, {"to": "8085", "prefix": "well tolerated. Steady-state conditions for carbamazepine, ", "from": "8076", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": ", and several of their metabolites were achieved by day 5 of"}, {"to": "8558", "prefix": "ugs significantly reduced the steady-state Cmax and AUC of ", "from": "8549", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " by 86% and 93%, respectively. Similar reductions in the Cma"}, {"to": "8916", "prefix": "stration of carbamazepine to result in insufficient plasma ", "from": "8907", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " and hydroxynefazodone concentrations for achieving an antid"}, {"to": "9007", "prefix": " concentrations for achieving an antidepressant effect for ", "from": "8998", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": ", it is recommended that nefazodone not be used in combinati"}, {"to": "9042", "prefix": "tidepressant effect for nefazodone, it is recommended that ", "from": "9033", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " not be used in combination with carbamazepine "}, {"to": "9298", "prefix": "ittle is known about the potential for interaction between ", "from": "9289", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " and general anesthetics; therefore, prior to elective surge"}, {"to": "9372", "prefix": "general anesthetics; therefore, prior to elective surgery, ", "from": "9363", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " should be discontinued for as long as clinically feasible.O"}, {"to": "9475", "prefix": "The use of ", "from": "9466", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " in combination with other CNS-active drugs has not been sys"}, {"to": "9648", "prefix": "ently, caution is advised if concomitant administration of ", "from": "9625", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone hydrochloride", "suffix": " and such drugs is required.\n\n\n\n\n\n\n\nCimetidine\nWhen nefazodo"}, {"to": "9710", "prefix": "hloride and such drugs is required.\n\n\n\n\n\n\n\nCimetidine\nWhen ", "from": "9701", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " "}, {"to": "9853", "prefix": ", no change in the steady-state pharmacokinetics of either ", "from": "9844", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " or cimetidine was observed compared to each dosed alone. Th"}, {"to": "10029", "prefix": " either drug when coadministered.\n\n\n\n\n\n\n\nTheophylline\nWhen ", "from": "10020", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " "}, {"to": "10238", "prefix": "s no change in the steady-state pharmacokinetics of either ", "from": "10229", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " or theophylline. FEV1 measurements taken when theophylline "}, {"to": "10312", "prefix": "heophylline. FEV1 measurements taken when theophylline and ", "from": "10303", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " were coadministered did not differ from baseline dosage "}, {"to": "10560", "prefix": "When ", "from": "10551", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " "}, {"to": "10862", "prefix": "ctively. Digoxin had no effects on the pharmacokinetics of ", "from": "10853", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " and its active metabolites. Because of the narrow therapeut"}, {"to": "10986", "prefix": "apeutic index of digoxin, caution should be exercised when ", "from": "10977", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " and digoxin are coadministered; plasma level monitoring for"}, {"to": "11122", "prefix": "The coadministration of ", "from": "11113", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " "}, {"to": "11447", "prefix": " for the metabolite, 4-hydroxypropranolol. The kinetics of ", "from": "11438", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": ", hydroxynefazodone, and triazole-dione were not affected by"}, {"to": "12017", "prefix": "4, were given to healthy adult volunteers who had received ", "from": "12008", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " 200 mg BID for 6 days, approximately 20-fold increases in p"}, {"to": "12311", "prefix": "se effects appear to be due to the inhibition of CYP3A4 by ", "from": "12302", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " because, in the same study, nefazodone had no significant e"}, {"to": "12350", "prefix": "bition of CYP3A4 by nefazodone because, in the same study, ", "from": "12341", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " had no significant effect on the plasma concentrations of p"}, {"to": "12597", "prefix": "domyolysis involving patients receiving the combination of ", "from": "12588", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " and either simvastatin or lovastatin, also a substrate of C"}, {"to": "13308", "prefix": "inhibitors of the CYP3A4 isozyme.Caution should be used if ", "from": "13299", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " is administered in combination with HMG-CoA reductase inhib"}, {"to": "13595", "prefix": "mmended. Since metabolic interactions are unlikely between ", "from": "13586", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " and HMG-CoA reductase inhibitors that undergo little or no "}, {"to": "13972", "prefix": "nges when patients received these drugs concomitantly with ", "from": "13963", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": ". Both cyclosporine and tacrolimus are substrates of CYP3A4,"}, {"to": "14047", "prefix": " cyclosporine and tacrolimus are substrates of CYP3A4, and ", "from": "14038", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " is known to inhibit this enzyme. If either cyclosporine or "}, {"to": "14149", "prefix": " If either cyclosporine or tacrolimus is administered with ", "from": "14140", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": ", blood concentrations of the immunosuppressive agent should"}, {"to": "14293", "prefix": "nd dosage adjusted accordingly.\n\n\n\n\n\n\n\nPharmacokinetics of ", "from": "14284", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "Nefazodone", "suffix": " in "}, {"to": "14566", "prefix": " This is consistent with the interactions observed between ", "from": "14557", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " and triazolam, alprazolam, buspirone, atorvastatin, and sim"}, {"to": "14739", "prefix": " Consequently, caution is indicated in the combined use of ", "from": "14730", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " with any drugs known to be metabolized by CYP3A4. In partic"}, {"to": "14835", "prefix": " metabolized by CYP3A4. In particular, the combined use of ", "from": "14826", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " with triazolam should be avoided for most patients, includi"}, {"to": "14941", "prefix": " most patients, including the elderly. The combined use of ", "from": "14932", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " with terfenadine, astemizole, cisapride, or pimozide is con"}, {"to": "15158", "prefix": " This is consistent with the interactions observed between ", "from": "15149", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " and triazolam, alprazolam, buspirone, atorvastatin, and sim"}, {"to": "15331", "prefix": " Consequently, caution is indicated in the combined use of ", "from": "15322", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " with any drugs known to be metabolized by CYP3A4. In partic"}, {"to": "15427", "prefix": " metabolized by CYP3A4. In particular, the combined use of ", "from": "15418", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " with triazolam should be avoided for most patients, includi"}, {"to": "15533", "prefix": " most patients, including the elderly. The combined use of ", "from": "15524", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " with terfenadine, astemizole, cisapride, or pimozide is con"}, {"to": "15722", "prefix": "ere are no clinical studies of the combined use of ECT and ", "from": "15713", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": ".\n\n\n\n\n"}, {"to": "838", "prefix": "There were no effects on the ", "from": "828", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "prothrombin", "suffix": " or bleeding times or upon the pharmacokinetics of R-warfari"}, {"to": "1160", "prefix": " exposure to S-warfarin by 12%, the lack of effects on the ", "from": "1150", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "prothrombin", "suffix": " and bleeding times indicates this modest change is not clin"}, {"to": "899", "prefix": "rombin or bleeding times or upon the pharmacokinetics of R-", "from": "892", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "warfarin", "suffix": " when nefazodone "}, {"to": "1018", "prefix": " week to subjects who had been pretreated for 2 weeks with ", "from": "1011", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "warfarin", "suffix": ". Although the coadministration of nefazodone did decrease t"}, {"to": "1113", "prefix": " exposure to S-", "from": "1106", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "warfarin", "suffix": " by 12%, the lack of effects on the prothrombin and bleeding"}, {"to": "1297", "prefix": "nificant. Although these results suggest no adjustments in ", "from": "1290", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "warfarin", "suffix": " dosage are required when nefazodone is administered to pati"}, {"to": "1384", "prefix": " when nefazodone is administered to patients stabilized on ", "from": "1377", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "warfarin", "suffix": ", such patients should be monitored as required by standard "}, {"to": "1593", "prefix": "When a single oral 5 mg dose of ", "from": "1583", "name": "Haloperidol", "fullId": "http://purl.bioontology.org/ontology/MESH/D006220", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "haloperidol", "suffix": " was coadministered with nefazodone "}, {"to": "1669", "prefix": " at steady state, ", "from": "1659", "name": "Haloperidol", "fullId": "http://purl.bioontology.org/ontology/MESH/D006220", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "haloperidol", "suffix": " apparent clearance decreased by 35% with no significant inc"}, {"to": "1754", "prefix": "ance decreased by 35% with no significant increase in peak ", "from": "1744", "name": "Haloperidol", "fullId": "http://purl.bioontology.org/ontology/MESH/D006220", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "haloperidol", "suffix": " plasma concentrations or time of peak. This change is of un"}, {"to": "1881", "prefix": " unknown clinical significance. Pharmacodynamic effects of ", "from": "1871", "name": "Haloperidol", "fullId": "http://purl.bioontology.org/ontology/MESH/D006220", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "haloperidol", "suffix": " were generally not altered significantly. There were no cha"}, {"to": "2028", "prefix": "acokinetic parameters for nefazodone. Dosage adjustment of ", "from": "2018", "name": "Haloperidol", "fullId": "http://purl.bioontology.org/ontology/MESH/D006220", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "haloperidol", "suffix": " may be necessary when coadministered with nefazodone.Loraze"}, {"to": "2106", "prefix": "When ", "from": "2098", "name": "Lorazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6470", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "lorazepam", "suffix": " "}, {"to": "2385", "prefix": "tment is not necessary for either drug when coadministered.", "from": "2377", "name": "Triazolam", "fullId": "http://purl.bioontology.org/ontology/MESH/D014229", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "Triazolam", "suffix": ""}, {"to": "14580", "prefix": "tent with the interactions observed between nefazodone and ", "from": "14572", "name": "Triazolam", "fullId": "http://purl.bioontology.org/ontology/MESH/D014229", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "triazolam", "suffix": ", alprazolam, buspirone, atorvastatin, and simvastatin, drug"}, {"to": "14850", "prefix": "CYP3A4. In particular, the combined use of nefazodone with ", "from": "14842", "name": "Triazolam", "fullId": "http://purl.bioontology.org/ontology/MESH/D014229", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "triazolam", "suffix": " should be avoided for most patients, including the elderly."}, {"to": "15172", "prefix": "tent with the interactions observed between nefazodone and ", "from": "15164", "name": "Triazolam", "fullId": "http://purl.bioontology.org/ontology/MESH/D014229", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "triazolam", "suffix": ", alprazolam, buspirone, atorvastatin, and simvastatin, drug"}, {"to": "15442", "prefix": "CYP3A4. In particular, the combined use of nefazodone with ", "from": "15434", "name": "Triazolam", "fullId": "http://purl.bioontology.org/ontology/MESH/D014229", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "triazolam", "suffix": " should be avoided for most patients, including the elderly."}, {"to": "2775", "prefix": "harmacokinetics in healthy volunteers, coadministration of ", "from": "2767", "name": "Buspirone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1827", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "buspirone", "suffix": " "}, {"to": "2871", "prefix": " resulted in marked increases in plasma ", "from": "2863", "name": "Buspirone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1827", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "buspirone", "suffix": " concentrations "}, {"to": "3040", "prefix": " in plasma concentrations of the ", "from": "3032", "name": "Buspirone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1827", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "buspirone", "suffix": " metabolite 1-pyrimidinylpiperazine. With 5mg BID doses of b"}, {"to": "3108", "prefix": " metabolite 1-pyrimidinylpiperazine. With 5mg BID doses of ", "from": "3100", "name": "Buspirone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1827", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "buspirone", "suffix": ", slight increases in AUC were observed for nefazodone "}, {"to": "3282", "prefix": ". Subjects receiving nefazodone 250 mg BID and ", "from": "3274", "name": "Buspirone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1827", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "buspirone", "suffix": " 5 mg BID experienced lightheadedness, asthenia, dizziness, "}, {"to": "3482", "prefix": "the two drugs are to be used in combination, a low dose of ", "from": "3474", "name": "Buspirone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1827", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "buspirone", "suffix": " "}, {"to": "3722", "prefix": " in plasma concentrations of the ", "from": "3714", "name": "Buspirone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1827", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "buspirone", "suffix": " metabolite 1-pyrimidinylpiperazine. With 5mg BID doses of b"}, {"to": "3790", "prefix": " metabolite 1-pyrimidinylpiperazine. With 5mg BID doses of ", "from": "3782", "name": "Buspirone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1827", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "buspirone", "suffix": ", slight increases in AUC were observed for nefazodone "}, {"to": "3964", "prefix": ". Subjects receiving nefazodone 250 mg BID and ", "from": "3956", "name": "Buspirone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1827", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "buspirone", "suffix": " 5 mg BID experienced lightheadedness, asthenia, dizziness, "}, {"to": "4164", "prefix": "the two drugs are to be used in combination, a low dose of ", "from": "4156", "name": "Buspirone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1827", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "buspirone", "suffix": " "}, {"to": "14603", "prefix": "ons observed between nefazodone and triazolam, alprazolam, ", "from": "14595", "name": "Buspirone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1827", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "buspirone", "suffix": ", atorvastatin, and simvastatin, drugs metabolized by this i"}, {"to": "15195", "prefix": "ons observed between nefazodone and triazolam, alprazolam, ", "from": "15187", "name": "Buspirone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1827", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "buspirone", "suffix": ", atorvastatin, and simvastatin, drugs metabolized by this i"}, {"to": "3206", "prefix": " and its metabolites ", "from": "3190", "name": "hydroxynefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092333", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "hydroxynefazodone", "suffix": " "}, {"to": "3888", "prefix": " and its metabolites ", "from": "3872", "name": "hydroxynefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092333", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "hydroxynefazodone", "suffix": " "}, {"to": "8938", "prefix": "bamazepine to result in insufficient plasma nefazodone and ", "from": "8922", "name": "hydroxynefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092333", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "hydroxynefazodone", "suffix": " concentrations for achieving an antidepressant effect for n"}, {"to": "11466", "prefix": "abolite, 4-hydroxypropranolol. The kinetics of nefazodone, ", "from": "11450", "name": "hydroxynefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092333", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "hydroxynefazodone", "suffix": ", and triazole-dione were not affected by coadministration o"}, {"to": "4553", "prefix": "When ", "from": "4544", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "fluoxetine", "suffix": " "}, {"to": "4697", "prefix": "here were no changes in the pharmacokinetic parameters for ", "from": "4688", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "fluoxetine", "suffix": " or its metabolite, norfluoxetine. Similarly, there were no "}, {"to": "5056", "prefix": "zodone was administered to subjects who had been receiving ", "from": "5047", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "fluoxetine", "suffix": " for 1 week, there was an increased incidence of transient a"}, {"to": "5272", "prefix": "o the elevated mCPP levels. Patients who are switched from ", "from": "5263", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "fluoxetine", "suffix": " to nefazodone without an adequate washout period may experi"}, {"to": "5579", "prefix": "itial dose of nefazodone. Because of the long half-life of ", "from": "5570", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "fluoxetine", "suffix": " and its metabolites, this washout period may range from one"}, {"to": "5692", "prefix": "y range from one to several weeks depending on the dose of ", "from": "5683", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "fluoxetine", "suffix": " and other individual patient variables.Phenytoin"}, {"to": "4730", "prefix": "armacokinetic parameters for fluoxetine or its metabolite, ", "from": "4718", "name": "norfluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C036139", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "norfluoxetine", "suffix": ". Similarly, there were no changes in the pharmacokinetic pa"}, {"to": "5875", "prefix": "ct on the pharmacokinetics of a single 300 mg oral dose of ", "from": "5867", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "phenytoin", "suffix": ". However, due to the nonlinear pharmacokinetics of phenytoi"}, {"to": "5936", "prefix": "enytoin. However, due to the nonlinear pharmacokinetics of ", "from": "5928", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "phenytoin", "suffix": ", the failure to observe a significant effect on the single-"}, {"to": "6030", "prefix": " significant effect on the single-dose pharmacokinetics of ", "from": "6022", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "phenytoin", "suffix": " does not preclude the possibility of a clinically significa"}, {"to": "6135", "prefix": " a clinically significant interaction with nefazodone when ", "from": "6127", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "phenytoin", "suffix": " is dosed chronically. However, no change in the initial dos"}, {"to": "6211", "prefix": "d chronically. However, no change in the initial dosage of ", "from": "6203", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "phenytoin", "suffix": " is considered necessary and any subsequent adjustment of ph"}, {"to": "6278", "prefix": "n is considered necessary and any subsequent adjustment of ", "from": "6270", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "phenytoin", "suffix": " dosage should be guided by usual clinical practices.Desipra"}, {"to": "6387", "prefix": " and ", "from": "6377", "name": "Desipramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003891", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "desipramine", "suffix": " "}, {"to": "6486", "prefix": " together there were no changes in the pharmacokinetics of ", "from": "6476", "name": "Desipramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003891", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "desipramine", "suffix": " or its metabolite, 2-hydroxy desipramine. There were also n"}, {"to": "6527", "prefix": "armacokinetics of desipramine or its metabolite, 2-hydroxy ", "from": "6517", "name": "Desipramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003891", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "desipramine", "suffix": ". There were also no changes in the pharmacokinetics of nefa"}, {"to": "6796", "prefix": "eased by 19%.  No changes in doses of either nefazodone or ", "from": "6786", "name": "Desipramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003891", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "desipramine", "suffix": " are necessary when the two drugs are given concomitantly. S"}, {"to": "7082", "prefix": "eased by 19%.  No changes in doses of either nefazodone or ", "from": "7072", "name": "Desipramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003891", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "desipramine", "suffix": " are necessary when the two drugs are given concomitantly. S"}, {"to": "7956", "prefix": " for 5 days to 12 healthy subjects on ", "from": "7944", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "carbamazepine", "suffix": " who had achieved steady state "}, {"to": "8073", "prefix": "as found to be well tolerated. Steady-state conditions for ", "from": "8061", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "carbamazepine", "suffix": ", nefazodone, and several of their metabolites were achieved"}, {"to": "8286", "prefix": "significant increases in the steady-state C max and AUC of ", "from": "8274", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "carbamazepine", "suffix": " "}, {"to": "8376", "prefix": ", while the steady-state Cmax and the AUC of the ", "from": "8364", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "carbamazepine", "suffix": " metabolite, 10,11 epoxycarbamazepine, decreased by 21% and "}, {"to": "8872", "prefix": ". Due to the potential for coadministration of ", "from": "8860", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "carbamazepine", "suffix": " to result in insufficient plasma nefazodone and hydroxynefa"}, {"to": "9088", "prefix": "ecommended that nefazodone not be used in combination with ", "from": "9076", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "carbamazepine", "suffix": " "}, {"to": "9154", "prefix": ".max and AUC of ", "from": "9142", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "carbamazepine", "suffix": " "}, {"to": "9694", "prefix": "efazodone hydrochloride and such drugs is required.\n\n\n\n\n\n\n\n", "from": "9685", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002927", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "Cimetidine", "suffix": "\nWhen nefazodone "}, {"to": "9738", "prefix": " and ", "from": "9729", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002927", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "cimetidine", "suffix": " "}, {"to": "9867", "prefix": " the steady-state pharmacokinetics of either nefazodone or ", "from": "9858", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002927", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "cimetidine", "suffix": " was observed compared to each dosed alone. Therefore, dosag"}, {"to": "10013", "prefix": " not necessary for either drug when coadministered.\n\n\n\n\n\n\n\n", "from": "10002", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10438", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "Theophylline", "suffix": "\nWhen nefazodone "}, {"to": "10096", "prefix": " was given to patients being treated with ", "from": "10085", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10438", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "theophylline", "suffix": " "}, {"to": "10254", "prefix": " the steady-state pharmacokinetics of either nefazodone or ", "from": "10243", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10438", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "theophylline", "suffix": ". FEV1 measurements taken when theophylline and nefazodone w"}, {"to": "10297", "prefix": "r nefazodone or theophylline. FEV1 measurements taken when ", "from": "10286", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10438", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "theophylline", "suffix": " and nefazodone were coadministered did not differ from base"}, {"to": "10393", "prefix": "i.e., when ", "from": "10382", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10438", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "theophylline", "suffix": " was administered alone"}, {"to": "10585", "prefix": " and ", "from": "10579", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004077", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "digoxin", "suffix": " "}, {"to": "10750", "prefix": " as CYP2D6 extensive metabolizers, C max, Cmin, and AUC of ", "from": "10744", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004077", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "digoxin", "suffix": " were increased by 29%, 27%, and 15%, respectively. Digoxin "}, {"to": "10809", "prefix": "digoxin were increased by 29%, 27%, and 15%, respectively. ", "from": "10803", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004077", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "Digoxin", "suffix": " had no effects on the pharmacokinetics of nefazodone and it"}, {"to": "10941", "prefix": "ve metabolites. Because of the narrow therapeutic index of ", "from": "10935", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004077", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "digoxin", "suffix": ", caution should be exercised when nefazodone and digoxin ar"}, {"to": "10998", "prefix": "f digoxin, caution should be exercised when nefazodone and ", "from": "10992", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004077", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "digoxin", "suffix": " are coadministered; plasma level monitoring for digoxin is "}, {"to": "11054", "prefix": "nd digoxin are coadministered; plasma level monitoring for ", "from": "11048", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004077", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "digoxin", "suffix": " is recommended.max, CPropranolol"}, {"to": "11151", "prefix": " and ", "from": "11141", "name": "Propranolol", "fullId": "http://purl.bioontology.org/ontology/MESH/D011433", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "propranolol", "suffix": " "}, {"to": "11335", "prefix": "rs, resulted in 30% and 14% reductions in C max and AUC of ", "from": "11325", "name": "Propranolol", "fullId": "http://purl.bioontology.org/ontology/MESH/D011433", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "propranolol", "suffix": ", respectively, and a 14% reduction in Cmax for the metaboli"}, {"to": "11539", "prefix": "nd triazole-dione were not affected by coadministration of ", "from": "11529", "name": "Propranolol", "fullId": "http://purl.bioontology.org/ontology/MESH/D011433", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "propranolol", "suffix": ". However, Cmax, Cmin, and AUC of m-chlorophenylpiperazine w"}, {"to": "11799", "prefix": "d be made on the basis of clinical response.max and AUC of ", "from": "11789", "name": "Propranolol", "fullId": "http://purl.bioontology.org/ontology/MESH/D011433", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "propranolol", "suffix": ", respectively, and a 14% reduction in CHMG-CoA Reductase In"}, {"to": "11906", "prefix": "When single 40 mg doses of ", "from": "11896", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "simvastatin", "suffix": " or atorvastatin, both substrates of CYP3A4, were given to h"}, {"to": "12112", "prefix": "pproximately 20-fold increases in plasma concentrations of ", "from": "12102", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "simvastatin", "suffix": " and simvastatin acid and 3- to 4- fold increases in plasma "}, {"to": "12620", "prefix": "atients receiving the combination of nefazodone and either ", "from": "12610", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "simvastatin", "suffix": " or lovastatin, also a substrate of CYP3A4 "}, {"to": "13425", "prefix": "ductase inhibitors that are metabolized by CYP3A4, such as ", "from": "13415", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "simvastatin", "suffix": ", atorvastatin, and lovastatin, and dosage adjustments of th"}, {"to": "14634", "prefix": "ne and triazolam, alprazolam, buspirone, atorvastatin, and ", "from": "14624", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "simvastatin", "suffix": ", drugs metabolized by this isozyme. Consequently, caution i"}, {"to": "15226", "prefix": "ne and triazolam, alprazolam, buspirone, atorvastatin, and ", "from": "15216", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "simvastatin", "suffix": ", drugs metabolized by this isozyme. Consequently, caution i"}, {"to": "11922", "prefix": "When single 40 mg doses of simvastatin or ", "from": "11911", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "atorvastatin", "suffix": ", both substrates of CYP3A4, were given to healthy adult vol"}, {"to": "12202", "prefix": "id and 3- to 4- fold increases in plasma concentrations of ", "from": "12191", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "atorvastatin", "suffix": " and atorvastatin lactone were seen. These effects appear to"}, {"to": "12219", "prefix": "old increases in plasma concentrations of atorvastatin and ", "from": "12208", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "atorvastatin", "suffix": " lactone were seen. These effects appear to be due to the in"}, {"to": "13439", "prefix": "itors that are metabolized by CYP3A4, such as simvastatin, ", "from": "13428", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "atorvastatin", "suffix": ", and lovastatin, and dosage adjustments of these HMG-CoA re"}, {"to": "14617", "prefix": "d between nefazodone and triazolam, alprazolam, buspirone, ", "from": "14606", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "atorvastatin", "suffix": ", and simvastatin, drugs metabolized by this isozyme. Conseq"}, {"to": "15209", "prefix": "d between nefazodone and triazolam, alprazolam, buspirone, ", "from": "15198", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "atorvastatin", "suffix": ", and simvastatin, drugs metabolized by this isozyme. Conseq"}, {"to": "12420", "prefix": " had no significant effect on the plasma concentrations of ", "from": "12410", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "pravastatin", "suffix": ", which is not metabolized by CYP3A4 to a clinically signifi"}, {"to": "13708", "prefix": "rgo little or no metabolism by the CYP3A4 isozyme, such as ", "from": "13698", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "pravastatin", "suffix": " or fluvastatin, dosage adjustments should not be necessary."}, {"to": "12634", "prefix": "ng the combination of nefazodone and either simvastatin or ", "from": "12625", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "lovastatin", "suffix": ", also a substrate of CYP3A4 "}, {"to": "13455", "prefix": "abolized by CYP3A4, such as simvastatin, atorvastatin, and ", "from": "13446", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "lovastatin", "suffix": ", and dosage adjustments of these HMG-CoA reductase inhibito"}, {"to": "13723", "prefix": "o metabolism by the CYP3A4 isozyme, such as pravastatin or ", "from": "13713", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "fluvastatin", "suffix": ", dosage adjustments should not be necessary.\n\n\n\n\n\n\n\nImmunos"}, {"to": "13874", "prefix": "ere have been reports of increased blood concentrations of ", "from": "13863", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016572", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "cyclosporine", "suffix": " and tacrolimus into toxic ranges when patients received the"}, {"to": "13991", "prefix": "s received these drugs concomitantly with nefazodone. Both ", "from": "13980", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016572", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "cyclosporine", "suffix": " and tacrolimus are substrates of CYP3A4, and nefazodone is "}, {"to": "14103", "prefix": " and nefazodone is known to inhibit this enzyme. If either ", "from": "14092", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016572", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "cyclosporine", "suffix": " or tacrolimus is administered with nefazodone, blood concen"}, {"to": "13889", "prefix": "orts of increased blood concentrations of cyclosporine and ", "from": "13880", "name": "Tacrolimus", "fullId": "http://purl.bioontology.org/ontology/MESH/D016559", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "tacrolimus", "suffix": " into toxic ranges when patients received these drugs concom"}, {"to": "14006", "prefix": "drugs concomitantly with nefazodone. Both cyclosporine and ", "from": "13997", "name": "Tacrolimus", "fullId": "http://purl.bioontology.org/ontology/MESH/D016559", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "tacrolimus", "suffix": " are substrates of CYP3A4, and nefazodone is known to inhibi"}, {"to": "14117", "prefix": "is known to inhibit this enzyme. If either cyclosporine or ", "from": "14108", "name": "Tacrolimus", "fullId": "http://purl.bioontology.org/ontology/MESH/D016559", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "tacrolimus", "suffix": " is administered with nefazodone, blood concentrations of th"}, {"to": "14592", "prefix": "he interactions observed between nefazodone and triazolam, ", "from": "14583", "name": "Alprazolam", "fullId": "http://purl.bioontology.org/ontology/MESH/D000525", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "alprazolam", "suffix": ", buspirone, atorvastatin, and simvastatin, drugs metabolize"}, {"to": "15184", "prefix": "he interactions observed between nefazodone and triazolam, ", "from": "15175", "name": "Alprazolam", "fullId": "http://purl.bioontology.org/ontology/MESH/D000525", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "alprazolam", "suffix": ", buspirone, atorvastatin, and simvastatin, drugs metabolize"}, {"to": "14958", "prefix": "including the elderly. The combined use of nefazodone with ", "from": "14948", "name": "Terfenadine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016593", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "terfenadine", "suffix": ", astemizole, cisapride, or pimozide is contraindicated "}, {"to": "15550", "prefix": "including the elderly. The combined use of nefazodone with ", "from": "15540", "name": "Terfenadine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016593", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "terfenadine", "suffix": ", astemizole, cisapride, or pimozide is contraindicated "}, {"to": "14970", "prefix": " elderly. The combined use of nefazodone with terfenadine, ", "from": "14961", "name": "Astemizole", "fullId": "http://purl.bioontology.org/ontology/MESH/D016589", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "astemizole", "suffix": ", cisapride, or pimozide is contraindicated "}, {"to": "15562", "prefix": " elderly. The combined use of nefazodone with terfenadine, ", "from": "15553", "name": "Astemizole", "fullId": "http://purl.bioontology.org/ontology/MESH/D016589", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "astemizole", "suffix": ", cisapride, or pimozide is contraindicated "}, {"to": "14981", "prefix": "e combined use of nefazodone with terfenadine, astemizole, ", "from": "14973", "name": "Cisapride", "fullId": "http://purl.bioontology.org/ontology/RXNORM/35255", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "cisapride", "suffix": ", or pimozide is contraindicated "}, {"to": "15573", "prefix": "e combined use of nefazodone with terfenadine, astemizole, ", "from": "15565", "name": "Cisapride", "fullId": "http://purl.bioontology.org/ontology/RXNORM/35255", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "cisapride", "suffix": ", or pimozide is contraindicated "}, {"to": "14994", "prefix": " of nefazodone with terfenadine, astemizole, cisapride, or ", "from": "14987", "name": "Pimozide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8331", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "pimozide", "suffix": " is contraindicated "}, {"to": "15586", "prefix": " of nefazodone with terfenadine, astemizole, cisapride, or ", "from": "15579", "name": "Pimozide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8331", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "pimozide", "suffix": " is contraindicated "}, {"to": "264", "prefix": "m of Action:\n                     \n                        ", "from": "254", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "Zafirlukast", "suffix": " is a selective and competitive receptor antagonist of leuko"}, {"to": "969", "prefix": "                        In vitro studies demonstrated that ", "from": "959", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "zafirlukast", "suffix": " antagonized the contractile activity of three leukotrienes "}, {"to": "1134", "prefix": " airway smooth muscle from laboratory animals and humans.  ", "from": "1124", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "Zafirlukast", "suffix": " prevented intradermal LTD4-induced increases in cutaneous v"}, {"to": "1366", "prefix": "lational challenge studies in sensitized sheep showed that ", "from": "1356", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "zafirlukast", "suffix": " suppressed the airway responses to antigen; this included b"}, {"to": "1552", "prefix": "ic hyperresponsiveness.\n                        In humans, ", "from": "1542", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "zafirlukast", "suffix": " inhibited bronchoconstriction caused by several kinds of in"}, {"to": "1686", "prefix": "tional challenges.  Pretreatment with single oral doses of ", "from": "1676", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "zafirlukast", "suffix": " inhibited the bronchoconstriction caused by sulfur dioxide "}, {"to": "1830", "prefix": "n patients with asthma.  Pretreatment with single doses of ", "from": "1820", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "zafirlukast", "suffix": " attenuated the early- and late-phase reaction caused by inh"}, {"to": "2009", "prefix": "nder, ragweed, and mixed antigens in patients with asthma. ", "from": "1999", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "Zafirlukast", "suffix": " also attenuated the increase in bronchial hyperresponsivene"}, {"to": "2652", "prefix": "\n                           \n                              ", "from": "2642", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "Zafirlukast", "suffix": " is rapidly absorbed following oral administration.  Peak pl"}, {"to": "2834", "prefix": "fter oral administration.  The absolute bioavailability of ", "from": "2824", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "zafirlukast", "suffix": " is unknown.  In two separate studies, one using a high fat "}, {"to": "2958", "prefix": "h fat and the other a high protein meal, administration of ", "from": "2948", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "zafirlukast", "suffix": " with food reduced the mean bioavailability by approximately"}, {"to": "3398", "prefix": "\n                           \n                              ", "from": "3388", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "Zafirlukast", "suffix": " is more than 99% bound to plasma proteins, predominantly al"}, {"to": "3729", "prefix": "ribution into tissues.  Studies in rats using radiolabeled ", "from": "3719", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "zafirlukast", "suffix": " indicate minimal distribution across the blood-brain barrie"}, {"to": "4164", "prefix": "\n                           \n                              ", "from": "4154", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "Zafirlukast", "suffix": " is extensively metabolized.  The most common metabolic prod"}, {"to": "4322", "prefix": "lites which are excreted in the feces.  The metabolites of ", "from": "4312", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "zafirlukast", "suffix": " identified in plasma are at least 90 times less potent as L"}, {"to": "4423", "prefix": "ast 90 times less potent as LTD4 receptor antagonists than ", "from": "4413", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "zafirlukast", "suffix": " in a standard in vitro test of activity.  In vitro studies "}, {"to": "4567", "prefix": "ver microsomes showed that the hydroxylated metabolites of ", "from": "4557", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "zafirlukast", "suffix": " excreted in the feces are formed through the cytochrome P45"}, {"to": "4734", "prefix": "n vitro studies utilizing human liver microsomes show that ", "from": "4724", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "zafirlukast", "suffix": " inhibits the cytochrome P450 CYP3A4 and CYP2C9 isoenzymes a"}, {"to": "5306", "prefix": " of ", "from": "5296", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "zafirlukast", "suffix": " is approximately 20 L"}, {"to": "5484", "prefix": " excretion.  Following oral administration of radiolabeled ", "from": "5474", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "zafirlukast", "suffix": " to volunteers, urinary excretion accounts for approximately"}, {"to": "5613", "prefix": "y 10% of the dose and the remainder is excreted in feces.  ", "from": "5603", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "Zafirlukast", "suffix": " is not detected in urine.\n                              In "}, {"to": "5749", "prefix": "votal bioequivalence study, the mean terminal half-life of ", "from": "5739", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "zafirlukast", "suffix": " is approximately 10 hours in both normal adult subjects and"}, {"to": "5891", "prefix": "th asthma.  In other studies, the mean plasma half-life of ", "from": "5881", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "zafirlukast", "suffix": " ranged from approximately 8 to 16 hours in both normal subj"}, {"to": "6018", "prefix": "ubjects and patients with asthma.  The pharmacokinetics of ", "from": "6008", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "zafirlukast", "suffix": " are approximately linear over the range from 5 mg to 80 mg."}, {"to": "6129", "prefix": "from 5 mg to 80 mg.  Steady-state plasma concentrations of ", "from": "6119", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "zafirlukast", "suffix": " are proportional to the dose and predictable from single-do"}, {"to": "6242", "prefix": "le from single-dose pharmacokinetic data.  Accumulation of ", "from": "6232", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "zafirlukast", "suffix": " in the plasma following twice-daily dosing is approximately"}, {"to": "6383", "prefix": "                         The pharmacokinetic parameters of ", "from": "6373", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "zafirlukast", "suffix": " 20 mg administered as a single dose to 36 male volunteers a"}, {"to": "6923", "prefix": "                           Gender: The pharmacokinetics of ", "from": "6913", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "zafirlukast", "suffix": " are similar in males and females.  Weight-adjusted apparent"}, {"to": "7119", "prefix": "           Race: No differences in the pharmacokinetics of ", "from": "7109", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "zafirlukast", "suffix": " due to race have been observed.\n                           "}, {"to": "7233", "prefix": "                   Elderly: The apparent oral clearance of ", "from": "7223", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "zafirlukast", "suffix": " decreases with age.  In patients above 65 years of age, the"}, {"to": "7482", "prefix": "ildren: Following administration of a single 20 mg dose of ", "from": "7472", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "zafirlukast", "suffix": " to 20 boys and girls between 7 and 11 years of age, and in "}, {"to": "8183", "prefix": ".\n                              ", "from": "8173", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "Zafirlukast", "suffix": " disposition was unchanged after multiple dosing "}, {"to": "8516", "prefix": ", there was a reduced clearance of ", "from": "8506", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "zafirlukast", "suffix": " resulting in a 50-60% greater Cmax and AUC compared to norm"}, {"to": "8747", "prefix": "ere are no apparent differences in the pharmacokinetics of ", "from": "8737", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "zafirlukast", "suffix": " between renally-impaired patients and normal subjects.\n    "}, {"to": "8966", "prefix": "ollowing drug interaction studies have been conducted with ", "from": "8956", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "zafirlukast", "suffix": " "}, {"to": "9156", "prefix": "Coadministration of multiple doses of ", "from": "9146", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "zafirlukast", "suffix": " "}, {"to": "9435", "prefix": "me increased by approximately 35%. The pharmacokinetics of ", "from": "9425", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "zafirlukast", "suffix": " were unaffected by coadministration with warfarin.\n        "}, {"to": "9589", "prefix": "Coadministration of ", "from": "9579", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "zafirlukast", "suffix": " "}, {"to": "9796", "prefix": "f age, resulted in decreased mean plasma concentrations of ", "from": "9786", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "zafirlukast", "suffix": " by approximately 30%, but no effect on plasma theophylline "}, {"to": "9987", "prefix": "Coadministration of ", "from": "9977", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "zafirlukast", "suffix": " "}, {"to": "10352", "prefix": "Coadministration of ", "from": "10342", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "zafirlukast", "suffix": " dosed at 40 mg twice daily in a single-blind, parallel-grou"}, {"to": "10692", "prefix": "Coadministration of ", "from": "10682", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "zafirlukast", "suffix": " "}, {"to": "10807", "prefix": " resulted in mean increased plasma concentrations of ", "from": "10797", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "zafirlukast", "suffix": " by approximately 45%.\n                                 \n   "}, {"to": "10949", "prefix": "Coadministration of a single dose of ", "from": "10939", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "zafirlukast", "suffix": " "}, {"to": "11118", "prefix": "tients resulted in decreased mean plasma concentrations of ", "from": "11108", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "zafirlukast", "suffix": " by approximately 40% due to a decrease in zafirlukast bioav"}, {"to": "11172", "prefix": "s of zafirlukast by approximately 40% due to a decrease in ", "from": "11162", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "zafirlukast", "suffix": " bioavailability.\n                                 \n        "}, {"to": "11292", "prefix": "Coadministration of ", "from": "11282", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "zafirlukast", "suffix": " with fluconazole, a moderate CYP2C9 inhibitor, resulted in "}, {"to": "11461", "prefix": "    \n                                      plasma levels of ", "from": "11451", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "zafirlukast", "suffix": ", by approximately 58% "}, {"to": "11641", "prefix": "                                    interaction is unknown. ", "from": "11631", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "Zafirlukast", "suffix": " exposure is likely to be increased by other moderate and st"}, {"to": "11827", "prefix": "                     CYP2C9 inhibitors. Coadministration of ", "from": "11817", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "zafirlukast", "suffix": " with itraconazole, a strong CYP3A4 inhibitor,\n             "}, {"to": "11993", "prefix": "                       caused no change in plasma levels of ", "from": "11983", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "zafirlukast", "suffix": ".\n                              \n                           "}, {"to": "12518", "prefix": "e and older with mild-to-moderate asthma demonstrated that ", "from": "12511", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "ACCOLATE", "suffix": " improved daytime asthma symptoms, nighttime awakenings, mor"}, {"to": "13049", "prefix": "           \n\n\nIn a second and smaller study, the effect of ", "from": "13042", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "ACCOLATE", "suffix": " on most efficacy parameters was comparable to the active co"}, {"to": "13421", "prefix": "toms occurred within one week of initiating treatment with ", "from": "13414", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "ACCOLATE", "suffix": ".  The role of ACCOLATE in the management of patients with m"}, {"to": "13444", "prefix": "e week of initiating treatment with ACCOLATE.  The role of ", "from": "13437", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "ACCOLATE", "suffix": " in the management of patients with more severe asthma, pati"}, {"to": "2092", "prefix": "d the increase in bronchial hyperresponsiveness to inhaled ", "from": "2084", "name": "Histamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5333", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "histamine", "suffix": " that followed inhaled allergen challenge.\n                 "}, {"to": "9222", "prefix": " to steady-state with a single 25 mg dose of ", "from": "9215", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "warfarin", "suffix": " "}, {"to": "9339", "prefix": " of S-", "from": "9332", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "warfarin", "suffix": ".  The mean prothrombin time increased by approximately 35%."}, {"to": "9485", "prefix": "cs of zafirlukast were unaffected by coadministration with ", "from": "9478", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "warfarin", "suffix": ".\n                                 \n                        "}, {"to": "9362", "prefix": " of S-warfarin.  The mean ", "from": "9352", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "prothrombin", "suffix": " time increased by approximately 35%. The pharmacokinetics o"}, {"to": "9661", "prefix": " at steady-state with a single dose of a liquid ", "from": "9650", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10438", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "theophylline", "suffix": " preparation "}, {"to": "9855", "prefix": " zafirlukast by approximately 30%, but no effect on plasma ", "from": "9844", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10438", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "theophylline", "suffix": " concentrations was observed.\n                              "}, {"to": "10079", "prefix": "bo at steady-state with a single dose of sustained release ", "from": "10068", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10438", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "theophylline", "suffix": " preparation "}, {"to": "10248", "prefix": "gnificant differences in the pharmacokinetic parameters of ", "from": "10237", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10438", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "theophylline", "suffix": ".\n                                 \n                        "}, {"to": "10540", "prefix": " oral contraceptives, resulted in no significant effect on ", "from": "10524", "name": "Ethinyl Estradiol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4124", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "ethinyl estradiol", "suffix": " plasma concentrations or contraceptive efficacy.\n          "}, {"to": "10717", "prefix": " with ", "from": "10711", "name": "Aspirin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1191", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "aspirin", "suffix": " "}, {"to": "10975", "prefix": " with ", "from": "10964", "name": "Erythromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004917", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "erythromycin", "suffix": " "}, {"to": "11309", "prefix": "Coadministration of zafirlukast with ", "from": "11299", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "fluconazole", "suffix": ", a moderate CYP2C9 inhibitor, resulted in increased\n       "}, {"to": "11845", "prefix": "    CYP2C9 inhibitors. Coadministration of zafirlukast with ", "from": "11834", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "itraconazole", "suffix": ", a strong CYP3A4 inhibitor,\n                               "}, {"to": "12860", "prefix": "ne beta2-agonist requirement of approximately 4-5 puffs of ", "from": "12852", "name": "Albuterol", "fullId": "http://purl.bioontology.org/ontology/MESH/D000420", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "albuterol", "suffix": " per day.  The results of the largest of the trials are show"}, {"to": "13139", "prefix": "inhaled ", "from": "13125", "name": "Cromolyn Sodium", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3538", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "cromolyn sodium", "suffix": " 1600 mcg four times per day"}, {"to": "293", "prefix": "       \n                        The mechanism of action of ", "from": "288", "name": "Fanapt", "fullId": "http://purl.bioontology.org/ontology/RXNORM/848723", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "FANAPT", "suffix": ", as with other drugs having efficacy in schizophrenia, is u"}, {"to": "412", "prefix": ", is unknown.  However it is proposed that the efficacy of ", "from": "407", "name": "Fanapt", "fullId": "http://purl.bioontology.org/ontology/RXNORM/848723", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "FANAPT", "suffix": " is mediated through a combination of dopamine type 2 "}, {"to": "766", "prefix": "macodynamics\n                     \n                        ", "from": "761", "name": "Fanapt", "fullId": "http://purl.bioontology.org/ontology/RXNORM/848723", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "FANAPT", "suffix": " exhibits high "}, {"to": "910", "prefix": ".  ", "from": "905", "name": "Fanapt", "fullId": "http://purl.bioontology.org/ontology/RXNORM/848723", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "FANAPT", "suffix": " has moderate affinity for dopamine D4, serotonin 5-HT6 and "}, {"to": "1203", "prefix": ".  ", "from": "1198", "name": "Fanapt", "fullId": "http://purl.bioontology.org/ontology/RXNORM/848723", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "FANAPT", "suffix": " has no appreciable affinity "}, {"to": "1290", "prefix": " for cholinergic muscarinic receptors.  ", "from": "1285", "name": "Fanapt", "fullId": "http://purl.bioontology.org/ontology/RXNORM/848723", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "FANAPT", "suffix": " functions as an antagonist at the dopamine D2, D3, serotoni"}, {"to": "1425", "prefix": "2C receptors.    The affinity of the ", "from": "1420", "name": "Fanapt", "fullId": "http://purl.bioontology.org/ontology/RXNORM/848723", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "FANAPT", "suffix": " metabolite P88 is generally equal or less than that of the "}, {"to": "2985", "prefix": "hour for iloperidone, 2 hours for P88 and 6 hours for P95. ", "from": "2980", "name": "Fanapt", "fullId": "http://purl.bioontology.org/ontology/RXNORM/848723", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "FANAPT", "suffix": " can be administered without regard to meals.\n              "}, {"to": "4241", "prefix": "xtensive or ultrarapid metabolizers.  Co-administration of ", "from": "4236", "name": "Fanapt", "fullId": "http://purl.bioontology.org/ontology/RXNORM/848723", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "FANAPT", "suffix": " with known strong inhibitors of CYP2D6 like fluoxetine resu"}, {"to": "4396", "prefix": "iloperidone plasma exposure, and therefore one-half of the ", "from": "4391", "name": "Fanapt", "fullId": "http://purl.bioontology.org/ontology/RXNORM/848723", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "FANAPT", "suffix": " dose should be administered.\n                        Simila"}, {"to": "1991", "prefix": "              The observed mean elimination half-lives for ", "from": "1981", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "iloperidone", "suffix": ", P88 and P95 in CYP2D6 extensive metabolizers "}, {"to": "2231", "prefix": "ate concentrations are attained within 3-4 days of dosing. ", "from": "2221", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "Iloperidone", "suffix": " accumulation is predictable from single-dose pharmacokineti"}, {"to": "2331", "prefix": "rom single-dose pharmacokinetics.  The pharmacokinetics of ", "from": "2321", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "iloperidone", "suffix": " is more than dose proportional. Elimination of iloperidone "}, {"to": "2390", "prefix": "iloperidone is more than dose proportional. Elimination of ", "from": "2380", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "iloperidone", "suffix": " is mainly through hepatic metabolism involving two P450 iso"}, {"to": "2552", "prefix": "                  \n                           Absorption:  ", "from": "2542", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "Iloperidone", "suffix": " is well absorbed after administration of the tablet with pe"}, {"to": "2793", "prefix": "ation compared to oral solution is 96%.  Administration of ", "from": "2783", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "iloperidone", "suffix": " with a standard high-fat meal did not significantly affect "}, {"to": "2883", "prefix": "h-fat meal did not significantly affect the Cmax or AUC of ", "from": "2873", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "iloperidone", "suffix": ", P88, or P95, but delayed Tmax by 1 hour for iloperidone, 2"}, {"to": "2940", "prefix": "f iloperidone, P88, or P95, but delayed Tmax by 1 hour for ", "from": "2930", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "iloperidone", "suffix": ", 2 hours for P88 and 6 hours for P95. FANAPT can be adminis"}, {"to": "3109", "prefix": "                \n                           Distribution:  ", "from": "3099", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "Iloperidone", "suffix": " has an apparent clearance "}, {"to": "3283", "prefix": "stribution of 1340-2800 L.  At therapeutic concentrations, ", "from": "3273", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "iloperidone", "suffix": " and its metabolites are "}, {"to": "3430", "prefix": "  \n                           Metabolism and Elimination:  ", "from": "3420", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "Iloperidone", "suffix": " is metabolized primarily by three biotransformation pathway"}, {"to": "3627", "prefix": ". There are two predominant ", "from": "3617", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "iloperidone", "suffix": " metabolites, P95 and P88. The iloperidone metabolite P95 re"}, {"to": "3669", "prefix": " two predominant iloperidone metabolites, P95 and P88. The ", "from": "3659", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "iloperidone", "suffix": " metabolite P95 represents 47.9% of the AUC of iloperidone a"}, {"to": "3727", "prefix": " iloperidone metabolite P95 represents 47.9% of the AUC of ", "from": "3717", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "iloperidone", "suffix": " and its metabolites in plasma at steady-state for extensive"}, {"to": "4342", "prefix": "f CYP2D6 like fluoxetine results in a 2.3 fold increase in ", "from": "4332", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "iloperidone", "suffix": " plasma exposure, and therefore one-half of the FANAPT dose "}, {"to": "4510", "prefix": "          Similarly, PMs of CYP2D6 have higher exposure to ", "from": "4500", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "iloperidone", "suffix": " compared with EMs and PMs should have their dose reduced by"}, {"to": "458", "prefix": "he efficacy of FANAPT is mediated through a combination of ", "from": "451", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D004298", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "dopamine", "suffix": " type 2 "}, {"to": "835", "prefix": " affinity binding to serotonin 5-HT2A and ", "from": "828", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D004298", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "dopamine", "suffix": " D2 and D3 receptors "}, {"to": "945", "prefix": ".  FANAPT has moderate affinity for ", "from": "938", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D004298", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "dopamine", "suffix": " D4, serotonin 5-HT6 and 5-HT7, and norepinephrine NE"}, {"to": "1114", "prefix": ", and low affinity for the serotonin 5-HT1A, ", "from": "1107", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D004298", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "dopamine", "suffix": " D1, and histamine H1 receptors "}, {"to": "1333", "prefix": "rinic receptors.  FANAPT functions as an antagonist at the ", "from": "1326", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D004298", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "dopamine", "suffix": " D2, D3, serotonin 5-HT1A and norepinephrine "}, {"to": "484", "prefix": " and ", "from": "476", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "serotonin", "suffix": " type 2 "}, {"to": "815", "prefix": " affinity binding to ", "from": "807", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "serotonin", "suffix": " 5-HT2A and dopamine D2 and D3 receptors "}, {"to": "959", "prefix": ".  FANAPT has moderate affinity for dopamine D4, ", "from": "951", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "serotonin", "suffix": " 5-HT6 and 5-HT7, and norepinephrine NE"}, {"to": "1097", "prefix": ", and low affinity for the ", "from": "1089", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "serotonin", "suffix": " 5-HT1A, dopamine D1, and histamine H1 receptors "}, {"to": "1351", "prefix": " FANAPT functions as an antagonist at the dopamine D2, D3, ", "from": "1343", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "serotonin", "suffix": " 5-HT1A and norepinephrine "}, {"to": "995", "prefix": "e affinity for dopamine D4, serotonin 5-HT6 and 5-HT7, and ", "from": "982", "name": "Norepinephrine", "fullId": "http://purl.bioontology.org/ontology/MESH/D009638", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "norepinephrine", "suffix": " NE"}, {"to": "1377", "prefix": "an antagonist at the dopamine D2, D3, serotonin 5-HT1A and ", "from": "1364", "name": "Norepinephrine", "fullId": "http://purl.bioontology.org/ontology/MESH/D009638", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "norepinephrine", "suffix": " "}, {"to": "1132", "prefix": "nd low affinity for the serotonin 5-HT1A, dopamine D1, and ", "from": "1124", "name": "Histamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5333", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "histamine", "suffix": " H1 receptors "}, {"to": "4296", "prefix": "tion of FANAPT with known strong inhibitors of CYP2D6 like ", "from": "4287", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "fluoxetine", "suffix": " results in a 2.3 fold increase in iloperidone plasma exposu"}, {"to": "240", "prefix": "thy male volunteers, coadministration of multiple doses of ", "from": "230", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "zafirlukast", "suffix": " "}, {"to": "531", "prefix": "35%.  This interaction is probably due to an inhibition by ", "from": "521", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "zafirlukast", "suffix": " of the cytochrome P450 2C9 isoenzyme system.  Patients on o"}, {"to": "638", "prefix": "stem.  Patients on oral warfarin anticoagulant therapy and ", "from": "631", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "ACCOLATE", "suffix": " should have their prothrombin times monitored closely and a"}, {"to": "844", "prefix": ".  No formal drug-drug interaction studies with ", "from": "837", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "ACCOLATE", "suffix": " and other drugs known to be metabolized by the cytochrome P"}, {"to": "1034", "prefix": "ave been conducted; however, care should be exercised when ", "from": "1027", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "ACCOLATE", "suffix": " is coadministered with these drugs.\n                       "}, {"to": "1197", "prefix": "1 asthmatic patients, coadministration of a single dose of ", "from": "1187", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "zafirlukast", "suffix": " "}, {"to": "1333", "prefix": "o steady-state resulted in decreased mean plasma levels of ", "from": "1323", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "zafirlukast", "suffix": " by approximately 40% due to a decrease in zafirlukast bioav"}, {"to": "1387", "prefix": "s of zafirlukast by approximately 40% due to a decrease in ", "from": "1377", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "zafirlukast", "suffix": " bioavailability.\n                        Coadministration o"}, {"to": "1460", "prefix": "oavailability.\n                        Coadministration of ", "from": "1450", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "zafirlukast", "suffix": " "}, {"to": "1778", "prefix": " theophylline.\n                        Coadministration of ", "from": "1768", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "zafirlukast", "suffix": " "}, {"to": "1977", "prefix": " years of age, resulted in decreased mean plasma levels of ", "from": "1967", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "zafirlukast", "suffix": " by approximately 30%, but no effect on plasma theophylline "}, {"to": "2246", "prefix": "or symptoms of theophylline toxicity after the addition of ", "from": "2239", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "ACCOLATE", "suffix": " to an existing theophylline regimen have been reported.  Th"}, {"to": "2353", "prefix": "e been reported.  The mechanism of the interaction between ", "from": "2346", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "ACCOLATE", "suffix": " and theophylline in these patients is unknown "}, {"to": "2480", "prefix": ".\n                        Coadministration of ", "from": "2470", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "zafirlukast", "suffix": " "}, {"to": "2587", "prefix": " resulted in mean increased plasma levels of ", "from": "2577", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "zafirlukast", "suffix": " by approximately 45%.\n                        In a single-b"}, {"to": "2772", "prefix": " subjects taking oral contraceptives, 40 mg twice daily of ", "from": "2762", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "zafirlukast", "suffix": " had no significant effect on ethinyl estradiol plasma conce"}, {"to": "2924", "prefix": "tive efficacy.\n                        Coadministration of ", "from": "2914", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "zafirlukast", "suffix": " with fluconazole, a moderate CYP2C9 inhibitor, resulted in "}, {"to": "3046", "prefix": "lted in increased\n                        plasma levels of ", "from": "3036", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "zafirlukast", "suffix": ", by approximately 58% "}, {"to": "3179", "prefix": "ce of this\n                        interaction is unknown. ", "from": "3169", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "Zafirlukast", "suffix": " exposure is likely to be increased by other moderate and st"}, {"to": "3318", "prefix": "                    CYP2C9 inhibitors. Coadministration of ", "from": "3308", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "zafirlukast", "suffix": " with itraconazole, a strong CYP3A4 inhibitor, caused\n      "}, {"to": "3437", "prefix": "used\n                        no change in plasma levels of ", "from": "3427", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "zafirlukast", "suffix": ".\n                        No other formal drug-drug interact"}, {"to": "3525", "prefix": "     No other formal drug-drug interaction studies between ", "from": "3518", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "ACCOLATE", "suffix": " and marketed drugs known to be metabolized by the P450 3A4 "}, {"to": "3707", "prefix": " have been conducted. As ", "from": "3700", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "ACCOLATE", "suffix": " is known to be an inhibitor of CYP3A4 in vitro, it is reaso"}, {"to": "3864", "prefix": "inical monitoring when these drugs are coadministered with ", "from": "3857", "name": "zafirlukast", "fullId": "http://purl.bioontology.org/ontology/MESH/C062735", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "ACCOLATE", "suffix": ".\n                     \n                     \n              "}, {"to": "306", "prefix": " to steady-state with a single 25 mg dose of ", "from": "299", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "warfarin", "suffix": " resulted in a significant increase in the mean AUC "}, {"to": "400", "prefix": " of S-", "from": "393", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "warfarin", "suffix": ".  The mean prothrombin time "}, {"to": "603", "prefix": "he cytochrome P450 2C9 isoenzyme system.  Patients on oral ", "from": "596", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "warfarin", "suffix": " anticoagulant therapy and ACCOLATE should have their prothr"}, {"to": "772", "prefix": "see WARNINGS, Concomitant ", "from": "765", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "Warfarin", "suffix": " Administration"}, {"to": "423", "prefix": " of S-warfarin.  The mean ", "from": "413", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "prothrombin", "suffix": " time "}, {"to": "668", "prefix": "farin anticoagulant therapy and ACCOLATE should have their ", "from": "658", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "prothrombin", "suffix": " times monitored closely and anticoagulant dose adjusted acc"}, {"to": "938", "prefix": "eg, ", "from": "928", "name": "Tolbutamide", "fullId": "http://purl.bioontology.org/ontology/MESH/D014044", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "tolbutamide", "suffix": ", phenytoin, carbamazepine"}, {"to": "949", "prefix": "eg, tolbutamide, ", "from": "941", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "phenytoin", "suffix": ", carbamazepine"}, {"to": "964", "prefix": "eg, tolbutamide, phenytoin, ", "from": "952", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "carbamazepine", "suffix": ""}, {"to": "1223", "prefix": " with ", "from": "1212", "name": "Erythromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004917", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "erythromycin", "suffix": " "}, {"to": "1552", "prefix": "bo at steady-state with a single dose of sustained release ", "from": "1541", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10438", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "theophylline", "suffix": " preparation "}, {"to": "1721", "prefix": "gnificant differences in the pharmacokinetic parameters of ", "from": "1710", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10438", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "theophylline", "suffix": ".\n                        Coadministration of zafirlukast "}, {"to": "1850", "prefix": " at steady-state with a single dose of a liquid ", "from": "1839", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10438", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "theophylline", "suffix": " preparation "}, {"to": "2036", "prefix": " zafirlukast by approximately 30%, but no effect on plasma ", "from": "2025", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10438", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "theophylline", "suffix": " levels was observed.\n                        Rare cases of "}, {"to": "2140", "prefix": "             Rare cases of patients experiencing increased ", "from": "2129", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10438", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "theophylline", "suffix": " levels with or without clinical signs or symptoms of theoph"}, {"to": "2206", "prefix": "lline levels with or without clinical signs or symptoms of ", "from": "2195", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10438", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "theophylline", "suffix": " toxicity after the addition of ACCOLATE to an existing theo"}, {"to": "2274", "prefix": "ine toxicity after the addition of ACCOLATE to an existing ", "from": "2263", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10438", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "theophylline", "suffix": " regimen have been reported.  The mechanism of the interacti"}, {"to": "2370", "prefix": "ed.  The mechanism of the interaction between ACCOLATE and ", "from": "2359", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10438", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "theophylline", "suffix": " in these patients is unknown "}, {"to": "2505", "prefix": " with ", "from": "2499", "name": "Aspirin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1191", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "aspirin", "suffix": " "}, {"to": "2819", "prefix": "mg twice daily of zafirlukast had no significant effect on ", "from": "2803", "name": "Ethinyl Estradiol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4124", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "ethinyl estradiol", "suffix": " plasma concentrations or contraceptive efficacy.\n          "}, {"to": "2941", "prefix": "                      Coadministration of zafirlukast with ", "from": "2931", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "fluconazole", "suffix": ", a moderate CYP2C9 inhibitor, resulted in increased\n       "}, {"to": "3336", "prefix": "   CYP2C9 inhibitors. Coadministration of zafirlukast with ", "from": "3325", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "itraconazole", "suffix": ", a strong CYP3A4 inhibitor, caused\n                        "}, {"to": "3662", "prefix": "eg, dihydropyridine calcium-channel blockers, ", "from": "3652", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016572", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "cyclosporin", "suffix": ", cisapride"}, {"to": "3673", "prefix": "eg, dihydropyridine calcium-channel blockers, cyclosporin, ", "from": "3665", "name": "Cisapride", "fullId": "http://purl.bioontology.org/ontology/RXNORM/35255", "setId": "5550433b-8c9c-4378-058f-6bb724c4f18c", "exact": "cisapride", "suffix": ""}, {"to": "115", "prefix": "     7 DRUG INTERACTIONS\n               \n                  ", "from": "103", "name": "telithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/C106791", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "Telithromycin", "suffix": " is a strong inhibitor of CYP3A4 and also a CYP3A4 substrate"}, {"to": "203", "prefix": "f CYP3A4 and also a CYP3A4 substrate. Co-administration of ", "from": "199", "name": "telithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/C106791", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "KETEK", "suffix": " and drugs that induce or inhibit the cytochrome P450 3A4 en"}, {"to": "291", "prefix": "r inhibit the cytochrome P450 3A4 enzyme system may affect ", "from": "287", "name": "telithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/C106791", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "KETEK", "suffix": " plasma concentrations resulting in diminished efficacy or a"}, {"to": "526", "prefix": "djustments may be necessary for drugs co-administered with ", "from": "514", "name": "telithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/C106791", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "telithromycin", "suffix": ". \n                  Studies were performed to evaluate the "}, {"to": "630", "prefix": "e performed to evaluate the effect of CYP3A4 inhibitors on ", "from": "618", "name": "telithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/C106791", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "telithromycin", "suffix": " and the effect of telithromycin on drugs that are substrate"}, {"to": "662", "prefix": "ct of CYP3A4 inhibitors on telithromycin and the effect of ", "from": "650", "name": "telithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/C106791", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "telithromycin", "suffix": " on drugs that are substrates of CYP3A4 and CYP2D6. In addit"}, {"to": "896", "prefix": "izes both drugs with pharmacokinetics that are affected by ", "from": "892", "name": "telithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/C106791", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "KETEK", "suffix": " as well as drugs that affect the pharmacokinetics of KETEK."}, {"to": "955", "prefix": "KETEK as well as drugs that affect the pharmacokinetics of ", "from": "951", "name": "telithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/C106791", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "KETEK", "suffix": ".\n                  \n\n\n               \n\n\n\n               \n  "}, {"to": "1186", "prefix": "\n                              CYP3A4 inducers:  Decreased ", "from": "1182", "name": "telithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/C106791", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "KETEK", "suffix": " levels resulting in loss of efficacy. Avoid concomitant use"}, {"to": "1345", "prefix": "                             CYP3A4 inhibitors:  Increased ", "from": "1341", "name": "telithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/C106791", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "KETEK", "suffix": " levels and risk of adverse reactions. Avoid concomitant use"}, {"to": "1514", "prefix": "                    Drugs metabolized via CYP3A4 pathway:  ", "from": "1510", "name": "telithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/C106791", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "KETEK", "suffix": " may increase levels of these concomitant medications. Avoid"}, {"to": "286", "prefix": "       \n                        The mechanism of action of ", "from": "277", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": ", as with other antidepressants, is unknown.\n               "}, {"to": "401", "prefix": "                       Preclinical studies have shown that ", "from": "392", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " inhibits neuronal uptake of serotonin and norepinephrine.\n "}, {"to": "494", "prefix": "e of serotonin and norepinephrine.\n                        ", "from": "485", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "Nefazodone", "suffix": " occupies central 5-HT2 receptors at nanomolar concentration"}, {"to": "611", "prefix": "oncentrations, and acts as an antagonist at this receptor. ", "from": "602", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "Nefazodone", "suffix": " was shown to antagonize alpha1-adrenergic receptors, a prop"}, {"to": "774", "prefix": "postural hypotension. In vitro binding studies showed that ", "from": "765", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " had no significant affinity for the following receptors: al"}, {"to": "1166", "prefix": "macokinetics\n                     \n                        ", "from": "1157", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "Nefazodone", "suffix": " is rapidly and completely absorbed but is subject to extens"}, {"to": "1394", "prefix": "oncentrations occur at about one hour and the half-life of ", "from": "1385", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " is 2 to 4 hours.\n                        Both nefazodone an"}, {"to": "1451", "prefix": "f nefazodone is 2 to 4 hours.\n                        Both ", "from": "1442", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " and its pharmacologically similar metabolite, hydroxynefazo"}, {"to": "1831", "prefix": "involving BID dosing with 50, 100, and 200 mg, the AUC for ", "from": "1822", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " and hydroxynefazodone increased by about 4 fold with an inc"}, {"to": "2107", "prefix": " with 25, 50, 100, and 150 mg, the accumulation ratios for ", "from": "2098", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " and hydroxynefazodone AUC, after 5 days of BID dosing relat"}, {"to": "2507", "prefix": "sting extensive and greater than predicted accumulation of ", "from": "2498", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " and its hydroxy metabolite with multiple dosing. Steady-sta"}, {"to": "2587", "prefix": "droxy metabolite with multiple dosing. Steady-state plasma ", "from": "2578", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " and metabolite concentrations are attained within 4 to 5 da"}, {"to": "2747", "prefix": "or upon dose increase or decrease.\n                        ", "from": "2738", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "Nefazodone", "suffix": " is extensively metabolized after oral administration by n-d"}, {"to": "2904", "prefix": "d aromatic hydroxylation, and less than 1% of administered ", "from": "2895", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " is excreted unchanged in urine. Attempts to characterize th"}, {"to": "3180", "prefix": "expressed as a multiple of the AUC for ", "from": "3171", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " dosed at 100 mg BID"}, {"to": "3433", "prefix": "rofile qualitatively and quantitatively similar to that of ", "from": "3424", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": ". mCPP has some similarities to nefazodone, but also has ago"}, {"to": "3475", "prefix": "milar to that of nefazodone. mCPP has some similarities to ", "from": "3466", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": ", but also has agonist activity at some serotonergic recepto"}, {"to": "3861", "prefix": "                 After oral administration of radiolabeled ", "from": "3852", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": ", the mean half-life of total label ranged between 11 and 24"}, {"to": "4347", "prefix": "\n                           \n                              ", "from": "4338", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "Nefazodone", "suffix": " is widely distributed in body tissues, including the centra"}, {"to": "4481", "prefix": ". In humans the volume of distribution of ", "from": "4472", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " ranges from 0.22 to 0.87 L"}, {"to": "4927", "prefix": "mL ", "from": "4918", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " is extensively "}, {"to": "5038", "prefix": "sma proteins in vitro. The administration of 200 mg BID of ", "from": "5029", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " for 1 week did not increase the fraction of unbound warfari"}, {"to": "5270", "prefix": ". While ", "from": "5261", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " did not alter the in vitro protein binding of chlorpromazin"}, {"to": "5478", "prefix": "or verapamil, it is unknown whether displacement of either ", "from": "5469", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " or these drugs occurs in vivo. There was a 5% decrease in t"}, {"to": "6024", "prefix": "                             Food delays the absorption of ", "from": "6015", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " and decreases the bioavailability of nefazodone by approxim"}, {"to": "6072", "prefix": "orption of nefazodone and decreases the bioavailability of ", "from": "6063", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " by approximately 20%.\n                           \n         "}, {"to": "6627", "prefix": " had no effect on steady-state ", "from": "6618", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " plasma concentrations.\n                           \n        "}, {"to": "7103", "prefix": "study of patients with liver cirrhosis, the AUC values for ", "from": "7094", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " and HO-NEF at steady state were approximately 25% greater t"}, {"to": "7690", "prefix": ", Cmax and AUC for ", "from": "7681", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " and hydroxynefazodone were up to twice as high in the older"}, {"to": "8021", "prefix": "ltiple doses.\n                              Treatment with ", "from": "8012", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " should be initiated at half the usual dose in elderly patie"}, {"to": "8850", "prefix": "      During its premarketing development, the efficacy of ", "from": "8841", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " was evaluated at doses within the therapeutic range in five"}, {"to": "9140", "prefix": " Among these trials, two demonstrated the effectiveness of ", "from": "9131", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": ", and two provided additional support for that conclusion.\n "}, {"to": "9293", "prefix": "     One trial was a 6 week dose-titration study comparing ", "from": "9284", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " in two dose ranges "}, {"to": "9511", "prefix": " second trial was an 8 week dose-titration study comparing ", "from": "9502", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " "}, {"to": "9667", "prefix": " placebo, all on a BID schedule. Both studies demonstrated ", "from": "9658", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": ", at doses titrated between 300 mg to 600 mg"}, {"to": "10176", "prefix": ". In the two supportive studies, ", "from": "10167", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " was titrated up to 500 or 600 mg"}, {"to": "10339", "prefix": "fifth study, the differentiation in response rates between ", "from": "10330", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " and placebo was not statistically significant. Three additi"}, {"to": "10466", "prefix": "tional trials were conducted using subtherapeutic doses of ", "from": "10457", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": ".\n                              Overall, approximately two t"}, {"to": "10942", "prefix": "essant drug product, additional clinical investigations of ", "from": "10933", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " have been conducted. These studies explored nefazodone"}, {"to": "11630", "prefix": "tients. These were 6 week, dose-titration trials comparing ", "from": "11621", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " "}, {"to": "11706", "prefix": " and placebo, on a BID schedule. In one study, ", "from": "11697", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " was superior to placebo. In this study, the mean modal dose"}, {"to": "11780", "prefix": "superior to placebo. In this study, the mean modal dose of ", "from": "11771", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " was 503 mg"}, {"to": "12097", "prefix": "other study, the differentiation in response rates between ", "from": "12088", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " and placebo was not statistically significant. This result "}, {"to": "12951", "prefix": " after a 16 week period of open treatment with ", "from": "12942", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " "}, {"to": "13006", "prefix": ". In one study, ", "from": "12997", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " was superior to placebo. In this study, patients "}, {"to": "13111", "prefix": " were randomized to continuation on ", "from": "13102", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " or placebo for an additional 36 weeks "}, {"to": "13279", "prefix": " for patients taking ", "from": "13270", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " compared to those on placebo. The second study was of appro"}, {"to": "439", "prefix": "ies have shown that nefazodone inhibits neuronal uptake of ", "from": "431", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "serotonin", "suffix": " and norepinephrine.\n                        Nefazodone occu"}, {"to": "458", "prefix": " that nefazodone inhibits neuronal uptake of serotonin and ", "from": "445", "name": "Norepinephrine", "fullId": "http://purl.bioontology.org/ontology/MESH/D009638", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "norepinephrine", "suffix": ".\n                        Nefazodone occupies central 5-HT2 "}, {"to": "912", "prefix": "and beta adrenergic, 5-HT1A, cholinergic, dopaminergic, or ", "from": "899", "name": "Benzodiazepines", "fullId": "http://purl.bioontology.org/ontology/MESH/D001569", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "benzodiazepine", "suffix": ".\n                     \n                     \n              "}, {"to": "1515", "prefix": "h nefazodone and its pharmacologically similar metabolite, ", "from": "1499", "name": "hydroxynefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092333", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "hydroxynefazodone", "suffix": ", exhibit nonlinear kinetics for both dose and time, with AU"}, {"to": "1853", "prefix": "osing with 50, 100, and 200 mg, the AUC for nefazodone and ", "from": "1837", "name": "hydroxynefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092333", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "hydroxynefazodone", "suffix": " increased by about 4 fold with an increase in dose from 200"}, {"to": "2129", "prefix": "00, and 150 mg, the accumulation ratios for nefazodone and ", "from": "2113", "name": "hydroxynefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092333", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "hydroxynefazodone", "suffix": " AUC, after 5 days of BID dosing relative to the first dose,"}, {"to": "3019", "prefix": "ts to characterize three metabolites identified in plasma, ", "from": "3003", "name": "hydroxynefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092333", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "hydroxynefazodone", "suffix": " "}, {"to": "7712", "prefix": ", Cmax and AUC for nefazodone and ", "from": "7696", "name": "hydroxynefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092333", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "hydroxynefazodone", "suffix": " were up to twice as high in the older patients. With multip"}, {"to": "5099", "prefix": "zodone for 1 week did not increase the fraction of unbound ", "from": "5092", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "warfarin", "suffix": " in subjects whose prothrombin times had been prolonged by w"}, {"to": "5166", "prefix": " in subjects whose prothrombin times had been prolonged by ", "from": "5159", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "warfarin", "suffix": " therapy to 120 to 150% of the laboratory control "}, {"to": "5129", "prefix": "ncrease the fraction of unbound warfarin in subjects whose ", "from": "5119", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "prothrombin", "suffix": " times had been prolonged by warfarin therapy to 120 to 150%"}, {"to": "5331", "prefix": "e nefazodone did not alter the in vitro protein binding of ", "from": "5318", "name": "Chlorpromazine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2403", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "chlorpromazine", "suffix": ", desipramine, diazepam, diphenylhydantoin, lidocaine, prazo"}, {"to": "5344", "prefix": " not alter the in vitro protein binding of chlorpromazine, ", "from": "5334", "name": "Desipramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003891", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "desipramine", "suffix": ", diazepam, diphenylhydantoin, lidocaine, prazosin, proprano"}, {"to": "5354", "prefix": "e in vitro protein binding of chlorpromazine, desipramine, ", "from": "5347", "name": "Diazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3322", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "diazepam", "suffix": ", diphenylhydantoin, lidocaine, prazosin, propranolol, or ve"}, {"to": "5373", "prefix": " protein binding of chlorpromazine, desipramine, diazepam, ", "from": "5357", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/MESH/D010672", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "diphenylhydantoin", "suffix": ", lidocaine, prazosin, propranolol, or verapamil, it is unkn"}, {"to": "5384", "prefix": " chlorpromazine, desipramine, diazepam, diphenylhydantoin, ", "from": "5376", "name": "Lidocaine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6387", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "lidocaine", "suffix": ", prazosin, propranolol, or verapamil, it is unknown whether"}, {"to": "5394", "prefix": "zine, desipramine, diazepam, diphenylhydantoin, lidocaine, ", "from": "5387", "name": "Prazosin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011224", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "prazosin", "suffix": ", propranolol, or verapamil, it is unknown whether displacem"}, {"to": "5407", "prefix": "pramine, diazepam, diphenylhydantoin, lidocaine, prazosin, ", "from": "5397", "name": "Propranolol", "fullId": "http://purl.bioontology.org/ontology/MESH/D011433", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "propranolol", "suffix": ", or verapamil, it is unknown whether displacement of either"}, {"to": "5421", "prefix": "m, diphenylhydantoin, lidocaine, prazosin, propranolol, or ", "from": "5413", "name": "Verapamil", "fullId": "http://purl.bioontology.org/ontology/RXNORM/11170", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "verapamil", "suffix": ", it is unknown whether displacement of either nefazodone or"}, {"to": "5571", "prefix": "in vivo. There was a 5% decrease in the protein binding of ", "from": "5561", "name": "Haloperidol", "fullId": "http://purl.bioontology.org/ontology/MESH/D006220", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "haloperidol", "suffix": "; this is probably of no clinical significance.\n            "}, {"to": "6538", "prefix": "", "from": "6529", "name": "Creatinine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003404", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "creatinine", "suffix": " clearances ranging from 7 to 60 mL"}, {"to": "9574", "prefix": ", ", "from": "9565", "name": "Imipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5691", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "imipramine", "suffix": " "}, {"to": "326", "prefix": "                  \n                        The efficacy of ", "from": "317", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "paroxetine", "suffix": " in the treatment of major depressive disorder, social anxie"}, {"to": "758", "prefix": "clinically relevant doses in humans have demonstrated that ", "from": "749", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "paroxetine", "suffix": " blocks the uptake of serotonin into human platelets. In vit"}, {"to": "868", "prefix": "n platelets. In vitro studies in animals also suggest that ", "from": "859", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "paroxetine", "suffix": " is a potent and highly selective inhibitor of neuronal sero"}, {"to": "1085", "prefix": "uptake. In vitro radioligand binding studies indicate that ", "from": "1076", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "paroxetine", "suffix": " has little affinity for muscarinic, alpha1-, alpha2-, beta-"}, {"to": "2058", "prefix": " after oral dosing of 30  mg tablets of ", "from": "2049", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "paroxetine", "suffix": " daily for 30  days. Paroxetine is extensively metabolized an"}, {"to": "2088", "prefix": "l dosing of 30  mg tablets of paroxetine daily for 30  days. ", "from": "2079", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "Paroxetine", "suffix": " is extensively metabolized and the metabolites are consider"}, {"to": "2245", "prefix": "ity in pharmacokinetics is observed with increasing doses. ", "from": "2236", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "Paroxetine", "suffix": " metabolism is mediated in part by CYP2D6, and the metabolit"}, {"to": "2415", "prefix": "d to some extent in the feces. Pharmacokinetic behavior of ", "from": "2406", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "paroxetine", "suffix": " has not been evaluated in subjects who are deficient in CYP"}, {"to": "2556", "prefix": ".\n                        In a meta-analysis of ", "from": "2547", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "paroxetine", "suffix": " from 4 studies done in healthy volunteers following multipl"}, {"to": "3076", "prefix": "\n                           \n                              ", "from": "3067", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "Paroxetine", "suffix": " is equally bioavailable from the oral suspension and tablet"}, {"to": "3390", "prefix": " received 30  mg tablets daily for 30  days, steady-state ", "from": "3381", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "paroxetine", "suffix": " concentrations were achieved by approximately 10  days for m"}, {"to": "4051", "prefix": "equence of the fact that 1 of the enzymes that metabolizes ", "from": "4042", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "paroxetine", "suffix": " is readily saturable.\n                              The eff"}, {"to": "4160", "prefix": "             The effects of food on the bioavailability of ", "from": "4151", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "paroxetine", "suffix": " were studied in subjects administered a single dose with an"}, {"to": "4481", "prefix": "rs post-dosing to 4.9  hours.\n                              ", "from": "4472", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "Paroxetine", "suffix": " distributes throughout the body, including the CNS, with on"}, {"to": "4641", "prefix": "                              Approximately 95% and 93% of ", "from": "4632", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "paroxetine", "suffix": " is bound to plasma protein at 100  ng"}, {"to": "4748", "prefix": "mL, respectively. Under clinical conditions, ", "from": "4739", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "paroxetine", "suffix": " concentrations would normally be less than 400  ng"}, {"to": "4813", "prefix": "mL. ", "from": "4804", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "Paroxetine", "suffix": " does not alter the in vitro protein binding of phenytoin or"}, {"to": "5423", "prefix": " after oral dosing of 30  mg tablets daily for 30  days of ", "from": "5414", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "Paroxetine", "suffix": "  hydrochloride. In steady-state dose proportionality studies"}, {"to": "5885", "prefix": " times greater than doubled.\n                              ", "from": "5876", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "Paroxetine", "suffix": " is extensively metabolized after oral administration. The p"}, {"to": "6324", "prefix": "compound at inhibiting serotonin uptake. The metabolism of ", "from": "6315", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "paroxetine", "suffix": " is accomplished in part by CYP2D6. Saturation of this enzym"}, {"to": "6457", "prefix": " clinical doses appears to account for the nonlinearity of ", "from": "6448", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "paroxetine", "suffix": " kinetics with increasing dose and increasing duration of tr"}, {"to": "6563", "prefix": "creasing duration of treatment. The role of this enzyme in ", "from": "6554", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "paroxetine", "suffix": " metabolism also suggests potential drug-drug interactions "}, {"to": "6832", "prefix": "        Approximately 64% of a 30-mg oral solution dose of ", "from": "6823", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "paroxetine", "suffix": " was excreted in the urine with 2% as the parent compound an"}, {"to": "8130", "prefix": "                        Increased plasma concentrations of ", "from": "8121", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "paroxetine", "suffix": " occur in subjects with renal and hepatic impairment. The me"}, {"to": "9297", "prefix": "          In a multiple-dose study in the elderly at daily ", "from": "9288", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "paroxetine", "suffix": " doses of 20, 30, and 40  mg, Cmin concentrations were about\n"}, {"to": "10202", "prefix": "             In vitro drug interaction studies reveal that ", "from": "10193", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "paroxetine", "suffix": " inhibits CYP2D6. Clinical drug interaction studies have bee"}, {"to": "10324", "prefix": "ave been performed with substrates of CYP2D6 and show that ", "from": "10315", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "paroxetine", "suffix": " can inhibit the metabolism of drugs metabolized by CYP2D6 i"}, {"to": "11342", "prefix": "               \n                           The efficacy of ", "from": "11333", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "paroxetine", "suffix": " as a treatment for major depressive disorder has been estab"}, {"to": "11529", "prefix": ". In these studies, ", "from": "11520", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "paroxetine", "suffix": " was shown to be significantly more effective than placebo i"}, {"to": "11814", "prefix": "-Severity of Illness. ", "from": "11805", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "Paroxetine", "suffix": " was significantly better than placebo in improvement of the"}, {"to": "12089", "prefix": "tients with major depressive disorder who had responded to ", "from": "12080", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "paroxetine", "suffix": "  "}, {"to": "12212", "prefix": "reatment phase and were then randomized to continuation on ", "from": "12203", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "paroxetine", "suffix": " or placebo for 1 year demonstrated a significantly lower re"}, {"to": "12313", "prefix": "ted a significantly lower relapse rate for patients taking ", "from": "12304", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "paroxetine", "suffix": " "}, {"to": "12798", "prefix": "          \n                           The effectiveness of ", "from": "12789", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "paroxetine", "suffix": " in the treatment of obsessive compulsive disorder "}, {"to": "13257", "prefix": "ients were treated with fixed doses of 20, 40, or 60  mg of ", "from": "13248", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "paroxetine", "suffix": ""}, {"to": "13305", "prefix": "day demonstrated that daily doses of ", "from": "13296", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "paroxetine", "suffix": " 40 and 60  mg are effective in the treatment of OCD. Patient"}, {"to": "13409", "prefix": "treatment of OCD. Patients receiving doses of 40 and 60  mg ", "from": "13400", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "paroxetine", "suffix": " experienced a mean reduction of approximately 6 and 7  point"}, {"to": "13702", "prefix": "ated patients. Study 2 was a flexible-dose study comparing ", "from": "13693", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "paroxetine", "suffix": " "}, {"to": "13807", "prefix": ". In this study, patients receiving ", "from": "13798", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "paroxetine", "suffix": " experienced a mean reduction of approximately 7  points on t"}, {"to": "14432", "prefix": "                      The long-term maintenance effects of ", "from": "14423", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "paroxetine", "suffix": " in OCD were demonstrated in a long-term extension to Study "}, {"to": "14537", "prefix": "term extension to Study 1. Patients who were responders on ", "from": "14528", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "paroxetine", "suffix": " during the 3-month double-blind phase and a 6-month extensi"}, {"to": "14624", "prefix": "h double-blind phase and a 6-month extension on open-label ", "from": "14615", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "paroxetine", "suffix": " "}, {"to": "14679", "prefix": " were randomized to either ", "from": "14670", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "paroxetine", "suffix": " or placebo in a 6-month double-blind relapse prevention pha"}, {"to": "14776", "prefix": "ble-blind relapse prevention phase. Patients randomized to ", "from": "14767", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "paroxetine", "suffix": " were significantly less likely to relapse than comparably t"}, {"to": "15255", "prefix": "          \n                           The effectiveness of ", "from": "15246", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "paroxetine", "suffix": " in the treatment of panic disorder was demonstrated in thre"}, {"to": "15523", "prefix": ", with or without agoraphobia. In these studies, ", "from": "15514", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "paroxetine", "suffix": " was shown to be significantly more effective than placebo i"}, {"to": "15847", "prefix": "dose-range finding study; patients were treated with fixed ", "from": "15838", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "paroxetine", "suffix": " doses of 10, 20, or 40  mg"}, {"to": "16020", "prefix": "day group. At endpoint, 76% of patients receiving ", "from": "16011", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "paroxetine", "suffix": " 40  mg"}, {"to": "16190", "prefix": "       Study 2 was a 12-week flexible-dose study comparing ", "from": "16181", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "paroxetine", "suffix": " "}, {"to": "16254", "prefix": " and placebo. At endpoint, 51% of ", "from": "16245", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "paroxetine", "suffix": " patients were free of panic attacks compared to 32% of plac"}, {"to": "16422", "prefix": "       Study 3 was a 12-week flexible-dose study comparing ", "from": "16413", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "paroxetine", "suffix": " "}, {"to": "16566", "prefix": "ized cognitive behavioral therapy. At endpoint, 33% of the ", "from": "16557", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "paroxetine", "suffix": "-treated patients showed a reduction to 0 or 1 panic attacks"}, {"to": "16732", "prefix": "\n                        In both Studies 2 and 3, the mean ", "from": "16723", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "paroxetine", "suffix": " dose for completers at endpoint was approximately 40  mg"}, {"to": "16806", "prefix": "day of ", "from": "16797", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "paroxetine", "suffix": ".\n                        Long-term maintenance effects of p"}, {"to": "16875", "prefix": ".\n                        Long-term maintenance effects of ", "from": "16866", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "paroxetine", "suffix": " in panic disorder were demonstrated in an extension to Stud"}, {"to": "17093", "prefix": "nth double-blind extension phase were randomized to either ", "from": "17084", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "paroxetine", "suffix": " "}, {"to": "17213", "prefix": "ble-blind relapse prevention phase. Patients randomized to ", "from": "17204", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "paroxetine", "suffix": " were significantly less likely to relapse than comparably t"}, {"to": "17846", "prefix": "          \n                           The effectiveness of ", "from": "17837", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "paroxetine", "suffix": " in the treatment of social anxiety disorder was demonstrate"}, {"to": "18097", "prefix": ". In these studies, the effectiveness of ", "from": "18088", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "paroxetine", "suffix": " compared to placebo was evaluated on the basis of "}, {"to": "18459", "prefix": "      Studies 1 and 2 were flexible-dose studies comparing ", "from": "18450", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "paroxetine", "suffix": " "}, {"to": "18503", "prefix": " and placebo. ", "from": "18494", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "Paroxetine", "suffix": " demonstrated statistically significant superiority over pla"}, {"to": "18731", "prefix": " In Study  1, for patients who completed to week  12, 69% of ", "from": "18722", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "paroxetine", "suffix": "-treated patients compared to 29% of placebo-treated patient"}, {"to": "18900", "prefix": "udy 2, CGI Improvement responders were 77% and 42% for the ", "from": "18891", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "paroxetine", "suffix": "- and placebo-treated patients, respectively.\n              "}, {"to": "19024", "prefix": "               Study 3 was a 12-week study comparing fixed ", "from": "19015", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "paroxetine", "suffix": " doses of 20, 40, or 60  mg"}, {"to": "19079", "prefix": "day with placebo. ", "from": "19070", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "Paroxetine", "suffix": " 20  mg was demonstrated to be significantly superior to plac"}, {"to": "19929", "prefix": "          \n                           The effectiveness of ", "from": "19920", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "paroxetine", "suffix": " in the treatment of Generalized Anxiety Disorder "}, {"to": "20219", "prefix": "               Study 1 was an 8-week study comparing fixed ", "from": "20210", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "paroxetine", "suffix": " doses of 20  mg or 40  mg"}, {"to": "20299", "prefix": "day with placebo. Doses of 20  mg or 40  mg of ", "from": "20290", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "paroxetine", "suffix": " were both demonstrated to be significantly superior to plac"}, {"to": "20636", "prefix": "               Study  2 was a flexible-dose study comparing ", "from": "20627", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "paroxetine", "suffix": " "}, {"to": "20683", "prefix": " and placebo. ", "from": "20674", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "Paroxetine", "suffix": " demonstrated statistically significant superiority over pla"}, {"to": "20864", "prefix": " total score. A third study, also flexible-dose comparing ", "from": "20855", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "paroxetine", "suffix": " "}, {"to": "20960", "prefix": "d not demonstrate statistically significant superiority of ", "from": "20951", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "paroxetine", "suffix": " over placebo on the Hamilton Rating Scale for Anxiety "}, {"to": "21498", "prefix": "day of ", "from": "21489", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "paroxetine", "suffix": ", were randomized to continuation of paroxetine at their sam"}, {"to": "21545", "prefix": "day of paroxetine, were randomized to continuation of ", "from": "21536", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "paroxetine", "suffix": " at their same dose, or to placebo, for up to 24  weeks of ob"}, {"to": "22024", "prefix": "awal due to lack of efficacy. Patients receiving continued ", "from": "22015", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "paroxetine", "suffix": " experienced a significantly lower relapse rate over the sub"}, {"to": "1861", "prefix": "macokinetics\n                     \n                        ", "from": "1838", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017374", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "Paroxetine hydrochloride", "suffix": " is completely absorbed after oral dosing of a solution of t"}, {"to": "3192", "prefix": " oral suspension and tablet.\n                              ", "from": "3169", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017374", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "Paroxetine hydrochloride", "suffix": " is completely absorbed after oral dosing of a solution of t"}, {"to": "647", "prefix": "s system resulting from inhibition of neuronal reuptake of ", "from": "639", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "serotonin", "suffix": " "}, {"to": "789", "prefix": "ans have demonstrated that paroxetine blocks the uptake of ", "from": "781", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "serotonin", "suffix": " into human platelets. In vitro studies in animals also sugg"}, {"to": "933", "prefix": "ine is a potent and highly selective inhibitor of neuronal ", "from": "925", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "serotonin", "suffix": " reuptake and has only very weak effects on norepinephrine a"}, {"to": "6287", "prefix": "50 the potency of the parent compound at inhibiting ", "from": "6279", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "serotonin", "suffix": " uptake. The metabolism of paroxetine is accomplished in par"}, {"to": "675", "prefix": "5-hydroxy-tryptamine, ", "from": "672", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/MESH/D012701", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "5-HT", "suffix": ""}, {"to": "669", "prefix": "5-hydroxy-", "from": "660", "name": "tryptamine", "fullId": "http://purl.bioontology.org/ontology/MESH/C030820", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "tryptamine", "suffix": ", 5-HT"}, {"to": "991", "prefix": "ronal serotonin reuptake and has only very weak effects on ", "from": "978", "name": "Norepinephrine", "fullId": "http://purl.bioontology.org/ontology/MESH/D009638", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "norepinephrine", "suffix": " and dopamine neuronal reuptake. In vitro radioligand bindin"}, {"to": "1004", "prefix": "ptake and has only very weak effects on norepinephrine and ", "from": "997", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D004298", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "dopamine", "suffix": " neuronal reuptake. In vitro radioligand binding studies ind"}, {"to": "1165", "prefix": "ffinity for muscarinic, alpha1-, alpha2-, beta-adrenergic- ", "from": "1158", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D004298", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "dopamine", "suffix": " "}, {"to": "1202", "prefix": "-, 5-HT1-, 5-HT2-, and ", "from": "1194", "name": "Histamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5333", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "histamine", "suffix": " "}, {"to": "4870", "prefix": " Paroxetine does not alter the in vitro protein binding of ", "from": "4862", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "phenytoin", "suffix": " or warfarin. \n                              \n              "}, {"to": "4882", "prefix": "oes not alter the in vitro protein binding of phenytoin or ", "from": "4875", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "warfarin", "suffix": ". \n                              \n                          "}, {"to": "6088", "prefix": "nd methylation, which are readily cleared. Conjugates with ", "from": "6074", "name": "Glucuronic Acid", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1426906", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "glucuronic acid", "suffix": " and sulfate predominate, and major metabolites have been is"}, {"to": "8242", "prefix": "mpairment. The mean plasma concentrations in patients with ", "from": "8233", "name": "Creatinine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003404", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "creatinine", "suffix": " clearance below 30  mL"}, {"to": "8361", "prefix": "imes greater than seen in normal volunteers. Patients with ", "from": "8352", "name": "Creatinine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003404", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "creatinine", "suffix": " clearance of 30 to 60  mL"}, {"to": "10404", "prefix": "it the metabolism of drugs metabolized by CYP2D6 including ", "from": "10394", "name": "Desipramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003891", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "desipramine", "suffix": ", risperidone, and atomoxetine "}, {"to": "10417", "prefix": "lism of drugs metabolized by CYP2D6 including desipramine, ", "from": "10407", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "risperidone", "suffix": ", and atomoxetine "}, {"to": "10434", "prefix": "abolized by CYP2D6 including desipramine, risperidone, and ", "from": "10424", "name": "atomoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C041930", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "atomoxetine", "suffix": " "}, {"to": "13740", "prefix": " with ", "from": "13729", "name": "Clomipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2597", "setId": "08320ea3-8f93-6f04-5d1c-f69af3eb5a81", "exact": "clomipramine", "suffix": " "}, {"to": "154", "prefix": "  \n                  The basic pharmacological activity of ", "from": "143", "name": "Thioridazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D013881", "setId": "56b3f4c2-52af-4947-b225-6808ae9f26f5", "exact": "thioridazine", "suffix": " is similar to that of other phenothiazines, but is associat"}, {"to": "297", "prefix": "mal extrapyramidal stimulation.\n                  However, ", "from": "286", "name": "Thioridazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D013881", "setId": "56b3f4c2-52af-4947-b225-6808ae9f26f5", "exact": "thioridazine", "suffix": " has been shown to prolong the QTc interval in a dose depend"}, {"to": "536", "prefix": "as Torsades de pointes type arrhythmias. Due to this risk, ", "from": "525", "name": "Thioridazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D013881", "setId": "56b3f4c2-52af-4947-b225-6808ae9f26f5", "exact": "thioridazine", "suffix": " is indicated only for schizophrenic patients who have not b"}, {"to": "755", "prefix": ". However, the prescriber should be aware that ", "from": "744", "name": "Thioridazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D013881", "setId": "56b3f4c2-52af-4947-b225-6808ae9f26f5", "exact": "thioridazine", "suffix": " has not been systematically evaluated in controlled trials "}, {"to": "213", "prefix": "                      Concomitant use with SSRIs, SNRIs or ", "from": "204", "name": "Tryptophan", "fullId": "http://purl.bioontology.org/ontology/MESH/D014364", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "Tryptophan", "suffix": " is not recommended "}, {"to": "348", "prefix": "NSAIDs, ", "from": "342", "name": "Aspirin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1191", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "Aspirin", "suffix": ", Warfarin"}, {"to": "2703", "prefix": "NSAIDs, ", "from": "2697", "name": "Aspirin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1191", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "Aspirin", "suffix": ", Warfarin, etc."}, {"to": "3123", "prefix": "leeding have also shown that concurrent use of an NSAID or ", "from": "3117", "name": "Aspirin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1191", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "aspirin", "suffix": " may potentiate the risk of bleeding. Altered anticoagulant "}, {"to": "358", "prefix": "NSAIDs, Aspirin, ", "from": "351", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "Warfarin", "suffix": ""}, {"to": "2713", "prefix": "NSAIDs, Aspirin, ", "from": "2706", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "Warfarin", "suffix": ", etc."}, {"to": "3294", "prefix": "been reported when SSRIs and SNRIs are coadministered with ", "from": "3287", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "warfarin", "suffix": ".  Patients receiving warfarin therapy should be carefully m"}, {"to": "3324", "prefix": "NRIs are coadministered with warfarin.  Patients receiving ", "from": "3317", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "warfarin", "suffix": " therapy should be carefully monitored when Lexapro is initi"}, {"to": "7043", "prefix": "          \n                     \n                     7.13 ", "from": "7036", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "Warfarin", "suffix": " \n\n                     \n                        Administrat"}, {"to": "7198", "prefix": "alopram for 21 days did not affect the pharmacokinetics of ", "from": "7191", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "warfarin", "suffix": ", a CYP3A4 substrate. Prothrombin time was increased by 5%, "}, {"to": "1373", "prefix": "             There have been rare postmarketing reports of ", "from": "1365", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "serotonin", "suffix": " syndrome with use of an SSRI and a triptan. If concomitant "}, {"to": "2777", "prefix": "\n\n                     \n                        ", "from": "2769", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "Serotonin", "suffix": " release by platelets plays an important role in hemostasis."}, {"to": "3001", "prefix": "tion between use of psychotropic drugs that interfere with ", "from": "2993", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "serotonin", "suffix": " reuptake and the occurrence of upper gastrointestinal bleed"}, {"to": "1453", "prefix": " use of an SSRI and a triptan. If concomitant treatment of ", "from": "1447", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "Lexapro", "suffix": " with a triptan is clinically warranted, careful observation"}, {"to": "1927", "prefix": " \n                        Given the primary CNS effects of ", "from": "1916", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": ", caution should be used when it is taken in combination wit"}, {"to": "2276", "prefix": "  \n\n                     \n                        Although ", "from": "2270", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "Lexapro", "suffix": " did not potentiate the cognitive and motor effects of alcoh"}, {"to": "2445", "prefix": "otropic medications, the use of alcohol by patients taking ", "from": "2439", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "Lexapro", "suffix": " is not recommended.\n\n                     \n                "}, {"to": "3375", "prefix": "eiving warfarin therapy should be carefully monitored when ", "from": "3369", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "Lexapro", "suffix": " is initiated or discontinued.\n\n                     \n      "}, {"to": "3717", "prefix": "day racemic ", "from": "3708", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "citalopram", "suffix": ", combined administration of 400 mg twice a day cimetidine f"}, {"to": "3824", "prefix": "ice a day cimetidine for 8 days resulted in an increase in ", "from": "3815", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "citalopram", "suffix": " AUC and Cmax of 43% and 39%, respectively. The clinical sig"}, {"to": "4232", "prefix": "day racemic ", "from": "4223", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "citalopram", "suffix": ", combined administration of citalopram and digoxin "}, {"to": "4271", "prefix": "day racemic citalopram, combined administration of ", "from": "4262", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "citalopram", "suffix": " and digoxin "}, {"to": "4376", "prefix": "id not significantly affect the pharmacokinetics of either ", "from": "4367", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "citalopram", "suffix": " or digoxin.\n\n                     \n                     \n  "}, {"to": "4667", "prefix": "      \n                        Coadministration of racemic ", "from": "4658", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "citalopram", "suffix": " "}, {"to": "4792", "prefix": " had no significant effect on the pharmacokinetics of ", "from": "4783", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "citalopram", "suffix": " or lithium. Nevertheless, plasma lithium levels should be m"}, {"to": "5024", "prefix": "e. Because lithium may enhance the serotonergic effects of ", "from": "5013", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": ", caution should be exercised when Lexapro and lithium are c"}, {"to": "5066", "prefix": " effects of escitalopram, caution should be exercised when ", "from": "5060", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "Lexapro", "suffix": " and lithium are coadministered.\n\n                     \n    "}, {"to": "5445", "prefix": " single dose of pimozide 2 mg co-administered with racemic ", "from": "5436", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "citalopram", "suffix": " 40 mg given once daily for 11 days was associated with a me"}, {"to": "5608", "prefix": "ximately 10 msec compared to pimozide given alone. Racemic ", "from": "5599", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "citalopram", "suffix": " did not alter the mean AUC or Cmax of pimozide. The mechani"}, {"to": "6243", "prefix": "e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, ", "from": "6234", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "citalopram", "suffix": ", escitalopram"}, {"to": "6257", "prefix": "uoxetine, fluvoxamine, paroxetine, sertraline, citalopram, ", "from": "6246", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": ""}, {"to": "6626", "prefix": "                        Combined administration of racemic ", "from": "6617", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "citalopram", "suffix": " "}, {"to": "6830", "prefix": "ine. The effect of theophylline on the pharmacokinetics of ", "from": "6821", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "citalopram", "suffix": " was not evaluated.\n\n                     \n                 "}, {"to": "7138", "prefix": "day racemic ", "from": "7129", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "citalopram", "suffix": " for 21 days did not affect the pharmacokinetics of warfarin"}, {"to": "7597", "prefix": "                        Combined administration of racemic ", "from": "7588", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "citalopram", "suffix": " "}, {"to": "7791", "prefix": "tics of carbamazepine, a CYP3A4 substrate. Although trough ", "from": "7782", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "citalopram", "suffix": " plasma levels were unaffected, given the enzyme-inducing pr"}, {"to": "7957", "prefix": "ibility that carbamazepine might increase the clearance of ", "from": "7946", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": " should be considered if the two drugs are coadministered.\n\n"}, {"to": "8304", "prefix": "                        Combined administration of racemic ", "from": "8295", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "citalopram", "suffix": " "}, {"to": "8471", "prefix": "id not significantly affect the pharmacokinetics of either ", "from": "8462", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "citalopram", "suffix": " or triazolam.\n\n                     \n                     \n"}, {"to": "8777", "prefix": "                        Combined administration of racemic ", "from": "8768", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "citalopram", "suffix": " "}, {"to": "8980", "prefix": ", and did not significantly affect the pharmacokinetics of ", "from": "8971", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "citalopram", "suffix": ".\n\n                     \n                     \n             "}, {"to": "9363", "prefix": "h a CYP3A4 substrate and a potent inhibitor of CYP3A4, and ", "from": "9352", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": " "}, {"to": "9443", "prefix": "did not affect the pharmacokinetics of either ritonavir or ", "from": "9432", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": ".\n\n                     \n                     \n             "}, {"to": "9849", "prefix": "2C19 are the primary enzymes involved in the metabolism of ", "from": "9838", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": ". However, coadministration of escitalopram "}, {"to": "9892", "prefix": "e metabolism of escitalopram. However, coadministration of ", "from": "9881", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": " "}, {"to": "10020", "prefix": "P3A4, did not significantly affect the pharmacokinetics of ", "from": "10009", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": ". Because escitalopram is metabolized by multiple enzyme sys"}, {"to": "10042", "prefix": "antly affect the pharmacokinetics of escitalopram. Because ", "from": "10031", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": " is metabolized by multiple enzyme systems, inhibition of a "}, {"to": "10157", "prefix": "inhibition of a single enzyme may not appreciably decrease ", "from": "10146", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": " clearance.\n\n                     \n                     \n   "}, {"to": "10538", "prefix": "   In vitro studies did not reveal an inhibitory effect of ", "from": "10527", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": " on CYP2D6. In addition, steady state levels of racemic cita"}, {"to": "10604", "prefix": "ram on CYP2D6. In addition, steady state levels of racemic ", "from": "10595", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "citalopram", "suffix": " were not significantly different in poor metabolizers and e"}, {"to": "10741", "prefix": " CYP2D6 metabolizers after multiple-dose administration of ", "from": "10732", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "citalopram", "suffix": ", suggesting that coadministration, with escitalopram, of a "}, {"to": "10794", "prefix": "tion of citalopram, suggesting that coadministration, with ", "from": "10783", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": ", of a drug that inhibits CYP2D6, is unlikely to have clinic"}, {"to": "10894", "prefix": "2D6, is unlikely to have clinically significant effects on ", "from": "10883", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": " metabolism. However, there are limited in vivo data suggest"}, {"to": "11008", "prefix": "vivo data suggesting a modest CYP2D6 inhibitory effect for ", "from": "10997", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": ", i.e., coadministration of escitalopram "}, {"to": "11048", "prefix": "ibitory effect for escitalopram, i.e., coadministration of ", "from": "11037", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": " "}, {"to": "11373", "prefix": "ertheless, caution is indicated in the coadministration of ", "from": "11362", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": " and drugs metabolized by CYP2D6.\n\n                     \n   "}, {"to": "11686", "prefix": "day ", "from": "11680", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "Lexapro", "suffix": " for 21 days in healthy volunteers resulted in a 50% increas"}, {"to": "11975", "prefix": "ated with decreased cardioselectivity. Coadministration of ", "from": "11969", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "Lexapro", "suffix": " and metoprolol had no clinically significant effects on blo"}, {"to": "12400", "prefix": "ere are no clinical studies of the combined use of ECT and ", "from": "12389", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": ".\n\n                     \n                     \n             "}, {"to": "3600", "prefix": "           \n                     \n                     7.7 ", "from": "3591", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002927", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "Cimetidine", "suffix": " \n\n                     \n                        In subjects"}, {"to": "3775", "prefix": " citalopram, combined administration of 400 mg twice a day ", "from": "3766", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002927", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "cimetidine", "suffix": " for 8 days resulted in an increase in citalopram AUC and Cm"}, {"to": "4115", "prefix": "           \n                     \n                     7.8 ", "from": "4109", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004077", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "Digoxin", "suffix": " \n\n                     \n                        In subjects"}, {"to": "4283", "prefix": "emic citalopram, combined administration of citalopram and ", "from": "4277", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004077", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "digoxin", "suffix": " "}, {"to": "4387", "prefix": "cantly affect the pharmacokinetics of either citalopram or ", "from": "4381", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004077", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "digoxin", "suffix": ".\n\n                     \n                     \n             "}, {"to": "5292", "prefix": "          \n                     \n                     7.10 ", "from": "5285", "name": "Pimozide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8331", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "Pimozide", "suffix": " and Celexa \n\n                     \n                        "}, {"to": "5400", "prefix": "                   In a controlled study, a single dose of ", "from": "5393", "name": "Pimozide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8331", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "pimozide", "suffix": " 2 mg co-administered with racemic citalopram 40 mg given on"}, {"to": "5576", "prefix": "ncrease in QTc values of approximately 10 msec compared to ", "from": "5569", "name": "Pimozide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8331", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "pimozide", "suffix": " given alone. Racemic citalopram did not alter the mean AUC "}, {"to": "5655", "prefix": ". Racemic citalopram did not alter the mean AUC or Cmax of ", "from": "5648", "name": "Pimozide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8331", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "pimozide", "suffix": ". The mechanism of this pharmacodynamic interaction is not k"}, {"to": "5303", "prefix": "                   \n                     7.10 Pimozide and ", "from": "5298", "name": "Celexa", "fullId": "http://purl.bioontology.org/ontology/RXNORM/215928", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "Celexa", "suffix": " \n\n                     \n                        In a contro"}, {"to": "5917", "prefix": "          \n                     \n                     7.11 ", "from": "5907", "name": "Sumatriptan", "fullId": "http://purl.bioontology.org/ontology/MESH/D018170", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "Sumatriptan", "suffix": "\n\n                     \n                        There have b"}, {"to": "6121", "prefix": "lexia, and incoordination following the use of an SSRI and ", "from": "6111", "name": "Sumatriptan", "fullId": "http://purl.bioontology.org/ontology/MESH/D018170", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "sumatriptan", "suffix": ". If concomitant treatment with sumatriptan and an SSRI "}, {"to": "6164", "prefix": " of an SSRI and sumatriptan. If concomitant treatment with ", "from": "6154", "name": "Sumatriptan", "fullId": "http://purl.bioontology.org/ontology/MESH/D018170", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "sumatriptan", "suffix": " and an SSRI "}, {"to": "6194", "prefix": "e.g., ", "from": "6185", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "fluoxetine", "suffix": ", fluvoxamine, paroxetine, sertraline, citalopram, escitalop"}, {"to": "6207", "prefix": "e.g., fluoxetine, ", "from": "6197", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "fluvoxamine", "suffix": ", paroxetine, sertraline, citalopram, escitalopram"}, {"to": "6219", "prefix": "e.g., fluoxetine, fluvoxamine, ", "from": "6210", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "paroxetine", "suffix": ", sertraline, citalopram, escitalopram"}, {"to": "6231", "prefix": "e.g., fluoxetine, fluvoxamine, paroxetine, ", "from": "6222", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "sertraline", "suffix": ", citalopram, escitalopram"}, {"to": "6532", "prefix": "          \n                     \n                     7.12 ", "from": "6521", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10438", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "Theophylline", "suffix": " \n\n                     \n                        Combined ad"}, {"to": "6688", "prefix": " and the CYP1A2 substrate ", "from": "6677", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10438", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "theophylline", "suffix": " "}, {"to": "6764", "prefix": " did not affect the pharmacokinetics of ", "from": "6753", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10438", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "theophylline", "suffix": ". The effect of theophylline on the pharmacokinetics of cita"}, {"to": "6792", "prefix": "affect the pharmacokinetics of theophylline. The effect of ", "from": "6781", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10438", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "theophylline", "suffix": " on the pharmacokinetics of citalopram was not evaluated.\n\n "}, {"to": "7231", "prefix": "fect the pharmacokinetics of warfarin, a CYP3A4 substrate. ", "from": "7221", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "Prothrombin", "suffix": " time was increased by 5%, the clinical significance of whic"}, {"to": "7503", "prefix": "          \n                     \n                     7.14 ", "from": "7491", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "Carbamazepine", "suffix": " \n\n                     \n                        Combined ad"}, {"to": "7639", "prefix": " and ", "from": "7627", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "carbamazepine", "suffix": " "}, {"to": "7743", "prefix": " did not significantly affect the pharmacokinetics of ", "from": "7731", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "carbamazepine", "suffix": ", a CYP3A4 substrate. Although trough citalopram plasma leve"}, {"to": "7876", "prefix": "s were unaffected, given the enzyme-inducing properties of ", "from": "7864", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "carbamazepine", "suffix": ", the possibility that carbamazepine might increase the clea"}, {"to": "7912", "prefix": "inducing properties of carbamazepine, the possibility that ", "from": "7900", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "carbamazepine", "suffix": " might increase the clearance of escitalopram should be cons"}, {"to": "8210", "prefix": "          \n                     \n                     7.15 ", "from": "8202", "name": "Triazolam", "fullId": "http://purl.bioontology.org/ontology/MESH/D014229", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "Triazolam", "suffix": " \n\n                     \n                        Combined ad"}, {"to": "8375", "prefix": " and the CYP3A4 substrate ", "from": "8367", "name": "Triazolam", "fullId": "http://purl.bioontology.org/ontology/MESH/D014229", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "triazolam", "suffix": " "}, {"to": "8484", "prefix": "cantly affect the pharmacokinetics of either citalopram or ", "from": "8476", "name": "Triazolam", "fullId": "http://purl.bioontology.org/ontology/MESH/D014229", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "triazolam", "suffix": ".\n\n                     \n                     \n             "}, {"to": "8683", "prefix": "          \n                     \n                     7.16 ", "from": "8672", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "Ketoconazole", "suffix": " \n\n                     \n                        Combined ad"}, {"to": "8802", "prefix": " and ", "from": "8791", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "ketoconazole", "suffix": " "}, {"to": "8882", "prefix": ", a potent CYP3A4 inhibitor, decreased the Cmax and AUC of ", "from": "8871", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "ketoconazole", "suffix": " by 21% and 10%, respectively, and did not significantly aff"}, {"to": "9176", "prefix": "          \n                     \n                     7.17 ", "from": "9168", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "Ritonavir", "suffix": " \n\n                     \n                        Combined ad"}, {"to": "9278", "prefix": "               Combined administration of a single dose of ", "from": "9270", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "ritonavir", "suffix": " "}, {"to": "9427", "prefix": " did not affect the pharmacokinetics of either ", "from": "9419", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "ritonavir", "suffix": " or escitalopram.\n\n                     \n                   "}, {"to": "9914", "prefix": " and ", "from": "9906", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "ritonavir", "suffix": " "}, {"to": "11118", "prefix": " with the tricyclic antidepressant ", "from": "11108", "name": "Desipramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003891", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "desipramine", "suffix": " "}, {"to": "11243", "prefix": "ed in a 40% increase in Cmax and a 100% increase in AUC of ", "from": "11233", "name": "Desipramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003891", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "desipramine", "suffix": ". The clinical significance of this finding is unknown. Neve"}, {"to": "11602", "prefix": "          \n                     \n                     7.20 ", "from": "11593", "name": "Metoprolol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6918", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "Metoprolol", "suffix": " \n\n                     \n                        Administrat"}, {"to": "11821", "prefix": "max and 82% increase in AUC of the beta-adrenergic blocker ", "from": "11812", "name": "Metoprolol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6918", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "metoprolol", "suffix": " "}, {"to": "11878", "prefix": ". Increased ", "from": "11869", "name": "Metoprolol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6918", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "metoprolol", "suffix": " plasma levels have been associated with decreased cardiosel"}, {"to": "11990", "prefix": "creased cardioselectivity. Coadministration of Lexapro and ", "from": "11981", "name": "Metoprolol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6918", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "metoprolol", "suffix": " had no clinically significant effects on blood pressure or "}, {"to": "279", "prefix": "sm of Action\n                     \n                        ", "from": "269", "name": "terbinafine", "fullId": "http://purl.bioontology.org/ontology/MESH/C041359", "setId": "7c6c1494-fb92-4442-bcff-764b77397495", "exact": "Terbinafine", "suffix": " is an allylamine antifungal [see Clinical Pharmacology "}, {"to": "627", "prefix": "          \n                        The pharmacodynamics of ", "from": "621", "name": "terbinafine", "fullId": "http://purl.bioontology.org/ontology/MESH/C041359", "setId": "7c6c1494-fb92-4442-bcff-764b77397495", "exact": "Lamisil", "suffix": " Tablets is unknown. \n                     \n                "}, {"to": "942", "prefix": "   \n                        Following oral administration, ", "from": "932", "name": "terbinafine", "fullId": "http://purl.bioontology.org/ontology/MESH/C041359", "setId": "7c6c1494-fb92-4442-bcff-764b77397495", "exact": "terbinafine", "suffix": " is well absorbed "}, {"to": "1001", "prefix": " and the bioavailability of ", "from": "995", "name": "terbinafine", "fullId": "http://purl.bioontology.org/ontology/MESH/C041359", "setId": "7c6c1494-fb92-4442-bcff-764b77397495", "exact": "Lamisil", "suffix": " Tablets as a result of first-pass metabolism is approximate"}, {"to": "1233", "prefix": "mL. An increase in the AUC of ", "from": "1223", "name": "terbinafine", "fullId": "http://purl.bioontology.org/ontology/MESH/C041359", "setId": "7c6c1494-fb92-4442-bcff-764b77397495", "exact": "terbinafine", "suffix": " of less than 20% is observed when Lamisil  Tablets are  admin"}, {"to": "1275", "prefix": "n the AUC of terbinafine of less than 20% is observed when ", "from": "1269", "name": "terbinafine", "fullId": "http://purl.bioontology.org/ontology/MESH/C041359", "setId": "7c6c1494-fb92-4442-bcff-764b77397495", "exact": "Lamisil", "suffix": "  Tablets are  administered with food. \n                      "}, {"to": "1359", "prefix": "dministered with food. \n                        In plasma, ", "from": "1349", "name": "terbinafine", "fullId": "http://purl.bioontology.org/ontology/MESH/C041359", "setId": "7c6c1494-fb92-4442-bcff-764b77397495", "exact": "terbinafine", "suffix": " is "}, {"to": "1520", "prefix": " in comparison to a single dose, the peak concentration of ", "from": "1510", "name": "terbinafine", "fullId": "http://purl.bioontology.org/ontology/MESH/C041359", "setId": "7c6c1494-fb92-4442-bcff-764b77397495", "exact": "terbinafine", "suffix": " is 25% higher and plasma AUC increases by a factor of 2.5; "}, {"to": "1674", "prefix": "36 hours. ", "from": "1664", "name": "terbinafine", "fullId": "http://purl.bioontology.org/ontology/MESH/C041359", "setId": "7c6c1494-fb92-4442-bcff-764b77397495", "exact": "Terbinafine", "suffix": " is distributed to the sebum and skin. A terminal half-life "}, {"to": "1800", "prefix": "ife of 200-400 hours may represent the slow elimination of ", "from": "1790", "name": "terbinafine", "fullId": "http://purl.bioontology.org/ontology/MESH/C041359", "setId": "7c6c1494-fb92-4442-bcff-764b77397495", "exact": "terbinafine", "suffix": " from tissues such as skin and adipose. Prior to excretion, "}, {"to": "1871", "prefix": "from tissues such as skin and adipose. Prior to excretion, ", "from": "1861", "name": "terbinafine", "fullId": "http://purl.bioontology.org/ontology/MESH/C041359", "setId": "7c6c1494-fb92-4442-bcff-764b77397495", "exact": "terbinafine", "suffix": " is extensively metabolized  by at least 7 CYP isoenzymes wit"}, {"to": "2092", "prefix": "e been identified that have antifungal activity similar to ", "from": "2082", "name": "terbinafine", "fullId": "http://purl.bioontology.org/ontology/MESH/C041359", "setId": "7c6c1494-fb92-4442-bcff-764b77397495", "exact": "terbinafine", "suffix": ".   Approximately 70% of the administered dose is eliminated "}, {"to": "2308", "prefix": " or hepatic cirrhosis, the clearance of ", "from": "2298", "name": "terbinafine", "fullId": "http://purl.bioontology.org/ontology/MESH/C041359", "setId": "7c6c1494-fb92-4442-bcff-764b77397495", "exact": "terbinafine", "suffix": " is decreased by approximately 50% compared to normal volunt"}, {"to": "2428", "prefix": "mal volunteers. No effect of gender on the blood levels of ", "from": "2418", "name": "terbinafine", "fullId": "http://purl.bioontology.org/ontology/MESH/C041359", "setId": "7c6c1494-fb92-4442-bcff-764b77397495", "exact": "terbinafine", "suffix": " was detected in clinical trials. No clinically relevant age"}, {"to": "2559", "prefix": "dependent changes in steady-state plasma concentrations of ", "from": "2549", "name": "terbinafine", "fullId": "http://purl.bioontology.org/ontology/MESH/C041359", "setId": "7c6c1494-fb92-4442-bcff-764b77397495", "exact": "terbinafine", "suffix": " have been reported.\n                     \n                 "}, {"to": "2838", "prefix": "Microbiology\n                     \n                        ", "from": "2828", "name": "terbinafine", "fullId": "http://purl.bioontology.org/ontology/MESH/C041359", "setId": "7c6c1494-fb92-4442-bcff-764b77397495", "exact": "Terbinafine", "suffix": ",  an allylamine antifungal, inhibits biosynthesis of ergoste"}, {"to": "3293", "prefix": "ntration of the drug and the fungal species test in vitro, ", "from": "3269", "name": "terbinafine", "fullId": "http://purl.bioontology.org/ontology/MESH/C041359", "setId": "7c6c1494-fb92-4442-bcff-764b77397495", "exact": "terbinafine hydrochloride", "suffix": " may be fungicidal. However, the clinical significance of in"}, {"to": "3412", "prefix": "cance of in vitro data is unknown.\n                        ", "from": "3402", "name": "terbinafine", "fullId": "http://purl.bioontology.org/ontology/MESH/C041359", "setId": "7c6c1494-fb92-4442-bcff-764b77397495", "exact": "Terbinafine", "suffix": " has been shown to be active against most strains of the fol"}, {"to": "3982", "prefix": "ble, but their clinical significance is unknown. In vitro, ", "from": "3972", "name": "terbinafine", "fullId": "http://purl.bioontology.org/ontology/MESH/C041359", "setId": "7c6c1494-fb92-4442-bcff-764b77397495", "exact": "terbinafine", "suffix": " exhibits satisfactory MIC"}, {"to": "4112", "prefix": "lowing microorganisms; however, the safety and efficacy of ", "from": "4102", "name": "terbinafine", "fullId": "http://purl.bioontology.org/ontology/MESH/C041359", "setId": "7c6c1494-fb92-4442-bcff-764b77397495", "exact": "terbinafine", "suffix": " in treating clinical infections due to these microorganisms"}, {"to": "296", "prefix": "                \n                        Terbinafine is an ", "from": "287", "name": "Allylamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D000499", "setId": "7c6c1494-fb92-4442-bcff-764b77397495", "exact": "allylamine", "suffix": " antifungal [see Clinical Pharmacology "}, {"to": "2853", "prefix": "                  \n                        Terbinafine,  an ", "from": "2844", "name": "Allylamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D000499", "setId": "7c6c1494-fb92-4442-bcff-764b77397495", "exact": "allylamine", "suffix": " antifungal, inhibits biosynthesis of ergosterol, an essenti"}, {"to": "2235", "prefix": "", "from": "2226", "name": "Creatinine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003404", "setId": "7c6c1494-fb92-4442-bcff-764b77397495", "exact": "creatinine", "suffix": " clearance "}, {"to": "2901", "prefix": "nafine,  an allylamine antifungal, inhibits biosynthesis of ", "from": "2892", "name": "Ergosterol", "fullId": "http://purl.bioontology.org/ontology/MESH/D004875", "setId": "7c6c1494-fb92-4442-bcff-764b77397495", "exact": "ergosterol", "suffix": ", an essential component of fungal cell membrane, via inhibi"}, {"to": "3173", "prefix": "mulation of high concentrations of squalene but not due to ", "from": "3164", "name": "Ergosterol", "fullId": "http://purl.bioontology.org/ontology/MESH/D004875", "setId": "7c6c1494-fb92-4442-bcff-764b77397495", "exact": "ergosterol", "suffix": " deficiency.  Depending on the concentration of the drug and"}, {"to": "2977", "prefix": "ntial component of fungal cell membrane, via inhibition of ", "from": "2970", "name": "Squalene", "fullId": "http://purl.bioontology.org/ontology/MESH/D013185", "setId": "7c6c1494-fb92-4442-bcff-764b77397495", "exact": "squalene", "suffix": "  epoxidase  enzyme.  This results in fungal cell death primar"}, {"to": "3147", "prefix": "ity mediated by the accumulation of high concentrations of ", "from": "3140", "name": "Squalene", "fullId": "http://purl.bioontology.org/ontology/MESH/D013185", "setId": "7c6c1494-fb92-4442-bcff-764b77397495", "exact": "squalene", "suffix": " but not due to ergosterol deficiency.  Depending on the con"}, {"to": "299", "prefix": "       \n                        The mechanism of action of ", "from": "290", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": ", as with other drugs having efficacy in schizophrenia, is u"}, {"to": "563", "prefix": " antagonism. The mechanism of action of ", "from": "554", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " in the treatment of acute manic or mixed episodes associate"}, {"to": "920", "prefix": "acodynamics\n\n                     \n                        ", "from": "911", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Olanzapine", "suffix": " binds with high affinity to the following receptors: seroto"}, {"to": "1138", "prefix": ". ", "from": "1129", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Olanzapine", "suffix": " is an antagonist with moderate affinity binding for seroton"}, {"to": "1294", "prefix": ". ", "from": "1285", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Olanzapine", "suffix": " binds weakly to GABAA, BZD, and "}, {"to": "1512", "prefix": " explain some of the other therapeutic and side effects of ", "from": "1503", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": ". Olanzapine's antagonism of muscarinic  M1-5 receptors may e"}, {"to": "1524", "prefix": "e of the other therapeutic and side effects of olanzapine. ", "from": "1515", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Olanzapine", "suffix": "'s antagonism of muscarinic  M1-5 receptors may explain its a"}, {"to": "1623", "prefix": "-5 receptors may explain its anticholinergic-like effects. ", "from": "1614", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Olanzapine", "suffix": "'s antagonism of histamine  H1 receptors may explain the somn"}, {"to": "1725", "prefix": "eptors may explain the somnolence observed with this drug. ", "from": "1716", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Olanzapine", "suffix": "'s antagonism of adrenergic  "}, {"to": "2296", "prefix": " ", "from": "2287", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Olanzapine", "suffix": " is well absorbed and reaches peak concentrations in approxi"}, {"to": "2592", "prefix": "ic circulation. Food does not affect the rate or extent of ", "from": "2583", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " absorption. Pharmacokinetic studies showed that ZYPREXA tab"}, {"to": "2648", "prefix": "olanzapine absorption. Pharmacokinetic studies showed that ", "from": "2642", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "ZYPREXA", "suffix": " tablets and ZYPREXA ZYDIS "}, {"to": "2668", "prefix": "n. Pharmacokinetic studies showed that ZYPREXA tablets and ", "from": "2662", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "ZYPREXA", "suffix": " ZYDIS "}, {"to": "2686", "prefix": "", "from": "2677", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " orally disintegrating tablets"}, {"to": "2744", "prefix": " dosage forms of ", "from": "2735", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " are bioequivalent.\n\n                              Olanzapin"}, {"to": "2805", "prefix": "anzapine are bioequivalent.\n\n                              ", "from": "2796", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Olanzapine", "suffix": " displays linear kinetics over the clinical dosing range. It"}, {"to": "3103", "prefix": ".\n\n                              Administration of ", "from": "3094", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " once daily leads to steady-state concentrations in about 1 "}, {"to": "3297", "prefix": " doses. Plasma concentrations, half-life, and clearance of ", "from": "3288", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " may vary between individuals on the basis of smoking status"}, {"to": "3417", "prefix": "ng status, gender, and age.\n\n                              ", "from": "3408", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Olanzapine", "suffix": " is extensively distributed throughout the body, with a volu"}, {"to": "4042", "prefix": " Following a single oral dose of 14C  labeled ", "from": "4033", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": ", 7% of the dose of olanzapine was recovered in the urine as"}, {"to": "4072", "prefix": "gle oral dose of 14C  labeled olanzapine, 7% of the dose of ", "from": "4063", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " was recovered in the urine as unchanged drug, indicating th"}, {"to": "4145", "prefix": " recovered in the urine as unchanged drug, indicating that ", "from": "4136", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " is highly metabolized. Approximately 57% and 30% of the dos"}, {"to": "4284", "prefix": "vered in the urine and feces, respectively. In the plasma, ", "from": "4275", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " accounted for only 12% of the AUC for total radioactivity, "}, {"to": "4541", "prefix": "de, present at steady state at 44% of the concentration of ", "from": "4532", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": ", and 4"}, {"to": "4572", "prefix": "-N-desmethyl ", "from": "4563", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": ", present at steady state at 31% of the concentration of ola"}, {"to": "4639", "prefix": "ne, present at steady state at 31% of the concentration of ", "from": "4630", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": ". Both metabolites lack pharmacological activity at the conc"}, {"to": "4868", "prefix": " mediated oxidation are the primary metabolic pathways for ", "from": "4859", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": ". In  vitro studies suggest that CYPs  1A2 and 2D6, and the fl"}, {"to": "4991", "prefix": "the flavin-containing monooxygenase system are involved in ", "from": "4982", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " oxidation. CYP2D6 mediated oxidation appears to be a minor "}, {"to": "5113", "prefix": " minor metabolic pathway in  vivo, because the clearance of ", "from": "5104", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " is not reduced in subjects who are deficient in this enzyme"}, {"to": "5512", "prefix": " ", "from": "5506", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "ZYPREXA", "suffix": " IntraMuscular results in rapid absorption with peak plasma "}, {"to": "5719", "prefix": " study in healthy volunteers, a 5  mg dose of intramuscular ", "from": "5710", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " for injection produces, on average, a maximum plasma concen"}, {"to": "5896", "prefix": "ximum plasma concentration produced by a 5  mg dose of oral ", "from": "5887", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": ". Area under the curve achieved after an intramuscular dose "}, {"to": "7012", "prefix": " Because ", "from": "7003", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " is highly metabolized before excretion and only 7% of the d"}, {"to": "7195", "prefix": "unlikely to have a major impact on the pharmacokinetics of ", "from": "7186", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": ". The pharmacokinetic characteristics of olanzapine were sim"}, {"to": "7246", "prefix": "tics of olanzapine. The pharmacokinetic characteristics of ", "from": "7237", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " were similar in patients with severe renal impairment and n"}, {"to": "7438", "prefix": "e degree of renal impairment is not required. In addition, ", "from": "7429", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " is not removed by dialysis. The effect of renal impairment "}, {"to": "7963", "prefix": "atic impairment may be expected to reduce the clearance of ", "from": "7954", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": ", a study of the effect of impaired liver function in subjec"}, {"to": "8167", "prefix": "irrhosis revealed little effect on the pharmacokinetics of ", "from": "8158", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": ".\n\n                           \n                           \n "}, {"to": "8566", "prefix": "ing 24 healthy subjects, the mean elimination half-life of ", "from": "8557", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " was about 1.5 times greater in elderly "}, {"to": "9194", "prefix": " Clearance of ", "from": "9185", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " is approximately 30% lower in women than in men. There were"}, {"to": "9733", "prefix": " ", "from": "9724", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Olanzapine", "suffix": " clearance is about 40% higher in smokers than in nonsmokers"}, {"to": "11066", "prefix": "ination of factors that may result in slower metabolism of ", "from": "11057", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " [see Dosage and Administration "}, {"to": "11589", "prefix": "ower average body weight, which resulted in higher average ", "from": "11580", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " exposure compared to adults.\n\n                           \n "}, {"to": "485", "prefix": "cacy in schizophrenia is mediated through a combination of ", "from": "478", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D004298", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "dopamine", "suffix": " and serotonin type  2  "}, {"to": "1043", "prefix": ", ", "from": "1036", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D004298", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "dopamine", "suffix": "  D1-4 "}, {"to": "1430", "prefix": "                        Antagonism at receptors other than ", "from": "1423", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D004298", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "dopamine", "suffix": " and 5HT2 may explain some of the other therapeutic and side"}, {"to": "499", "prefix": "ophrenia is mediated through a combination of dopamine and ", "from": "491", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "serotonin", "suffix": " type  2  "}, {"to": "983", "prefix": "apine binds with high affinity to the following receptors: ", "from": "975", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "serotonin", "suffix": "  5HT2A"}, {"to": "1200", "prefix": "zapine is an antagonist with moderate affinity binding for ", "from": "1192", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "serotonin", "suffix": "  5HT3 "}, {"to": "1073", "prefix": ", ", "from": "1065", "name": "Histamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5333", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "histamine", "suffix": "  H1 "}, {"to": "1649", "prefix": "s anticholinergic-like effects. Olanzapine's antagonism of ", "from": "1641", "name": "Histamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5333", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "histamine", "suffix": "  H1 receptors may explain the somnolence observed with this "}, {"to": "273", "prefix": "sm of Action\n                     \n                        ", "from": "261", "name": "telithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/C106791", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "Telithromycin", "suffix": " is a ketolide antibacterial drug. [see Clinical Pharmacolog"}, {"to": "652", "prefix": "          \n                        The pharmacokinetics of ", "from": "640", "name": "telithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/C106791", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "telithromycin", "suffix": " after administration of single and multiple "}, {"to": "992", "prefix": ", respectively, after 3 to 5 days of ", "from": "988", "name": "telithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/C106791", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "KETEK", "suffix": " 800 mg once daily. Steady-state plasma concentrations are r"}, {"to": "1109", "prefix": "s are reached within 2 to 3 days of once daily dosing with ", "from": "1105", "name": "telithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/C106791", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "KETEK", "suffix": " 800 mg.\n                     \n                     \n       "}, {"to": "1473", "prefix": "                            Following oral administration, ", "from": "1461", "name": "telithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/C106791", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "telithromycin", "suffix": " reached maximal concentration at about 1 hour "}, {"to": "1542", "prefix": ". ", "from": "1538", "name": "telithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/C106791", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "KETEK", "suffix": " has an absolute bioavailability of 57% in both young and el"}, {"to": "1723", "prefix": "d extent of absorption are unaffected by food intake, thus ", "from": "1719", "name": "telithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/C106791", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "KETEK", "suffix": " tablets can be given without regard to food.\n              "}, {"to": "2440", "prefix": "                             The volume of distribution of ", "from": "2428", "name": "telithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/C106791", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "telithromycin", "suffix": " after intravenous infusion is 2.9 L"}, {"to": "2524", "prefix": "kg.\n                              ", "from": "2512", "name": "telithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/C106791", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "Telithromycin", "suffix": " concentrations in bronchial mucosa, epithelial lining fluid"}, {"to": "3146", "prefix": "                        In total, approximately 70% of the ", "from": "3134", "name": "telithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/C106791", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "telithromycin", "suffix": " dose is metabolized. In plasma, the main circulating compou"}, {"to": "3395", "prefix": "ivity. The main metabolite represented 12.6% of the AUC of ", "from": "3383", "name": "telithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/C106791", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "telithromycin", "suffix": ". Three other plasma metabolites were quantified, each repre"}, {"to": "3501", "prefix": "ere quantified, each representing 3% or less of the AUC of ", "from": "3489", "name": "telithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/C106791", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "telithromycin", "suffix": ".\n                              It is estimated that approxi"}, {"to": "4065", "prefix": " \n                              The systemically available ", "from": "4053", "name": "telithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/C106791", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "telithromycin", "suffix": " is eliminated by multiple pathways as follows: 7% of the do"}, {"to": "4394", "prefix": "ng oral dosing, the mean terminal elimination half-life of ", "from": "4382", "name": "telithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/C106791", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "telithromycin", "suffix": " is 10 hours.\n                           \n                  "}, {"to": "5457", "prefix": ", given single and multiple once daily doses of 800 mg of ", "from": "5453", "name": "telithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/C106791", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "KETEK", "suffix": ".\n                                 \n                        "}, {"to": "5896", "prefix": "epatic impairment\n                                       : ", "from": "5884", "name": "telithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/C106791", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "Telithromycin", "suffix": " is excreted via the liver and kidney. [see Dosage and Admin"}, {"to": "6256", "prefix": "2 of ", "from": "6244", "name": "telithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/C106791", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "telithromycin", "suffix": " were similar to those obtained in age- and sex-matched heal"}, {"to": "6954", "prefix": " Renal impairment\n                                       : ", "from": "6942", "name": "telithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/C106791", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "Telithromycin", "suffix": " is excreted via the liver and kidney. [see Dosage and Admin"}, {"to": "7224", "prefix": "ees of renal impairment received 400 mg, 600 mg, or 800 mg ", "from": "7220", "name": "telithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/C106791", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "KETEK", "suffix": " once daily for 5 days.  There was a 1.4-fold increase in Cm"}, {"to": "7535", "prefix": "retion may serve as a compensatory elimination pathway for ", "from": "7523", "name": "telithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/C106791", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "telithromycin", "suffix": " in situations where metabolic clearance is impaired. Patien"}, {"to": "7897", "prefix": "nd AUC values were similar to normal healthy subjects when ", "from": "7893", "name": "telithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/C106791", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "KETEK", "suffix": " was administered 2 hours post-dialysis. However, the effect"}, {"to": "7995", "prefix": "post-dialysis. However, the effect of dialysis on removing ", "from": "7983", "name": "telithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/C106791", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "telithromycin", "suffix": " from the body has not been studied.\n                       "}, {"to": "8795", "prefix": "ant impairment of CYP 3A4 metabolism pathway were present, ", "from": "8783", "name": "telithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/C106791", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "telithromycin", "suffix": " exposure "}, {"to": "8956", "prefix": "e in healthy subjects with normal renal function receiving ", "from": "8944", "name": "telithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/C106791", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "telithromycin", "suffix": " alone. In the presence of severe renal impairment "}, {"to": "9096", "prefix": ", with coexisting hepatic impairment, a reduced dosage of ", "from": "9092", "name": "telithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/C106791", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "KETEK", "suffix": " is recommended. [see Dosage and Administration "}, {"to": "11368", "prefix": "         During concomitant administration of rifampin and ", "from": "11364", "name": "telithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/C106791", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "KETEK", "suffix": " in repeated doses, Cmax and AUC of telithromycin were decre"}, {"to": "11417", "prefix": "n of rifampin and KETEK in repeated doses, Cmax and AUC of ", "from": "11405", "name": "telithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/C106791", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "telithromycin", "suffix": " were decreased by 79%, and 86%, respectively. [see Drug Int"}, {"to": "12579", "prefix": "se interaction study with itraconazole showed that Cmax of ", "from": "12567", "name": "telithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/C106791", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "telithromycin", "suffix": " was increased by 22% and AUC by 54%. [see Drug Interactions"}, {"to": "13312", "prefix": "se interaction study with ketoconazole showed that Cmax of ", "from": "13300", "name": "telithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/C106791", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "telithromycin", "suffix": " was increased by 51% and AUC by 95%. [see Drug Interactions"}, {"to": "13982", "prefix": " juice:\n                                              When ", "from": "13970", "name": "telithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/C106791", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "telithromycin", "suffix": " was given with 240 mL of grapefruit juice after an overnigh"}, {"to": "14107", "prefix": "vernight fast to healthy subjects, the pharmacokinetics of ", "from": "14095", "name": "telithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/C106791", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "telithromycin", "suffix": " were not affected.\n                                       \n"}, {"to": "15044", "prefix": "    Simvastatin: When simvastatin was co-administered with ", "from": "15032", "name": "telithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/C106791", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "telithromycin", "suffix": ", there was a 5.3-fold increase in simvastatin Cmax, an 8.9-"}, {"to": "15318", "prefix": "ve metabolite AUC.  In another study, when simvastatin and ", "from": "15306", "name": "telithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/C106791", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "telithromycin", "suffix": " were administered 12 hours apart, there was a 3.4-fold incr"}, {"to": "16138", "prefix": "                  Midazolam: Concomitant administration of ", "from": "16126", "name": "telithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/C106791", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "telithromycin", "suffix": " with intravenous or oral midazolam resulted in 2- and 6-fol"}, {"to": "17464", "prefix": "pectively, in healthy volunteers when co-administered with ", "from": "17460", "name": "telithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/C106791", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "KETEK", "suffix": ". However, trough plasma concentrations of digoxin "}, {"to": "18376", "prefix": "en theophylline was co-administered with repeated doses of ", "from": "18372", "name": "telithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/C106791", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "KETEK", "suffix": ", there was an increase of approximately 16% and 17% on the "}, {"to": "19078", "prefix": "                \n                                          ", "from": "19074", "name": "telithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/C106791", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "KETEK", "suffix": " has been shown to decrease the Cmax and AUC of sotalol by 3"}, {"to": "19832", "prefix": "nyl estradiol and levonorgestrel were co-administered with ", "from": "19828", "name": "telithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/C106791", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "KETEK", "suffix": ", the steady-state AUC of ethinyl estradiol did not change a"}, {"to": "20023", "prefix": "pharmacodynamic study showed that ", "from": "20011", "name": "telithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/C106791", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "telithromycin", "suffix": " did not interfere with the antiovulatory effect of oral con"}, {"to": "20716", "prefix": "                  When metoprolol was co-administered with ", "from": "20712", "name": "telithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/C106791", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "KETEK", "suffix": ", there was an increase of approximately 38% on the Cmax and"}, {"to": "20882", "prefix": " was no effect on the elimination half-life of metoprolol. ", "from": "20870", "name": "telithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/C106791", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "Telithromycin", "suffix": " exposure is not modified with concomitant single-dose admin"}, {"to": "21719", "prefix": "or antacids containing aluminum and magnesium hydroxide on ", "from": "21707", "name": "telithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/C106791", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "telithromycin", "suffix": ".\n                                       \n                  "}, {"to": "22307", "prefix": "    There was no pharmacokinetic effect on paroxetine when ", "from": "22303", "name": "telithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/C106791", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "KETEK", "suffix": " was co-administered.\n                                      "}, {"to": "23040", "prefix": "creased by 95% when c0-administered with repeated doses of ", "from": "23028", "name": "telithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/C106791", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "telithromycin", "suffix": ", resulting in significant increases in QTc. [see Contraindi"}, {"to": "23762", "prefix": "   In vitro studies using a model compound have shown that ", "from": "23750", "name": "telithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/C106791", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "telithromycin", "suffix": " may act as an inhibitor for the hepatic uptake transporters"}, {"to": "23959", "prefix": "unknown, it is possible that concomitant administration of ", "from": "23955", "name": "telithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/C106791", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "KETEK", "suffix": " with drugs that are substrates of OATP family members could"}, {"to": "24815", "prefix": "                            \n                              ", "from": "24803", "name": "telithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/C106791", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "Telithromycin", "suffix": " belongs to the ketolide class of antibacterials and is stru"}, {"to": "24924", "prefix": "ibacterials and is structurally related to the macrolides. ", "from": "24912", "name": "telithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/C106791", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "Telithromycin", "suffix": " blocks protein synthesis by binding to domains II and V of "}, {"to": "25036", "prefix": "domains II and V of 23S rRNA of the 50S ribosomal subunit. ", "from": "25024", "name": "telithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/C106791", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "Telithromycin", "suffix": " may also inhibit the assembly of nascent ribosomal units.\n "}, {"to": "25138", "prefix": " of nascent ribosomal units.\n                              ", "from": "25126", "name": "telithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/C106791", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "Telithromycin", "suffix": " concentrates in phagocytes where it exhibits activity again"}, {"to": "25261", "prefix": "ity against intracellular respiratory pathogens. In vitro, ", "from": "25249", "name": "telithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/C106791", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "telithromycin", "suffix": " has been shown to demonstrate concentration-dependent bacte"}, {"to": "26210", "prefix": "          Production of Erm dimethyltransferases may cause ", "from": "26198", "name": "telithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/C106791", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "telithromycin", "suffix": " resistance in some Gram-positive bacteria.\n                "}, {"to": "26649", "prefix": "                            \n                              ", "from": "26637", "name": "telithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/C106791", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "Telithromycin", "suffix": " has been shown to be active against most strains of the fol"}, {"to": "28153", "prefix": " less than or equal to the susceptible breakpoint for ", "from": "28141", "name": "telithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/C106791", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "telithromycin", "suffix": ". However, the safety and efficacy of KETEK in treating clin"}, {"to": "28196", "prefix": "int for telithromycin. However, the safety and efficacy of ", "from": "28192", "name": "telithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/C106791", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "KETEK", "suffix": " in treating clinical infections due to these microorganisms"}, {"to": "30748", "prefix": "uivalent with standardized inoculum and  concentrations of ", "from": "30736", "name": "telithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/C106791", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "telithromycin", "suffix": " powder. The MIC values should be interpreted according to c"}, {"to": "31609", "prefix": "g ", "from": "31597", "name": "telithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/C106791", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "telithromycin", "suffix": " to test the susceptibility of microorganisms to telithromyc"}, {"to": "31671", "prefix": "ithromycin to test the susceptibility of microorganisms to ", "from": "31659", "name": "telithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/C106791", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "telithromycin", "suffix": ". Disc diffusion zone sizes should be interpreted according "}, {"to": "33406", "prefix": "mine the performance of the test procedures1,2,3. Standard ", "from": "33394", "name": "telithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/C106791", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "telithromycin", "suffix": " powder should provide the MIC ranges for the quality contro"}, {"to": "33547", "prefix": "g ", "from": "33535", "name": "telithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/C106791", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "telithromycin", "suffix": " disk should provide the zone diameter ranges for the qualit"}, {"to": "8523", "prefix": "                     : The effects of co-administration of ", "from": "8512", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "ketoconazole", "suffix": " in 12 subjects "}, {"to": "13179", "prefix": "          \n                                                ", "from": "13168", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "Ketoconazole", "suffix": ":\n                                              A multiple-d"}, {"to": "13278", "prefix": "                    A multiple-dose interaction study with ", "from": "13267", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "ketoconazole", "suffix": " showed that Cmax of telithromycin was increased by 51% and "}, {"to": "11181", "prefix": "          \n                                                ", "from": "11174", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "Rifampin", "suffix": "\n                                             \n             "}, {"to": "11358", "prefix": "                      During concomitant administration of ", "from": "11351", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "rifampin", "suffix": " and KETEK in repeated doses, Cmax and AUC of telithromycin "}, {"to": "12446", "prefix": "          \n                                                ", "from": "12435", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "Itraconazole", "suffix": ":\n                                              A multiple-d"}, {"to": "12545", "prefix": "                    A multiple-dose interaction study with ", "from": "12534", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "itraconazole", "suffix": " showed that Cmax of telithromycin was increased by 22% and "}, {"to": "14987", "prefix": "             \n                                             ", "from": "14977", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "Simvastatin", "suffix": ": When simvastatin was co-administered with telithromycin, t"}, {"to": "15005", "prefix": "                                         Simvastatin: When ", "from": "14995", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "simvastatin", "suffix": " was co-administered with telithromycin, there was a 5.3-fol"}, {"to": "15090", "prefix": "tered with telithromycin, there was a 5.3-fold increase in ", "from": "15080", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "simvastatin", "suffix": " Cmax, an 8.9-fold increase in simvastatin AUC, a 15-fold in"}, {"to": "15132", "prefix": "fold increase in simvastatin Cmax, an 8.9-fold increase in ", "from": "15122", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "simvastatin", "suffix": " AUC, a 15-fold increase in the simvastatin active metabolit"}, {"to": "15175", "prefix": "old increase in simvastatin AUC, a 15-fold increase in the ", "from": "15165", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "simvastatin", "suffix": " active metabolite Cmax, and a 12-fold increase in the simva"}, {"to": "15241", "prefix": "atin active metabolite Cmax, and a 12-fold increase in the ", "from": "15231", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "simvastatin", "suffix": " active metabolite AUC.  In another study, when simvastatin "}, {"to": "15300", "prefix": "simvastatin active metabolite AUC.  In another study, when ", "from": "15290", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "simvastatin", "suffix": " and telithromycin were administered 12 hours apart, there w"}, {"to": "15397", "prefix": "inistered 12 hours apart, there was a 3.4-fold increase in ", "from": "15387", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "simvastatin", "suffix": " Cmax, a 4.0-fold increase in simvastatin AUC, a 3.2-fold in"}, {"to": "15438", "prefix": "-fold increase in simvastatin Cmax, a 4.0-fold increase in ", "from": "15428", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "simvastatin", "suffix": " AUC, a 3.2-fold increase in the active metabolite Cmax, and"}, {"to": "16093", "prefix": "             \n                                             ", "from": "16085", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "Midazolam", "suffix": ": Concomitant administration of telithromycin with intraveno"}, {"to": "16173", "prefix": "t administration of telithromycin with intravenous or oral ", "from": "16165", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "midazolam", "suffix": " resulted in 2- and 6-fold increases, respectively, in the A"}, {"to": "16248", "prefix": "ed in 2- and 6-fold increases, respectively, in the AUC of ", "from": "16240", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "midazolam", "suffix": " due to inhibition of CYP 3A4-dependent metabolism of midazo"}, {"to": "16311", "prefix": "zolam due to inhibition of CYP 3A4-dependent metabolism of ", "from": "16303", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "midazolam", "suffix": ". [see Drug Interactions "}, {"to": "17235", "prefix": "             \n                                             ", "from": "17229", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004077", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "Digoxin", "suffix": "\n                                          \n                "}, {"to": "17365", "prefix": "                      The plasma peak and trough levels of ", "from": "17359", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004077", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "digoxin", "suffix": " were increased by 73% and 21%, respectively, in healthy vol"}, {"to": "17514", "prefix": "tered with KETEK. However, trough plasma concentrations of ", "from": "17508", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004077", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "digoxin", "suffix": " "}, {"to": "17700", "prefix": "e no significant changes in ECG parameters and no signs of ", "from": "17694", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004077", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "digoxin", "suffix": " toxicity. [see Drug Interactions "}, {"to": "18224", "prefix": "             \n                                             ", "from": "18213", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10438", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "Theophylline", "suffix": "\n                                          \n                "}, {"to": "18327", "prefix": "           \n                                          When ", "from": "18316", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10438", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "theophylline", "suffix": " was co-administered with repeated doses of KETEK, there was"}, {"to": "18477", "prefix": "roximately 16% and 17% on the steady-state Cmax and AUC of ", "from": "18466", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10438", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "theophylline", "suffix": ". [see Drug Interactions "}, {"to": "18987", "prefix": "             \n                                             ", "from": "18981", "name": "Sotalol", "fullId": "http://purl.bioontology.org/ontology/MESH/D013015", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "Sotalol", "suffix": "\n                                          \n                "}, {"to": "19133", "prefix": "      KETEK has been shown to decrease the Cmax and AUC of ", "from": "19127", "name": "Sotalol", "fullId": "http://purl.bioontology.org/ontology/MESH/D013015", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "sotalol", "suffix": " by 34% and 20%, respectively, due to decreased absorption.\n"}, {"to": "19781", "prefix": "                       When oral contraceptives containing ", "from": "19765", "name": "Ethinyl Estradiol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4124", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "ethinyl estradiol", "suffix": " and levonorgestrel were co-administered with KETEK, the ste"}, {"to": "19875", "prefix": "l were co-administered with KETEK, the steady-state AUC of ", "from": "19859", "name": "Ethinyl Estradiol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4124", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "ethinyl estradiol", "suffix": " did not change and the steady-state AUC of levonorgestrel w"}, {"to": "20123", "prefix": "the antiovulatory effect of oral contraceptives containing ", "from": "20107", "name": "Ethinyl Estradiol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4124", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "ethinyl estradiol", "suffix": " and levonorgestrel.\n                                       "}, {"to": "19800", "prefix": " When oral contraceptives containing ethinyl estradiol and ", "from": "19787", "name": "Levonorgestrel", "fullId": "http://purl.bioontology.org/ontology/MESH/D016912", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "levonorgestrel", "suffix": " were co-administered with KETEK, the steady-state AUC of et"}, {"to": "19933", "prefix": "hinyl estradiol did not change and the steady-state AUC of ", "from": "19920", "name": "Levonorgestrel", "fullId": "http://purl.bioontology.org/ontology/MESH/D016912", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "levonorgestrel", "suffix": " was increased by 50%. The pharmacokinetic"}, {"to": "20142", "prefix": "ct of oral contraceptives containing ethinyl estradiol and ", "from": "20129", "name": "Levonorgestrel", "fullId": "http://purl.bioontology.org/ontology/MESH/D016912", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "levonorgestrel", "suffix": ".\n                                       \n                  "}, {"to": "20584", "prefix": "             \n                                             ", "from": "20575", "name": "Metoprolol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6918", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "Metoprolol", "suffix": "\n                                          \n                "}, {"to": "20685", "prefix": "           \n                                          When ", "from": "20676", "name": "Metoprolol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6918", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "metoprolol", "suffix": " was co-administered with KETEK, there was an increase of ap"}, {"to": "20794", "prefix": "as an increase of approximately 38% on the Cmax and AUC of ", "from": "20785", "name": "Metoprolol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6918", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "metoprolol", "suffix": "; however, there was no effect on the elimination half-life "}, {"to": "20867", "prefix": "wever, there was no effect on the elimination half-life of ", "from": "20858", "name": "Metoprolol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6918", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "metoprolol", "suffix": ". Telithromycin exposure is not modified with concomitant si"}, {"to": "20965", "prefix": "ot modified with concomitant single-dose administration of ", "from": "20956", "name": "Metoprolol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6918", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "metoprolol", "suffix": ". [see Drug Interactions "}, {"to": "21478", "prefix": "             \n                                             ", "from": "21469", "name": "Ranitidine", "fullId": "http://purl.bioontology.org/ontology/MESH/D011899", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "Ranitidine", "suffix": ""}, {"to": "21646", "prefix": " was no clinically relevant pharmacokinetic interaction of ", "from": "21637", "name": "Ranitidine", "fullId": "http://purl.bioontology.org/ontology/MESH/D011899", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "ranitidine", "suffix": " or antacids containing aluminum and magnesium hydroxide on "}, {"to": "22161", "prefix": "             \n                                             ", "from": "22152", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "Paroxetine", "suffix": "\n                                          \n                "}, {"to": "22296", "prefix": "                    There was no pharmacokinetic effect on ", "from": "22287", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "paroxetine", "suffix": " when KETEK was co-administered.\n                           "}, {"to": "22768", "prefix": "             \n                                             ", "from": "22760", "name": "Cisapride", "fullId": "http://purl.bioontology.org/ontology/RXNORM/35255", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "Cisapride", "suffix": "\n                                          \n                "}, {"to": "22906", "prefix": "                Steady state peak plasma concentrations of ", "from": "22898", "name": "Cisapride", "fullId": "http://purl.bioontology.org/ontology/RXNORM/35255", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "cisapride", "suffix": " "}, {"to": "25525", "prefix": "", "from": "25516", "name": "Penicillin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/70618", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "penicillin", "suffix": "-resistant Streptococcus pneumoniae"}, {"to": "25648", "prefix": " resistant to two or more of the following antimicrobials: ", "from": "25639", "name": "Penicillin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/70618", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "penicillin", "suffix": ", 2nd generation cephalosporins "}, {"to": "25697", "prefix": "e.g., ", "from": "25688", "name": "Cefuroxime", "fullId": "http://purl.bioontology.org/ontology/MESH/D002444", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "cefuroxime", "suffix": ""}, {"to": "25743", "prefix": ", macrolides, tetracyclines, and ", "from": "25732", "name": "Trimethoprim", "fullId": "http://purl.bioontology.org/ontology/MESH/D014295", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "trimethoprim", "suffix": ""}, {"to": "25760", "prefix": "", "from": "25745", "name": "Sulfamethoxazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10180", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "sulfamethoxazole", "suffix": ".]"}, {"to": "28602", "prefix": "", "from": "28592", "name": "Methicillin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008712", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "methicillin", "suffix": " and erythromycin susceptible isolates only"}, {"to": "28619", "prefix": "methicillin and ", "from": "28608", "name": "Erythromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004917", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "erythromycin", "suffix": " susceptible isolates only"}, {"to": "28720", "prefix": "", "from": "28709", "name": "Erythromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004917", "setId": "4471223e-9023-457e-be2e-8e4e0c2d94d1", "exact": "erythromycin", "suffix": " susceptible isolates only"}, {"to": "347", "prefix": "not use MAOIs intended to treat psychiatric disorders with ", "from": "334", "name": "O-desmethylvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C086816", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "desvenlafaxine", "suffix": " or within 7 days of stopping treatment with desvenlafaxine."}, {"to": "406", "prefix": "desvenlafaxine or within 7 days of stopping treatment with ", "from": "393", "name": "O-desmethylvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C086816", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "desvenlafaxine", "suffix": ". Do not use desvenlafaxine within 14 days of stopping an MA"}, {"to": "433", "prefix": "days of stopping treatment with desvenlafaxine. Do not use ", "from": "420", "name": "O-desmethylvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C086816", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "desvenlafaxine", "suffix": " within 14 days of stopping an MAOI intended to treat psychi"}, {"to": "550", "prefix": " to treat psychiatric disorders. In addition, do not start ", "from": "537", "name": "O-desmethylvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C086816", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "desvenlafaxine", "suffix": " in a patient who is being treated with linezolid or intrave"}, {"to": "1051", "prefix": "                       Based on the mechanism of action of ", "from": "1038", "name": "O-desmethylvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C086816", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "desvenlafaxine", "suffix": " and the potential for serotonin syndrome, caution is advise"}, {"to": "1132", "prefix": " potential for serotonin syndrome, caution is advised when ", "from": "1119", "name": "O-desmethylvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C086816", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "desvenlafaxine", "suffix": " is co-administered with other drugs that may affect the ser"}, {"to": "2273", "prefix": "eiving warfarin therapy should be carefully monitored when ", "from": "2267", "name": "O-desmethylvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C086816", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "PRISTIQ", "suffix": " is initiated or discontinued [see Warnings and Precautions "}, {"to": "2575", "prefix": "                   7.4 Potential for Other Drugs to Affect ", "from": "2562", "name": "O-desmethylvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C086816", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "Desvenlafaxine", "suffix": " \n                     \n                        Based on in "}, {"to": "2689", "prefix": "Based on in vitro data, no dose adjustment is required for ", "from": "2683", "name": "O-desmethylvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C086816", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "PRISTIQ", "suffix": " when used concomitantly with inhibitors of CYP3A4 and CYP1A"}, {"to": "2928", "prefix": "clinically significant pharmacokinetic interaction between ", "from": "2922", "name": "O-desmethylvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C086816", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "PRISTIQ", "suffix": " and strong CYP 3A4 inhibitors "}, {"to": "3478", "prefix": "                   \n                     7.5 Potential for ", "from": "3465", "name": "O-desmethylvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C086816", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "Desvenlafaxine", "suffix": " to Affect Other Drugs \n                     \n              "}, {"to": "3595", "prefix": " \n                        Clinical studies have shown that ", "from": "3582", "name": "O-desmethylvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C086816", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "desvenlafaxine", "suffix": " does not have a clinically relevant effect on CYP2D6 metabo"}, {"to": "3916", "prefix": "d be dosed at the original level when co-administered with ", "from": "3910", "name": "O-desmethylvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C086816", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "PRISTIQ", "suffix": " 100 mg or lower or when PRISTIQ is discontinued. Reduce the"}, {"to": "3948", "prefix": " when co-administered with PRISTIQ 100 mg or lower or when ", "from": "3942", "name": "O-desmethylvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C086816", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "PRISTIQ", "suffix": " is discontinued. Reduce the dose of these substrates by up "}, {"to": "4061", "prefix": "trates by up to one-half if co-administered with 400 mg of ", "from": "4055", "name": "O-desmethylvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C086816", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "PRISTIQ", "suffix": ". \n                        No additional dose adjustment is "}, {"to": "4350", "prefix": "clinically significant pharmacokinetic interaction between ", "from": "4344", "name": "O-desmethylvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C086816", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "PRISTIQ", "suffix": " and CYP3A4 substrates "}, {"to": "4458", "prefix": " \n                        Clinical studies have shown that ", "from": "4445", "name": "O-desmethylvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C086816", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "desvenlafaxine", "suffix": " "}, {"to": "4761", "prefix": "      In vitro studies showed minimal inhibitory effect of ", "from": "4748", "name": "O-desmethylvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C086816", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "desvenlafaxine", "suffix": " on the CYP2D6 isoenzyme.\n                        \n         "}, {"to": "4863", "prefix": "                     \n                           In vitro, ", "from": "4850", "name": "O-desmethylvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C086816", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "desvenlafaxine", "suffix": " does not inhibit or induce the CYP3A4 isozyme. \n           "}, {"to": "4988", "prefix": "                     \n                           In vitro, ", "from": "4975", "name": "O-desmethylvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C086816", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "desvenlafaxine", "suffix": " does not inhibit CYP1A2, 2A6, 2C8, 2C9, and 2C19, isozymes,"}, {"to": "5724", "prefix": "          \n                     7.6 Other Drugs Containing ", "from": "5711", "name": "O-desmethylvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C086816", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "Desvenlafaxine", "suffix": " or Venlafaxine\n                     \n                      "}, {"to": "5806", "prefix": "                     \n                        Avoid use of ", "from": "5800", "name": "O-desmethylvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C086816", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "PRISTIQ", "suffix": " with other desvenlafaxine-containing products or venlafaxin"}, {"to": "5832", "prefix": "  \n                        Avoid use of PRISTIQ with other ", "from": "5819", "name": "O-desmethylvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C086816", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "desvenlafaxine", "suffix": "-containing products or venlafaxine products. The concomitan"}, {"to": "5908", "prefix": "g products or venlafaxine products. The concomitant use of ", "from": "5902", "name": "O-desmethylvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C086816", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "PRISTIQ", "suffix": " with other desvenlafaxine-containing products or venlafaxin"}, {"to": "5934", "prefix": "faxine products. The concomitant use of PRISTIQ with other ", "from": "5921", "name": "O-desmethylvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C086816", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "desvenlafaxine", "suffix": "-containing products or venlafaxine will increase desvenlafa"}, {"to": "5998", "prefix": "nlafaxine-containing products or venlafaxine will increase ", "from": "5985", "name": "O-desmethylvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C086816", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "desvenlafaxine", "suffix": " blood levels and increase dose-related adverse reactions [s"}, {"to": "6387", "prefix": "  \n                        A clinical study has shown that ", "from": "6381", "name": "O-desmethylvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C086816", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "PRISTIQ", "suffix": " does not increase the impairment of mental and motor skills"}, {"to": "6582", "prefix": "hould be advised to avoid alcohol consumption while taking ", "from": "6576", "name": "O-desmethylvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C086816", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "PRISTIQ", "suffix": ". \n                     \n                     \n             "}, {"to": "6989", "prefix": " and amphetamine have been reported in patients taking ", "from": "6976", "name": "O-desmethylvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C086816", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "desvenlafaxine", "suffix": ". This is due to lack of specificity of the screening tests."}, {"to": "7154", "prefix": " be expected for several days following discontinuation of ", "from": "7141", "name": "O-desmethylvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C086816", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "desvenlafaxine", "suffix": " therapy. Confirmatory tests, such as gas chromatography"}, {"to": "7261", "prefix": "mass spectrometry, will distinguish ", "from": "7248", "name": "O-desmethylvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C086816", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "desvenlafaxine", "suffix": " from PCP and amphetamine.\n                     \n           "}, {"to": "599", "prefix": "tart desvenlafaxine in a patient who is being treated with ", "from": "591", "name": "linezolid", "fullId": "http://purl.bioontology.org/ontology/RXNORM/190376", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "linezolid", "suffix": " or intravenous methylene blue [see Dosage and Administratio"}, {"to": "629", "prefix": "patient who is being treated with linezolid or intravenous ", "from": "616", "name": "Methylene Blue", "fullId": "http://purl.bioontology.org/ontology/MESH/D008751", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "methylene blue", "suffix": " [see Dosage and Administration "}, {"to": "1083", "prefix": "echanism of action of desvenlafaxine and the potential for ", "from": "1075", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "serotonin", "suffix": " syndrome, caution is advised when desvenlafaxine is co-admi"}, {"to": "1663", "prefix": " \n                     \n                        ", "from": "1655", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "Serotonin", "suffix": " release by platelets plays an important role in hemostasis."}, {"to": "1883", "prefix": "tion between use of psychotropic drugs that interfere with ", "from": "1875", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "serotonin", "suffix": " reuptake and the occurrence of upper gastrointestinal bleed"}, {"to": "1591", "prefix": "e.g., NSAIDs, ", "from": "1585", "name": "Aspirin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1191", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "Aspirin", "suffix": ", and Warfarin"}, {"to": "2020", "prefix": "studies have also shown that concurrent use of an NSAID or ", "from": "2014", "name": "Aspirin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1191", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "aspirin", "suffix": " may potentiate this risk of bleeding. Altered anticoagulant"}, {"to": "1605", "prefix": "e.g., NSAIDs, Aspirin, and ", "from": "1598", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "Warfarin", "suffix": ""}, {"to": "2193", "prefix": "een reported when SSRIs and SNRIs are co-administered with ", "from": "2186", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "warfarin", "suffix": ". Patients receiving warfarin therapy should be carefully mo"}, {"to": "2222", "prefix": "NRIs are co-administered with warfarin. Patients receiving ", "from": "2215", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "warfarin", "suffix": " therapy should be carefully monitored when PRISTIQ is initi"}, {"to": "3761", "prefix": "e.g., ", "from": "3751", "name": "Desipramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003891", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "desipramine", "suffix": " , atomoxetine, dextromethorphan, metoprolol, nebivolol, per"}, {"to": "3775", "prefix": "e.g., desipramine , ", "from": "3765", "name": "atomoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C041930", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "atomoxetine", "suffix": ", dextromethorphan, metoprolol, nebivolol, perphenazine, tol"}, {"to": "3793", "prefix": "e.g., desipramine , atomoxetine, ", "from": "3778", "name": "Dextromethorphan", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3289", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "dextromethorphan", "suffix": ", metoprolol, nebivolol, perphenazine, tolterodine"}, {"to": "3805", "prefix": "e.g., desipramine , atomoxetine, dextromethorphan, ", "from": "3796", "name": "Metoprolol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6918", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "metoprolol", "suffix": ", nebivolol, perphenazine, tolterodine"}, {"to": "3816", "prefix": ", desipramine , atomoxetine, dextromethorphan, metoprolol, ", "from": "3808", "name": "nebivolol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/31555", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "nebivolol", "suffix": ", perphenazine, tolterodine"}, {"to": "3830", "prefix": "ne , atomoxetine, dextromethorphan, metoprolol, nebivolol, ", "from": "3819", "name": "Perphenazine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8076", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "perphenazine", "suffix": ", tolterodine"}, {"to": "3843", "prefix": "ne, dextromethorphan, metoprolol, nebivolol, perphenazine, ", "from": "3833", "name": "tolterodine", "fullId": "http://purl.bioontology.org/ontology/MESH/C099041", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "tolterodine", "suffix": ""}, {"to": "4529", "prefix": " does not have a clinically relevant effect on ", "from": "4521", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/MESH/D013629", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "tamoxifen", "suffix": " and aripiprazole, compounds that are metabolized by a combi"}, {"to": "4546", "prefix": "oes not have a clinically relevant effect on tamoxifen and ", "from": "4535", "name": "aripiprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/89013", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "aripiprazole", "suffix": ", compounds that are metabolized by a combination of both CY"}, {"to": "5739", "prefix": "              7.6 Other Drugs Containing Desvenlafaxine or ", "from": "5729", "name": "venlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39786", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "Venlafaxine", "suffix": "\n                     \n                        Avoid use of "}, {"to": "5867", "prefix": "f PRISTIQ with other desvenlafaxine-containing products or ", "from": "5857", "name": "venlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39786", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "venlafaxine", "suffix": " products. The concomitant use of PRISTIQ with other desvenl"}, {"to": "5969", "prefix": "f PRISTIQ with other desvenlafaxine-containing products or ", "from": "5959", "name": "venlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39786", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "venlafaxine", "suffix": " will increase desvenlafaxine blood levels and increase dose"}, {"to": "6300", "prefix": "           \n                     \n                     7.7 ", "from": "6294", "name": "Ethanol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/448", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "Ethanol", "suffix": " \n                     \n                        A clinical s"}, {"to": "6465", "prefix": "crease the impairment of mental and motor skills caused by ", "from": "6459", "name": "Ethanol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/448", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "ethanol", "suffix": ". However, as with all CNS-active drugs, patients should be "}, {"to": "6914", "prefix": "      False-positive urine immunoassay screening tests for ", "from": "6902", "name": "Phencyclidine", "fullId": "http://purl.bioontology.org/ontology/MESH/D010622", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "phencyclidine", "suffix": " "}, {"to": "6936", "prefix": " and ", "from": "6926", "name": "Amphetamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D000661", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "amphetamine", "suffix": " have been reported in patients taking desvenlafaxine. This "}, {"to": "7286", "prefix": "spectrometry, will distinguish desvenlafaxine from PCP and ", "from": "7276", "name": "Amphetamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D000661", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "amphetamine", "suffix": ".\n                     \n                     \n              "}, {"to": "306", "prefix": "       \n                        The mechanism of action of ", "from": "288", "name": "Fluvoxamine Maleate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/203143", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine maleate", "suffix": " in obsessive compulsive disorder is presumed to be linked t"}, {"to": "858", "prefix": "             \n                        In in vitro studies, ", "from": "840", "name": "Fluvoxamine Maleate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/203143", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine maleate", "suffix": " had no significant affinity for histaminergic, alpha or bet"}, {"to": "1746", "prefix": "                           The absolute bioavailability of ", "from": "1728", "name": "Fluvoxamine Maleate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/203143", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine maleate", "suffix": " is 53%. Oral bioavailability is not significantly affected "}, {"to": "1907", "prefix": "                 In a dose proportionality study involving ", "from": "1889", "name": "Fluvoxamine Maleate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/203143", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine maleate", "suffix": " at 100, 200 and 300 mg"}, {"to": "2311", "prefix": "armacokinetics over this dose range, i.e., higher doses of ", "from": "2293", "name": "Fluvoxamine Maleate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/203143", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine maleate", "suffix": " produced disproportionately higher concentrations than pred"}, {"to": "3554", "prefix": "\n                           \n                              ", "from": "3536", "name": "Fluvoxamine Maleate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/203143", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "Fluvoxamine maleate", "suffix": " is extensively metabolized by the liver; the main metabolic"}, {"to": "3758", "prefix": "tes were identified following a 5 mg radiolabelled dose of ", "from": "3740", "name": "Fluvoxamine Maleate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/203143", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine maleate", "suffix": ", constituting approximately 85% of the urinary excretion pr"}, {"to": "4994", "prefix": "                     Following a 14C-labelled oral dose of ", "from": "4976", "name": "Fluvoxamine Maleate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/203143", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine maleate", "suffix": " "}, {"to": "5729", "prefix": "              \n                              In a study of ", "from": "5711", "name": "Fluvoxamine Maleate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/203143", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine maleate", "suffix": " tablets at 50 mg and 100 mg comparing elderly "}, {"to": "6211", "prefix": "ce of fluvoxamine was reduced by about 50% and, therefore, ", "from": "6193", "name": "Fluvoxamine Maleate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/203143", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine maleate", "suffix": " tablets should be slowly titrated during initiation of ther"}, {"to": "7358", "prefix": "x compared to male children and, therefore, lower doses of ", "from": "7340", "name": "Fluvoxamine Maleate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/203143", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine maleate", "suffix": " tablets may produce therapeutic benefit. "}, {"to": "440", "prefix": "s specific serotonin reuptake inhibition in brain neurons. ", "from": "430", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "Fluvoxamine", "suffix": " has been shown to be a potent inhibitor of the serotonin re"}, {"to": "2216", "prefix": "mL, respectively. Thus, ", "from": "2206", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine", "suffix": " had nonlinear pharmacokinetics over this dose range, i.e., "}, {"to": "2883", "prefix": "              The mean apparent volume of distribution for ", "from": "2873", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine", "suffix": " is approximately 25 L"}, {"to": "3015", "prefix": "ution. \n                              Approximately 80% of ", "from": "3005", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine", "suffix": " is bound to plasma protein, mostly albumin, over a concentr"}, {"to": "3839", "prefix": "ing approximately 85% of the urinary excretion products of ", "from": "3829", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine", "suffix": ". The main human metabolite was fluvoxamine acid which, toge"}, {"to": "3882", "prefix": "ion products of fluvoxamine. The main human metabolite was ", "from": "3872", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine", "suffix": " acid which, together with its N-acetylated analog, accounte"}, {"to": "4097", "prefix": " formed by oxidative deamination, accounted for about 10%. ", "from": "4087", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "Fluvoxamine", "suffix": " acid and fluvoxethanol were tested in an in vitro assay of "}, {"to": "4416", "prefix": ". Approximately 2% of ", "from": "4406", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine", "suffix": " was excreted in urine unchanged [see Drug Interactions "}, {"to": "5161", "prefix": "                              The mean plasma half-life of ", "from": "5151", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine", "suffix": " at steady state after multiple oral doses of 100 mg"}, {"to": "5949", "prefix": "ere 40% higher. The multiple dose elimination half-life of ", "from": "5939", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine", "suffix": " was 17.4 and 25.9 hours in the elderly compared to 13.6 and"}, {"to": "6150", "prefix": "doses, respectively. In elderly patients, the clearance of ", "from": "6140", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine", "suffix": " was reduced by about 50% and, therefore, fluvoxamine maleat"}, {"to": "6829", "prefix": "                     The multiple-dose pharmacokinetics of ", "from": "6819", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine", "suffix": " were determined in male and female children "}, {"to": "6953", "prefix": ". Steady-state plasma ", "from": "6943", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine", "suffix": " concentrations were 2- to 3-fold higher in children than in"}, {"to": "7498", "prefix": "ferences were observed in adolescents. Steady-state plasma ", "from": "7488", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine", "suffix": " concentrations were similar in adults and adolescents at a "}, {"to": "7605", "prefix": "day, indicating that ", "from": "7595", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine", "suffix": " exposure was similar in these two populations. "}, {"to": "8458", "prefix": " suggested a 30% decrease in ", "from": "8448", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine", "suffix": " clearance in association with hepatic dysfunction. The mean"}, {"to": "8747", "prefix": "re comparable to each other, suggesting no accumulation of ", "from": "8737", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine", "suffix": " in these patients [see Warnings and Precautions: Use In Pat"}, {"to": "390", "prefix": "mpulsive disorder is presumed to be linked to its specific ", "from": "382", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "serotonin", "suffix": " reuptake inhibition in brain neurons. Fluvoxamine has been "}, {"to": "497", "prefix": "Fluvoxamine has been shown to be a potent inhibitor of the ", "from": "489", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "serotonin", "suffix": " reuptake transporter in preclinical studies, both in vitro "}, {"to": "4166", "prefix": "acid and fluvoxethanol were tested in an in vitro assay of ", "from": "4158", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "serotonin", "suffix": " and norepinephrine reuptake inhibition in rats; they were i"}, {"to": "4310", "prefix": "or a weak effect of the former metabolite on inhibition of ", "from": "4302", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "serotonin", "suffix": " uptake "}, {"to": "4185", "prefix": "xethanol were tested in an in vitro assay of serotonin and ", "from": "4172", "name": "Norepinephrine", "fullId": "http://purl.bioontology.org/ontology/MESH/D009638", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "norepinephrine", "suffix": " reuptake inhibition in rats; they were inactive except for "}, {"to": "8589", "prefix": "", "from": "8580", "name": "Creatinine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003404", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "creatinine", "suffix": " clearance of 5 to 45 mL"}, {"to": "316", "prefix": "                 The mechanism of antidepressant action of ", "from": "305", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": ", the S-enantiomer of racemic citalopram, is presumed to be "}, {"to": "356", "prefix": "essant action of escitalopram, the S-enantiomer of racemic ", "from": "347", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "citalopram", "suffix": ", is presumed to be linked to potentiation of serotonergic a"}, {"to": "878", "prefix": "      In vitro and in vivo studies in animals suggest that ", "from": "867", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": " is a highly selective serotonin reuptake inhibitor "}, {"to": "1020", "prefix": " effects on norepinephrine and dopamine neuronal reuptake. ", "from": "1009", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "Escitalopram", "suffix": " is at least 100-fold more potent than the R-enantiomer with"}, {"to": "1291", "prefix": " treatment with ", "from": "1280", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": ". Escitalopram has no or very low affinity for serotonergic "}, {"to": "1305", "prefix": " treatment with escitalopram. ", "from": "1294", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "Escitalopram", "suffix": " has no or very low affinity for serotonergic "}, {"to": "1514", "prefix": ", and benzodiazepine receptors. ", "from": "1503", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "Escitalopram", "suffix": " also does not bind to, or has low affinity for, various ion"}, {"to": "2144", "prefix": "         The single- and multiple-dose pharmacokinetics of ", "from": "2133", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": " are linear and dose-proportional in a dose range of 10 to 3"}, {"to": "2247", "prefix": "day. Biotransformation of ", "from": "2236", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": " is mainly hepatic, with a mean terminal half-life of about "}, {"to": "2482", "prefix": "y one week. At steady state, the extent of accumulation of ", "from": "2471", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": " in plasma in young healthy subjects was 2.2-2.5 times the p"}, {"to": "3018", "prefix": " of ", "from": "3007", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": ", peak blood levels occur at about 5 hours. Absorption of es"}, {"to": "3088", "prefix": "m, peak blood levels occur at about 5 hours. Absorption of ", "from": "3077", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": " is not affected by food.\n\n                              The"}, {"to": "3187", "prefix": "                           The absolute bioavailability of ", "from": "3178", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "citalopram", "suffix": " is about 80% relative to an intravenous dose, and the volum"}, {"to": "3278", "prefix": " to an intravenous dose, and the volume of distribution of ", "from": "3269", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "citalopram", "suffix": " is about 12 L"}, {"to": "3326", "prefix": "kg. Data specific on ", "from": "3315", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": " are unavailable.\n\n                              The binding"}, {"to": "3402", "prefix": "unavailable.\n\n                              The binding of ", "from": "3391", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": " to human plasma proteins is approximately 56%.\n\n           "}, {"to": "3819", "prefix": "                         Following oral administrations of ", "from": "3808", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": ", the fraction of drug recovered in the urine as escitalopra"}, {"to": "3880", "prefix": "citalopram, the fraction of drug recovered in the urine as ", "from": "3869", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": " and S-demethylcitalopram "}, {"to": "3983", "prefix": " is about 8% and 10%, respectively. The oral clearance of ", "from": "3972", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": " is 600 mL"}, {"to": "4096", "prefix": "hat due to renal clearance.\n\n                              ", "from": "4085", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "Escitalopram", "suffix": " is metabolized to S-DCT and S-didemethylcitalopram "}, {"to": "4191", "prefix": ". In humans, unchanged ", "from": "4180", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": " is the predominant compound in plasma. At steady state, the"}, {"to": "4285", "prefix": "pound in plasma. At steady state, the concentration of the ", "from": "4274", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": " metabolite S-DCT in plasma is approximately one-third that "}, {"to": "4360", "prefix": "abolite S-DCT in plasma is approximately one-third that of ", "from": "4349", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": ". The level of S-DDCT was not detectable in most subjects. I"}, {"to": "4458", "prefix": "ot detectable in most subjects. In vitro studies show that ", "from": "4447", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": " is at least 7 and 27 times more potent than S-DCT and S-DDC"}, {"to": "4623", "prefix": " of serotonin reuptake, suggesting that the metabolites of ", "from": "4612", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": " do not contribute significantly to the antidepressant actio"}, {"to": "4701", "prefix": " contribute significantly to the antidepressant actions of ", "from": "4690", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": ". S-DCT and S-DDCT also have no or very low affinity for ser"}, {"to": "5240", "prefix": "re the primary isozymes involved in the N-demethylation of ", "from": "5229", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": ".\n\n                           \n                           \n "}, {"to": "6222", "prefix": "             Adolescents - In a single dose study of 10 mg ", "from": "6211", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": ", AUC of escitalopram decreased by 19%, and Cmax increased b"}, {"to": "6243", "prefix": "nts - In a single dose study of 10 mg escitalopram, AUC of ", "from": "6232", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": " decreased by 19%, and Cmax increased by 26% in healthy adol"}, {"to": "6412", "prefix": "day ", "from": "6403", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "citalopram", "suffix": ", escitalopram elimination half-life, steady-state Cmax and "}, {"to": "6426", "prefix": "day citalopram, ", "from": "6415", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": " elimination half-life, steady-state Cmax and AUC were simil"}, {"to": "7028", "prefix": "      \n                                          Elderly - ", "from": "7017", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "Escitalopram", "suffix": " pharmacokinetics in subjects "}, {"to": "7166", "prefix": "unger subjects in a single-dose and a multiple-dose study. ", "from": "7155", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "Escitalopram", "suffix": " AUC and half-life were increased by approximately 50% in el"}, {"to": "7888", "prefix": "d on data from single- and multiple-dose studies measuring ", "from": "7877", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": " in elderly, young adults, and adolescents, no dosage adjust"}, {"to": "8389", "prefix": "                                Reduced hepatic function - ", "from": "8380", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "Citalopram", "suffix": " oral clearance was reduced by 37% and half-life was doubled"}, {"to": "8566", "prefix": "pared to normal subjects. 10 mg is the recommended dose of ", "from": "8555", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": " for most hepatically impaired patients [see Dosage and Admi"}, {"to": "9124", "prefix": "d to moderate renal function impairment, oral clearance of ", "from": "9115", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "citalopram", "suffix": " was reduced by 17% compared to normal subjects. No adjustme"}, {"to": "9301", "prefix": " No information is available about the pharmacokinetics of ", "from": "9290", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": " in patients with severely reduced renal function "}, {"to": "9971", "prefix": "yme inhibition data did not reveal an inhibitory effect of ", "from": "9960", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": " on CYP3A4, -1A2, -2C9, -2C19, and -2E1. Based on in vitro d"}, {"to": "10048", "prefix": "P3A4, -1A2, -2C9, -2C19, and -2E1. Based on in vitro data, ", "from": "10037", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": " would be expected to have little inhibitory effect on in vi"}, {"to": "10273", "prefix": "imited, results from drug interaction studies suggest that ", "from": "10262", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": ", at a dose of 20 mg, has no 3A4 inhibitory effect and a mod"}, {"to": "527", "prefix": " resulting from its inhibition of CNS neuronal reuptake of ", "from": "519", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "serotonin", "suffix": " "}, {"to": "910", "prefix": "in animals suggest that escitalopram is a highly selective ", "from": "902", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "serotonin", "suffix": " reuptake inhibitor "}, {"to": "4565", "prefix": " than S-DCT and S-DDCT, respectively, in the inhibition of ", "from": "4557", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "serotonin", "suffix": " reuptake, suggesting that the metabolites of escitalopram d"}, {"to": "533", "prefix": "", "from": "530", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/MESH/D012701", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "5-HT", "suffix": ""}, {"to": "1110", "prefix": "potent than the R-enantiomer with respect to inhibition of ", "from": "1107", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/MESH/D012701", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "5-HT", "suffix": " reuptake and inhibition of 5-HT neuronal firing rate. Toler"}, {"to": "1142", "prefix": "h respect to inhibition of 5-HT reuptake and inhibition of ", "from": "1139", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/MESH/D012701", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "5-HT", "suffix": " neuronal firing rate. Tolerance to a model of antidepressan"}, {"to": "975", "prefix": " with minimal effects on ", "from": "962", "name": "Norepinephrine", "fullId": "http://purl.bioontology.org/ontology/MESH/D009638", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "norepinephrine", "suffix": " and dopamine neuronal reuptake. Escitalopram is at least 10"}, {"to": "988", "prefix": " with minimal effects on norepinephrine and ", "from": "981", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D004298", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "dopamine", "suffix": " neuronal reuptake. Escitalopram is at least 100-fold more p"}, {"to": "1426", "prefix": " or other receptors including alpha- and beta-adrenergic, ", "from": "1419", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D004298", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "dopamine", "suffix": " "}, {"to": "4846", "prefix": " or other receptors including alpha- and beta-adrenergic, ", "from": "4839", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D004298", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "dopamine", "suffix": " "}, {"to": "1444", "prefix": ", ", "from": "1436", "name": "Histamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5333", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "histamine", "suffix": " "}, {"to": "4864", "prefix": ", ", "from": "4856", "name": "Histamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5333", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "histamine", "suffix": " "}, {"to": "1490", "prefix": ", and ", "from": "1477", "name": "Benzodiazepines", "fullId": "http://purl.bioontology.org/ontology/MESH/D001569", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "benzodiazepine", "suffix": " receptors. Escitalopram also does not bind to, or has low a"}, {"to": "4910", "prefix": ", and ", "from": "4897", "name": "Benzodiazepines", "fullId": "http://purl.bioontology.org/ontology/MESH/D001569", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "benzodiazepine", "suffix": " receptors. S-DCT and S-DDCT also do not bind to various ion"}, {"to": "2662", "prefix": "gle dose. The tablet and the oral solution dosage forms of ", "from": "2643", "name": "Escitalopram oxalate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/353108", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram oxalate", "suffix": " are bioequivalent.\n\n                     \n                 "}, {"to": "3905", "prefix": "ction of drug recovered in the urine as escitalopram and S-", "from": "3888", "name": "demethylcitalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/C514709", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "demethylcitalopram", "suffix": " "}, {"to": "4147", "prefix": "                Escitalopram is metabolized to S-DCT and S-", "from": "4128", "name": "didemethylcitalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/C514710", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "didemethylcitalopram", "suffix": " "}, {"to": "9362", "prefix": "", "from": "9353", "name": "Creatinine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003404", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "creatinine", "suffix": " clearance "}, {"to": "37", "prefix": "\n\n\nDrug Interactions\nSince ", "from": "28", "name": "Mexiletine", "fullId": "http://purl.bioontology.org/ontology/MESH/D008801", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "mexiletine", "suffix": " is a substrate for the metabolic pathways involving CYP2D6 "}, {"to": "205", "prefix": "tion of either of these enzymes would be expected to alter ", "from": "196", "name": "Mexiletine", "fullId": "http://purl.bioontology.org/ontology/MESH/D008801", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "mexiletine", "suffix": " plasma concentrations. In a formal, single-dose interaction"}, {"to": "313", "prefix": " the clearance of ", "from": "304", "name": "Mexiletine", "fullId": "http://purl.bioontology.org/ontology/MESH/D008801", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "mexiletine", "suffix": " was decreased by 38% following the coadministration of fluv"}, {"to": "559", "prefix": "dministration of propafenone did not alter the kinetics of ", "from": "550", "name": "Mexiletine", "fullId": "http://purl.bioontology.org/ontology/MESH/D008801", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "mexiletine", "suffix": " in the poor CYP2D6 metabolizer group. However, the metaboli"}, {"to": "644", "prefix": "2D6 metabolizer group. However, the metabolic clearance of ", "from": "635", "name": "Mexiletine", "fullId": "http://purl.bioontology.org/ontology/MESH/D008801", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "mexiletine", "suffix": " in the extensive metabolizer phenotype decreased by about 7"}, {"to": "922", "prefix": " unaffected in either phenotype by the coadministration of ", "from": "913", "name": "Mexiletine", "fullId": "http://purl.bioontology.org/ontology/MESH/D008801", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "mexiletine", "suffix": ". Addition of mexiletine to propafenone did not lead to furt"}, {"to": "946", "prefix": "enotype by the coadministration of mexiletine. Addition of ", "from": "937", "name": "Mexiletine", "fullId": "http://purl.bioontology.org/ontology/MESH/D008801", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "mexiletine", "suffix": " to propafenone did not lead to further electrocardiographic"}, {"to": "1160", "prefix": "ncomitant administration of either of these two drugs with ", "from": "1151", "name": "Mexiletine", "fullId": "http://purl.bioontology.org/ontology/MESH/D008801", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "mexiletine", "suffix": " is initiated, the dose of mexiletine should be slowly titra"}, {"to": "1197", "prefix": " these two drugs with mexiletine is initiated, the dose of ", "from": "1188", "name": "Mexiletine", "fullId": "http://purl.bioontology.org/ontology/MESH/D008801", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "mexiletine", "suffix": " should be slowly titrated to desired effect.In a large comp"}, {"to": "1289", "prefix": "ted to desired effect.In a large compassionate use program ", "from": "1280", "name": "Mexiletine", "fullId": "http://purl.bioontology.org/ontology/MESH/D008801", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "mexiletine", "suffix": " has been used concurrently with commonly employed antiangin"}, {"to": "1701", "prefix": "fampin and phenobarbital have been taken concurrently with ", "from": "1678", "name": "Mexiletine", "fullId": "http://purl.bioontology.org/ontology/MESH/D008801", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "mexiletine hydrochloride", "suffix": ", lowered mexiletine plasma levels have been reported. Monit"}, {"to": "1721", "prefix": " taken concurrently with mexiletine hydrochloride, lowered ", "from": "1712", "name": "Mexiletine", "fullId": "http://purl.bioontology.org/ontology/MESH/D008801", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "mexiletine", "suffix": " plasma levels have been reported. Monitoring of mexiletine "}, {"to": "1780", "prefix": "mexiletine plasma levels have been reported. Monitoring of ", "from": "1771", "name": "Mexiletine", "fullId": "http://purl.bioontology.org/ontology/MESH/D008801", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "mexiletine", "suffix": " plasma levels is recommended during such concurrent use to "}, {"to": "1936", "prefix": "n a formal study, benzodiazepines were shown not to affect ", "from": "1927", "name": "Mexiletine", "fullId": "http://purl.bioontology.org/ontology/MESH/D008801", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "mexiletine", "suffix": " plasma concentrations. ECG intervals "}, {"to": "2034", "prefix": " were not affected by concurrent ", "from": "2025", "name": "Mexiletine", "fullId": "http://purl.bioontology.org/ontology/MESH/D008801", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "mexiletine", "suffix": " and digoxin, diuretics, or propranolol.Concurrent administr"}, {"to": "2128", "prefix": "or propranolol.Concurrent administration of cimetidine and ", "from": "2119", "name": "Mexiletine", "fullId": "http://purl.bioontology.org/ontology/MESH/D008801", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "mexiletine", "suffix": " has been reported to increase, decrease, or leave unchanged"}, {"to": "2199", "prefix": "as been reported to increase, decrease, or leave unchanged ", "from": "2190", "name": "Mexiletine", "fullId": "http://purl.bioontology.org/ontology/MESH/D008801", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "mexiletine", "suffix": " plasma levels; therefore patients should be followed carefu"}, {"to": "2299", "prefix": "nts should be followed carefully during concurrent therapy.", "from": "2290", "name": "Mexiletine", "fullId": "http://purl.bioontology.org/ontology/MESH/D008801", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "Mexiletine", "suffix": " does not alter serum digoxin levels but magnesium-aluminum "}, {"to": "2446", "prefix": "oxide, when used to treat gastrointestinal symptoms due to ", "from": "2423", "name": "Mexiletine", "fullId": "http://purl.bioontology.org/ontology/MESH/D008801", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "mexiletine hydrochloride", "suffix": " USP capsules, has been reported to lower serum digoxin leve"}, {"to": "2537", "prefix": "n reported to lower serum digoxin levels.Concurrent use of ", "from": "2528", "name": "Mexiletine", "fullId": "http://purl.bioontology.org/ontology/MESH/D008801", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "mexiletine", "suffix": " and theophylline may lead to increased plasma theophylline "}, {"to": "2829", "prefix": "e first test point which was the second day after starting ", "from": "2820", "name": "Mexiletine", "fullId": "http://purl.bioontology.org/ontology/MESH/D008801", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "mexiletine", "suffix": ". Theophylline plasma levels returned to pre-mexiletine valu"}, {"to": "2884", "prefix": "ing mexiletine. Theophylline plasma levels returned to pre-", "from": "2875", "name": "Mexiletine", "fullId": "http://purl.bioontology.org/ontology/MESH/D008801", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "mexiletine", "suffix": " values within 48 hours after discontinuing mexiletine. If m"}, {"to": "2938", "prefix": " pre-mexiletine values within 48 hours after discontinuing ", "from": "2929", "name": "Mexiletine", "fullId": "http://purl.bioontology.org/ontology/MESH/D008801", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "mexiletine", "suffix": ". If mexiletine and theophylline are to be used concurrently"}, {"to": "2953", "prefix": " values within 48 hours after discontinuing mexiletine. If ", "from": "2944", "name": "Mexiletine", "fullId": "http://purl.bioontology.org/ontology/MESH/D008801", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "mexiletine", "suffix": " and theophylline are to be used concurrently, theophylline "}, {"to": "3079", "prefix": "ne blood levels should be monitored, particularly when the ", "from": "3070", "name": "Mexiletine", "fullId": "http://purl.bioontology.org/ontology/MESH/D008801", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "mexiletine", "suffix": " dose is changed. An appropriate adjustment in theophylline "}, {"to": "3333", "prefix": "caffeine was decreased 50% following the administration of ", "from": "3324", "name": "Mexiletine", "fullId": "http://purl.bioontology.org/ontology/MESH/D008801", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "mexiletine", "suffix": ".\n\n\n"}, {"to": "380", "prefix": "ine was decreased by 38% following the coadministration of ", "from": "370", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "fluvoxamine", "suffix": ", an inhibitor of CYP1A2. In another formal study "}, {"to": "518", "prefix": ", coadministration of ", "from": "508", "name": "Propafenone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8754", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "propafenone", "suffix": " did not alter the kinetics of mexiletine in the poor CYP2D6"}, {"to": "848", "prefix": "this crossover steady state study, the pharmacokinetics of ", "from": "838", "name": "Propafenone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8754", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "propafenone", "suffix": " were unaffected in either phenotype by the coadministration"}, {"to": "961", "prefix": " coadministration of mexiletine. Addition of mexiletine to ", "from": "951", "name": "Propafenone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8754", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "propafenone", "suffix": " did not lead to further electrocardiographic parameters cha"}, {"to": "1076", "prefix": " parameters changes of QRS, QTc, RR, and PR intervals than ", "from": "1066", "name": "Propafenone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8754", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "propafenone", "suffix": " alone. When concomitant administration of either of these t"}, {"to": "1472", "prefix": "bserved interactions. A variety of antiarrhythmics such as ", "from": "1464", "name": "Quinidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9068", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "quinidine", "suffix": " or propranolol were also added, sometimes with improved con"}, {"to": "1487", "prefix": "actions. A variety of antiarrhythmics such as quinidine or ", "from": "1477", "name": "Propranolol", "fullId": "http://purl.bioontology.org/ontology/MESH/D011433", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "propranolol", "suffix": " were also added, sometimes with improved control of ventric"}, {"to": "2073", "prefix": "fected by concurrent mexiletine and digoxin, diuretics, or ", "from": "2063", "name": "Propranolol", "fullId": "http://purl.bioontology.org/ontology/MESH/D011433", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "propranolol", "suffix": ".Concurrent administration of cimetidine and mexiletine has "}, {"to": "1574", "prefix": "ometimes with improved control of ventricular ectopy. When ", "from": "1566", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "phenytoin", "suffix": " or other hepatic enzyme inducers such as rifampin and pheno"}, {"to": "1624", "prefix": "y. When phenytoin or other hepatic enzyme inducers such as ", "from": "1617", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "rifampin", "suffix": " and phenobarbital have been taken concurrently with mexilet"}, {"to": "1642", "prefix": "toin or other hepatic enzyme inducers such as rifampin and ", "from": "1630", "name": "Phenobarbital", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8134", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "phenobarbital", "suffix": " have been taken concurrently with mexiletine hydrochloride,"}, {"to": "1900", "prefix": "urrent use to avoid ineffective therapy.In a formal study, ", "from": "1886", "name": "Benzodiazepines", "fullId": "http://purl.bioontology.org/ontology/MESH/D001569", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "benzodiazepines", "suffix": " were shown not to affect mexiletine plasma concentrations. "}, {"to": "2046", "prefix": " were not affected by concurrent mexiletine and ", "from": "2040", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004077", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "digoxin", "suffix": ", diuretics, or propranolol.Concurrent administration of cim"}, {"to": "2328", "prefix": " during concurrent therapy.Mexiletine does not alter serum ", "from": "2322", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004077", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "digoxin", "suffix": " levels but magnesium-aluminum hydroxide, when used to treat"}, {"to": "2501", "prefix": "drochloride USP capsules, has been reported to lower serum ", "from": "2495", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004077", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "digoxin", "suffix": " levels.Concurrent use of mexiletine and theophylline may le"}, {"to": "2113", "prefix": "in, diuretics, or propranolol.Concurrent administration of ", "from": "2104", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002927", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "cimetidine", "suffix": " and mexiletine has been reported to increase, decrease, or "}, {"to": "2554", "prefix": "ower serum digoxin levels.Concurrent use of mexiletine and ", "from": "2543", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10438", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "theophylline", "suffix": " may lead to increased plasma theophylline levels. One contr"}, {"to": "2596", "prefix": "f mexiletine and theophylline may lead to increased plasma ", "from": "2585", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10438", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "theophylline", "suffix": " levels. One controlled study in eight normal subjects showe"}, {"to": "2719", "prefix": " in plasma ", "from": "2708", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10438", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "theophylline", "suffix": " levels. This increase was observed at the first test point "}, {"to": "2843", "prefix": " point which was the second day after starting mexiletine. ", "from": "2832", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10438", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "Theophylline", "suffix": " plasma levels returned to pre-mexiletine values within 48 h"}, {"to": "2970", "prefix": "48 hours after discontinuing mexiletine. If mexiletine and ", "from": "2959", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10438", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "theophylline", "suffix": " are to be used concurrently, theophylline blood levels shou"}, {"to": "3012", "prefix": "f mexiletine and theophylline are to be used concurrently, ", "from": "3001", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10438", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "theophylline", "suffix": " blood levels should be monitored, particularly when the mex"}, {"to": "3138", "prefix": "e mexiletine dose is changed. An appropriate adjustment in ", "from": "3127", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10438", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "theophylline", "suffix": " dose should be considered.Additionally, in one controlled s"}, {"to": "3272", "prefix": " five normal subjects and seven patients, the clearance of ", "from": "3265", "name": "Caffeine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002110", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "caffeine", "suffix": " was decreased 50% following the administration of mexiletin"}, {"to": "70", "prefix": "\n\n\nCLINICAL PHARMACOLOGY\nMechanism of Action: ", "from": "47", "name": "Mexiletine Hydrochloride", "fullId": "http://purl.bioontology.org/ontology/RXNORM/142138", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "Mexiletine hydrochloride", "suffix": " is a local anesthetic, antiarrhythmic agent, structurally s"}, {"to": "760", "prefix": "APD ratio.Mechanism of Action: ", "from": "737", "name": "Mexiletine Hydrochloride", "fullId": "http://purl.bioontology.org/ontology/RXNORM/142138", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "Mexiletine hydrochloride", "suffix": " is a local anesthetic, antiarrhythmic agent, structurally s"}, {"to": "2758", "prefix": "gainst placebo, quinidine, procainamide, and disopyramide. ", "from": "2735", "name": "Mexiletine Hydrochloride", "fullId": "http://purl.bioontology.org/ontology/RXNORM/142138", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "Mexiletine hydrochloride", "suffix": ", at doses of 200 to 400 mg q8h, produced a significant redu"}, {"to": "3493", "prefix": "rmal myocardial function, following oral administration of ", "from": "3470", "name": "Mexiletine Hydrochloride", "fullId": "http://purl.bioontology.org/ontology/RXNORM/142138", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "mexiletine hydrochloride", "suffix": ", have shown small, usually not statistically significant, d"}, {"to": "3889", "prefix": "aine, has occasionally been observed following intravenous ", "from": "3866", "name": "Mexiletine Hydrochloride", "fullId": "http://purl.bioontology.org/ontology/RXNORM/142138", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "mexiletine hydrochloride", "suffix": " therapy in patients with cardiac disease.Hemodynamics: Hemo"}, {"to": "4100", "prefix": "rmal myocardial function, following oral administration of ", "from": "4077", "name": "Mexiletine Hydrochloride", "fullId": "http://purl.bioontology.org/ontology/RXNORM/142138", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "mexiletine hydrochloride", "suffix": ", have shown small, usually not statistically significant, d"}, {"to": "4496", "prefix": "aine, has occasionally been observed following intravenous ", "from": "4473", "name": "Mexiletine Hydrochloride", "fullId": "http://purl.bioontology.org/ontology/RXNORM/142138", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "mexiletine hydrochloride", "suffix": " therapy in patients with cardiac disease.Pharmacokinetics: "}, {"to": "199", "prefix": "imilar to lidocaine, but orally active. In animal studies, ", "from": "190", "name": "Mexiletine", "fullId": "http://purl.bioontology.org/ontology/MESH/D008801", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "mexiletine", "suffix": " has been shown to be effective in the suppression of induce"}, {"to": "372", "prefix": "nduced by glycoside toxicity and coronary artery ligation. ", "from": "363", "name": "Mexiletine", "fullId": "http://purl.bioontology.org/ontology/MESH/D008801", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "Mexiletine", "suffix": ", like lidocaine, inhibits the inward sodium current, thus r"}, {"to": "501", "prefix": "educing the rate of rise of the action potential, Phase 0. ", "from": "492", "name": "Mexiletine", "fullId": "http://purl.bioontology.org/ontology/MESH/D008801", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "Mexiletine", "suffix": " decreased the effective refractory period "}, {"to": "889", "prefix": "imilar to lidocaine, but orally active. In animal studies, ", "from": "880", "name": "Mexiletine", "fullId": "http://purl.bioontology.org/ontology/MESH/D008801", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "mexiletine", "suffix": " has been shown to be effective in the suppression of induce"}, {"to": "1062", "prefix": "nduced by glycoside toxicity and coronary artery ligation. ", "from": "1053", "name": "Mexiletine", "fullId": "http://purl.bioontology.org/ontology/MESH/D008801", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "Mexiletine", "suffix": ", like lidocaine, inhibits the inward sodium current, thus r"}, {"to": "1191", "prefix": "educing the rate of rise of the action potential, Phase 0. ", "from": "1182", "name": "Mexiletine", "fullId": "http://purl.bioontology.org/ontology/MESH/D008801", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "Mexiletine", "suffix": " decreased the effective refractory period "}, {"to": "1441", "prefix": "APD ratio.Electrophysiology in Man: ", "from": "1432", "name": "Mexiletine", "fullId": "http://purl.bioontology.org/ontology/MESH/D008801", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "Mexiletine", "suffix": " is a Class 1B antiarrhythmic compound with electrophysiolog"}, {"to": "1651", "prefix": ", procainamide, and disopyramide.Electrophysiology in Man: ", "from": "1642", "name": "Mexiletine", "fullId": "http://purl.bioontology.org/ontology/MESH/D008801", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "Mexiletine", "suffix": " is a Class 1B antiarrhythmic compound with electrophysiolog"}, {"to": "1879", "prefix": "d disopyramide.In patients with normal conduction systems, ", "from": "1870", "name": "Mexiletine", "fullId": "http://purl.bioontology.org/ontology/MESH/D008801", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "mexiletine", "suffix": " has a minimal effect on cardiac impulse generation and prop"}, {"to": "2049", "prefix": "nt of second-degree or third-degree AV block was observed. ", "from": "2040", "name": "Mexiletine", "fullId": "http://purl.bioontology.org/ontology/MESH/D008801", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "Mexiletine", "suffix": " did not prolong ventricular depolarization "}, {"to": "2213", "prefix": "measured by electrocardiography. Theoretically, therefore, ", "from": "2204", "name": "Mexiletine", "fullId": "http://purl.bioontology.org/ontology/MESH/D008801", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "mexiletine", "suffix": " may be useful in the treatment of ventricular arrhythmias a"}, {"to": "2619", "prefix": "ve occasionally been observed.The antiarrhythmic effect of ", "from": "2610", "name": "Mexiletine", "fullId": "http://purl.bioontology.org/ontology/MESH/D008801", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "mexiletine", "suffix": " has been established in controlled comparative trials again"}, {"to": "3306", "prefix": "trolled trials has demonstrated continued effectiveness of ", "from": "3297", "name": "Mexiletine", "fullId": "http://purl.bioontology.org/ontology/MESH/D008801", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "mexiletine", "suffix": " in long-term use.Hemodynamics: Hemodynamic studies in a lim"}, {"to": "4566", "prefix": "therapy in patients with cardiac disease.Pharmacokinetics: ", "from": "4557", "name": "Mexiletine", "fullId": "http://purl.bioontology.org/ontology/MESH/D008801", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "Mexiletine", "suffix": " is well absorbed "}, {"to": "4795", "prefix": "s. In normal subjects, the plasma elimination half-life of ", "from": "4786", "name": "Mexiletine", "fullId": "http://purl.bioontology.org/ontology/MESH/D008801", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "mexiletine", "suffix": " is approximately 10 to 12 hours. It is 50 to 60% bound to p"}, {"to": "4931", "prefix": "kg. ", "from": "4922", "name": "Mexiletine", "fullId": "http://purl.bioontology.org/ontology/MESH/D008801", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "Mexiletine", "suffix": " is mainly metabolized in the liver, the primary pathway bei"}, {"to": "5184", "prefix": "tensive metabolizer phenotypes. Since approximately 90% of ", "from": "5175", "name": "Mexiletine", "fullId": "http://purl.bioontology.org/ontology/MESH/D008801", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "mexiletine", "suffix": " is metabolized in the liver into inactive metabolites, path"}, {"to": "5318", "prefix": "cal changes in the liver can restrict hepatic clearance of ", "from": "5309", "name": "Mexiletine", "fullId": "http://purl.bioontology.org/ontology/MESH/D008801", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "mexiletine", "suffix": " and its metabolites. The metabolic degradation proceeds via"}, {"to": "5713", "prefix": "-hydroxymexiletine, hydroxy-methylmexiletine and N-hydroxy-", "from": "5704", "name": "Mexiletine", "fullId": "http://purl.bioontology.org/ontology/MESH/D008801", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "mexiletine", "suffix": ". Approximately 10% is excreted unchanged by the kidney. Whi"}, {"to": "6006", "prefix": "n, while alkalinization retards it. Several metabolites of ", "from": "5997", "name": "Mexiletine", "fullId": "http://purl.bioontology.org/ontology/MESH/D008801", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "mexiletine", "suffix": " have shown minimal antiarrhythmic activity in animal models"}, {"to": "6174", "prefix": "te N-methylmexiletine, which is less than 20% as potent as ", "from": "6165", "name": "Mexiletine", "fullId": "http://purl.bioontology.org/ontology/MESH/D008801", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "mexiletine", "suffix": ". The urinary excretion of N-methylmexiletine in man is less"}, {"to": "6289", "prefix": "in man is less than 0.5%. Thus the therapeutic activity of ", "from": "6280", "name": "Mexiletine", "fullId": "http://purl.bioontology.org/ontology/MESH/D008801", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "mexiletine", "suffix": " is due to the parent compound. Hepatic impairment prolongs "}, {"to": "6388", "prefix": ". Hepatic impairment prolongs the elimination half-life of ", "from": "6379", "name": "Mexiletine", "fullId": "http://purl.bioontology.org/ontology/MESH/D008801", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "mexiletine", "suffix": ". In eight patients with moderate to severe liver disease, t"}, {"to": "6521", "prefix": "ean half-life was approximately 25 hours.Pharmacokinetics: ", "from": "6512", "name": "Mexiletine", "fullId": "http://purl.bioontology.org/ontology/MESH/D008801", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "Mexiletine", "suffix": " is well absorbed "}, {"to": "6750", "prefix": "s. In normal subjects, the plasma elimination half-life of ", "from": "6741", "name": "Mexiletine", "fullId": "http://purl.bioontology.org/ontology/MESH/D008801", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "mexiletine", "suffix": " is approximately 10 to 12 hours. It is 50 to 60% bound to p"}, {"to": "6886", "prefix": "kg. ", "from": "6877", "name": "Mexiletine", "fullId": "http://purl.bioontology.org/ontology/MESH/D008801", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "Mexiletine", "suffix": " is mainly metabolized in the liver, the primary pathway bei"}, {"to": "7139", "prefix": "tensive metabolizer phenotypes. Since approximately 90% of ", "from": "7130", "name": "Mexiletine", "fullId": "http://purl.bioontology.org/ontology/MESH/D008801", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "mexiletine", "suffix": " is metabolized in the liver into inactive metabolites, path"}, {"to": "7273", "prefix": "cal changes in the liver can restrict hepatic clearance of ", "from": "7264", "name": "Mexiletine", "fullId": "http://purl.bioontology.org/ontology/MESH/D008801", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "mexiletine", "suffix": " and its metabolites. The metabolic degradation proceeds via"}, {"to": "7668", "prefix": "-hydroxymexiletine, hydroxy-methylmexiletine and N-hydroxy-", "from": "7659", "name": "Mexiletine", "fullId": "http://purl.bioontology.org/ontology/MESH/D008801", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "mexiletine", "suffix": ". Approximately 10% is excreted unchanged by the kidney. Whi"}, {"to": "7961", "prefix": "n, while alkalinization retards it. Several metabolites of ", "from": "7952", "name": "Mexiletine", "fullId": "http://purl.bioontology.org/ontology/MESH/D008801", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "mexiletine", "suffix": " have shown minimal antiarrhythmic activity in animal models"}, {"to": "8129", "prefix": "te N-methylmexiletine, which is less than 20% as potent as ", "from": "8120", "name": "Mexiletine", "fullId": "http://purl.bioontology.org/ontology/MESH/D008801", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "mexiletine", "suffix": ". The urinary excretion of N-methylmexiletine in man is less"}, {"to": "8244", "prefix": "in man is less than 0.5%. Thus the therapeutic activity of ", "from": "8235", "name": "Mexiletine", "fullId": "http://purl.bioontology.org/ontology/MESH/D008801", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "mexiletine", "suffix": " is due to the parent compound. Hepatic impairment prolongs "}, {"to": "8343", "prefix": ". Hepatic impairment prolongs the elimination half-life of ", "from": "8334", "name": "Mexiletine", "fullId": "http://purl.bioontology.org/ontology/MESH/D008801", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "mexiletine", "suffix": ". In eight patients with moderate to severe liver disease, t"}, {"to": "8507", "prefix": " 25 hours.Consistent with the limited renal elimination of ", "from": "8498", "name": "Mexiletine", "fullId": "http://purl.bioontology.org/ontology/MESH/D008801", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "mexiletine", "suffix": ", little change in the half-life has been detected in patien"}, {"to": "8854", "prefix": ", the mean half-life was 13.4 hours.The absorption rate of ", "from": "8845", "name": "Mexiletine", "fullId": "http://purl.bioontology.org/ontology/MESH/D008801", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "mexiletine", "suffix": " is reduced in clinical situations such as acute myocardial "}, {"to": "9084", "prefix": "ydroxide have also been reported to slow the absorption of ", "from": "9075", "name": "Mexiletine", "fullId": "http://purl.bioontology.org/ontology/MESH/D008801", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "mexiletine", "suffix": ". Metoclopramide has been reported to accelerate absorption."}, {"to": "9154", "prefix": " Metoclopramide has been reported to accelerate absorption.", "from": "9145", "name": "Mexiletine", "fullId": "http://purl.bioontology.org/ontology/MESH/D008801", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "Mexiletine", "suffix": " plasma levels of at least 0.5 mcg"}, {"to": "149", "prefix": " anesthetic, antiarrhythmic agent, structurally similar to ", "from": "141", "name": "Lidocaine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6387", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "lidocaine", "suffix": ", but orally active. In animal studies, mexiletine has been "}, {"to": "388", "prefix": "de toxicity and coronary artery ligation. Mexiletine, like ", "from": "380", "name": "Lidocaine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6387", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "lidocaine", "suffix": ", inhibits the inward sodium current, thus reducing the rate"}, {"to": "839", "prefix": " anesthetic, antiarrhythmic agent, structurally similar to ", "from": "831", "name": "Lidocaine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6387", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "lidocaine", "suffix": ", but orally active. In animal studies, mexiletine has been "}, {"to": "1078", "prefix": "de toxicity and coronary artery ligation. Mexiletine, like ", "from": "1070", "name": "Lidocaine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6387", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "lidocaine", "suffix": ", inhibits the inward sodium current, thus reducing the rate"}, {"to": "1551", "prefix": "h electrophysiologic properties in man similar to those of ", "from": "1543", "name": "Lidocaine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6387", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "lidocaine", "suffix": ", but dissimilar from quinidine, procainamide, and disopyram"}, {"to": "1761", "prefix": "h electrophysiologic properties in man similar to those of ", "from": "1753", "name": "Lidocaine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6387", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "lidocaine", "suffix": ", but dissimilar from quinidine, procainamide, and disopyram"}, {"to": "3810", "prefix": "ession of myocardial function, similar to that produced by ", "from": "3802", "name": "Lidocaine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6387", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "lidocaine", "suffix": ", has occasionally been observed following intravenous mexil"}, {"to": "4417", "prefix": "ession of myocardial function, similar to that produced by ", "from": "4409", "name": "Lidocaine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6387", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "lidocaine", "suffix": ", has occasionally been observed following intravenous mexil"}, {"to": "4640", "prefix": " from the gastrointestinal tract. Unlike ", "from": "4632", "name": "Lidocaine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6387", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "lidocaine", "suffix": ", its first-pass metabolism is low. Peak blood levels are re"}, {"to": "6595", "prefix": " from the gastrointestinal tract. Unlike ", "from": "6587", "name": "Lidocaine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6387", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "lidocaine", "suffix": ", its first-pass metabolism is low. Peak blood levels are re"}, {"to": "665", "prefix": "", "from": "663", "name": "pamidronate", "fullId": "http://purl.bioontology.org/ontology/MESH/C019248", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "APD", "suffix": ""}, {"to": "708", "prefix": "", "from": "706", "name": "pamidronate", "fullId": "http://purl.bioontology.org/ontology/MESH/C019248", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "APD", "suffix": " ratio.Mechanism of Action: Mexiletine hydrochloride is a lo"}, {"to": "1355", "prefix": "", "from": "1353", "name": "pamidronate", "fullId": "http://purl.bioontology.org/ontology/MESH/C019248", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "APD", "suffix": ""}, {"to": "1398", "prefix": "", "from": "1396", "name": "pamidronate", "fullId": "http://purl.bioontology.org/ontology/MESH/C019248", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "APD", "suffix": " ratio.Electrophysiology in Man: Mexiletine is a Class 1B an"}, {"to": "1582", "prefix": " in man similar to those of lidocaine, but dissimilar from ", "from": "1574", "name": "Quinidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9068", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "quinidine", "suffix": ", procainamide, and disopyramide.Electrophysiology in Man: M"}, {"to": "1792", "prefix": " in man similar to those of lidocaine, but dissimilar from ", "from": "1784", "name": "Quinidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9068", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "quinidine", "suffix": ", procainamide, and disopyramide.In patients with normal con"}, {"to": "2700", "prefix": "ablished in controlled comparative trials against placebo, ", "from": "2692", "name": "Quinidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9068", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "quinidine", "suffix": ", procainamide, and disopyramide. Mexiletine hydrochloride, "}, {"to": "1596", "prefix": "ilar to those of lidocaine, but dissimilar from quinidine, ", "from": "1585", "name": "Procainamide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8700", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "procainamide", "suffix": ", and disopyramide.Electrophysiology in Man: Mexiletine is a"}, {"to": "1806", "prefix": "ilar to those of lidocaine, but dissimilar from quinidine, ", "from": "1795", "name": "Procainamide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8700", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "procainamide", "suffix": ", and disopyramide.In patients with normal conduction system"}, {"to": "2714", "prefix": " controlled comparative trials against placebo, quinidine, ", "from": "2703", "name": "Procainamide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8700", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "procainamide", "suffix": ", and disopyramide. Mexiletine hydrochloride, at doses of 20"}, {"to": "1614", "prefix": "idocaine, but dissimilar from quinidine, procainamide, and ", "from": "1603", "name": "Disopyramide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3541", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "disopyramide", "suffix": ".Electrophysiology in Man: Mexiletine is a Class 1B antiarrh"}, {"to": "1824", "prefix": "idocaine, but dissimilar from quinidine, procainamide, and ", "from": "1813", "name": "Disopyramide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3541", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "disopyramide", "suffix": ".In patients with normal conduction systems, mexiletine has "}, {"to": "2732", "prefix": "ative trials against placebo, quinidine, procainamide, and ", "from": "2721", "name": "Disopyramide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3541", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "disopyramide", "suffix": ". Mexiletine hydrochloride, at doses of 200 to 400 mg q8h, p"}, {"to": "5581", "prefix": "ting metabolites are submitted to further conjugation with ", "from": "5567", "name": "Glucuronic Acid", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1426906", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "glucuronic acid", "suffix": " "}, {"to": "7536", "prefix": "ting metabolites are submitted to further conjugation with ", "from": "7522", "name": "Glucuronic Acid", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1426906", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "glucuronic acid", "suffix": " "}, {"to": "8632", "prefix": "tients with reduced renal function. In eight patients with ", "from": "8623", "name": "Creatinine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003404", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "creatinine", "suffix": " clearance less than 10 ml"}, {"to": "8751", "prefix": "imination half-life was 15.7 hours; in seven patients with ", "from": "8742", "name": "Creatinine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003404", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "creatinine", "suffix": " clearance between 11 to 40 ml"}, {"to": "8989", "prefix": "on in which gastric emptying time is increased. Narcotics, ", "from": "8982", "name": "Atropine", "fullId": "http://purl.bioontology.org/ontology/MESH/D001285", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "atropine", "suffix": ", and magnesium-aluminum hydroxide have also been reported t"}, {"to": "9100", "prefix": "e also been reported to slow the absorption of mexiletine. ", "from": "9087", "name": "Metoclopramide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6915", "setId": "AB73778B-6794-441C-B127-610A6D0733EA", "exact": "Metoclopramide", "suffix": " has been reported to accelerate absorption.Mexiletine plasm"}, {"to": "375", "prefix": "ressant, central pain inhibitory and anxiolytic actions of ", "from": "366", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "duloxetine", "suffix": " in humans are unknown, these actions are believed to be rel"}, {"to": "810", "prefix": "                       Preclinical studies have shown that ", "from": "801", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "duloxetine", "suffix": " is a potent inhibitor of neuronal serotonin and norepinephr"}, {"to": "943", "prefix": "reuptake and a less potent inhibitor of dopamine reuptake. ", "from": "934", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "Duloxetine", "suffix": " has no significant affinity for dopaminergic, adrenergic, c"}, {"to": "1088", "prefix": "aminergic, opioid, glutamate, and GABA receptors in vitro. ", "from": "1079", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "Duloxetine", "suffix": " does not inhibit monoamine oxidase "}, {"to": "1640", "prefix": "acokinetics\n\n                     \n                        ", "from": "1631", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "Duloxetine", "suffix": " has an elimination half-life of about 12 hours "}, {"to": "1892", "prefix": " typically achieved after 3 days of dosing. Elimination of ", "from": "1883", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "duloxetine", "suffix": " is mainly through hepatic metabolism involving two P450 iso"}, {"to": "2427", "prefix": " of ", "from": "2418", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "duloxetine", "suffix": " occurring 6 hours post dose. Food does not affect the Cmax "}, {"to": "2500", "prefix": "urring 6 hours post dose. Food does not affect the Cmax of ", "from": "2491", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "duloxetine", "suffix": ", but delays the time to reach peak concentration from 6 to "}, {"to": "2740", "prefix": "sorption and a one-third increase in apparent clearance of ", "from": "2731", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "duloxetine", "suffix": " after an evening dose as compared to a morning dose.\n\n     "}, {"to": "2894", "prefix": "The apparent volume of distribution averages about 1640  L. ", "from": "2885", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "Duloxetine", "suffix": " is highly bound "}, {"to": "3036", "prefix": "1-acid glycoprotein. The interaction between ", "from": "3027", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "duloxetine", "suffix": " and other highly protein bound drugs has not been fully eva"}, {"to": "3140", "prefix": "gs has not been fully evaluated. Plasma protein binding of ", "from": "3131", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "duloxetine", "suffix": " is not affected by renal or hepatic impairment.\n\n          "}, {"to": "3564", "prefix": " Biotransformation and disposition of ", "from": "3555", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "duloxetine", "suffix": " in humans have been determined following oral administratio"}, {"to": "3651", "prefix": "en determined following oral administration of 14C-labeled ", "from": "3642", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "duloxetine", "suffix": ". Duloxetine comprises about 3% of the total radiolabeled ma"}, {"to": "3663", "prefix": "d following oral administration of 14C-labeled duloxetine. ", "from": "3654", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "Duloxetine", "suffix": " comprises about 3% of the total radiolabeled material in th"}, {"to": "3859", "prefix": "rous metabolites. The major biotransformation pathways for ", "from": "3850", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "duloxetine", "suffix": " involve oxidation of the naphthyl ring followed by conjugat"}, {"to": "4079", "prefix": "ng in vitro. Metabolites found in plasma include 4-hydroxy ", "from": "4070", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "duloxetine", "suffix": " glucuronide and 5-hydroxy, 6-methoxy duloxetine sulfate. Ma"}, {"to": "4127", "prefix": " 4-hydroxy duloxetine glucuronide and 5-hydroxy, 6-methoxy ", "from": "4118", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "duloxetine", "suffix": " sulfate. Many additional metabolites have been identified i"}, {"to": "4310", "prefix": " amounts of unchanged ", "from": "4301", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "duloxetine", "suffix": " are present in the urine. Most "}, {"to": "4371", "prefix": " of the ", "from": "4362", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "duloxetine", "suffix": " dose appears in the urine as metabolites of duloxetine; abo"}, {"to": "4426", "prefix": "the duloxetine dose appears in the urine as metabolites of ", "from": "4417", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "duloxetine", "suffix": "; about 20% is excreted in the feces. Duloxetine undergoes e"}, {"to": "4474", "prefix": "bolites of duloxetine; about 20% is excreted in the feces. ", "from": "4465", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "Duloxetine", "suffix": " undergoes extensive metabolism, but the major circulating m"}, {"to": "4636", "prefix": " contribute significantly to the pharmacologic activity of ", "from": "4627", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "duloxetine", "suffix": ".\n\n                           \n                           \n "}, {"to": "4995", "prefix": " ", "from": "4986", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "Duloxetine", "suffix": " steady-state plasma concentration was comparable in childre"}, {"to": "5164", "prefix": " and adults. The average steady-state ", "from": "5155", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "duloxetine", "suffix": " concentration was approximately 30% lower in the pediatric "}, {"to": "5316", "prefix": " relative to the adults. The model-predicted ", "from": "5307", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "duloxetine", "suffix": " steady state plasma concentrations in children and adolesce"}, {"to": "1164", "prefix": ".\n\n                        ", "from": "1157", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C058218", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "CYMBALTA", "suffix": " is in a class of drugs known to affect urethral resistance."}, {"to": "1297", "prefix": "mptoms of urinary hesitation develop during treatment with ", "from": "1290", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C058218", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "CYMBALTA", "suffix": ", consideration should be given to the possibility that they"}, {"to": "2292", "prefix": " Orally administered ", "from": "2269", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C058218", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "duloxetine hydrochloride", "suffix": " is well absorbed. There is a median 2 hour lag until absorp"}, {"to": "854", "prefix": "ve shown that duloxetine is a potent inhibitor of neuronal ", "from": "846", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "serotonin", "suffix": " and norepinephrine reuptake and a less potent inhibitor of "}, {"to": "873", "prefix": "duloxetine is a potent inhibitor of neuronal serotonin and ", "from": "860", "name": "Norepinephrine", "fullId": "http://purl.bioontology.org/ontology/MESH/D009638", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "norepinephrine", "suffix": " reuptake and a less potent inhibitor of dopamine reuptake. "}, {"to": "922", "prefix": "and norepinephrine reuptake and a less potent inhibitor of ", "from": "915", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D004298", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "dopamine", "suffix": " reuptake. Duloxetine has no significant affinity for dopami"}, {"to": "1047", "prefix": "aminergic, adrenergic, cholinergic, histaminergic, opioid, ", "from": "1039", "name": "Glutamic Acid", "fullId": "http://purl.bioontology.org/ontology/MESH/D018698", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "glutamate", "suffix": ", and GABA receptors in vitro. Duloxetine does not inhibit m"}, {"to": "1057", "prefix": "nergic, cholinergic, histaminergic, opioid, glutamate, and ", "from": "1054", "name": "gamma-Aminobutyric Acid", "fullId": "http://purl.bioontology.org/ontology/MESH/D005680", "setId": "2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba", "exact": "GABA", "suffix": " receptors in vitro. Duloxetine does not inhibit monoamine o"}, {"to": "434", "prefix": "\n                           \n                              ", "from": "426", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "Indinavir", "suffix": " was rapidly absorbed in the fasted state with a time to pea"}, {"to": "619", "prefix": ". A greater than dose-proportional increase in ", "from": "611", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "indinavir", "suffix": " plasma concentrations was observed over the 200-1000 mg dos"}, {"to": "1326", "prefix": "    \n                                    Administration of ", "from": "1318", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "indinavir", "suffix": " with a meal high in calories, fat, and protein "}, {"to": "2119", "prefix": "\n                           \n                              ", "from": "2111", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "Indinavir", "suffix": " was approximately 60% bound to human plasma proteins over a"}, {"to": "2566", "prefix": "                            Following a 400-mg dose of 14C-", "from": "2558", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "indinavir", "suffix": ", 83  "}, {"to": "3325", "prefix": "           \n                              Less than 20% of ", "from": "3317", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "indinavir", "suffix": " is excreted unchanged in the urine. Mean urinary excretion "}, {"to": "3516", "prefix": " following a single 700-mg and 1000-mg dose, respectively. ", "from": "3508", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "Indinavir", "suffix": " was rapidly eliminated with a half-life of 1.8  "}, {"to": "4301", "prefix": "dence of cirrhosis had evidence of decreased metabolism of ", "from": "4293", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "indinavir", "suffix": " resulting in approximately 60% higher mean AUC following a "}, {"to": "4414", "prefix": ". The half-life of ", "from": "4406", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "indinavir", "suffix": " increased to 2.8  "}, {"to": "4454", "prefix": " 0.5 hours. ", "from": "4446", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "Indinavir", "suffix": " pharmacokinetics have not been studied in patients with sev"}, {"to": "4941", "prefix": "    \n                              The pharmacokinetics of ", "from": "4933", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "indinavir", "suffix": " have not been studied in patients with renal insufficiency."}, {"to": "5358", "prefix": "           The effect of gender on the pharmacokinetics of ", "from": "5350", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "indinavir", "suffix": " was evaluated in 10 HIV seropositive women who received CRI"}, {"to": "5539", "prefix": "ry 8 hours and lamivudine 150 mg twice a day for one week. ", "from": "5531", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "Indinavir", "suffix": " pharmacokinetic parameters in these women were compared to "}, {"to": "5687", "prefix": ". Differences in ", "from": "5679", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "indinavir", "suffix": " exposure, peak concentrations, and trough concentrations be"}, {"to": "5955", "prefix": "nce of these gender differences in the pharmacokinetics of ", "from": "5947", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "indinavir", "suffix": " is not known.\n                           \n                 "}, {"to": "6296", "prefix": "        \n                              Pharmacokinetics of ", "from": "6288", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "indinavir", "suffix": " appear to be comparable in Caucasians and Blacks based on p"}, {"to": "6802", "prefix": "                     The optimal dosing regimen for use of ", "from": "6794", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "indinavir", "suffix": " in pediatric patients has not been established. In HIV-infe"}, {"to": "6933", "prefix": ", a dosage regimen of ", "from": "6925", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "indinavir", "suffix": " capsules, 500 mg"}, {"to": "7145", "prefix": ". The pharmacokinetic profiles of ", "from": "7137", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "indinavir", "suffix": " in pediatric patients were not comparable to profiles previ"}, {"to": "8039", "prefix": "                     The optimal dosing regimen for use of ", "from": "8031", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "indinavir", "suffix": " in pregnant patients has not been established. A CRIXIVAN d"}, {"to": "8336", "prefix": ". The mean ", "from": "8328", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "indinavir", "suffix": " plasma AUC0-8hr at weeks 30-32 of gestation "}, {"to": "8530", "prefix": " patients had mean ", "from": "8522", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "indinavir", "suffix": " plasma concentrations 8 hours post-dose "}, {"to": "8661", "prefix": "eshold of reliable quantification. The pharmacokinetics of ", "from": "8653", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "indinavir", "suffix": " in these 11 patients at 6 weeks postpartum were generally s"}, {"to": "9226", "prefix": "\n                        ", "from": "9218", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "Indinavir", "suffix": " is an inhibitor of the cytochrome P450 isoform CYP3A4. Coad"}, {"to": "9583", "prefix": ". Based on in vitro data in human liver microsomes, ", "from": "9575", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "indinavir", "suffix": " does not inhibit CYP1A2, CYP2C9, CYP2E1 and CYP2B6. However"}, {"to": "9654", "prefix": "es not inhibit CYP1A2, CYP2C9, CYP2E1 and CYP2B6. However, ", "from": "9646", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "indinavir", "suffix": " may be a weak inhibitor of CYP2D6.\n                        "}, {"to": "9723", "prefix": "may be a weak inhibitor of CYP2D6.\n                        ", "from": "9715", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "Indinavir", "suffix": " is metabolized by CYP3A4. Drugs that induce CYP3A4 activity"}, {"to": "9840", "prefix": "A4 activity would be expected to increase the clearance of ", "from": "9832", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "indinavir", "suffix": ", resulting in lowered plasma concentrations of indinavir. C"}, {"to": "9897", "prefix": "f indinavir, resulting in lowered plasma concentrations of ", "from": "9889", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "indinavir", "suffix": ". Coadministration of CRIXIVAN and other drugs that inhibit "}, {"to": "10003", "prefix": "er drugs that inhibit CYP3A4 may decrease the clearance of ", "from": "9995", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "indinavir", "suffix": " and may result in increased plasma concentrations of indina"}, {"to": "10066", "prefix": "navir and may result in increased plasma concentrations of ", "from": "10058", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "indinavir", "suffix": ".\n                        Drug interaction studies were perf"}, {"to": "10394", "prefix": "effect of other drugs on ", "from": "10386", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "indinavir", "suffix": ""}, {"to": "10428", "prefix": "effect of ", "from": "10420", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "indinavir", "suffix": " on other drugs"}, {"to": "10672", "prefix": "      Delavirdine:  Delavirdine inhibits the metabolism of ", "from": "10664", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "indinavir", "suffix": " such that coadministration of 400-mg or 600-mg indinavir th"}, {"to": "10729", "prefix": "f indinavir such that coadministration of 400-mg or 600-mg ", "from": "10721", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "indinavir", "suffix": " three times daily with 400-mg delavirdine three times daily"}, {"to": "10806", "prefix": "mes daily with 400-mg delavirdine three times daily alters ", "from": "10798", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "indinavir", "suffix": " AUC, Cmax and Cmin "}, {"to": "10850", "prefix": ". ", "from": "10842", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "Indinavir", "suffix": " had no effect on delavirdine pharmacokinetics "}, {"to": "11124", "prefix": "  \n                           Methadone: Administration of ", "from": "11116", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "indinavir", "suffix": " "}, {"to": "11360", "prefix": "rison to historical data, there was little or no change in ", "from": "11352", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "indinavir", "suffix": " AUC.\n                        \n                           Ri"}, {"to": "11491", "prefix": "avir: Compared to historical data in patients who received ", "from": "11483", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "indinavir", "suffix": " 800 mg every 8 hours alone, twice-daily coadministration to"}, {"to": "11575", "prefix": "hours alone, twice-daily coadministration to volunteers of ", "from": "11567", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "indinavir", "suffix": " 800 mg and ritonavir with food for two weeks resulted in a "}, {"to": "11665", "prefix": "with food for two weeks resulted in a 2.7-fold increase of ", "from": "11657", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "indinavir", "suffix": " AUC24h, a 1.6-fold increase in indinavir Cmax, and an 11-fo"}, {"to": "11706", "prefix": "-fold increase of indinavir AUC24h, a 1.6-fold increase in ", "from": "11698", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "indinavir", "suffix": " Cmax, and an 11-fold increase in indinavir Cmin for a 100-m"}, {"to": "11749", "prefix": "old increase in indinavir Cmax, and an 11-fold increase in ", "from": "11741", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "indinavir", "suffix": " Cmin for a 100-mg ritonavir dose and a 3.6-fold increase of"}, {"to": "11819", "prefix": "min for a 100-mg ritonavir dose and a 3.6-fold increase of ", "from": "11811", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "indinavir", "suffix": " AUC24h, a 1.8- fold increase in indinavir Cmax, and a 24-fo"}, {"to": "11861", "prefix": "fold increase of indinavir AUC24h, a 1.8- fold increase in ", "from": "11853", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "indinavir", "suffix": " Cmax, and a 24-fold increase in indinavir Cmin for a 200-mg"}, {"to": "11903", "prefix": "fold increase in indinavir Cmax, and a 24-fold increase in ", "from": "11895", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "indinavir", "suffix": " Cmin for a 200-mg ritonavir dose. In the same study, twice-"}, {"to": "11998", "prefix": "r dose. In the same study, twice-daily coadministration of ", "from": "11990", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "indinavir", "suffix": " "}, {"to": "12303", "prefix": " indicated that coadministration of ", "from": "12295", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "indinavir", "suffix": " "}, {"to": "12438", "prefix": "denafil resulted in an 11% increase in average AUC0-8hr of ", "from": "12430", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "indinavir", "suffix": " and a 48% increase in average indinavir peak concentration "}, {"to": "12478", "prefix": "verage AUC0-8hr of indinavir and a 48% increase in average ", "from": "12470", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "indinavir", "suffix": " peak concentration "}, {"to": "12644", "prefix": "eased by 340% following coadministration of sildenafil and ", "from": "12636", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "indinavir", "suffix": " compared to historical data following administration of sil"}, {"to": "12880", "prefix": "                   \n                           Vardenafil: ", "from": "12872", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "Indinavir", "suffix": " "}, {"to": "5423", "prefix": "ir was evaluated in 10 HIV seropositive women who received ", "from": "5416", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019469", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "CRIXIVAN", "suffix": " 800 mg every 8 hours with zidovudine 200  mg every 8 hours a"}, {"to": "8097", "prefix": "indinavir in pregnant patients has not been established. A ", "from": "8090", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019469", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "CRIXIVAN", "suffix": " dose of 800 mg every 8 hours "}, {"to": "9310", "prefix": "of the cytochrome P450 isoform CYP3A4. Coadministration of ", "from": "9303", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019469", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "CRIXIVAN", "suffix": " and drugs primarily metabolized by CYP3A4 may result in inc"}, {"to": "9927", "prefix": "ed plasma concentrations of indinavir. Coadministration of ", "from": "9920", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019469", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "CRIXIVAN", "suffix": " and other drugs that inhibit CYP3A4 may decrease the cleara"}, {"to": "10145", "prefix": "              Drug interaction studies were performed with ", "from": "10138", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019469", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "CRIXIVAN", "suffix": " and other drugs likely to be coadministered and some drugs "}, {"to": "10306", "prefix": "cokinetic interactions. The effects of coadministration of ", "from": "10299", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019469", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "CRIXIVAN", "suffix": " on the AUC, Cmax and Cmin are summarized in Table 2 "}, {"to": "5460", "prefix": "tive women who received CRIXIVAN 800 mg every 8 hours with ", "from": "5451", "name": "Zidovudine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/11413", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "zidovudine", "suffix": " 200  mg every 8 hours and lamivudine 150 mg twice a day for "}, {"to": "8143", "prefix": "with ", "from": "8134", "name": "Zidovudine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/11413", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "zidovudine", "suffix": " 200 mg every 8 hours and lamivudine 150 mg twice a day"}, {"to": "5496", "prefix": " mg every 8 hours with zidovudine 200  mg every 8 hours and ", "from": "5487", "name": "Lamivudine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/68244", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "lamivudine", "suffix": " 150 mg twice a day for one week. Indinavir pharmacokinetic "}, {"to": "8179", "prefix": "with zidovudine 200 mg every 8 hours and ", "from": "8170", "name": "Lamivudine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/68244", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "lamivudine", "suffix": " 150 mg twice a day"}, {"to": "10621", "prefix": "\n\n\n\n                        \n\n\n\n                           ", "from": "10611", "name": "Delavirdine", "fullId": "http://purl.bioontology.org/ontology/MESH/D020008", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "Delavirdine", "suffix": ":  Delavirdine inhibits the metabolism of indinavir such tha"}, {"to": "10635", "prefix": "              \n\n\n\n                           Delavirdine:  ", "from": "10625", "name": "Delavirdine", "fullId": "http://purl.bioontology.org/ontology/MESH/D020008", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "Delavirdine", "suffix": " inhibits the metabolism of indinavir such that coadministra"}, {"to": "10771", "prefix": "f 400-mg or 600-mg indinavir three times daily with 400-mg ", "from": "10761", "name": "Delavirdine", "fullId": "http://purl.bioontology.org/ontology/MESH/D020008", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "delavirdine", "suffix": " three times daily alters indinavir AUC, Cmax and Cmin "}, {"to": "10879", "prefix": ". Indinavir had no effect on ", "from": "10869", "name": "Delavirdine", "fullId": "http://purl.bioontology.org/ontology/MESH/D020008", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "delavirdine", "suffix": " pharmacokinetics "}, {"to": "10961", "prefix": "see DOSAGE AND ADMINISTRATION, Concomitant Therapy, ", "from": "10951", "name": "Delavirdine", "fullId": "http://purl.bioontology.org/ontology/MESH/D020008", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "Delavirdine", "suffix": ""}, {"to": "11011", "prefix": ", based on a comparison to historical ", "from": "11001", "name": "Delavirdine", "fullId": "http://purl.bioontology.org/ontology/MESH/D020008", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "delavirdine", "suffix": " pharmacokinetic data.\n                        \n            "}, {"to": "11095", "prefix": " data.\n                        \n                           ", "from": "11087", "name": "Methadone", "fullId": "http://purl.bioontology.org/ontology/MESH/D008691", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "Methadone", "suffix": ": Administration of indinavir "}, {"to": "11162", "prefix": " with ", "from": "11154", "name": "Methadone", "fullId": "http://purl.bioontology.org/ontology/MESH/D008691", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "methadone", "suffix": " "}, {"to": "11223", "prefix": " for one week in subjects on ", "from": "11215", "name": "Methadone", "fullId": "http://purl.bioontology.org/ontology/MESH/D008691", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "methadone", "suffix": " maintenance resulted in no change in methadone AUC. Based o"}, {"to": "11270", "prefix": "subjects on methadone maintenance resulted in no change in ", "from": "11262", "name": "Methadone", "fullId": "http://purl.bioontology.org/ontology/MESH/D008691", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "methadone", "suffix": " AUC. Based on a comparison to historical data, there was li"}, {"to": "11427", "prefix": "r AUC.\n                        \n                           ", "from": "11419", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "Ritonavir", "suffix": ": Compared to historical data in patients who received indin"}, {"to": "11596", "prefix": "ily coadministration to volunteers of indinavir 800 mg and ", "from": "11588", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "ritonavir", "suffix": " with food for two weeks resulted in a 2.7-fold increase of "}, {"to": "11777", "prefix": "ax, and an 11-fold increase in indinavir Cmin for a 100-mg ", "from": "11769", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "ritonavir", "suffix": " dose and a 3.6-fold increase of indinavir AUC24h, a 1.8- fo"}, {"to": "11931", "prefix": "max, and a 24-fold increase in indinavir Cmin for a 200-mg ", "from": "11923", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "ritonavir", "suffix": " dose. In the same study, twice-daily coadministration of in"}, {"to": "12021", "prefix": " and ", "from": "12013", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "ritonavir", "suffix": " "}, {"to": "12059", "prefix": " resulted in ", "from": "12051", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "ritonavir", "suffix": " AUC24h increases versus the same doses of ritonavir alone "}, {"to": "12111", "prefix": "ted in ritonavir AUC24h increases versus the same doses of ", "from": "12103", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "ritonavir", "suffix": " alone "}, {"to": "12195", "prefix": ".\n                        \n                           ", "from": "12186", "name": "sildenafil", "fullId": "http://purl.bioontology.org/ontology/RXNORM/136411", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "Sildenafil", "suffix": ":  The results of one published study in HIV-infected men "}, {"to": "12377", "prefix": " with a single 25-mg dose of ", "from": "12368", "name": "sildenafil", "fullId": "http://purl.bioontology.org/ontology/RXNORM/136411", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "sildenafil", "suffix": " resulted in an 11% increase in average AUC0-8hr of indinavi"}, {"to": "12563", "prefix": " compared to 800 mg every 8 hours alone. Average ", "from": "12554", "name": "sildenafil", "fullId": "http://purl.bioontology.org/ontology/RXNORM/136411", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "sildenafil", "suffix": " AUC was increased by 340% following coadministration of sil"}, {"to": "12630", "prefix": "il AUC was increased by 340% following coadministration of ", "from": "12621", "name": "sildenafil", "fullId": "http://purl.bioontology.org/ontology/RXNORM/136411", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "sildenafil", "suffix": " and indinavir compared to historical data following adminis"}, {"to": "12711", "prefix": "ir compared to historical data following administration of ", "from": "12702", "name": "sildenafil", "fullId": "http://purl.bioontology.org/ontology/RXNORM/136411", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "sildenafil", "suffix": " alone "}, {"to": "12869", "prefix": ".\n                        \n                           ", "from": "12860", "name": "vardenafil", "fullId": "http://purl.bioontology.org/ontology/MESH/C426063", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "Vardenafil", "suffix": ": Indinavir "}, {"to": "12957", "prefix": " coadministered with a single 10-mg dose of ", "from": "12948", "name": "vardenafil", "fullId": "http://purl.bioontology.org/ontology/MESH/C426063", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "vardenafil", "suffix": " resulted in a 16-fold increase in vardenafil AUC, a 7-fold "}, {"to": "13002", "prefix": "10-mg dose of vardenafil resulted in a 16-fold increase in ", "from": "12993", "name": "vardenafil", "fullId": "http://purl.bioontology.org/ontology/MESH/C426063", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "vardenafil", "suffix": " AUC, a 7-fold increase in vardenafil Cmax, and a 2-fold inc"}, {"to": "13039", "prefix": "a 16-fold increase in vardenafil AUC, a 7-fold increase in ", "from": "13030", "name": "vardenafil", "fullId": "http://purl.bioontology.org/ontology/MESH/C426063", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "vardenafil", "suffix": " Cmax, and a 2-fold increase in vardenafil half-life "}, {"to": "13081", "prefix": "fold increase in vardenafil Cmax, and a 2-fold increase in ", "from": "13072", "name": "vardenafil", "fullId": "http://purl.bioontology.org/ontology/MESH/C426063", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "vardenafil", "suffix": " half-life "}, {"to": "342", "prefix": "            \n                     \n                        ", "from": "334", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "Bupropion", "suffix": " is a relatively weak inhibitor of the neuronal uptake of no"}, {"to": "545", "prefix": "dase or the re-uptake of serotonin. The mechanism by which ", "from": "523", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "Bupropion Hydrochloride", "suffix": " Extended-Release Tablets, USP "}, {"to": "1051", "prefix": "            \n                     \n                        ", "from": "1043", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "Bupropion", "suffix": " is a racemic mixture. The pharmacologic activity and pharma"}, {"to": "1184", "prefix": "etics of the individual enantiomers have not been studied. ", "from": "1176", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "Bupropion", "suffix": " follows biphasic pharmacokinetics best described by a 2-com"}, {"to": "1474", "prefix": "                   \n                           Absorption: ", "from": "1466", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "Bupropion", "suffix": " has not been administered intravenously to humans; therefor"}, {"to": "1592", "prefix": "usly to humans; therefore, the absolute bioavailability of ", "from": "1570", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "Bupropion Hydrochloride", "suffix": " Extended-Release Tablets, USP "}, {"to": "1719", "prefix": "determined. In rat and dog studies, the bioavailability of ", "from": "1711", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "bupropion", "suffix": " ranged from 5% to 20%.\n                        Following or"}, {"to": "1823", "prefix": ".\n                        Following oral administration of ", "from": "1801", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "Bupropion Hydrochloride", "suffix": " Extended-Release Tablets, USP "}, {"to": "1921", "prefix": " to healthy volunteers, peak plasma concentrations of ", "from": "1913", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "bupropion", "suffix": " are achieved within 3 hours. The mean peak concentration "}, {"to": "2181", "prefix": "mL.\n                        Exposure to ", "from": "2173", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "bupropion", "suffix": " may be increased when Bupropion Hydrochloride Extended-Rele"}, {"to": "2227", "prefix": "               Exposure to bupropion may be increased when ", "from": "2205", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "Bupropion Hydrochloride", "suffix": " Extended-Release Tablets, USP "}, {"to": "2379", "prefix": " of ", "from": "2371", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "bupropion", "suffix": " increased by 11% to 35% when administered with food, while "}, {"to": "2474", "prefix": " to ", "from": "2466", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "bupropion", "suffix": " increased by 16% to 19%. The food effect is not considered "}, {"to": "2584", "prefix": "e food effect is not considered clinically significant and ", "from": "2562", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "Bupropion Hydrochloride", "suffix": " Extended-Release Tablets, USP "}, {"to": "2782", "prefix": "ution:\n                           In vitro tests show that ", "from": "2774", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "bupropion", "suffix": " is 84% bound to human plasma proteins at concentrations up "}, {"to": "2954", "prefix": " of the hydroxybupropion metabolite is similar to that for ", "from": "2946", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "bupropion", "suffix": ", whereas the extent of protein binding of the threohydrobup"}, {"to": "3070", "prefix": "hreohydrobupropion metabolite is about half that seen with ", "from": "3062", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "bupropion", "suffix": ". The volume of distribution "}, {"to": "3258", "prefix": "                   \n                           Metabolism: ", "from": "3250", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "Bupropion", "suffix": " is extensively metabolized in humans. Three metabolites hav"}, {"to": "3433", "prefix": "ich is formed via hydroxylation of the tert-butyl group of ", "from": "3425", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "bupropion", "suffix": ", and the amino-alcohol isomers threohydrobupropion and eryt"}, {"to": "3817", "prefix": " in the formation of threohydrobupropion. Oxidation of the ", "from": "3809", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "bupropion", "suffix": " side chain results in the formation of a glycine conjugate "}, {"to": "4026", "prefix": "e. The potency and toxicity of the metabolites relative to ", "from": "4018", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "bupropion", "suffix": " have not been fully characterized. However, it has been dem"}, {"to": "4196", "prefix": "est in mice that hydroxybupropion is one-half as potent as ", "from": "4188", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "bupropion", "suffix": ", while threohydrobupropion and erythrohydrobupropion are 5-"}, {"to": "4287", "prefix": "pion and erythrohydrobupropion are 5-fold less potent than ", "from": "4279", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "bupropion", "suffix": ". This may be of clinical importance because the plasma conc"}, {"to": "4422", "prefix": "ons of the metabolites are as high or higher than those of ", "from": "4414", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "bupropion", "suffix": ".\n                        Because bupropion is extensively m"}, {"to": "4465", "prefix": "r than those of bupropion.\n                        Because ", "from": "4457", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "bupropion", "suffix": " is extensively metabolized, there is the potential for drug"}, {"to": "4809", "prefix": "t a dose of 100 mg twice daily reduced the AUC and Cmax of ", "from": "4801", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "bupropion", "suffix": " by 22% and 21%, respectively. The exposure of the hydroxybu"}, {"to": "5146", "prefix": "se of 600 mg twice daily decreased the AUC and the Cmax of ", "from": "5138", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "bupropion", "suffix": " by 66% and 62%, respectively. The exposure of the hydroxybu"}, {"to": "5473", "prefix": " decreased ", "from": "5465", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "bupropion", "suffix": " AUC and Cmax by 57%. The AUC and Cmax of hydroxybupropion w"}, {"to": "5749", "prefix": " 600 mg once daily for 2 weeks reduced the AUC and Cmax of ", "from": "5741", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "bupropion", "suffix": " by approximately 55% and 34%, respectively. The AUC of hydr"}, {"to": "5934", "prefix": "ion was increased by 50%.\n                        Although ", "from": "5926", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "bupropion", "suffix": " is not metabolized by cytochrome P450IID6 "}, {"to": "6051", "prefix": ", there is the potential for drug-drug interactions when ", "from": "6043", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "bupropion", "suffix": " is coadministered with drugs metabolized by this isoenzyme "}, {"to": "6330", "prefix": "ropion occur approximately 6 hours after administration of ", "from": "6308", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "Bupropion Hydrochloride", "suffix": " Extended-Release Tablets, USP "}, {"to": "6633", "prefix": "urs, and its AUC at steady state is about 17 times that of ", "from": "6625", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "bupropion", "suffix": ". The times to peak concentrations for the erythrohydrobupro"}, {"to": "6942", "prefix": "ctively, and steady-state AUCs are 1.5 and 7 times that of ", "from": "6934", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "bupropion", "suffix": ", respectively.\n                        Bupropion and its me"}, {"to": "6991", "prefix": "s that of bupropion, respectively.\n                        ", "from": "6983", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "Bupropion", "suffix": " and its metabolites exhibit linear kinetics following chron"}, {"to": "7342", "prefix": ". Following chronic dosing of 150 mg of ", "from": "7320", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "Bupropion Hydrochloride", "suffix": " Extended-Release Tablets, USP "}, {"to": "7509", "prefix": ". The mean elimination half-life of ", "from": "7501", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "bupropion", "suffix": " estimated from a series of studies is approximately 21 hour"}, {"to": "7835", "prefix": "ythrohydrobupropion. Steady-state plasma concentrations of ", "from": "7827", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "bupropion", "suffix": " and metabolites are reached within 5 and 8 days, respective"}, {"to": "7979", "prefix": "            Following oral administration of 200 mg of 14C-", "from": "7971", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "bupropion", "suffix": " in humans, 87% and 10% of the radioactive dose were recover"}, {"to": "8122", "prefix": " and feces, respectively. The fraction of the oral dose of ", "from": "8114", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "bupropion", "suffix": " excreted unchanged was only 0.5%.\n                        T"}, {"to": "8250", "prefix": "he effects of cigarette smoking on the pharmacokinetics of ", "from": "8242", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "bupropion", "suffix": " were studied in 34 healthy male and female volunteers; 17 w"}, {"to": "8444", "prefix": ". Following oral administration of a single 150-mg dose of ", "from": "8422", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "Bupropion Hydrochloride", "suffix": " Extended-Release Tablets, USP "}, {"to": "8587", "prefix": " difference in Cmax, half-life, Tmax, AUC, or clearance of ", "from": "8579", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "bupropion", "suffix": " or its major metabolites between smokers and nonsmokers.\n  "}, {"to": "8742", "prefix": "         In a study comparing the treatment combination of ", "from": "8720", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "Bupropion Hydrochloride", "suffix": " Extended-Release Tablets, USP "}, {"to": "8846", "prefix": " versus ", "from": "8824", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "Bupropion Hydrochloride", "suffix": " Extended-Release Tablets, USP "}, {"to": "9013", "prefix": "ere observed between the 2 treatment groups of combination ", "from": "8991", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "Bupropion Hydrochloride", "suffix": " Extended-Release Tablets, USP "}, {"to": "9094", "prefix": " and ", "from": "9072", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "Bupropion Hydrochloride", "suffix": " Extended-Release Tablets, USP "}, {"to": "9187", "prefix": " in the plasma concentrations of ", "from": "9179", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "bupropion", "suffix": " or its active metabolites at weeks 3 and 6.\n               "}, {"to": "9566", "prefix": "ee and extent of accumulation of the active metabolites of ", "from": "9558", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "bupropion", "suffix": ". The elimination of the major metabolites of bupropion may "}, {"to": "9621", "prefix": " of bupropion. The elimination of the major metabolites of ", "from": "9613", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "bupropion", "suffix": " may be affected by reduced renal or hepatic function becaus"}, {"to": "9975", "prefix": "he effect of hepatic impairment on the pharmacokinetics of ", "from": "9967", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "bupropion", "suffix": " was characterized in 2 single-dose studies, one in patients"}, {"to": "10388", "prefix": ". Although not statistically significant, the AUCs for ", "from": "10380", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "bupropion", "suffix": " and hydroxybupropion were more variable and tended to be gr"}, {"to": "10554", "prefix": " alcoholic liver disease. The differences in half-life for ", "from": "10546", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "bupropion", "suffix": " and the other metabolites in the 2 patient groups were mini"}, {"to": "10760", "prefix": "tically significant differences in the pharmacokinetics of ", "from": "10752", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "bupropion", "suffix": " and its active metabolites in 9 patients with mild-to-moder"}, {"to": "10970", "prefix": "was observed in some of the pharmacokinetic parameters for ", "from": "10962", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "bupropion", "suffix": " "}, {"to": "11147", "prefix": "n addition, in patients with severe hepatic cirrhosis, the ", "from": "11139", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "bupropion", "suffix": " Cmax and AUC were substantially increased "}, {"to": "11338", "prefix": "le when compared to values in healthy volunteers; the mean ", "from": "11330", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "bupropion", "suffix": " half-life was also longer "}, {"to": "12244", "prefix": "l: There is limited information on the pharmacokinetics of ", "from": "12236", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "bupropion", "suffix": " in patients with renal impairment. An inter-study compariso"}, {"to": "12818", "prefix": "that exposure to a single 150-mg dose of sustained-release ", "from": "12810", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "bupropion", "suffix": " was approximately 2-fold higher in patients with impaired r"}, {"to": "13042", "prefix": "tabolites were similar in the 2 groups. The elimination of ", "from": "13034", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "bupropion", "suffix": " and"}, {"to": "13084", "prefix": "or the major metabolites of ", "from": "13076", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "bupropion", "suffix": " may be reduced by impaired renal function "}, {"to": "13290", "prefix": "entricular Dysfunction: During a chronic dosing study with ", "from": "13282", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "bupropion", "suffix": " in 14 depressed patients with left ventricular dysfunction "}, {"to": "13453", "prefix": ", no apparent effect on the pharmacokinetics of ", "from": "13445", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "bupropion", "suffix": " or its metabolites, compared to healthy normal volunteers, "}, {"to": "13664", "prefix": "        Age: The effects of age on the pharmacokinetics of ", "from": "13656", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "bupropion", "suffix": " and its metabolites have not been fully characterized, but "}, {"to": "13764", "prefix": "en fully characterized, but an exploration of steady-state ", "from": "13756", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "bupropion", "suffix": " concentrations from several depression efficacy studies inv"}, {"to": "13999", "prefix": " and plasma concentration of ", "from": "13991", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "bupropion", "suffix": ". A single-dose pharmacokinetic study demonstrated that the "}, {"to": "14083", "prefix": "pharmacokinetic study demonstrated that the disposition of ", "from": "14075", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "bupropion", "suffix": " and its metabolites in elderly subjects was similar to that"}, {"to": "14232", "prefix": " These data suggest there is no prominent effect of age on ", "from": "14224", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "bupropion", "suffix": " concentration; however, another pharmacokinetic study, sing"}, {"to": "14396", "prefix": "that the elderly are at increased risk for accumulation of ", "from": "14388", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "bupropion", "suffix": " and its metabolites "}, {"to": "14672", "prefix": "x-related differences in the pharmacokinetic parameters of ", "from": "14664", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "bupropion", "suffix": ".\n                     \n                     \n              "}, {"to": "14981", "prefix": "                  \n                        The efficacy of ", "from": "14959", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "Bupropion Hydrochloride", "suffix": " Extended-Release Tablets, USP "}, {"to": "15230", "prefix": ". In these studies, ", "from": "15208", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "Bupropion Hydrochloride", "suffix": " Extended-Release Tablets, USP "}, {"to": "15527", "prefix": "n this study were treated for 7 weeks with 1 of 3 doses of ", "from": "15505", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "Bupropion Hydrochloride", "suffix": " Extended-Release Tablets, USP "}, {"to": "15894", "prefix": "                  Results of this dose-response trial with ", "from": "15872", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "Bupropion Hydrochloride", "suffix": " Extended-Release Tablets, USP "}, {"to": "16092", "prefix": ". Treatment with ", "from": "16070", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "Bupropion Hydrochloride", "suffix": " Extended-Release Tablets, USP "}, {"to": "16530", "prefix": " 4 of the study through the specified week. Treatment with ", "from": "16508", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "Bupropion Hydrochloride", "suffix": " Extended-Release Tablets, USP "}, {"to": "16716", "prefix": "nts achieve 4-week abstinence. In addition, treatment with ", "from": "16694", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "Bupropion Hydrochloride", "suffix": " Extended-Release Tablets, USP "}, {"to": "17083", "prefix": "ted at 4 clinical centers. Four treatments were evaluated: ", "from": "17061", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "Bupropion Hydrochloride", "suffix": " Extended-Release Tablets, USP "}, {"to": "17214", "prefix": "day, combination of ", "from": "17192", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "Bupropion Hydrochloride", "suffix": " Extended-Release Tablets, USP "}, {"to": "17367", "prefix": "placebo. Patients were treated for 9 weeks. Treatment with ", "from": "17345", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "Bupropion Hydrochloride", "suffix": " Extended-Release Tablets, USP "}, {"to": "17606", "prefix": "day was added to treatment with ", "from": "17584", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "Bupropion Hydrochloride", "suffix": " Extended-Release Tablets, USP "}, {"to": "18358", "prefix": "is study were followed out to one year, the superiority of ", "from": "18336", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "Bupropion Hydrochloride", "suffix": " Extended-Release Tablets, USP "}, {"to": "18440", "prefix": " and the combination of ", "from": "18418", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "Bupropion Hydrochloride", "suffix": " Extended-Release Tablets, USP "}, {"to": "18677", "prefix": " in the patients treated with ", "from": "18655", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "Bupropion Hydrochloride", "suffix": " Extended-Release Tablets, USP "}, {"to": "18973", "prefix": " in the patients treated with ", "from": "18951", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "Bupropion Hydrochloride", "suffix": " Extended-Release Tablets, USP "}, {"to": "19194", "prefix": "n the placebo group. Although the treatment combination of ", "from": "19172", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "Bupropion Hydrochloride", "suffix": " Extended-Release Tablets, USP "}, {"to": "19419", "prefix": " than for ", "from": "19397", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "Bupropion Hydrochloride", "suffix": " Extended-Release Tablets, USP "}, {"to": "19533", "prefix": " alone.\n                        The comparisons between ", "from": "19511", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "Bupropion Hydrochloride", "suffix": " Extended-Release Tablets, USP "}, {"to": "19940", "prefix": "inical centers. Patients in this study received open-label ", "from": "19918", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "Bupropion Hydrochloride", "suffix": " Extended-Release Tablets, USP "}, {"to": "20065", "prefix": "day for 7 weeks. Patients who quit smoking while receiving ", "from": "20043", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "Bupropion Hydrochloride", "suffix": " Extended-Release Tablets, USP "}, {"to": "20158", "prefix": " were then randomized to ", "from": "20136", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "Bupropion Hydrochloride", "suffix": " Extended-Release Tablets, USP "}, {"to": "20522", "prefix": "re significantly higher for patients continuing to receive ", "from": "20500", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "Bupropion Hydrochloride", "suffix": " Extended-Release Tablets, USP "}, {"to": "20828", "prefix": "pulation may be lower than the above rates. Quit rates for ", "from": "20806", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "Bupropion Hydrochloride", "suffix": " Extended-Release Tablets, USP "}, {"to": "21024", "prefix": "eplacement therapy.\n                        Treatment with ", "from": "21002", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "Bupropion Hydrochloride", "suffix": " Extended-Release Tablets, USP "}, {"to": "21387", "prefix": "epending on the study and the measure used, treatment with ", "from": "21365", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "Bupropion Hydrochloride", "suffix": " Extended-Release Tablets, USP "}, {"to": "21658", "prefix": ": ", "from": "21636", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "Bupropion Hydrochloride", "suffix": " Extended-Release Tablets, USP "}, {"to": "21985", "prefix": "s disease. Patients aged 36 to 76 years were randomized to ", "from": "21963", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "Bupropion Hydrochloride", "suffix": " Extended-Release Tablets, USP "}, {"to": "22127", "prefix": " and treated for 12 weeks. Treatment with ", "from": "22105", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "Bupropion Hydrochloride", "suffix": " Extended-Release Tablets, USP "}, {"to": "414", "prefix": "n is a relatively weak inhibitor of the neuronal uptake of ", "from": "401", "name": "Norepinephrine", "fullId": "http://purl.bioontology.org/ontology/MESH/D009638", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "norepinephrine", "suffix": " and dopamine, and does not inhibit monoamine oxidase or the"}, {"to": "427", "prefix": "eak inhibitor of the neuronal uptake of norepinephrine and ", "from": "420", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D004298", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "dopamine", "suffix": ", and does not inhibit monoamine oxidase or the re-uptake of"}, {"to": "497", "prefix": "and does not inhibit monoamine oxidase or the re-uptake of ", "from": "489", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "serotonin", "suffix": ". The mechanism by which Bupropion Hydrochloride Extended-Re"}, {"to": "3866", "prefix": " of the bupropion side chain results in the formation of a ", "from": "3860", "name": "Glycine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4919", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "glycine", "suffix": " conjugate of meta-chlorobenzoic acid, which is then excrete"}, {"to": "4685", "prefix": " isoenzyme, such as ", "from": "4677", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "ritonavir", "suffix": " or efavirenz. In a healthy volunteer study, ritonavir at a "}, {"to": "4739", "prefix": "h as ritonavir or efavirenz. In a healthy volunteer study, ", "from": "4731", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "ritonavir", "suffix": " at a dose of 100 mg twice daily reduced the AUC and Cmax of"}, {"to": "5070", "prefix": "                      In a second healthy volunteer study, ", "from": "5062", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "ritonavir", "suffix": " at a dose of 600 mg twice daily decreased the AUC and the C"}, {"to": "5433", "prefix": "", "from": "5425", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "ritonavir", "suffix": " 100 mg twice daily"}, {"to": "4698", "prefix": " isoenzyme, such as ritonavir or ", "from": "4690", "name": "efavirenz", "fullId": "http://purl.bioontology.org/ontology/RXNORM/195085", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "efavirenz", "suffix": ". In a healthy volunteer study, ritonavir at a dose of 100 m"}, {"to": "5681", "prefix": "\n                        In a study in healthy volunteers, ", "from": "5673", "name": "efavirenz", "fullId": "http://purl.bioontology.org/ontology/RXNORM/195085", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "efavirenz", "suffix": " 600 mg once daily for 2 weeks reduced the AUC and Cmax of b"}, {"to": "5404", "prefix": "                       In another healthy volunteer study, ", "from": "5398", "name": "Kaletra", "fullId": "http://purl.bioontology.org/ontology/RXNORM/284756", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "KALETRA", "suffix": " "}, {"to": "5416", "prefix": "", "from": "5408", "name": "Lopinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D061466", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "lopinavir", "suffix": " 400 mg"}, {"to": "8790", "prefix": " and ", "from": "8783", "name": "Nicotine", "fullId": "http://purl.bioontology.org/ontology/MESH/D009538", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "nicotine", "suffix": " transdermal system "}, {"to": "17139", "prefix": "day, ", "from": "17132", "name": "Nicotine", "fullId": "http://purl.bioontology.org/ontology/MESH/D009538", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "nicotine", "suffix": " transdermal system "}, {"to": "20940", "prefix": "lar in patients with and without prior quit attempts using ", "from": "20933", "name": "Nicotine", "fullId": "http://purl.bioontology.org/ontology/MESH/D009538", "setId": "c2126e2d-3b46-40dd-8168-6d0368e5d233", "exact": "nicotine", "suffix": " replacement therapy.\n                        Treatment with"}, {"to": "94", "prefix": "PharmacodynamicsPharmacodynamicsThe mechanism of action of ", "from": "85", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": ", as with other antidepressants, is unknown.Preclinical stud"}, {"to": "184", "prefix": "epressants, is unknown.Preclinical studies have shown that ", "from": "175", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " inhibits neuronal uptake of serotonin and norepinephrine.Ne"}, {"to": "252", "prefix": "e inhibits neuronal uptake of serotonin and norepinephrine.", "from": "243", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "Nefazodone", "suffix": " occupies central 5-HT 2 receptors at nanomolar concentratio"}, {"to": "370", "prefix": "oncentrations, and acts as an antagonist at this receptor. ", "from": "361", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "Nefazodone", "suffix": " was shown to antagonize alpha1-adrenergic receptors, a prop"}, {"to": "533", "prefix": "postural hypotension. In vitro binding studies showed that ", "from": "524", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " had no significant affinity for the following receptors: al"}, {"to": "767", "prefix": "oncentrations, and acts as an antagonist at this receptor. ", "from": "758", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "Nefazodone", "suffix": " was shown to antagonize alphaPharmacokineticsPharmacokineti"}, {"to": "1081", "prefix": "oncentrations occur at about one hour and the half-life of ", "from": "1072", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " is 2 to 4 hours.Both nefazodone and its pharmacologically s"}, {"to": "1113", "prefix": " hour and the half-life of nefazodone is 2 to 4 hours.Both ", "from": "1104", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " and its pharmacologically similar metabolite, hydroxynefazo"}, {"to": "1494", "prefix": "involving BID dosing with 50, 100, and 200 mg, the AUC for ", "from": "1485", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " and hydroxynefazodone increased by about 4-fold with an inc"}, {"to": "1770", "prefix": " with 25, 50, 100, and 150 mg, the accumulation ratios for ", "from": "1761", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " and hydroxynefazodone AUC, after 5 days of BID dosing relat"}, {"to": "2171", "prefix": "sting extensive and greater than predicted accumulation of ", "from": "2162", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " and its hydroxy metabolite with multiple dosing. Steady-sta"}, {"to": "2251", "prefix": "droxy metabolite with multiple dosing. Steady-state plasma ", "from": "2242", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " and metabolite concentrations are attained within 4 to 5 da"}, {"to": "2625", "prefix": "involving BID dosing with 50, 100, and 200 mg, the AUC for ", "from": "2616", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " and hydroxynefazodone increased by about 4-fold with an inc"}, {"to": "2895", "prefix": "d aromatic hydroxylation, and less than 1% of administered ", "from": "2886", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " is excreted unchanged in urine. Attempts to characterize th"}, {"to": "3171", "prefix": "expressed as a multiple of the AUC for ", "from": "3162", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " dosed at 100 mg BID"}, {"to": "3374", "prefix": "rofile qualitatively and quantitatively similar to that of ", "from": "3365", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": ". mCPP has some similarities to nefazodone, but also has ago"}, {"to": "3416", "prefix": "milar to that of nefazodone. mCPP has some similarities to ", "from": "3407", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": ", but also has agonist activity at some serotonergic recepto"}, {"to": "3777", "prefix": "logical activity.After oral administration of radiolabeled ", "from": "3768", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": ", the mean half-life of total label ranged between 11 and 24"}, {"to": "4105", "prefix": ". In humans the volume of distribution of ", "from": "4096", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " ranges from 0.22 to 0.87 L"}, {"to": "4293", "prefix": ". In humans the volume of distribution of ", "from": "4284", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " ranges from 0.22 to 0.87 L"}, {"to": "4388", "prefix": "mL ", "from": "4379", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " is extensively "}, {"to": "4499", "prefix": "sma proteins in vitro. The administration of 200 mg BID of ", "from": "4490", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " for 1 week did not increase the fraction of unbound warfari"}, {"to": "4731", "prefix": ". While ", "from": "4722", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " did not alter the in vitro protein binding of chlorpromazin"}, {"to": "4939", "prefix": "or verapamil, it is unknown whether displacement of either ", "from": "4930", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " or these drugs occurs in vivo. There was a 5% decrease in t"}, {"to": "5143", "prefix": "mL ", "from": "5134", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " is extensively "}, {"to": "5253", "prefix": "Food delays the absorption of ", "from": "5244", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " and decreases the bioavailability of nefazodone by approxim"}, {"to": "5301", "prefix": "orption of nefazodone and decreases the bioavailability of ", "from": "5292", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " by approximately 20%.Effect of Food"}, {"to": "5378", "prefix": "Food delays the absorption of ", "from": "5369", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " and decreases the bioavailability of nefazodone by approxim"}, {"to": "5426", "prefix": "orption of nefazodone and decreases the bioavailability of ", "from": "5417", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " by approximately 20%.Renal Disease"}, {"to": "5631", "prefix": " had no effect on steady-state ", "from": "5622", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " plasma concentrations.Renal Disease"}, {"to": "5896", "prefix": "study of patients with liver cirrhosis, the AUC values for ", "from": "5887", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " and HO-NEF at steady state were approximately 25% greater t"}, {"to": "6098", "prefix": "study of patients with liver cirrhosis, the AUC values for ", "from": "6089", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " and HO-NEF at steady state were approximately 25% greater t"}, {"to": "6335", "prefix": ", C max and AUC for ", "from": "6326", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " and hydroxynefazodone were up to twice as high in the older"}, {"to": "6747", "prefix": ", C Treatment with ", "from": "6738", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " should be initiated at half the usual dose in elderly patie"}, {"to": "7235", "prefix": "essionDuring its premarketing development, the efficacy of ", "from": "7226", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " was evaluated at doses within the therapeutic range in five"}, {"to": "7526", "prefix": " Among these trials, two demonstrated the effectiveness of ", "from": "7517", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": ", and two provided additional support for that conclusion.On"}, {"to": "7648", "prefix": "sion.One trial was a 6-week dose-titration study comparing ", "from": "7639", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " in two dose ranges "}, {"to": "7866", "prefix": " second trial was an 8-week dose-titration study comparing ", "from": "7857", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " "}, {"to": "8022", "prefix": " placebo, all on a BID schedule. Both studies demonstrated ", "from": "8013", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": ", at doses titrated between 300 mg to 600 mg"}, {"to": "8531", "prefix": ". In the two supportive studies, ", "from": "8522", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " was titrated up to 500 or 600 mg"}, {"to": "8694", "prefix": "fifth study, the differentiation in response rates between ", "from": "8685", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " and placebo was not statistically significant. Three additi"}, {"to": "8821", "prefix": "tional trials were conducted using subtherapeutic doses of ", "from": "8812", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": ".Overall, approximately two thirds of patients in these tria"}, {"to": "9235", "prefix": "essant drug product, additional clinical investigations of ", "from": "9226", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " have been conducted. These studies explored nefazodone"}, {"to": "9594", "prefix": "tients. These were 6-week, dose-titration trials comparing ", "from": "9585", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " "}, {"to": "9670", "prefix": " and placebo, on a BID schedule. In one study, ", "from": "9661", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " was superior to placebo. In this study, the mean modal dose"}, {"to": "9744", "prefix": "superior to placebo. In this study, the mean modal dose of ", "from": "9735", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " was 503 mg"}, {"to": "10060", "prefix": "other study, the differentiation in response rates between ", "from": "10051", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " and placebo was not statistically significant.This result m"}, {"to": "10652", "prefix": " after a 16-week period of open treatment with ", "from": "10643", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " "}, {"to": "10707", "prefix": ". In one study, ", "from": "10698", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " was superior to placebo. In this study, patients "}, {"to": "10812", "prefix": " were randomized to continuation on ", "from": "10803", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " or placebo for an additional 36 weeks "}, {"to": "10980", "prefix": " for patients taking ", "from": "10971", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "nefazodone", "suffix": " compared to those on placebo. The second study was of appro"}, {"to": "222", "prefix": "ies have shown that nefazodone inhibits neuronal uptake of ", "from": "214", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "serotonin", "suffix": " and norepinephrine.Nefazodone occupies central 5-HT 2 recep"}, {"to": "274", "prefix": "f serotonin and norepinephrine.Nefazodone occupies central ", "from": "271", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/MESH/D012701", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "5-HT", "suffix": " 2 receptors at nanomolar concentrations, and acts as an ant"}, {"to": "241", "prefix": " that nefazodone inhibits neuronal uptake of serotonin and ", "from": "228", "name": "Norepinephrine", "fullId": "http://purl.bioontology.org/ontology/MESH/D009638", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "norepinephrine", "suffix": ".Nefazodone occupies central 5-HT 2 receptors at nanomolar c"}, {"to": "671", "prefix": "and beta adrenergic, 5-HT1A, cholinergic, dopaminergic, or ", "from": "658", "name": "Benzodiazepines", "fullId": "http://purl.bioontology.org/ontology/MESH/D001569", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "benzodiazepine", "suffix": ".2 receptors at nanomolar concentrations, and acts as an ant"}, {"to": "1177", "prefix": "h nefazodone and its pharmacologically similar metabolite, ", "from": "1161", "name": "hydroxynefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092333", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "hydroxynefazodone", "suffix": ", exhibit nonlinear kinetics for both dose and time, with AU"}, {"to": "1516", "prefix": "osing with 50, 100, and 200 mg, the AUC for nefazodone and ", "from": "1500", "name": "hydroxynefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092333", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "hydroxynefazodone", "suffix": " increased by about 4-fold with an increase in dose from 200"}, {"to": "1792", "prefix": "00, and 150 mg, the accumulation ratios for nefazodone and ", "from": "1776", "name": "hydroxynefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092333", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "hydroxynefazodone", "suffix": " AUC, after 5 days of BID dosing relative to the first dose,"}, {"to": "2647", "prefix": "osing with 50, 100, and 200 mg, the AUC for nefazodone and ", "from": "2631", "name": "hydroxynefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092333", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "hydroxynefazodone", "suffix": " increased by about 4-fold with an increase in dose from 200"}, {"to": "3010", "prefix": "ts to characterize three metabolites identified in plasma, ", "from": "2994", "name": "hydroxynefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092333", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "hydroxynefazodone", "suffix": " "}, {"to": "6357", "prefix": ", C max and AUC for nefazodone and ", "from": "6341", "name": "hydroxynefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092333", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "hydroxynefazodone", "suffix": " were up to twice as high in the older patients. With multip"}, {"to": "4560", "prefix": "zodone for 1 week did not increase the fraction of unbound ", "from": "4553", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "warfarin", "suffix": " in subjects whose prothrombin times had been prolonged by w"}, {"to": "4627", "prefix": " in subjects whose prothrombin times had been prolonged by ", "from": "4620", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "warfarin", "suffix": " therapy to 120 to 150% of the laboratory control "}, {"to": "4590", "prefix": "ncrease the fraction of unbound warfarin in subjects whose ", "from": "4580", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "prothrombin", "suffix": " times had been prolonged by warfarin therapy to 120 to 150%"}, {"to": "4792", "prefix": "e nefazodone did not alter the in vitro protein binding of ", "from": "4779", "name": "Chlorpromazine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2403", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "chlorpromazine", "suffix": ", desipramine, diazepam, diphenylhydantoin, lidocaine, prazo"}, {"to": "4805", "prefix": " not alter the in vitro protein binding of chlorpromazine, ", "from": "4795", "name": "Desipramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003891", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "desipramine", "suffix": ", diazepam, diphenylhydantoin, lidocaine, prazosin, proprano"}, {"to": "4815", "prefix": "e in vitro protein binding of chlorpromazine, desipramine, ", "from": "4808", "name": "Diazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3322", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "diazepam", "suffix": ", diphenylhydantoin, lidocaine, prazosin, propranolol, or ve"}, {"to": "4834", "prefix": " protein binding of chlorpromazine, desipramine, diazepam, ", "from": "4818", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/MESH/D010672", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "diphenylhydantoin", "suffix": ", lidocaine, prazosin, propranolol, or verapamil, it is unkn"}, {"to": "4845", "prefix": " chlorpromazine, desipramine, diazepam, diphenylhydantoin, ", "from": "4837", "name": "Lidocaine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6387", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "lidocaine", "suffix": ", prazosin, propranolol, or verapamil, it is unknown whether"}, {"to": "4855", "prefix": "zine, desipramine, diazepam, diphenylhydantoin, lidocaine, ", "from": "4848", "name": "Prazosin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011224", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "prazosin", "suffix": ", propranolol, or verapamil, it is unknown whether displacem"}, {"to": "4868", "prefix": "pramine, diazepam, diphenylhydantoin, lidocaine, prazosin, ", "from": "4858", "name": "Propranolol", "fullId": "http://purl.bioontology.org/ontology/MESH/D011433", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "propranolol", "suffix": ", or verapamil, it is unknown whether displacement of either"}, {"to": "4882", "prefix": "m, diphenylhydantoin, lidocaine, prazosin, propranolol, or ", "from": "4874", "name": "Verapamil", "fullId": "http://purl.bioontology.org/ontology/RXNORM/11170", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "verapamil", "suffix": ", it is unknown whether displacement of either nefazodone or"}, {"to": "5032", "prefix": "in vivo. There was a 5% decrease in the protein binding of ", "from": "5022", "name": "Haloperidol", "fullId": "http://purl.bioontology.org/ontology/MESH/D006220", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "haloperidol", "suffix": "; this is probably of no clinical significance.Protein Bindi"}, {"to": "5541", "prefix": "", "from": "5532", "name": "Creatinine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003404", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "creatinine", "suffix": " clearances ranging from 7 to 60 mL"}, {"to": "5747", "prefix": "", "from": "5738", "name": "Creatinine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003404", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "creatinine", "suffix": " clearances ranging from 7 to 60 mL"}, {"to": "7929", "prefix": ", ", "from": "7920", "name": "Imipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5691", "setId": "b1d149db-ad43-4f3f-aef1-fb0395ba4191", "exact": "imipramine", "suffix": " "}, {"to": "141", "prefix": "       \n                  Given the primary CNS effects of ", "from": "136", "name": "Fanapt", "fullId": "http://purl.bioontology.org/ontology/RXNORM/848723", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "FANAPT", "suffix": ", caution should be used when it is taken in combination wit"}, {"to": "298", "prefix": "1-adrenergic receptor antagonism, ", "from": "293", "name": "Fanapt", "fullId": "http://purl.bioontology.org/ontology/RXNORM/848723", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "FANAPT", "suffix": " has the potential to enhance the effect of certain antihype"}, {"to": "534", "prefix": "                   \n                           The dose of ", "from": "529", "name": "Fanapt", "fullId": "http://purl.bioontology.org/ontology/RXNORM/848723", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "FANAPT", "suffix": " should be reduced in patients co-administered a strong CYP2"}, {"to": "885", "prefix": "Potential for Other Drugs to Affect ", "from": "880", "name": "Fanapt", "fullId": "http://purl.bioontology.org/ontology/RXNORM/848723", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "FANAPT", "suffix": "\n                     \n                        Iloperidone i"}, {"to": "4879", "prefix": "Potential for ", "from": "4874", "name": "Fanapt", "fullId": "http://purl.bioontology.org/ontology/RXNORM/848723", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "FANAPT", "suffix": " to Affect Other Drugs\n                     \n               "}, {"to": "6290", "prefix": " QT Interval\n                     \n                        ", "from": "6285", "name": "Fanapt", "fullId": "http://purl.bioontology.org/ontology/RXNORM/848723", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "FANAPT", "suffix": " should not be used with any other drugs that prolong the QT"}, {"to": "943", "prefix": "ffect FANAPT\n                     \n                        ", "from": "933", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "Iloperidone", "suffix": " is not a substrate for CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2"}, {"to": "1092", "prefix": ", or CYP2E1 enzymes.  This suggests that an interaction of ", "from": "1082", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "iloperidone", "suffix": " with inhibitors or inducers of these enzymes, or other fact"}, {"to": "1262", "prefix": "                Both CYP3A4 and CYP2D6 are responsible for ", "from": "1252", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "iloperidone", "suffix": " metabolism.  Inhibitors of CYP3A4 "}, {"to": "1382", "prefix": " can inhibit ", "from": "1372", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "iloperidone", "suffix": " elimination and cause increased blood levels.\n             "}, {"to": "1631", "prefix": " a potent inhibitor of CYP3A4, with a 3 mg single dose of  ", "from": "1621", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "iloperidone", "suffix": " to 19 healthy volunteers, ages 18-45, increased the AUC of "}, {"to": "1702", "prefix": "to 19 healthy volunteers, ages 18-45, increased the AUC of ", "from": "1692", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "iloperidone", "suffix": " and its metabolites P88 and P95 by 57%, 55% and 35%, respec"}, {"to": "1782", "prefix": "etabolites P88 and P95 by 57%, 55% and 35%, respectively.  ", "from": "1772", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "Iloperidone", "suffix": " doses should be reduced by about one-half when administered"}, {"to": "2086", "prefix": "4 inhibitor is withdrawn from the combination therapy, the ", "from": "2076", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "iloperidone", "suffix": " dose should be returned to the previous level.\n            "}, {"to": "2456", "prefix": "ied as CYP2D6 extensive metabolizers, increased the AUC of ", "from": "2446", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "iloperidone", "suffix": " and its metabolite P88, by about 2-3 fold, and decreased th"}, {"to": "2569", "prefix": " and decreased the AUC of its metabolite P95 by one-half.  ", "from": "2559", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "Iloperidone", "suffix": " doses should be reduced by one-half when administered with "}, {"to": "2716", "prefix": " fluoxetine is withdrawn from the combination therapy, the ", "from": "2706", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "iloperidone", "suffix": " dose should be returned to the previous level.   Other stro"}, {"to": "2966", "prefix": "YP2D6 inhibitor is withdrawn from the combination therapy, ", "from": "2956", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "iloperidone", "suffix": " dose could then be increased to the previous level.\n       "}, {"to": "3205", "prefix": ", a potent inhibitor of CYP2D6, with multiple doses of ", "from": "3195", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "iloperidone", "suffix": " "}, {"to": "3347", "prefix": "lted in increased mean steady-state peak concentrations of ", "from": "3337", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "iloperidone", "suffix": " and its metabolite P88, by about 1.6 fold, and decreased me"}, {"to": "3490", "prefix": "te peak concentrations of its metabolite P95 by one-half.  ", "from": "3480", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "Iloperidone", "suffix": " doses should be reduced by one-half when administered with "}, {"to": "3637", "prefix": " paroxetine is withdrawn from the combination therapy, the ", "from": "3627", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "iloperidone", "suffix": " dose should be returned to the previous level.  Other stron"}, {"to": "3886", "prefix": "YP2D6 inhibitor is withdrawn from the combination therapy, ", "from": "3876", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "iloperidone", "suffix": " dose could then be increased to previous levels.\n          "}, {"to": "4174", "prefix": " with multiple doses of ", "from": "4164", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "iloperidone", "suffix": " "}, {"to": "4319", "prefix": "d in a 1.4 fold increase in steady-state concentrations of ", "from": "4309", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "iloperidone", "suffix": " and its metabolite P88 and a 1.4 fold decrease in the P95 i"}, {"to": "4431", "prefix": "rease in the P95 in the presence of paroxetine.  So giving ", "from": "4421", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "iloperidone", "suffix": " with inhibitors of both of its metabolic pathways did not a"}, {"to": "4552", "prefix": "did not add to the effect of either inhibitor given alone. ", "from": "4542", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "Iloperidone", "suffix": " doses should therefore be reduced by about one-half if admi"}, {"to": "5042", "prefix": "    In vitro studies in human liver microsomes showed that ", "from": "5032", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "iloperidone", "suffix": " does not substantially inhibit the metabolism of drugs meta"}, {"to": "5292", "prefix": "re, in vitro studies in human liver microsomes showed that ", "from": "5282", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "iloperidone", "suffix": " does not have enzyme inducing properties, specifically for "}, {"to": "5652", "prefix": " when a 3 mg dose of ", "from": "5642", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "iloperidone", "suffix": " was co-administered resulted in a 17% increase in total exp"}, {"to": "5807", "prefix": "in Cmax of dextromethorphan.  Thus, an interaction between ", "from": "5797", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "iloperidone", "suffix": " and other CYP2D6 substrates is unlikely.\n                  "}, {"to": "5946", "prefix": "                         Fluoxetine: A single 3 mg dose of ", "from": "5936", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "iloperidone", "suffix": " had no effect on the pharmacokinetics of fluoxetine "}, {"to": "1316", "prefix": "e.g., ", "from": "1305", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "ketoconazole", "suffix": ""}, {"to": "1493", "prefix": "evels.\n                        \n                           ", "from": "1482", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "Ketoconazole", "suffix": ": Co-administration of ketoconazole "}, {"to": "1528", "prefix": "                        Ketoconazole: Co-administration of ", "from": "1517", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "ketoconazole", "suffix": " "}, {"to": "1860", "prefix": "should be reduced by about one-half when administered with ", "from": "1849", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "ketoconazole", "suffix": " or other strong inhibitors of CYP3A4 "}, {"to": "4015", "prefix": "                \n                           Paroxetine and ", "from": "4004", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "Ketoconazole", "suffix": ":  Co-administration of paroxetine "}, {"to": "4118", "prefix": ", a CYP2D6 inhibitor, and ", "from": "4107", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "ketoconazole", "suffix": " "}, {"to": "1345", "prefix": "e.g., ", "from": "1336", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "fluoxetine", "suffix": ", paroxetine"}, {"to": "2196", "prefix": "level.\n                        \n                           ", "from": "2187", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "Fluoxetine", "suffix": ": Co-administration of fluoxetine "}, {"to": "2229", "prefix": "                          Fluoxetine: Co-administration of ", "from": "2220", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "fluoxetine", "suffix": " "}, {"to": "2639", "prefix": "doses should be reduced by one-half when administered with ", "from": "2630", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "fluoxetine", "suffix": ".  When fluoxetine is withdrawn from the combination therapy"}, {"to": "2657", "prefix": "duced by one-half when administered with fluoxetine.  When ", "from": "2648", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "fluoxetine", "suffix": " is withdrawn from the combination therapy, the iloperidone "}, {"to": "5911", "prefix": "ikely.\n                        \n                           ", "from": "5902", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "Fluoxetine", "suffix": ": A single 3 mg dose of iloperidone had no effect on the pha"}, {"to": "5998", "prefix": "se of iloperidone had no effect on the pharmacokinetics of ", "from": "5989", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "fluoxetine", "suffix": " "}, {"to": "1357", "prefix": "e.g., fluoxetine, ", "from": "1348", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "paroxetine", "suffix": ""}, {"to": "3081", "prefix": "level.\n                        \n                           ", "from": "3072", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "Paroxetine", "suffix": ": Co-administration of paroxetine "}, {"to": "3114", "prefix": "                          Paroxetine: Co-administration of ", "from": "3105", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "paroxetine", "suffix": " "}, {"to": "3560", "prefix": "doses should be reduced by one-half when administered with ", "from": "3551", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "paroxetine", "suffix": ".  When paroxetine is withdrawn from the combination therapy"}, {"to": "3578", "prefix": "duced by one-half when administered with paroxetine.  When ", "from": "3569", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "paroxetine", "suffix": " is withdrawn from the combination therapy, the iloperidone "}, {"to": "3998", "prefix": "evels.\n                        \n                           ", "from": "3989", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "Paroxetine", "suffix": " and Ketoconazole:  Co-administration of paroxetine "}, {"to": "4049", "prefix": "        Paroxetine and Ketoconazole:  Co-administration of ", "from": "4040", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "paroxetine", "suffix": " "}, {"to": "4407", "prefix": " P88 and a 1.4 fold decrease in the P95 in the presence of ", "from": "4398", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "paroxetine", "suffix": ".  So giving iloperidone with inhibitors of both of its meta"}, {"to": "1917", "prefix": "e.g., ", "from": "1906", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "itraconazole", "suffix": ""}, {"to": "1958", "prefix": "e.g., ", "from": "1947", "name": "Erythromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004917", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "erythromycin", "suffix": ", grapefruit juice"}, {"to": "5512", "prefix": "YP3A5.\n                        \n                           ", "from": "5497", "name": "Dextromethorphan", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3289", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "Dextromethorphan", "suffix": ": A study in healthy volunteers showed that changes in the p"}, {"to": "5607", "prefix": " volunteers showed that changes in the pharmacokinetics of ", "from": "5592", "name": "Dextromethorphan", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3289", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "dextromethorphan", "suffix": " "}, {"to": "5764", "prefix": "% increase in total exposure and a 26% increase in Cmax of ", "from": "5749", "name": "Dextromethorphan", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3289", "setId": "33f60b40-3fca-11de-8f56-0002a5d5c51b", "exact": "dextromethorphan", "suffix": ".  Thus, an interaction between iloperidone and other CYP2D6"}, {"to": "309", "prefix": "\n                        The pharmacokinetic properties of ", "from": "299", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " are similar following administration by the intravenous or "}, {"to": "458", "prefix": "mal volunteers, the bioavailability of orally administered ", "from": "448", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " is over 90% compared with intravenous administration. Bioeq"}, {"to": "992", "prefix": "volunteers, administration of a single oral 400 mg dose of ", "from": "982", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " leads to a mean Cmax of 6.72 mcg"}, {"to": "1117", "prefix": " and after single oral doses of 50 mg to 400 mg, ", "from": "1107", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " plasma concentrations and AUC "}, {"to": "1331", "prefix": " data from a food-effect study involving administration of ", "from": "1321", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " tablets to healthy volunteers under fasting conditions and "}, {"to": "1495", "prefix": "t exposure to the drug is not affected by food. Therefore, ", "from": "1485", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " may be taken without regard to meals. "}, {"to": "1651", "prefix": "          Administration of a single oral 150 mg tablet of ", "from": "1641", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " to ten lactating women resulted in a mean Cmax of 2.61 mcg"}, {"to": "2085", "prefix": " by the second day. The apparent volume of distribution of ", "from": "2075", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " approximates that of total body water. Plasma protein bindi"}, {"to": "2247", "prefix": "g either single- or multiple-oral doses for up to 14 days, ", "from": "2237", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " penetrates into all body fluids studied "}, {"to": "2365", "prefix": ". In normal volunteers, saliva concentrations of ", "from": "2355", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " were equal to or slightly greater than plasma concentration"}, {"to": "2545", "prefix": " In patients with bronchiectasis, sputum concentrations of ", "from": "2535", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " following a single 150 mg oral dose were equal to plasma co"}, {"to": "2699", "prefix": "nd 24 hours post dose. In patients with fungal meningitis, ", "from": "2689", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " concentrations in the CSF are approximately 80% of the corr"}, {"to": "2857", "prefix": "ons. \n                        A single oral 150 mg dose of ", "from": "2847", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " administered to 27 patients penetrated into vaginal tissue,"}, {"to": "3085", "prefix": "ing. \n                        A single oral 150 mg dose of ", "from": "3075", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " administered to 14 patients penetrated into vaginal fluid, "}, {"to": "3334", "prefix": "       \n\n\n                        \n\n\nIn normal volunteers, ", "from": "3324", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " is cleared primarily by renal excretion, with approximately"}, {"to": "3589", "prefix": "abolites. \n                        The pharmacokinetics of ", "from": "3579", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " are markedly affected by reduction in renal function. There"}, {"to": "3760", "prefix": "limination half-life and creatinine clearance. The dose of ", "from": "3750", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " may need to be reduced in patients with impaired renal func"}, {"to": "4001", "prefix": "mately 50%. \n                        In normal volunteers, ", "from": "3991", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " administration "}, {"to": "5596", "prefix": "ears of age or older receiving a single 50 mg oral dose of ", "from": "5586", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": ". Ten of these patients were concomitantly receiving diureti"}, {"to": "6130", "prefix": " and the ", "from": "6120", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " renal clearance estimates "}, {"to": "6281", "prefix": " than those of younger volunteers. Thus, the alteration of ", "from": "6271", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " disposition in the elderly appears to be related to reduced"}, {"to": "7553", "prefix": "ngle dose both before and after the oral administration of ", "from": "7543", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " 50 mg once daily for 10 days in ten healthy women. There wa"}, {"to": "7732", "prefix": "or levonorgestrel AUC after the administration of 50 mg of ", "from": "7722", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": ". The mean increase in ethinyl estradiol AUC was 6% "}, {"to": "7981", "prefix": "udy, 25 normal females received daily doses of both 200 mg ", "from": "7971", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " tablets or placebo for two, 10-day periods. The treatment c"}, {"to": "8107", "prefix": "nt cycles were one month apart with all subjects receiving ", "from": "8097", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " during one cycle and placebo during the other. The order of"}, {"to": "8408", "prefix": " of both cycles. Following administration of 200 mg of ", "from": "8398", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": ", the mean percentage increase of AUC for levonorgestrel com"}, {"to": "8818", "prefix": "aluated the potential interaction of once weekly dosing of ", "from": "8808", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " 300 mg to 21 normal females taking an oral contraceptive co"}, {"to": "9076", "prefix": "ied out over three cycles of oral contraceptive treatment, ", "from": "9066", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " dosing resulted in small increases in the mean AUCs of ethi"}, {"to": "9383", "prefix": ", respectively relative to placebo. ", "from": "9373", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "Fluconazole", "suffix": " treatment did not cause a decrease in the ethinyl estradiol"}, {"to": "9631", "prefix": " in 3 of the 21 subjects after ", "from": "9621", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " treatment.\n                           \n                    "}, {"to": "9956", "prefix": "\n                           \n                              ", "from": "9946", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "Fluconazole", "suffix": " 100 mg was administered as a single oral dose alone and 2 h"}, {"to": "10181", "prefix": "tration of cimetidine, there was a significant decrease in ", "from": "10171", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " AUC and Cmax. There was a mean  "}, {"to": "10241", "prefix": " SD decrease in ", "from": "10231", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " AUC of 13%  "}, {"to": "10497", "prefix": "from 1 hour before to 3 hours after a single oral dose of ", "from": "10487", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " 200 mg"}, {"to": "10575", "prefix": " did not affect the bioavailability or pharmacokinetics of ", "from": "10565", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " in 24 healthy male volunteers.\n                           \n"}, {"to": "11019", "prefix": "rmal male volunteers immediately prior to a single dose of ", "from": "11009", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " 100 mg had no effect on the absorption or elimination of fl"}, {"to": "11088", "prefix": "e 100 mg had no effect on the absorption or elimination of ", "from": "11078", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": ".\n                              "}, {"to": "11553", "prefix": "                 Concomitant oral administration of 100 mg ", "from": "11543", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " and 50 mg hydrochlorothiazide for 10 days in 13 normal volu"}, {"to": "11669", "prefix": "13 normal volunteers resulted in a significant increase in ", "from": "11659", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " AUC and Cmax compared to fluconazole given alone. There was"}, {"to": "11706", "prefix": "gnificant increase in fluconazole AUC and Cmax compared to ", "from": "11696", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " given alone. There was a mean  "}, {"to": "11765", "prefix": " SD increase in ", "from": "11755", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " AUC and Cmax of 45%  "}, {"to": "12331", "prefix": "            Administration of a single oral 200 mg dose of ", "from": "12321", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " after 15 days of rifampin administered as 600 mg daily in e"}, {"to": "12469", "prefix": "lthy male volunteers resulted in a significant decrease in ", "from": "12459", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " AUC and a significant increase in apparent oral clearance o"}, {"to": "12542", "prefix": "C and a significant increase in apparent oral clearance of ", "from": "12532", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": ". There was a mean  "}, {"to": "12590", "prefix": " SD reduction in ", "from": "12580", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " AUC of 23%  "}, {"to": "12668", "prefix": ". Apparent oral clearance of ", "from": "12658", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " increased 32%  "}, {"to": "12721", "prefix": ". ", "from": "12711", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "Fluconazole", "suffix": " half-life decreased from 33.4  "}, {"to": "13324", "prefix": " administered to 13 normal male volunteers following oral ", "from": "13314", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " 200 mg administered daily for 14 days as compared to the ad"}, {"to": "14200", "prefix": " both with and without the administration of ", "from": "14190", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " "}, {"to": "14218", "prefix": "oral ", "from": "14208", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " 200 mg daily for 16 days"}, {"to": "14938", "prefix": "max were determined before and after the administration of ", "from": "14928", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " 200 mg daily for 14 days in eight renal transplant patients"}, {"to": "15301", "prefix": "in apparent oral clearance following the administration of ", "from": "15291", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": ". The mean  "}, {"to": "15964", "prefix": "before and following ", "from": "15954", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " 200 mg daily for 15 days"}, {"to": "16178", "prefix": "increase in zidovudine AUC following the administration of ", "from": "16168", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": ". The mean  "}, {"to": "16353", "prefix": " ratio significantly decreased after the administration of ", "from": "16343", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": ", from 7.6  "}, {"to": "16855", "prefix": " before and after the oral administration of ", "from": "16845", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " 200 mg daily for 14 days in 16 normal male volunteers. Ther"}, {"to": "17697", "prefix": "thy volunteers received terfenadine 60 mg BID for 15 days. ", "from": "17687", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "Fluconazole", "suffix": " 200 mg was administered daily from days 9 through 15. Fluco"}, {"to": "17763", "prefix": "zole 200 mg was administered daily from days 9 through 15. ", "from": "17753", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "Fluconazole", "suffix": " did not affect terfenadine plasma concentrations. Terfenadi"}, {"to": "17957", "prefix": "rom day 8 to day 15 with the concomitant administration of ", "from": "17947", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": ". There was no change in cardiac repolarization as measured "}, {"to": "18104", "prefix": "ervals. Another study at a 400 mg and 800 mg daily dose of ", "from": "18094", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " demonstrated that fluconazole taken in doses of 400 mg per "}, {"to": "18134", "prefix": " mg and 800 mg daily dose of fluconazole demonstrated that ", "from": "18124", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " taken in doses of 400 mg per day or greater significantly i"}, {"to": "18636", "prefix": "             \n                              The effects of ", "from": "18626", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " on the pharmacokinetics of the sulfonylurea oral hypoglycem"}, {"to": "18949", "prefix": "and again as a single dose following the administration of ", "from": "18939", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " 100 mg daily for 7 days. In these three studies, 22"}, {"to": "19027", "prefix": " of ", "from": "19017", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " treated patients and 9"}, {"to": "19683", "prefix": " AUC and Cmax following the administration of ", "from": "19673", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": ". There was a mean  "}, {"to": "20406", "prefix": "re significantly increased following the administration of ", "from": "20396", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " in 13 normal male volunteers. There was a mean  "}, {"to": "21146", "prefix": "re significantly increased following the administration of ", "from": "21136", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " in 20 normal male volunteers. There was a mean  "}, {"to": "21401", "prefix": "ucose following the ingestion of glyburide after 7 days of ", "from": "21391", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " administration. "}, {"to": "21887", "prefix": "ave been published reports that an interaction exists when ", "from": "21877", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " is administered concomitantly with rifabutin, leading to in"}, {"to": "22381", "prefix": "ave been published reports that an interaction exists when ", "from": "22371", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " is administered concomitantly with tacrolimus, leading to i"}, {"to": "22902", "prefix": " multiple-dose study examined the potential interaction of ", "from": "22892", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " with cisapride. Two groups of ten normal subjects were admi"}, {"to": "22982", "prefix": "pride. Two groups of ten normal subjects were administered ", "from": "22972", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " 200 mg daily or placebo. Cisapride 20 mg four times daily w"}, {"to": "23080", "prefix": "sapride 20 mg four times daily was started after 7 days of ", "from": "23070", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " or placebo dosing. Following a single dose of fluconazole, "}, {"to": "23138", "prefix": " fluconazole or placebo dosing. Following a single dose of ", "from": "23128", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": ", there was a 101% increase in the cisapride AUC and a 91% i"}, {"to": "23268", "prefix": "ncrease in the cisapride Cmax. Following multiple doses of ", "from": "23258", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": ", there was a 192% increase in the cisapride AUC and a 154% "}, {"to": "23371", "prefix": "e cisapride AUC and a 154% increase in the cisapride Cmax. ", "from": "23361", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "Fluconazole", "suffix": " significantly increased the QTc interval in subjects receiv"}, {"to": "23847", "prefix": "              \n                              The effect of ", "from": "23837", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " on the pharmacokinetics and pharmacodynamics of midazolam w"}, {"to": "24031", "prefix": "unteers. In the study, subjects ingested placebo or 400 mg ", "from": "24021", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " on Day 1 followed by 200 mg daily from Day 2 to Day 6. In a"}, {"to": "24272", "prefix": "usly on the fourth day and 7.5 mg orally on the sixth day. ", "from": "24262", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "Fluconazole", "suffix": " reduced the clearance of IV midazolam by 51%. On the first "}, {"to": "24358", "prefix": "arance of IV midazolam by 51%. On the first day of dosing, ", "from": "24348", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " increased the midazolam AUC and Cmax by 259% and 150%, resp"}, {"to": "24467", "prefix": "y 259% and 150%, respectively. On the sixth day of dosing, ", "from": "24457", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " increased the midazolam AUC and Cmax by 259% and 74%, respe"}, {"to": "24901", "prefix": "rmed to determine the effect of route of administration of ", "from": "24891", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " on the interaction between fluconazole and midazolam. In ea"}, {"to": "24940", "prefix": "f administration of fluconazole on the interaction between ", "from": "24930", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " and midazolam. In each phase the subjects were given oral f"}, {"to": "25010", "prefix": " and midazolam. In each phase the subjects were given oral ", "from": "25000", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " 400 mg and intravenous saline; oral placebo and intravenous"}, {"to": "25082", "prefix": "00 mg and intravenous saline; oral placebo and intravenous ", "from": "25072", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " 400 mg; and oral placebo and IV saline. An oral dose of 7.5"}, {"to": "25189", "prefix": "ne. An oral dose of 7.5 mg of midazolam was ingested after ", "from": "25179", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": ""}, {"to": "25303", "prefix": " significantly higher after oral than IV administration of ", "from": "25293", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": ". Oral fluconazole increased the midazolam AUC and Cmax by 2"}, {"to": "25321", "prefix": "her after oral than IV administration of fluconazole. Oral ", "from": "25311", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " increased the midazolam AUC and Cmax by 272% and 129%, resp"}, {"to": "25405", "prefix": " midazolam AUC and Cmax by 272% and 129%, respectively. IV ", "from": "25395", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " increased the midazolam AUC and Cmax by 244% and 79%, respe"}, {"to": "25502", "prefix": "C and Cmax by 244% and 79%, respectively. Both oral and IV ", "from": "25492", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " increased the pharmacodynamic effects of midazolam. "}, {"to": "26017", "prefix": "bjects assessed the effect of a single 800 mg oral dose of ", "from": "26007", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " on the pharmacokinetics of a single 1200 mg oral dose of az"}, {"to": "26165", "prefix": " as the effects of azithromycin on the pharmacokinetics of ", "from": "26155", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": ". There was no significant pharmacokinetic interaction betwe"}, {"to": "26239", "prefix": "ere was no significant pharmacokinetic interaction between ", "from": "26229", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " and azithromycin.\n                           \n             "}, {"to": "26751", "prefix": " and oral ", "from": "26741", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " "}, {"to": "27101", "prefix": "or frequency of voriconazole and ", "from": "27091", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " did not eliminate or diminish this effect. Concomitant admi"}, {"to": "27203", "prefix": "his effect. Concomitant administration of voriconazole and ", "from": "27193", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " at any dose is not recommended. Close monitoring for advers"}, {"to": "27365", "prefix": " is recommended if voriconazole is used sequentially after ", "from": "27355", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": ", especially within 24 hours of the last dose of fluconazole"}, {"to": "27425", "prefix": "luconazole, especially within 24 hours of the last dose of ", "from": "27415", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": ". "}, {"to": "27939", "prefix": "\n                           \n                              ", "from": "27929", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "Fluconazole", "suffix": " is a highly selective inhibitor of fungal cytochrome P-450 "}, {"to": "28273", "prefix": "ngi and may be responsible for the fungistatic activity of ", "from": "28263", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": ". Mammalian cell demethylation is much less sensitive to flu"}, {"to": "28341", "prefix": "le. Mammalian cell demethylation is much less sensitive to ", "from": "28331", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " inhibition.\n                           \n                   "}, {"to": "28694", "prefix": "l Infections\n                     \n                        ", "from": "28684", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "Fluconazole", "suffix": " has been shown to be active against most strains of the fol"}, {"to": "29357", "prefix": " In a majority of the studies, ", "from": "29347", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " MIC90 values against C. glabrata were above the susceptible"}, {"to": "29977", "prefix": "unknown. \n                        \n                        ", "from": "29967", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "Fluconazole", "suffix": " exhibits in vitro minimum inhibitory concentrations "}, {"to": "30177", "prefix": "g microorganisms, however, the safety and effectiveness of ", "from": "30167", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " in treating clinical infections due to these microorganisms"}, {"to": "30744", "prefix": "    Candida krusei should be considered to be resistant to ", "from": "30734", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": ". Resistance in C. krusei appears to be mediated by reduced "}, {"to": "31042", "prefix": "C. albicans, which are often inherently not susceptible to ", "from": "31032", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " "}, {"to": "32614", "prefix": "1 with standardized inoculum concentrations of ", "from": "32604", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " powder. The MIC values should be interpreted according to t"}, {"to": "33407", "prefix": "This procedure uses paper disks impregnated with 25 mcg of ", "from": "33397", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " to test the susceptibility of yeasts to fluconazole. Disk d"}, {"to": "33459", "prefix": "mcg of fluconazole to test the susceptibility of yeasts to ", "from": "33449", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": ". Disk diffusion interpretive criteria are also provided in "}, {"to": "34766", "prefix": "the technical aspects of the test procedures. Standardized ", "from": "34756", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " powder and 25 mcg disks should provide the following range "}, {"to": "35775", "prefix": "l agents, most fungi show a higher apparent sensitivity to ", "from": "35765", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " in vivo than in vitro. Fluconazole administered orally and"}, {"to": "35810", "prefix": "apparent sensitivity to fluconazole in vivo than in vitro. ", "from": "35800", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "Fluconazole", "suffix": " administered orally and"}, {"to": "36096", "prefix": "pergillus flavus and Aspergillus fumigatus in normal mice. ", "from": "36086", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "Fluconazole", "suffix": " has also been shown to be active in animal models of endemi"}, {"to": "36543", "prefix": " in these studies is unknown.\n                        Oral ", "from": "36533", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " has been shown to be active in an animal model of vaginal c"}, {"to": "36679", "prefix": "asis.\n                        Concurrent administration of ", "from": "36669", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " and amphotericin B in infected normal and immunosuppressed "}, {"to": "37320", "prefix": "g Resistance\n                     \n                        ", "from": "37310", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "Fluconazole", "suffix": " resistance may arise from a modification in the quality or "}, {"to": "37986", "prefix": "jor mechanism of drug resistance involves active efflux of ", "from": "37976", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " out of the cell through the activation of two types of mult"}, {"to": "38242", "prefix": ". Upregulation of the MDR gene leads to ", "from": "38232", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " resistance, whereas, upregulation of CDR genes may lead to "}, {"to": "38577", "prefix": ", the highest ", "from": "38567", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " dose is recommended.\n                        \n             "}, {"to": "38717", "prefix": "    Candida krusei should be considered to be resistant to ", "from": "38707", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": ". Resistance in C. krusei appears to be mediated by reduced "}, {"to": "39015", "prefix": "C. albicans, which are often inherently not susceptible to ", "from": "39005", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "fluconazole", "suffix": " "}, {"to": "3725", "prefix": "inverse relationship between the elimination half-life and ", "from": "3716", "name": "Creatinine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003404", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "creatinine", "suffix": " clearance. The dose of fluconazole may need to be reduced i"}, {"to": "6020", "prefix": "tics did not significantly alter AUC or Cmax. In addition, ", "from": "6011", "name": "Creatinine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003404", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "creatinine", "suffix": " clearance "}, {"to": "6460", "prefix": "s terminal elimination half-life versus ", "from": "6451", "name": "Creatinine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003404", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "creatinine", "suffix": " clearance compared with the predicted half-life "}, {"to": "6732", "prefix": " ", "from": "6723", "name": "Creatinine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003404", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "creatinine", "suffix": " clearance curves. These results are consistent with the hyp"}, {"to": "4150", "prefix": " was associated with small and inconsistent effects on ", "from": "4139", "name": "Testosterone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10379", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "testosterone", "suffix": " concentrations, endogenous corticosteroid concentrations an"}, {"to": "4220", "prefix": "trations, endogenous corticosteroid concentrations and the ", "from": "4217", "name": "Adrenocorticotropic Hormone", "fullId": "http://purl.bioontology.org/ontology/MESH/D000324", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "ACTH", "suffix": "-stimulated cortisol response. \n                     \n      "}, {"to": "4240", "prefix": "nous corticosteroid concentrations and the ACTH-stimulated ", "from": "4233", "name": "Hydrocortisone", "fullId": "http://purl.bioontology.org/ontology/MESH/D006854", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "cortisol", "suffix": " response. \n                     \n                     \n    "}, {"to": "7661", "prefix": " ten healthy women. There was no significant difference in ", "from": "7645", "name": "Ethinyl Estradiol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4124", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "ethinyl estradiol", "suffix": " or levonorgestrel AUC after the administration of 50 mg of "}, {"to": "7772", "prefix": "ministration of 50 mg of fluconazole. The mean increase in ", "from": "7756", "name": "Ethinyl Estradiol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4124", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "ethinyl estradiol", "suffix": " AUC was 6% "}, {"to": "8288", "prefix": "an oral contraceptive tablet containing levonorgestrel and ", "from": "8272", "name": "Ethinyl Estradiol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4124", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "ethinyl estradiol", "suffix": " were administered on the final treatment day "}, {"to": "8568", "prefix": " and the mean percentage increase for ", "from": "8552", "name": "Ethinyl Estradiol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4124", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "ethinyl estradiol", "suffix": " compared to placebo was 38% "}, {"to": "8904", "prefix": " 21 normal females taking an oral contraceptive containing ", "from": "8888", "name": "Ethinyl Estradiol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4124", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "ethinyl estradiol", "suffix": " and norethindrone. In this placebo-controlled, double-blind"}, {"to": "9149", "prefix": "ole dosing resulted in small increases in the mean AUCs of ", "from": "9133", "name": "Ethinyl Estradiol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4124", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "ethinyl estradiol", "suffix": " and norethindrone compared to similar placebo dosing. The m"}, {"to": "9238", "prefix": "drone compared to similar placebo dosing. The mean AUCs of ", "from": "9222", "name": "Ethinyl Estradiol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4124", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "ethinyl estradiol", "suffix": " and norethindrone increased by 24% "}, {"to": "9443", "prefix": "ebo. Fluconazole treatment did not cause a decrease in the ", "from": "9427", "name": "Ethinyl Estradiol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4124", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "ethinyl estradiol", "suffix": " AUC of any individual subject in this study compared to pla"}, {"to": "7679", "prefix": "here was no significant difference in ethinyl estradiol or ", "from": "7666", "name": "Levonorgestrel", "fullId": "http://purl.bioontology.org/ontology/MESH/D016912", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "levonorgestrel", "suffix": " AUC after the administration of 50 mg of fluconazole. The m"}, {"to": "7824", "prefix": " and ", "from": "7811", "name": "Levonorgestrel", "fullId": "http://purl.bioontology.org/ontology/MESH/D016912", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "levonorgestrel", "suffix": " AUC increased 17% "}, {"to": "8266", "prefix": "m. Single doses of an oral contraceptive tablet containing ", "from": "8253", "name": "Levonorgestrel", "fullId": "http://purl.bioontology.org/ontology/MESH/D016912", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "levonorgestrel", "suffix": " and ethinyl estradiol were administered on the final treatm"}, {"to": "8464", "prefix": "mg of fluconazole, the mean percentage increase of AUC for ", "from": "8451", "name": "Levonorgestrel", "fullId": "http://purl.bioontology.org/ontology/MESH/D016912", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "levonorgestrel", "suffix": " compared to placebo was 25% "}, {"to": "8922", "prefix": "ing an oral contraceptive containing ethinyl estradiol and ", "from": "8910", "name": "Norethindrone", "fullId": "http://purl.bioontology.org/ontology/MESH/D009640", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "norethindrone", "suffix": ". In this placebo-controlled, double-blind, randomized, two-"}, {"to": "9167", "prefix": " small increases in the mean AUCs of ethinyl estradiol and ", "from": "9155", "name": "Norethindrone", "fullId": "http://purl.bioontology.org/ontology/MESH/D009640", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "norethindrone", "suffix": " compared to similar placebo dosing. The mean AUCs of ethiny"}, {"to": "9256", "prefix": "lar placebo dosing. The mean AUCs of ethinyl estradiol and ", "from": "9244", "name": "Norethindrone", "fullId": "http://purl.bioontology.org/ontology/MESH/D009640", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "norethindrone", "suffix": " increased by 24% "}, {"to": "9558", "prefix": "y compared to placebo dosing. The individual AUC values of ", "from": "9546", "name": "Norethindrone", "fullId": "http://purl.bioontology.org/ontology/MESH/D009640", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "norethindrone", "suffix": " decreased very slightly "}, {"to": "9886", "prefix": "   \n                           \n                           ", "from": "9877", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002927", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "Cimetidine", "suffix": "\n                           \n                              F"}, {"to": "10054", "prefix": " single oral dose alone and 2 hours after a single dose of ", "from": "10045", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002927", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "cimetidine", "suffix": " 400 mg to six healthy male volunteers. After the administra"}, {"to": "10132", "prefix": "o six healthy male volunteers. After the administration of ", "from": "10123", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002927", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "cimetidine", "suffix": ", there was a significant decrease in fluconazole AUC and Cm"}, {"to": "10374", "prefix": ". However, the administration of ", "from": "10365", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002927", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "cimetidine", "suffix": " 600 mg to 900 mg intravenously over a 4-hour period "}, {"to": "10930", "prefix": "          \n                              Administration of ", "from": "10925", "name": "Maalox", "fullId": "http://purl.bioontology.org/ontology/RXNORM/29115", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "Maalox", "suffix": " "}, {"to": "11128", "prefix": " ", "from": "11123", "name": "Maalox", "fullId": "http://purl.bioontology.org/ontology/RXNORM/29115", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "Maalox", "suffix": " "}, {"to": "11441", "prefix": "   \n                           \n                           ", "from": "11423", "name": "Hydrochlorothiazide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5487", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "Hydrochlorothiazide", "suffix": "\n                           \n                              C"}, {"to": "11583", "prefix": "mitant oral administration of 100 mg fluconazole and 50 mg ", "from": "11565", "name": "Hydrochlorothiazide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5487", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "hydrochlorothiazide", "suffix": " for 10 days in 13 normal volunteers resulted in a significa"}, {"to": "12214", "prefix": "   \n                           \n                           ", "from": "12207", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "Rifampin", "suffix": "\n                           \n                              A"}, {"to": "12357", "prefix": " a single oral 200 mg dose of fluconazole after 15 days of ", "from": "12350", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "rifampin", "suffix": " administered as 600 mg daily in eight healthy male voluntee"}, {"to": "13046", "prefix": "   \n                           \n                           ", "from": "13039", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "Warfarin", "suffix": "\n                           \n                              T"}, {"to": "13247", "prefix": " following a single dose of ", "from": "13240", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "warfarin", "suffix": " "}, {"to": "13408", "prefix": "red daily for 14 days as compared to the administration of ", "from": "13401", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "warfarin", "suffix": " alone. There was a mean  "}, {"to": "13152", "prefix": "                       There was a significant increase in ", "from": "13142", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "prothrombin", "suffix": " time response "}, {"to": "13194", "prefix": "area under the ", "from": "13184", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "prothrombin", "suffix": " time-time curve"}, {"to": "13465", "prefix": " SD increase in the ", "from": "13455", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "prothrombin", "suffix": " time response "}, {"to": "13507", "prefix": "area under the ", "from": "13497", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "prothrombin", "suffix": " time-time curve"}, {"to": "13685", "prefix": "as one of 13 subjects experienced a 2-fold increase in his ", "from": "13675", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "prothrombin", "suffix": " time response. \n                           \n               "}, {"to": "13944", "prefix": "   \n                           \n                           ", "from": "13936", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "Phenytoin", "suffix": "\n                           \n                              P"}, {"to": "14012", "prefix": "\n                           \n                              ", "from": "14004", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "Phenytoin", "suffix": " AUC was determined after 4 days of phenytoin dosing "}, {"to": "14057", "prefix": "              Phenytoin AUC was determined after 4 days of ", "from": "14049", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "phenytoin", "suffix": " dosing "}, {"to": "14321", "prefix": "ormal male volunteers. There was a significant increase in ", "from": "14313", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "phenytoin", "suffix": " AUC. The mean  "}, {"to": "14362", "prefix": " SD increase in ", "from": "14354", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "phenytoin", "suffix": " AUC was 88%  "}, {"to": "14520", "prefix": "nown because of the intrinsically nonlinear disposition of ", "from": "14512", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "phenytoin", "suffix": ". "}, {"to": "14787", "prefix": "   \n                           \n                           ", "from": "14776", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016572", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "Cyclosporine", "suffix": "\n                           \n                              C"}, {"to": "14858", "prefix": "\n                           \n                              ", "from": "14847", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016572", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "Cyclosporine", "suffix": " AUC and Cmax were determined before and after the administr"}, {"to": "15027", "prefix": "14 days in eight renal transplant patients who had been on ", "from": "15016", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016572", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "cyclosporine", "suffix": " therapy for at least 6 months and on a stable cyclosporine "}, {"to": "15086", "prefix": "cyclosporine therapy for at least 6 months and on a stable ", "from": "15075", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016572", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "cyclosporine", "suffix": " dose for at least 6 weeks. There was a significant increase"}, {"to": "15162", "prefix": " for at least 6 weeks. There was a significant increase in ", "from": "15151", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016572", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "cyclosporine", "suffix": " AUC, Cmax, Cmin "}, {"to": "15806", "prefix": "   \n                           \n                           ", "from": "15797", "name": "Zidovudine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/11413", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "Zidovudine", "suffix": "\n                           \n                              P"}, {"to": "15882", "prefix": "                     \n                              Plasma ", "from": "15873", "name": "Zidovudine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/11413", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "zidovudine", "suffix": " concentrations were determined on two occasions "}, {"to": "16056", "prefix": " in 13 volunteers with AIDS or ARC who were on a stable ", "from": "16047", "name": "Zidovudine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/11413", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "zidovudine", "suffix": " dose for at least 2 weeks. There was a significant increase"}, {"to": "16130", "prefix": " for at least 2 weeks. There was a significant increase in ", "from": "16121", "name": "Zidovudine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/11413", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "zidovudine", "suffix": " AUC following the administration of fluconazole. The mean  "}, {"to": "16630", "prefix": "   \n                           \n                           ", "from": "16619", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10438", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "Theophylline", "suffix": "\n                           \n                              T"}, {"to": "16725", "prefix": "    \n                              The pharmacokinetics of ", "from": "16714", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10438", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "theophylline", "suffix": " were determined from a single intravenous dose of aminophyl"}, {"to": "16959", "prefix": "ormal male volunteers. There were significant increases in ", "from": "16948", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10438", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "theophylline", "suffix": " AUC, Cmax and half-life with a corresponding decrease in cl"}, {"to": "17054", "prefix": " SD ", "from": "17043", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10438", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "theophylline", "suffix": " AUC increased 21%  "}, {"to": "17163", "prefix": ". ", "from": "17152", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10438", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "Theophylline", "suffix": " clearance decreased 16%  "}, {"to": "17244", "prefix": ". The half-life of ", "from": "17233", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10438", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "theophylline", "suffix": " increased from 6.6  "}, {"to": "16789", "prefix": "phylline were determined from a single intravenous dose of ", "from": "16777", "name": "Aminophylline", "fullId": "http://purl.bioontology.org/ontology/MESH/D000628", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "aminophylline", "suffix": " "}, {"to": "17560", "prefix": "   \n                           \n                           ", "from": "17550", "name": "Terfenadine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016593", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "Terfenadine", "suffix": "\n                           \n                              S"}, {"to": "17662", "prefix": "                           Six healthy volunteers received ", "from": "17652", "name": "Terfenadine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016593", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "terfenadine", "suffix": " 60 mg BID for 15 days. Fluconazole 200 mg was administered "}, {"to": "17790", "prefix": "d daily from days 9 through 15. Fluconazole did not affect ", "from": "17780", "name": "Terfenadine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016593", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "terfenadine", "suffix": " plasma concentrations. Terfenadine acid metabolite AUC incr"}, {"to": "17825", "prefix": "conazole did not affect terfenadine plasma concentrations. ", "from": "17815", "name": "Terfenadine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016593", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "Terfenadine", "suffix": " acid metabolite AUC increased 36%  "}, {"to": "18231", "prefix": "er day or greater significantly increases plasma levels of ", "from": "18221", "name": "Terfenadine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016593", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "terfenadine", "suffix": " when taken concomitantly. "}, {"to": "18717", "prefix": "rmacokinetics of the sulfonylurea oral hypoglycemic agents ", "from": "18707", "name": "Tolbutamide", "fullId": "http://purl.bioontology.org/ontology/MESH/D014044", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "tolbutamide", "suffix": ", glipizide, and glyburide were evaluated in three placebo-c"}, {"to": "19425", "prefix": "                      \n                                    ", "from": "19415", "name": "Tolbutamide", "fullId": "http://purl.bioontology.org/ontology/MESH/D014044", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "Tolbutamide", "suffix": "\n                                 \n                         "}, {"to": "19605", "prefix": " normal male volunteers, there was significant increase in ", "from": "19595", "name": "Tolbutamide", "fullId": "http://purl.bioontology.org/ontology/MESH/D014044", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "tolbutamide", "suffix": " "}, {"to": "19730", "prefix": " SD increase in ", "from": "19720", "name": "Tolbutamide", "fullId": "http://purl.bioontology.org/ontology/MESH/D014044", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "tolbutamide", "suffix": " AUC of 26%  "}, {"to": "19779", "prefix": ". ", "from": "19769", "name": "Tolbutamide", "fullId": "http://purl.bioontology.org/ontology/MESH/D014044", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "Tolbutamide", "suffix": " Cmax increased 11%  "}, {"to": "18728", "prefix": " of the sulfonylurea oral hypoglycemic agents tolbutamide, ", "from": "18720", "name": "Glipizide", "fullId": "http://purl.bioontology.org/ontology/MESH/D005913", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "glipizide", "suffix": ", and glyburide were evaluated in three placebo-controlled s"}, {"to": "20178", "prefix": "                      \n                                    ", "from": "20170", "name": "Glipizide", "fullId": "http://purl.bioontology.org/ontology/MESH/D005913", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "Glipizide", "suffix": "\n                                 \n                         "}, {"to": "20312", "prefix": "  \n                                    The AUC and Cmax of ", "from": "20304", "name": "Glipizide", "fullId": "http://purl.bioontology.org/ontology/MESH/D005913", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "glipizide", "suffix": " "}, {"to": "18743", "prefix": "lurea oral hypoglycemic agents tolbutamide, glipizide, and ", "from": "18735", "name": "Glyburide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4815", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "glyburide", "suffix": " were evaluated in three placebo-controlled studies in norma"}, {"to": "20920", "prefix": "                      \n                                    ", "from": "20912", "name": "Glyburide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4815", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "Glyburide", "suffix": "\n                                 \n                         "}, {"to": "21054", "prefix": "  \n                                    The AUC and Cmax of ", "from": "21046", "name": "Glyburide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4815", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "glyburide", "suffix": " "}, {"to": "21373", "prefix": " subjects required oral glucose following the ingestion of ", "from": "21365", "name": "Glyburide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4815", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "glyburide", "suffix": " after 7 days of fluconazole administration. "}, {"to": "21751", "prefix": "   \n                           \n                           ", "from": "21743", "name": "Rifabutin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017828", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "Rifabutin", "suffix": "\n                           \n                              T"}, {"to": "21932", "prefix": "exists when fluconazole is administered concomitantly with ", "from": "21924", "name": "Rifabutin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017828", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "rifabutin", "suffix": ", leading to increased serum levels of rifabutin. "}, {"to": "21980", "prefix": "antly with rifabutin, leading to increased serum levels of ", "from": "21972", "name": "Rifabutin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017828", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "rifabutin", "suffix": ". "}, {"to": "22245", "prefix": "   \n                           \n                           ", "from": "22236", "name": "Tacrolimus", "fullId": "http://purl.bioontology.org/ontology/MESH/D016559", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "Tacrolimus", "suffix": "\n                           \n                              T"}, {"to": "22427", "prefix": "exists when fluconazole is administered concomitantly with ", "from": "22418", "name": "Tacrolimus", "fullId": "http://purl.bioontology.org/ontology/MESH/D016559", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "tacrolimus", "suffix": ", leading to increased serum levels of tacrolimus. "}, {"to": "22476", "prefix": "ntly with tacrolimus, leading to increased serum levels of ", "from": "22467", "name": "Tacrolimus", "fullId": "http://purl.bioontology.org/ontology/MESH/D016559", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "tacrolimus", "suffix": ". "}, {"to": "22740", "prefix": "   \n                           \n                           ", "from": "22732", "name": "Cisapride", "fullId": "http://purl.bioontology.org/ontology/RXNORM/35255", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "Cisapride", "suffix": "\n                           \n                              A"}, {"to": "22917", "prefix": "udy examined the potential interaction of fluconazole with ", "from": "22909", "name": "Cisapride", "fullId": "http://purl.bioontology.org/ontology/RXNORM/35255", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "cisapride", "suffix": ". Two groups of ten normal subjects were administered flucon"}, {"to": "23017", "prefix": "cts were administered fluconazole 200 mg daily or placebo. ", "from": "23009", "name": "Cisapride", "fullId": "http://purl.bioontology.org/ontology/RXNORM/35255", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "Cisapride", "suffix": " 20 mg four times daily was started after 7 days of fluconaz"}, {"to": "23182", "prefix": "ngle dose of fluconazole, there was a 101% increase in the ", "from": "23174", "name": "Cisapride", "fullId": "http://purl.bioontology.org/ontology/RXNORM/35255", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "cisapride", "suffix": " AUC and a 91% increase in the cisapride Cmax. Following mul"}, {"to": "23222", "prefix": "1% increase in the cisapride AUC and a 91% increase in the ", "from": "23214", "name": "Cisapride", "fullId": "http://purl.bioontology.org/ontology/RXNORM/35255", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "cisapride", "suffix": " Cmax. Following multiple doses of fluconazole, there was a "}, {"to": "23312", "prefix": "ple doses of fluconazole, there was a 192% increase in the ", "from": "23304", "name": "Cisapride", "fullId": "http://purl.bioontology.org/ontology/RXNORM/35255", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "cisapride", "suffix": " AUC and a 154% increase in the cisapride Cmax. Fluconazole "}, {"to": "23353", "prefix": "% increase in the cisapride AUC and a 154% increase in the ", "from": "23345", "name": "Cisapride", "fullId": "http://purl.bioontology.org/ontology/RXNORM/35255", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "cisapride", "suffix": " Cmax. Fluconazole significantly increased the QTc interval "}, {"to": "23444", "prefix": "ificantly increased the QTc interval in subjects receiving ", "from": "23436", "name": "Cisapride", "fullId": "http://purl.bioontology.org/ontology/RXNORM/35255", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "cisapride", "suffix": " 20 mg four times daily for 5 days. "}, {"to": "23763", "prefix": "   \n                           \n                           ", "from": "23755", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "Midazolam", "suffix": "\n                           \n                              T"}, {"to": "23905", "prefix": "luconazole on the pharmacokinetics and pharmacodynamics of ", "from": "23897", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "midazolam", "suffix": " was examined in a randomized, crossover study in 12 volunte"}, {"to": "24126", "prefix": "g daily from Day 2 to Day 6. In addition, a 7.5 mg dose of ", "from": "24118", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "midazolam", "suffix": " was orally ingested on the first day, 0.05 mg"}, {"to": "24310", "prefix": " on the sixth day. Fluconazole reduced the clearance of IV ", "from": "24302", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "midazolam", "suffix": " by 51%. On the first day of dosing, fluconazole increased t"}, {"to": "24382", "prefix": "51%. On the first day of dosing, fluconazole increased the ", "from": "24374", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "midazolam", "suffix": " AUC and Cmax by 259% and 150%, respectively. On the sixth d"}, {"to": "24491", "prefix": "ely. On the sixth day of dosing, fluconazole increased the ", "from": "24483", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "midazolam", "suffix": " AUC and Cmax by 259% and 74%, respectively. The psychomotor"}, {"to": "24572", "prefix": " by 259% and 74%, respectively. The psychomotor effects of ", "from": "24564", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "midazolam", "suffix": " were significantly increased after oral administration of m"}, {"to": "24640", "prefix": " were significantly increased after oral administration of ", "from": "24632", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "midazolam", "suffix": " but not significantly affected following intravenous midazo"}, {"to": "24703", "prefix": "zolam but not significantly affected following intravenous ", "from": "24695", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "midazolam", "suffix": ".\n                              A second randomized, double-"}, {"to": "24954", "prefix": " of fluconazole on the interaction between fluconazole and ", "from": "24946", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "midazolam", "suffix": ". In each phase the subjects were given oral fluconazole 400"}, {"to": "25158", "prefix": " and oral placebo and IV saline. An oral dose of 7.5 mg of ", "from": "25150", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "midazolam", "suffix": " was ingested after fluconazole"}, {"to": "25228", "prefix": "placebo. The AUC and Cmax of ", "from": "25220", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "midazolam", "suffix": " were significantly higher after oral than IV administration"}, {"to": "25345", "prefix": "inistration of fluconazole. Oral fluconazole increased the ", "from": "25337", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "midazolam", "suffix": " AUC and Cmax by 272% and 129%, respectively. IV fluconazole"}, {"to": "25429", "prefix": " 272% and 129%, respectively. IV fluconazole increased the ", "from": "25421", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "midazolam", "suffix": " AUC and Cmax by 244% and 79%, respectively. Both oral and I"}, {"to": "25553", "prefix": "nd IV fluconazole increased the pharmacodynamic effects of ", "from": "25545", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "midazolam", "suffix": ". "}, {"to": "25819", "prefix": "   \n                           \n                           ", "from": "25808", "name": "Azithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/18631", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "Azithromycin", "suffix": "\n                           \n                              A"}, {"to": "26087", "prefix": "e on the pharmacokinetics of a single 1200 mg oral dose of ", "from": "26076", "name": "Azithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/18631", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "azithromycin", "suffix": " as well as the effects of azithromycin on the pharmacokinet"}, {"to": "26126", "prefix": "200 mg oral dose of azithromycin as well as the effects of ", "from": "26115", "name": "Azithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/18631", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "azithromycin", "suffix": " on the pharmacokinetics of fluconazole. There was no signif"}, {"to": "26256", "prefix": "ficant pharmacokinetic interaction between fluconazole and ", "from": "26245", "name": "Azithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/18631", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "azithromycin", "suffix": ".\n                           \n                           \n  "}, {"to": "26503", "prefix": "   \n                           \n                           ", "from": "26492", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "Voriconazole", "suffix": "\n                           \n                              V"}, {"to": "26574", "prefix": "\n                           \n                              ", "from": "26563", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "Voriconazole", "suffix": " is a substrate for both CYP2C9 and CYP3A4 isoenzymes. Concu"}, {"to": "26675", "prefix": "9 and CYP3A4 isoenzymes. Concurrent administration of oral ", "from": "26664", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "voriconazole", "suffix": " "}, {"to": "26884", "prefix": " of ", "from": "26873", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "voriconazole", "suffix": " by an average of 57% "}, {"to": "27085", "prefix": "or frequency of ", "from": "27074", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "voriconazole", "suffix": " and fluconazole did not eliminate or diminish this effect. "}, {"to": "27187", "prefix": "ate or diminish this effect. Concomitant administration of ", "from": "27176", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "voriconazole", "suffix": " and fluconazole at any dose is not recommended. Close monit"}, {"to": "27295", "prefix": "ecommended. Close monitoring for adverse events related to ", "from": "27284", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "voriconazole", "suffix": " is recommended if voriconazole is used sequentially after f"}, {"to": "27326", "prefix": "r adverse events related to voriconazole is recommended if ", "from": "27315", "name": "voriconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/121243", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "voriconazole", "suffix": " is used sequentially after fluconazole, especially within 2"}, {"to": "28026", "prefix": "tive inhibitor of fungal cytochrome P-450 dependent enzyme ", "from": "28017", "name": "Lanosterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1442199", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "lanosterol", "suffix": " 14-"}, {"to": "28088", "prefix": "-demethylase. This enzyme functions to convert ", "from": "28079", "name": "Lanosterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1442199", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "lanosterol", "suffix": " to ergosterol. The subsequent loss of normal sterols correl"}, {"to": "37421", "prefix": "", "from": "37412", "name": "Lanosterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1442199", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "lanosterol", "suffix": " 14-"}, {"to": "28102", "prefix": "emethylase. This enzyme functions to convert lanosterol to ", "from": "28093", "name": "Ergosterol", "fullId": "http://purl.bioontology.org/ontology/MESH/D004875", "setId": "cf26b007-df4f-4936-b2d3-183969761f69", "exact": "ergosterol", "suffix": ". The subsequent loss of normal sterols correlates with the "}, {"to": "132", "prefix": "IONS\n\n               \n                  The risks of using ", "from": "123", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " in combination with other drugs have not been extensively e"}, {"to": "679", "prefix": "                     Carbamazepine: Increased clearance of ", "from": "670", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": ". "}, {"to": "782", "prefix": "  \n                              Fluvoxamine: May increase ", "from": "773", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " levels. "}, {"to": "863", "prefix": "\n                           \n                              ", "from": "857", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "ZYPREXA", "suffix": " and Fluoxetine in Combination: Also refer to the Drug Inter"}, {"to": "1537", "prefix": ": Increased somnolence with IM ", "from": "1528", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": ". "}, {"to": "1657", "prefix": "                Other Concomitant Drug Therapy: When using ", "from": "1648", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " in combination with lithium or valproate, refer to the Drug"}, {"to": "2021", "prefix": "                   7.1 Potential for Other Drugs to Affect ", "from": "2012", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Olanzapine", "suffix": "\n\n                     \n                     \n              "}, {"to": "2300", "prefix": " The co-administration of diazepam with ", "from": "2291", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " potentiated the orthostatic hypotension observed with olanz"}, {"to": "2365", "prefix": "pine potentiated the orthostatic hypotension observed with ", "from": "2356", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " [see Drug Interactions "}, {"to": "2858", "prefix": "aining antacids did not affect the oral bioavailability of ", "from": "2849", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": ".\n\n                           \n                           \n "}, {"to": "3282", "prefix": " causes an approximately 50% increase in the clearance of ", "from": "3273", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": ". This increase is likely due to the fact that carbamazepine"}, {"to": "3467", "prefix": "ses of carbamazepine may cause an even greater increase in ", "from": "3458", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " clearance.\n\n                           \n                   "}, {"to": "3858", "prefix": " did not have an effect on ", "from": "3849", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " pharmacokinetics. The co-administration of alcohol "}, {"to": "3941", "prefix": " with ", "from": "3932", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " potentiated the orthostatic hypotension observed with olanz"}, {"to": "4006", "prefix": "pine potentiated the orthostatic hypotension observed with ", "from": "3997", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " [see Drug Interactions "}, {"to": "4770", "prefix": "luvoxamine, a CYP1A2 inhibitor, decreases the clearance of ", "from": "4761", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": ". This results in a mean increase in olanzapine Cmax followi"}, {"to": "4817", "prefix": "learance of olanzapine. This results in a mean increase in ", "from": "4808", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " Cmax following fluvoxamine of 54% in female nonsmokers and "}, {"to": "4929", "prefix": "e nonsmokers and 77% in male smokers. The mean increase in ", "from": "4920", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " AUC is 52% and 108%, respectively. Lower doses of olanzapin"}, {"to": "4990", "prefix": "anzapine AUC is 52% and 108%, respectively. Lower doses of ", "from": "4981", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " should be considered in patients receiving concomitant trea"}, {"to": "5874", "prefix": " increase in the maximum concentration of ", "from": "5865", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " and a small "}, {"to": "5920", "prefix": " decrease in ", "from": "5911", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " clearance. The magnitude of the impact of this factor is sm"}, {"to": "6126", "prefix": "dose modification is not routinely recommended. When using ", "from": "6120", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "ZYPREXA", "suffix": " and fluoxetine in combination, also refer to the Drug Inter"}, {"to": "6601", "prefix": " did not affect ", "from": "6592", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " pharmacokinetics [see Drug Interactions "}, {"to": "7055", "prefix": " Omeprazole and rifampin may cause an increase in ", "from": "7046", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " clearance.\n\n                           \n                   "}, {"to": "7467", "prefix": " reduced the Cmax and AUC of oral ", "from": "7458", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " by about 60%. As peak olanzapine levels are not typically o"}, {"to": "7500", "prefix": " the Cmax and AUC of oral olanzapine by about 60%. As peak ", "from": "7491", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " levels are not typically obtained until about 6 hours after"}, {"to": "7618", "prefix": "hours after dosing, charcoal may be a useful treatment for ", "from": "7609", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " overdose.\n\n                           \n                    "}, {"to": "7896", "prefix": "                   \n                     7.2 Potential for ", "from": "7887", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Olanzapine", "suffix": " to Affect Other Drugs\n\n                     \n              "}, {"to": "8199", "prefix": " Given the primary CNS effects of ", "from": "8190", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": ", caution should be used when olanzapine is taken in combina"}, {"to": "8239", "prefix": "ary CNS effects of olanzapine, caution should be used when ", "from": "8230", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " is taken in combination with other centrally acting drugs a"}, {"to": "8646", "prefix": " ", "from": "8637", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Olanzapine", "suffix": ", because of its potential for inducing hypotension, may enh"}, {"to": "9101", "prefix": " ", "from": "9092", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Olanzapine", "suffix": " may antagonize the effects of levodopa and dopamine agonist"}, {"to": "9566", "prefix": " 1 hour after intramuscular ", "from": "9557", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " for injection "}, {"to": "9651", "prefix": " did not significantly affect the pharmacokinetics of ", "from": "9642", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": ", unconjugated lorazepam, or total lorazepam. However, this "}, {"to": "9784", "prefix": "dministration of intramuscular lorazepam and intramuscular ", "from": "9775", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " for injection added to the somnolence observed with either "}, {"to": "10230", "prefix": " Multiple doses of ", "from": "10221", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " "}, {"to": "10326", "prefix": " influence the kinetics of lithium. Therefore, concomitant ", "from": "10317", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " administration does not require dosage adjustment of lithiu"}, {"to": "10748", "prefix": " ", "from": "10739", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Olanzapine", "suffix": " "}, {"to": "10876", "prefix": "plasma concentrations of valproate. Therefore, concomitant ", "from": "10867", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " administration does not require dosage adjustment of valpro"}, {"to": "11298", "prefix": "               \n                                 Effect of ", "from": "11289", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Olanzapine", "suffix": " on Drug Metabolizing Enzymes "}, {"to": "11403", "prefix": "itro studies utilizing human liver microsomes suggest that ", "from": "11394", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " has little potential to inhibit CYP1A2, CYP2C9, CYP2C19, CY"}, {"to": "11496", "prefix": " inhibit CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A. Thus, ", "from": "11487", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " is unlikely to cause clinically important drug interactions"}, {"to": "11922", "prefix": " Single doses of ", "from": "11913", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " did not affect the pharmacokinetics of imipramine or its ac"}, {"to": "12347", "prefix": " Single doses of ", "from": "12338", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " did not affect the pharmacokinetics of warfarin [see Drug I"}, {"to": "12747", "prefix": " ", "from": "12738", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Olanzapine", "suffix": " did not influence the pharmacokinetics of diazepam or its a"}, {"to": "12894", "prefix": "-desmethyldiazepam. However, diazepam co-administered with ", "from": "12885", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " increased the orthostatic hypotension observed with either "}, {"to": "13339", "prefix": " Multiple doses of ", "from": "13330", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " did not influence the kinetics of ethanol [see Drug Interac"}, {"to": "13752", "prefix": " Multiple doses of ", "from": "13743", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " did not influence the kinetics of biperiden.\n\n             "}, {"to": "14140", "prefix": " Multiple doses of ", "from": "14131", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " did not affect the pharmacokinetics of theophylline or its "}, {"to": "405", "prefix": "\n                           \n                              ", "from": "398", "name": "Diazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3322", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Diazepam", "suffix": ": May potentiate orthostatic hypotension. "}, {"to": "2248", "prefix": "                         \n                                 ", "from": "2241", "name": "Diazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3322", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Diazepam", "suffix": " "}, {"to": "2284", "prefix": " The co-administration of ", "from": "2277", "name": "Diazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3322", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "diazepam", "suffix": " with olanzapine potentiated the orthostatic hypotension obs"}, {"to": "12734", "prefix": "                         \n                                 ", "from": "12727", "name": "Diazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3322", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Diazepam", "suffix": " "}, {"to": "12798", "prefix": " Olanzapine did not influence the pharmacokinetics of ", "from": "12791", "name": "Diazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3322", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "diazepam", "suffix": " or its active metabolite N-desmethyldiazepam. However, diaz"}, {"to": "12862", "prefix": "pam or its active metabolite N-desmethyldiazepam. However, ", "from": "12855", "name": "Diazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3322", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "diazepam", "suffix": " co-administered with olanzapine increased the orthostatic h"}, {"to": "644", "prefix": "\n                           \n                              ", "from": "632", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Carbamazepine", "suffix": ": Increased clearance of olanzapine. "}, {"to": "3193", "prefix": " ", "from": "3181", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Carbamazepine", "suffix": " therapy "}, {"to": "3342", "prefix": "f olanzapine. This increase is likely due to the fact that ", "from": "3330", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "carbamazepine", "suffix": " is a potent inducer of CYP1A2 activity. Higher daily doses "}, {"to": "3418", "prefix": "a potent inducer of CYP1A2 activity. Higher daily doses of ", "from": "3406", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "carbamazepine", "suffix": " may cause an even greater increase in olanzapine clearance."}, {"to": "757", "prefix": "\n                           \n                              ", "from": "747", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Fluvoxamine", "suffix": ": May increase olanzapine levels. "}, {"to": "4698", "prefix": "                         \n                                 ", "from": "4688", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Fluvoxamine", "suffix": ": Fluvoxamine, a CYP1A2 inhibitor, decreases the clearance o"}, {"to": "4711", "prefix": "            \n                                 Fluvoxamine: ", "from": "4701", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Fluvoxamine", "suffix": ", a CYP1A2 inhibitor, decreases the clearance of olanzapine."}, {"to": "4844", "prefix": "is results in a mean increase in olanzapine Cmax following ", "from": "4834", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "fluvoxamine", "suffix": " of 54% in female nonsmokers and 77% in male smokers. The me"}, {"to": "5072", "prefix": "onsidered in patients receiving concomitant treatment with ", "from": "5062", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "fluvoxamine", "suffix": ".\n\n                           \n                           \n "}, {"to": "878", "prefix": "                \n                              ZYPREXA and ", "from": "869", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Fluoxetine", "suffix": " in Combination: Also refer to the Drug Interactions section"}, {"to": "5733", "prefix": "                         \n                                 ", "from": "5724", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Fluoxetine", "suffix": ": Fluoxetine "}, {"to": "5745", "prefix": "             \n                                 Fluoxetine: ", "from": "5736", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Fluoxetine", "suffix": " "}, {"to": "6141", "prefix": "ation is not routinely recommended. When using ZYPREXA and ", "from": "6132", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "fluoxetine", "suffix": " in combination, also refer to the Drug Interactions section"}, {"to": "972", "prefix": "to the Drug Interactions section of the package insert for ", "from": "966", "name": "Symbyax", "fullId": "http://purl.bioontology.org/ontology/RXNORM/405343", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Symbyax", "suffix": ". "}, {"to": "6235", "prefix": "to the Drug Interactions section of the package insert for ", "from": "6229", "name": "Symbyax", "fullId": "http://purl.bioontology.org/ontology/RXNORM/405343", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Symbyax", "suffix": ".\n\n                           \n                           \n "}, {"to": "1350", "prefix": "\n                           \n                              ", "from": "1343", "name": "Levodopa", "fullId": "http://purl.bioontology.org/ontology/MESH/D007980", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Levodopa", "suffix": " and Dopamine Agonists: May antagonize levodopa"}, {"to": "1397", "prefix": "            Levodopa and Dopamine Agonists: May antagonize ", "from": "1390", "name": "Levodopa", "fullId": "http://purl.bioontology.org/ontology/MESH/D007980", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "levodopa", "suffix": ""}, {"to": "9066", "prefix": "                         \n                                 ", "from": "9059", "name": "Levodopa", "fullId": "http://purl.bioontology.org/ontology/MESH/D007980", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Levodopa", "suffix": " and Dopamine Agonists "}, {"to": "9140", "prefix": " Olanzapine may antagonize the effects of ", "from": "9133", "name": "Levodopa", "fullId": "http://purl.bioontology.org/ontology/MESH/D007980", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "levodopa", "suffix": " and dopamine agonists.\n\n                           \n       "}, {"to": "1491", "prefix": "\n                           \n                              ", "from": "1483", "name": "Lorazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6470", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Lorazepam", "suffix": " "}, {"to": "9472", "prefix": "                         \n                                 ", "from": "9464", "name": "Lorazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6470", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Lorazepam", "suffix": " "}, {"to": "9521", "prefix": " Administration of intramuscular ", "from": "9513", "name": "Lorazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6470", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "lorazepam", "suffix": " "}, {"to": "9675", "prefix": "ly affect the pharmacokinetics of olanzapine, unconjugated ", "from": "9667", "name": "Lorazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6470", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "lorazepam", "suffix": ", or total lorazepam. However, this co-administration of int"}, {"to": "9695", "prefix": "cokinetics of olanzapine, unconjugated lorazepam, or total ", "from": "9687", "name": "Lorazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6470", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "lorazepam", "suffix": ". However, this co-administration of intramuscular lorazepam"}, {"to": "9755", "prefix": "orazepam. However, this co-administration of intramuscular ", "from": "9747", "name": "Lorazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6470", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "lorazepam", "suffix": " and intramuscular olanzapine for injection added to the som"}, {"to": "1698", "prefix": "rapy: When using olanzapine in combination with lithium or ", "from": "1690", "name": "Valproate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/40254", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "valproate", "suffix": ", refer to the Drug Interactions sections of the package ins"}, {"to": "10735", "prefix": "                         \n                                 ", "from": "10727", "name": "Valproate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/40254", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Valproate", "suffix": " "}, {"to": "10841", "prefix": " did not affect the steady state plasma concentrations of ", "from": "10833", "name": "Valproate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/40254", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "valproate", "suffix": ". Therefore, concomitant olanzapine administration does not "}, {"to": "10939", "prefix": "apine administration does not require dosage adjustment of ", "from": "10931", "name": "Valproate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/40254", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "valproate", "suffix": " [see Warnings and Precautions "}, {"to": "2706", "prefix": "                         \n                                 ", "from": "2697", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002927", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Cimetidine", "suffix": " and Antacids "}, {"to": "2748", "prefix": " Single doses of ", "from": "2739", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002927", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "cimetidine", "suffix": " "}, {"to": "3795", "prefix": " ", "from": "3789", "name": "Ethanol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/448", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Ethanol", "suffix": " "}, {"to": "3924", "prefix": "i.e., ", "from": "3918", "name": "Ethanol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/448", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "ethanol", "suffix": ""}, {"to": "13381", "prefix": "iple doses of olanzapine did not influence the kinetics of ", "from": "13375", "name": "Ethanol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/448", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "ethanol", "suffix": " [see Drug Interactions "}, {"to": "6544", "prefix": "                         \n                                 ", "from": "6537", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Warfarin", "suffix": " "}, {"to": "6555", "prefix": " ", "from": "6548", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Warfarin", "suffix": " "}, {"to": "12318", "prefix": "                         \n                                 ", "from": "12311", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Warfarin", "suffix": " "}, {"to": "12395", "prefix": "doses of olanzapine did not affect the pharmacokinetics of ", "from": "12388", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "warfarin", "suffix": " [see Drug Interactions "}, {"to": "7006", "prefix": " ", "from": "6997", "name": "Omeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/7646", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Omeprazole", "suffix": " and rifampin may cause an increase in olanzapine clearance."}, {"to": "7019", "prefix": " Omeprazole and ", "from": "7012", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "rifampin", "suffix": " may cause an increase in olanzapine clearance.\n\n           "}, {"to": "11893", "prefix": "                         \n                                 ", "from": "11884", "name": "Imipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5691", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Imipramine", "suffix": " "}, {"to": "11972", "prefix": "doses of olanzapine did not affect the pharmacokinetics of ", "from": "11963", "name": "Imipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5691", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "imipramine", "suffix": " or its active metabolite desipramine.\n\n                    "}, {"to": "12009", "prefix": "he pharmacokinetics of imipramine or its active metabolite ", "from": "11999", "name": "Desipramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003891", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "desipramine", "suffix": ".\n\n                           \n                           \n "}, {"to": "12843", "prefix": "he pharmacokinetics of diazepam or its active metabolite N-", "from": "12827", "name": "Nordazepam", "fullId": "http://purl.bioontology.org/ontology/MESH/D003708", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "desmethyldiazepam", "suffix": ". However, diazepam co-administered with olanzapine increase"}, {"to": "13721", "prefix": "                         \n                                 ", "from": "13713", "name": "Biperiden", "fullId": "http://purl.bioontology.org/ontology/MESH/D001712", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Biperiden", "suffix": " "}, {"to": "13796", "prefix": "iple doses of olanzapine did not influence the kinetics of ", "from": "13788", "name": "Biperiden", "fullId": "http://purl.bioontology.org/ontology/MESH/D001712", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "biperiden", "suffix": ".\n\n                           \n                           \n "}, {"to": "14109", "prefix": "                         \n                                 ", "from": "14098", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10438", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Theophylline", "suffix": " "}, {"to": "14192", "prefix": "doses of olanzapine did not affect the pharmacokinetics of ", "from": "14181", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10438", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "theophylline", "suffix": " or its metabolites.\n\n                           \n          "}, {"to": "326", "prefix": "       The exact mechanism of the antidepressant action of ", "from": "313", "name": "O-desmethylvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C086816", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "desvenlafaxine", "suffix": " is unknown, but is thought to be related to the potentiatio"}, {"to": "540", "prefix": "on of their reuptake. Non-clinical studies have shown that ", "from": "527", "name": "O-desmethylvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C086816", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "desvenlafaxine", "suffix": " is a potent and selective serotonin and norepinephrine reup"}, {"to": "884", "prefix": "macodynamics\n                     \n                        ", "from": "871", "name": "O-desmethylvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C086816", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "Desvenlafaxine", "suffix": " lacked significant affinity for numerous receptors, includi"}, {"to": "1040", "prefix": "1-adrenergic receptors in vitro. ", "from": "1027", "name": "O-desmethylvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C086816", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "Desvenlafaxine", "suffix": " also lacked monoamine oxidase "}, {"to": "1469", "prefix": "               Electrocardiograms were obtained from 1,492 ", "from": "1456", "name": "O-desmethylvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C086816", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "desvenlafaxine", "suffix": " treated patients with major depressive disorder and 984 pla"}, {"to": "1665", "prefix": ". No clinically relevant differences were observed between ", "from": "1652", "name": "O-desmethylvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C086816", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "desvenlafaxine", "suffix": " treated and placebo-treated patients for QT, QTc, PR, and Q"}, {"to": "1817", "prefix": "thorough QTc study with prospectively determined criteria, ", "from": "1804", "name": "O-desmethylvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C086816", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "desvenlafaxine", "suffix": " did not cause QT prolongation. No difference was observed b"}, {"to": "1910", "prefix": "olongation. No difference was observed between placebo and ", "from": "1897", "name": "O-desmethylvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C086816", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "desvenlafaxine", "suffix": " treatments for the QRS interval.\n                          "}, {"to": "2300", "prefix": "                       The single-dose pharmacokinetics of ", "from": "2287", "name": "O-desmethylvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C086816", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "desvenlafaxine", "suffix": " are linear and dose-proportional in a dose range of 50 to 6"}, {"to": "2542", "prefix": " to 5 days. At steady-state, multiple-dose accumulation of ", "from": "2529", "name": "O-desmethylvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C086816", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "desvenlafaxine", "suffix": " is linear and predictable from the single-dose pharmacokine"}, {"to": "2987", "prefix": "                      The absolute oral bioavailability of ", "from": "2981", "name": "O-desmethylvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C086816", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "PRISTIQ", "suffix": " after oral administration is about 80%.\n                   "}, {"to": "3113", "prefix": "           A food-effect study involving administration of ", "from": "3107", "name": "O-desmethylvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C086816", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "PRISTIQ", "suffix": " to healthy subjects under fasting and fed conditions "}, {"to": "3234", "prefix": " indicated that ", "from": "3221", "name": "O-desmethylvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C086816", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "desvenlafaxine", "suffix": " Cmax was increased about 16% in the fed state, while the AU"}, {"to": "3391", "prefix": "e is not expected to be clinically significant; therefore, ", "from": "3385", "name": "O-desmethylvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C086816", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "PRISTIQ", "suffix": " can be taken without regard to meals [see Dosage and Admini"}, {"to": "3543", "prefix": "                             The plasma protein binding of ", "from": "3530", "name": "O-desmethylvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C086816", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "desvenlafaxine", "suffix": " is low "}, {"to": "3617", "prefix": " and is independent of drug concentration. The ", "from": "3604", "name": "O-desmethylvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C086816", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "desvenlafaxine", "suffix": " volume of distribution at steady-state following intravenou"}, {"to": "4164", "prefix": "                            \n                              ", "from": "4151", "name": "O-desmethylvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C086816", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "Desvenlafaxine", "suffix": " is primarily metabolized by conjugation "}, {"to": "4394", "prefix": " of ", "from": "4381", "name": "O-desmethylvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C086816", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "desvenlafaxine", "suffix": ". The CYP2D6 metabolic pathway is not involved, and after ad"}, {"to": "4516", "prefix": "nd after administration of 100 mg, the pharmacokinetics of ", "from": "4503", "name": "O-desmethylvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C086816", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "desvenlafaxine", "suffix": " was similar in subjects with CYP2D6 poor and extensive meta"}, {"to": "4630", "prefix": " and extensive metabolizer phenotype. Approximately 45% of ", "from": "4617", "name": "O-desmethylvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C086816", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "desvenlafaxine", "suffix": " is excreted unchanged in urine at 72 hours after oral admin"}, {"to": "5680", "prefix": "           CYP3A4 is a minor pathway for the metabolism of ", "from": "5667", "name": "O-desmethylvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C086816", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "desvenlafaxine", "suffix": ". In a clinical study, ketoconazole "}, {"to": "5810", "prefix": " of ", "from": "5797", "name": "O-desmethylvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C086816", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "desvenlafaxine", "suffix": " "}, {"to": "5900", "prefix": " by about 43% and Cmax by about 8%. Concomitant use of ", "from": "5887", "name": "O-desmethylvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C086816", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "desvenlafaxine", "suffix": " with potent inhibitors of CYP3A4 may result in higher conce"}, {"to": "5987", "prefix": "nhibitors of CYP3A4 may result in higher concentrations of ", "from": "5974", "name": "O-desmethylvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C086816", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "desvenlafaxine", "suffix": ". \n                                 \n                       "}, {"to": "6651", "prefix": " have significant impact on the pharmacokinetic profile of ", "from": "6638", "name": "O-desmethylvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C086816", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "desvenlafaxine", "suffix": ". \n                                 \n                       "}, {"to": "7249", "prefix": "      In vitro studies showed minimal inhibitory effect of ", "from": "7236", "name": "O-desmethylvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C086816", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "desvenlafaxine", "suffix": " on CYP2D6. Clinical studies have shown that desvenlafaxine "}, {"to": "7308", "prefix": "desvenlafaxine on CYP2D6. Clinical studies have shown that ", "from": "7295", "name": "O-desmethylvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C086816", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "desvenlafaxine", "suffix": " does not have a clinically relevant effect on CYP2D6 metabo"}, {"to": "7431", "prefix": "ect on CYP2D6 metabolism at the dose of 100 mg daily. When ", "from": "7408", "name": "O-desmethylvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C086816", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "desvenlafaxine succinate", "suffix": " was administered at a dose of 100 mg daily in conjunction w"}, {"to": "7817", "prefix": "pproximately 50% and 90%, respectively. Concomitant use of ", "from": "7804", "name": "O-desmethylvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C086816", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "desvenlafaxine", "suffix": " with a drug metabolized by CYP2D6 can result in higher conc"}, {"to": "8471", "prefix": "            \n                                    In vitro, ", "from": "8458", "name": "O-desmethylvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C086816", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "desvenlafaxine", "suffix": " does not inhibit or induce the CYP3A4 isozyme. In a clinica"}, {"to": "8554", "prefix": "inhibit or induce the CYP3A4 isozyme. In a clinical study, ", "from": "8541", "name": "O-desmethylvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C086816", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "desvenlafaxine", "suffix": " 400 mg daily "}, {"to": "8801", "prefix": "pproximately 31% and 16%, respectively. Concomitant use of ", "from": "8788", "name": "O-desmethylvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C086816", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "desvenlafaxine", "suffix": " with a drug metabolized by CYP3A4 can result in lower expos"}, {"to": "9395", "prefix": "            \n                                    In vitro, ", "from": "9382", "name": "O-desmethylvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C086816", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "desvenlafaxine", "suffix": " does not inhibit CYP1A2, 2A6, 2C8, 2C9, and 2C19 isozymes a"}, {"to": "9625", "prefix": "P isozymes. \n                                    In vitro, ", "from": "9612", "name": "O-desmethylvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C086816", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "desvenlafaxine", "suffix": " is not a substrate or an inhibitor for the P-glycoprotein t"}, {"to": "9735", "prefix": "or the P-glycoprotein transporter. The pharmacokinetics of ", "from": "9722", "name": "O-desmethylvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C086816", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "desvenlafaxine", "suffix": " are unlikely to be affected by drugs that inhibit the P-gly"}, {"to": "9836", "prefix": " by drugs that inhibit the P-glycoprotein transporter, and ", "from": "9823", "name": "O-desmethylvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C086816", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "desvenlafaxine", "suffix": " is not likely to affect the pharmacokinetics of drugs that "}, {"to": "12445", "prefix": " had no apparent effect on the pharmacokinetics of ", "from": "12439", "name": "O-desmethylvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C086816", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "PRISTIQ", "suffix": ". No adjustment of dosage on the basis of race is needed. \n "}, {"to": "13006", "prefix": "   \n                                    The disposition of ", "from": "12983", "name": "O-desmethylvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C086816", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "desvenlafaxine succinate", "suffix": " after administration of 100 mg was studied in subjects with"}, {"to": "14715", "prefix": "   \n                                    The disposition of ", "from": "14702", "name": "O-desmethylvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C086816", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "desvenlafaxine", "suffix": " after administration of 100 mg was studied in subjects with"}, {"to": "400", "prefix": "known, but is thought to be related to the potentiation of ", "from": "392", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "serotonin", "suffix": " and norepinephrine in the central nervous system, through i"}, {"to": "576", "prefix": "s have shown that desvenlafaxine is a potent and selective ", "from": "568", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "serotonin", "suffix": " and norepinephrine reuptake inhibitor "}, {"to": "419", "prefix": "thought to be related to the potentiation of serotonin and ", "from": "406", "name": "Norepinephrine", "fullId": "http://purl.bioontology.org/ontology/MESH/D009638", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "norepinephrine", "suffix": " in the central nervous system, through inhibition of their "}, {"to": "595", "prefix": "hat desvenlafaxine is a potent and selective serotonin and ", "from": "582", "name": "Norepinephrine", "fullId": "http://purl.bioontology.org/ontology/MESH/D009638", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "norepinephrine", "suffix": " reuptake inhibitor "}, {"to": "5543", "prefix": "", "from": "5532", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "ketoconazole", "suffix": ""}, {"to": "5715", "prefix": "for the metabolism of desvenlafaxine. In a clinical study, ", "from": "5704", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "ketoconazole", "suffix": " "}, {"to": "7063", "prefix": "e.g. ", "from": "7053", "name": "Desipramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003891", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "desipramine", "suffix": ", dextromethorphan, metoprolol, atomoxetine"}, {"to": "7529", "prefix": "of 100 mg daily in conjunction with a single 50 mg dose of ", "from": "7519", "name": "Desipramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003891", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "desipramine", "suffix": ", a CYP2D6 substrate, the Cmax and AUC of desipramine increa"}, {"to": "7582", "prefix": "se of desipramine, a CYP2D6 substrate, the Cmax and AUC of ", "from": "7572", "name": "Desipramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003891", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "desipramine", "suffix": " increased approximately 25% and 17%, respectively. When 400"}, {"to": "7732", "prefix": " was administered, the Cmax and AUC of ", "from": "7722", "name": "Desipramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003891", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "desipramine", "suffix": " increased approximately 50% and 90%, respectively. Concomit"}, {"to": "7081", "prefix": "e.g. desipramine, ", "from": "7066", "name": "Dextromethorphan", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3289", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "dextromethorphan", "suffix": ", metoprolol, atomoxetine"}, {"to": "7093", "prefix": "e.g. desipramine, dextromethorphan, ", "from": "7084", "name": "Metoprolol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6918", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "metoprolol", "suffix": ", atomoxetine"}, {"to": "7106", "prefix": "e.g. desipramine, dextromethorphan, metoprolol, ", "from": "7096", "name": "atomoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C041930", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "atomoxetine", "suffix": ""}, {"to": "8371", "prefix": "", "from": "8363", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "midazolam", "suffix": ""}, {"to": "8661", "prefix": " was co-administered with a single 4 mg dose of ", "from": "8653", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "midazolam", "suffix": " "}, {"to": "8713", "prefix": ". The AUC and Cmax of ", "from": "8705", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "midazolam", "suffix": " decreased by approximately 31% and 16%, respectively. Conco"}, {"to": "14995", "prefix": ". Elimination was significantly correlated with ", "from": "14986", "name": "Creatinine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003404", "setId": "0f43610c-f290-46ea-d186-4f998ed99fce", "exact": "creatinine", "suffix": " clearance. Increases in AUCs of about 42% in mild renal imp"}, {"to": "266", "prefix": "7.1, ", "from": "257", "name": "Imipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5691", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "Imipramine", "suffix": ": Decreased alertness observed with combination use. "}, {"to": "912", "prefix": "otentially enhance the CNS-depressant effects of zolpidem. ", "from": "903", "name": "Imipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5691", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "Imipramine", "suffix": " in combination with zolpidem produced an additive effect of"}, {"to": "349", "prefix": "7.1, ", "from": "336", "name": "Chlorpromazine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2403", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "Chlorpromazine", "suffix": ": Impaired alertness and psychomotor performance observed wi"}, {"to": "1019", "prefix": "uced an additive effect of decreased alertness. Similarly, ", "from": "1006", "name": "Chlorpromazine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2403", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "chlorpromazine", "suffix": " in combination with zolpidem produced an additive effect of"}, {"to": "453", "prefix": "7.1, ", "from": "446", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "Rifampin", "suffix": ": Combination use decreases exposure to, and effect of zolpi"}, {"to": "2134", "prefix": "carefully evaluated.Co-administration of multiple doses of ", "from": "2127", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "rifampin", "suffix": " and a single dose of zolpidem tartrate "}, {"to": "2228", "prefix": " given 17 hours after the last dose of ", "from": "2221", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "rifampin", "suffix": " showed significant reductions of the AUC "}, {"to": "516", "prefix": "mpin: Combination use decreases exposure to, and effect of ", "from": "509", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem", "suffix": ". "}, {"to": "609", "prefix": "zole: Combination use increases exposure to, and effect of ", "from": "602", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem", "suffix": ". "}, {"to": "900", "prefix": "ts could potentially enhance the CNS-depressant effects of ", "from": "893", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem", "suffix": ". Imipramine in combination with zolpidem produced an additi"}, {"to": "941", "prefix": "essant effects of zolpidem. Imipramine in combination with ", "from": "934", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem", "suffix": " produced an additive effect of decreased alertness. Similar"}, {"to": "1048", "prefix": "d alertness. Similarly, chlorpromazine in combination with ", "from": "1041", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem", "suffix": " produced an additive effect of decreased alertness and psyc"}, {"to": "1240", "prefix": "rmacokinetic interaction.A study involving haloperidol and ", "from": "1233", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem", "suffix": " revealed no effect of haloperidol on the pharmacokinetics o"}, {"to": "1330", "prefix": "haloperidol on the pharmacokinetics or pharmacodynamics of ", "from": "1323", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem", "suffix": ". The lack of a drug interaction following single-dose admin"}, {"to": "1537", "prefix": "effect on psychomotor performance between alcohol and oral ", "from": "1530", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem", "suffix": " was demonstrated [see Warnings and Precautions: CNS depress"}, {"to": "1655", "prefix": "]. Concomitant administration of ", "from": "1648", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem", "suffix": " and sertraline increased zolpidem Cmax "}, {"to": "1689", "prefix": "mitant administration of zolpidem and sertraline increased ", "from": "1682", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem", "suffix": " Cmax "}, {"to": "1800", "prefix": "r or not these changes alter the pharmacodynamic effect of ", "from": "1793", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem", "suffix": " is unknown. [see Warnings and Precautions: CNS depressant e"}, {"to": "2005", "prefix": " compounds known to inhibit CYP3A may increase exposure to ", "from": "1998", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem", "suffix": ". The effect of inhibitors of other P450 enzymes has not bee"}, {"to": "2173", "prefix": "tration of multiple doses of rifampin and a single dose of ", "from": "2157", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem tartrate", "suffix": " "}, {"to": "2315", "prefix": " of ", "from": "2308", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem", "suffix": " together with significant reductions in the pharmacodynamic"}, {"to": "2404", "prefix": "h significant reductions in the pharmacodynamic effects of ", "from": "2388", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem tartrate", "suffix": ". max "}, {"to": "2477", "prefix": ", and TCo-administration of a single dose of ", "from": "2461", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem tartrate", "suffix": " with 4 doses of ketoconazole, a potent CYP3A4 inhibitor inc"}, {"to": "2560", "prefix": " ketoconazole, a potent CYP3A4 inhibitor increased Cmax of ", "from": "2553", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem", "suffix": " "}, {"to": "2596", "prefix": " and the total AUC of ", "from": "2589", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem", "suffix": " "}, {"to": "2623", "prefix": " compared to ", "from": "2616", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem", "suffix": " alone and prolonged the elimination half-life "}, {"to": "2741", "prefix": " along with an increase in the pharmacodynamic effects of ", "from": "2734", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem", "suffix": ". Consideration should be given to using a lower dose of zol"}, {"to": "2806", "prefix": "em. Consideration should be given to using a lower dose of ", "from": "2799", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem", "suffix": " when ketoconazole and zolpidem are given together. Patients"}, {"to": "2837", "prefix": "en to using a lower dose of zolpidem when ketoconazole and ", "from": "2830", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem", "suffix": " are given together. Patients should be advised that use of "}, {"to": "2971", "prefix": "with ketoconazole may enhance the sedative effects. max of ", "from": "2964", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem", "suffix": " "}, {"to": "3007", "prefix": " and the total AUC of ", "from": "3000", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem", "suffix": " "}, {"to": "3034", "prefix": " compared to ", "from": "3027", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem", "suffix": " alone and prolonged the elimination half-life "}, {"to": "3152", "prefix": " along with an increase in the pharmacodynamic effects of ", "from": "3145", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem", "suffix": ". Consideration should be given to using a lower dose of zol"}, {"to": "3217", "prefix": "em. Consideration should be given to using a lower dose of ", "from": "3210", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem", "suffix": " when ketoconazole and zolpidem are given together. Patients"}, {"to": "3248", "prefix": "en to using a lower dose of zolpidem when ketoconazole and ", "from": "3241", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem", "suffix": " are given together. Patients should be advised that use of "}, {"to": "3421", "prefix": "ive effects. \n\n\n\n\n\n\n\n7.3 Drug-laboratory test interactions\n", "from": "3414", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "Zolpidem", "suffix": " is not known to interfere with commonly employed clinical l"}, {"to": "3547", "prefix": "laboratory tests. In addition, clinical data indicate that ", "from": "3540", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem", "suffix": " does not cross-react with benzodiazepines, opiates, barbitu"}, {"to": "546", "prefix": "7.2, ", "from": "535", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "Ketoconazole", "suffix": ": Combination use increases exposure to, and effect of zolpi"}, {"to": "2506", "prefix": "tion of a single dose of zolpidem tartrate with 4 doses of ", "from": "2495", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "ketoconazole", "suffix": ", a potent CYP3A4 inhibitor increased Cmax of zolpidem "}, {"to": "2824", "prefix": "ion should be given to using a lower dose of zolpidem when ", "from": "2813", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "ketoconazole", "suffix": " and zolpidem are given together. Patients should be advised"}, {"to": "2921", "prefix": "gether. Patients should be advised that use of Edluar with ", "from": "2910", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "ketoconazole", "suffix": " may enhance the sedative effects. max of zolpidem "}, {"to": "3235", "prefix": "ion should be given to using a lower dose of zolpidem when ", "from": "3224", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "ketoconazole", "suffix": " and zolpidem are given together. Patients should be advised"}, {"to": "3332", "prefix": "gether. Patients should be advised that use of Edluar with ", "from": "3321", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "ketoconazole", "suffix": " may enhance the sedative effects. \n\n\n\n\n\n\n\n7.3 Drug-laborato"}, {"to": "1227", "prefix": " significant pharmacokinetic interaction.A study involving ", "from": "1217", "name": "Haloperidol", "fullId": "http://purl.bioontology.org/ontology/MESH/D006220", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "haloperidol", "suffix": " and zolpidem revealed no effect of haloperidol on the pharm"}, {"to": "1274", "prefix": "y involving haloperidol and zolpidem revealed no effect of ", "from": "1264", "name": "Haloperidol", "fullId": "http://purl.bioontology.org/ontology/MESH/D006220", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "haloperidol", "suffix": " on the pharmacokinetics or pharmacodynamics of zolpidem. Th"}, {"to": "1670", "prefix": "]. Concomitant administration of zolpidem and ", "from": "1661", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "sertraline", "suffix": " increased zolpidem Cmax "}, {"to": "2903", "prefix": "are given together. Patients should be advised that use of ", "from": "2898", "name": "Edluar", "fullId": "http://purl.bioontology.org/ontology/RXNORM/836642", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "Edluar", "suffix": " with ketoconazole may enhance the sedative effects. max of "}, {"to": "3314", "prefix": "are given together. Patients should be advised that use of ", "from": "3309", "name": "Edluar", "fullId": "http://purl.bioontology.org/ontology/RXNORM/836642", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "Edluar", "suffix": " with ketoconazole may enhance the sedative effects. \n\n\n\n\n\n\n"}, {"to": "3589", "prefix": "ical data indicate that zolpidem does not cross-react with ", "from": "3575", "name": "Benzodiazepines", "fullId": "http://purl.bioontology.org/ontology/MESH/D001569", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "benzodiazepines", "suffix": ", opiates, barbiturates, cocaine, cannabinoids, or amphetami"}, {"to": "3621", "prefix": "t cross-react with benzodiazepines, opiates, barbiturates, ", "from": "3615", "name": "Cocaine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2653", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "cocaine", "suffix": ", cannabinoids, or amphetamines in two standard urine drug s"}, {"to": "66", "prefix": "\n\n\n12 CLINICAL PHARMACOLOGY\n\n\n\n\n\n12.1 Mechanism of action\n", "from": "59", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "Zolpidem", "suffix": ", the active moiety of zolpidem tartrate, is a hypnotic agen"}, {"to": "106", "prefix": "\n\n\n12.1 Mechanism of action\nZolpidem, the active moiety of ", "from": "90", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem tartrate", "suffix": ", is a hypnotic agent with a chemical structure unrelated to"}, {"to": "477", "prefix": "selectively bind to and activate all BZ receptor subtypes, ", "from": "470", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem", "suffix": " in vitro binds the BZ1 receptor preferentially with a high "}, {"to": "843", "prefix": " in human studies of ", "from": "827", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem tartrate", "suffix": " at hypnotic doses.in vitro binds the BZ\n\n\n\n\n\n\n\n12.3 Pharmac"}, {"to": "960", "prefix": "", "from": "944", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem tartrate", "suffix": ""}, {"to": "1006", "prefix": " sublingual tablet is bioequivalent to ", "from": "1001", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "Ambien", "suffix": " "}, {"to": "1091", "prefix": " with respect to Cmax and AUC. Similar to ", "from": "1075", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem tartrate", "suffix": " oral tablets, Edluar sublingual tablet results in a pharmac"}, {"to": "1243", "prefix": " characterized by rapid absorption.max and AUC. Similar to ", "from": "1227", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem tartrate", "suffix": " oral tablets, Edluar sublingual tablet results in a pharmac"}, {"to": "1500", "prefix": " of ", "from": "1493", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem", "suffix": " was 106 ng"}, {"to": "1625", "prefix": " of ", "from": "1618", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem", "suffix": " was 106 ng"}, {"to": "2273", "prefix": "Distribution:Distribution:Based on data obtained with oral ", "from": "2266", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem", "suffix": ", the total protein binding was found to be 92.5  "}, {"to": "2469", "prefix": "mL.Metabolism:Metabolism:Based on data obtained with oral ", "from": "2462", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem", "suffix": ", zolpidem is converted to inactive metabolites that are eli"}, {"to": "2479", "prefix": "lism:Metabolism:Based on data obtained with oral zolpidem, ", "from": "2472", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem", "suffix": " is converted to inactive metabolites that are eliminated pr"}, {"to": "2692", "prefix": "single 5 or 10 mg dose in healthy adult subjects, the mean ", "from": "2685", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem", "suffix": " elimination half-life was 2.85 hours "}, {"to": "3051", "prefix": "]. This recommendation is based on several studies with ", "from": "3035", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem tartrate", "suffix": " in which the mean Cmax, T1"}, {"to": "3457", "prefix": " following a single 20 mg oral dose. ", "from": "3450", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "Zolpidem", "suffix": " did not accumulate in elderly subjects following nightly or"}, {"to": "3658", "prefix": "atic impairment:Hepatic impairment:The pharmacokinetics of ", "from": "3642", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem tartrate", "suffix": " in eight patients with chronic hepatic insufficiency were c"}, {"to": "3805", "prefix": "results in healthy subjects. Following a single 20-mg oral ", "from": "3789", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem tartrate", "suffix": " dose, mean Cmax and AUC were found to be two times "}, {"to": "4544", "prefix": "al impairment:  Renal impairment:  The pharmacokinetics of ", "from": "4528", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem tartrate", "suffix": " were studied in 11 patients with end-stage 4 renal failure "}, {"to": "4716", "prefix": "going hemodialysis three times a week, who were dosed with ", "from": "4700", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem tartrate", "suffix": " 10 mg orally each day for 14 or 21 days. No statistically s"}, {"to": "5698", "prefix": "mL after repeated dosing. ", "from": "5691", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "Zolpidem", "suffix": " was not hemodialyzable. No accumulation of unchanged drug a"}, {"to": "5795", "prefix": "cumulation of unchanged drug appeared after 14 or 21 days. ", "from": "5788", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "Zolpidem", "suffix": " pharmacokinetics were not significantly different in renall"}, {"to": "6069", "prefix": "going hemodialysis three times a week, who were dosed with ", "from": "6053", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem tartrate", "suffix": " 10 mg orally each day for 14 or 21 days. No statistically s"}, {"to": "6285", "prefix": "drugs:CNS-active drugs:Since the systematic evaluations of ", "from": "6278", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem", "suffix": " in combination with other CNS-active drugs have been limite"}, {"to": "6453", "prefix": "to the pharmacology of any CNS-active drug to be used with ", "from": "6446", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem", "suffix": ". Any drug with CNS-depressant effects could potentially enh"}, {"to": "6556", "prefix": "ts could potentially enhance the CNS-depressant effects of ", "from": "6549", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem", "suffix": ".Zolpidem tartrate was evaluated in healthy volunteers in si"}, {"to": "6574", "prefix": "potentially enhance the CNS-depressant effects of zolpidem.", "from": "6558", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "Zolpidem tartrate", "suffix": " was evaluated in healthy volunteers in single-dose interact"}, {"to": "6708", "prefix": "dies for several CNS drugs. Imipramine in combination with ", "from": "6701", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem", "suffix": " produced no pharmacokinetic interaction other than a 20% de"}, {"to": "6916", "prefix": "d alertness. Similarly, chlorpromazine in combination with ", "from": "6909", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem", "suffix": " produced no pharmacokinetic interaction, but there was an a"}, {"to": "7084", "prefix": " psychomotor performance.A study involving haloperidol and ", "from": "7077", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem", "suffix": " revealed no effect of haloperidol on the pharmacokinetics o"}, {"to": "7174", "prefix": "haloperidol on the pharmacokinetics or pharmacodynamics of ", "from": "7167", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem", "suffix": ". The lack of a drug interaction following single-dose admin"}, {"to": "7380", "prefix": "effect on psychomotor performance between alcohol and oral ", "from": "7373", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem", "suffix": " was demonstrated [see Warnings and Precautions: CNS depress"}, {"to": "7559", "prefix": "A single-dose interaction study with ", "from": "7552", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem", "suffix": " tartrate10 mg and fluoxetine 20 mg at steady-state levels i"}, {"to": "7764", "prefix": "ic or pharmacodynamic interactions. When multiple doses of ", "from": "7757", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem", "suffix": " and fluoxetine at steady state the concentrations were eval"}, {"to": "7874", "prefix": "rations were evaluated in healthy females, increase in the ", "from": "7867", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem", "suffix": " half-life "}, {"to": "8033", "prefix": "rformance.Following five consecutive nightly doses of oral ", "from": "8026", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem", "suffix": " tartrate10 mg in the presence of sertraline 50 mg "}, {"to": "8164", "prefix": ", ", "from": "8157", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem", "suffix": " Cmax was significantly higher "}, {"to": "8329", "prefix": "of sertraline and N-desmethylsertraline were unaffected by ", "from": "8322", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem", "suffix": ".max was significantly higher "}, {"to": "8549", "prefix": " compounds known to inhibit CYP3A may increase exposure to ", "from": "8542", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem", "suffix": ". The effect of inhibitors of other P450 enzymes has not bee"}, {"to": "8803", "prefix": " and a single dose of ", "from": "8787", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem tartrate", "suffix": " "}, {"to": "8919", "prefix": " of ", "from": "8903", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem tartrate", "suffix": ". There were no significant pharmacodynamic effects of zolpi"}, {"to": "8982", "prefix": "rate. There were no significant pharmacodynamic effects of ", "from": "8975", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem", "suffix": " on subjective drowsiness, postural sway, or psychomotor per"}, {"to": "9075", "prefix": " of ", "from": "9059", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem tartrate", "suffix": ". There were no significant pharmacodynamic effects of zolpi"}, {"to": "9138", "prefix": "rate. There were no significant pharmacodynamic effects of ", "from": "9131", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem", "suffix": " on subjective drowsiness, postural sway, or psychomotor per"}, {"to": "9398", "prefix": " and a single dose of ", "from": "9382", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem tartrate", "suffix": " "}, {"to": "9541", "prefix": " of ", "from": "9534", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem", "suffix": " together with significant reductions in the pharmacodynamic"}, {"to": "9630", "prefix": "h significant reductions in the pharmacodynamic effects of ", "from": "9614", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem tartrate", "suffix": ".max "}, {"to": "9800", "prefix": "cts showed that co-administration of a single 5 mg dose of ", "from": "9784", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem tartrate", "suffix": " with ketoconazole, a potent CYP3A4 inhibitor, given as 200 "}, {"to": "9912", "prefix": ", given as 200 mg twice daily for 2 days increased Cmax of ", "from": "9905", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem", "suffix": " "}, {"to": "9948", "prefix": " and the total AUC of ", "from": "9941", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem", "suffix": " "}, {"to": "9975", "prefix": " compared to ", "from": "9968", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem", "suffix": " alone and prolonged the elimination half-life "}, {"to": "10094", "prefix": " along with an increase in the pharmacodynamic effects of ", "from": "10087", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem", "suffix": ". Consideration should be given to using a lower dose of zol"}, {"to": "10159", "prefix": "em. Consideration should be given to using a lower dose of ", "from": "10152", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem", "suffix": " when ketoconazole and zolpidem are given together. Patients"}, {"to": "10190", "prefix": "en to using a lower dose of zolpidem when ketoconazole and ", "from": "10183", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem", "suffix": " are given together. Patients should be advised that use of "}, {"to": "10354", "prefix": "the sedative effects.Other drugs with no interactions with ", "from": "10347", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem", "suffix": ":Other drugs with no interactions with zolpidem:A study invo"}, {"to": "10401", "prefix": "ctions with zolpidem:Other drugs with no interactions with ", "from": "10394", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem", "suffix": ":A study involving cimetidine"}, {"to": "10448", "prefix": "", "from": "10432", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem tartrate", "suffix": " and ranitidine"}, {"to": "10481", "prefix": "", "from": "10465", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem tartrate", "suffix": " combinations revealed no effect of either drug on the pharm"}, {"to": "10584", "prefix": "either drug on the pharmacokinetics or pharmacodynamics of ", "from": "10577", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "zolpidem", "suffix": ".Zolpidem tartrate had no effect on digoxin pharmacokinetics"}, {"to": "10602", "prefix": "ug on the pharmacokinetics or pharmacodynamics of zolpidem.", "from": "10586", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "Zolpidem tartrate", "suffix": " had no effect on digoxin pharmacokinetics and did not affec"}, {"to": "182", "prefix": "is a hypnotic agent with a chemical structure unrelated to ", "from": "168", "name": "Benzodiazepines", "fullId": "http://purl.bioontology.org/ontology/MESH/D001569", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "benzodiazepines", "suffix": ", barbiturates, or other drugs with known hypnotic propertie"}, {"to": "362", "prefix": "x and shares some of the pharmacological properties of the ", "from": "348", "name": "Benzodiazepines", "fullId": "http://purl.bioontology.org/ontology/MESH/D001569", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "benzodiazepines", "suffix": ". In contrast to the benzodiazepines, which non-selectively "}, {"to": "398", "prefix": "ical properties of the benzodiazepines. In contrast to the ", "from": "384", "name": "Benzodiazepines", "fullId": "http://purl.bioontology.org/ontology/MESH/D001569", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "benzodiazepines", "suffix": ", which non-selectively bind to and activate all BZ receptor"}, {"to": "269", "prefix": " drugs with known hypnotic properties. It interacts with a ", "from": "266", "name": "gamma-Aminobutyric Acid", "fullId": "http://purl.bioontology.org/ontology/MESH/D005680", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "GABA", "suffix": "-BZ receptor complex and shares some of the pharmacological "}, {"to": "941", "prefix": " the BZ\n\n\n\n\n\n\n\n12.3 Pharmacokinetics\nAbsorption:Absorption:", "from": "936", "name": "Edluar", "fullId": "http://purl.bioontology.org/ontology/RXNORM/836642", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "Edluar", "suffix": " "}, {"to": "1112", "prefix": "o Cmax and AUC. Similar to zolpidem tartrate oral tablets, ", "from": "1107", "name": "Edluar", "fullId": "http://purl.bioontology.org/ontology/RXNORM/836642", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "Edluar", "suffix": " sublingual tablet results in a pharmacokinetic profile char"}, {"to": "1264", "prefix": "on.max and AUC. Similar to zolpidem tartrate oral tablets, ", "from": "1259", "name": "Edluar", "fullId": "http://purl.bioontology.org/ontology/RXNORM/836642", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "Edluar", "suffix": " sublingual tablet results in a pharmacokinetic profile char"}, {"to": "1401", "prefix": " rapid absorption.Following administration of single 10 mg ", "from": "1396", "name": "Edluar", "fullId": "http://purl.bioontology.org/ontology/RXNORM/836642", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "Edluar", "suffix": ", in 18 "}, {"to": "1778", "prefix": " in 18 healthy volunteers compared the pharmacokinetics of ", "from": "1773", "name": "Edluar", "fullId": "http://purl.bioontology.org/ontology/RXNORM/836642", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "Edluar", "suffix": " 10 mg when administered while fasting or within 20 minutes "}, {"to": "2081", "prefix": "anged. These results suggest that, for faster sleep onset, ", "from": "2076", "name": "Edluar", "fullId": "http://purl.bioontology.org/ontology/RXNORM/836642", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "Edluar", "suffix": " should not be administered with or immediately after a meal"}, {"to": "2602", "prefix": "primarily by renal excretion. Elimination:Elimination:When ", "from": "2597", "name": "Edluar", "fullId": "http://purl.bioontology.org/ontology/RXNORM/836642", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "Edluar", "suffix": " was administered as a single 5 or 10 mg dose in healthy adu"}, {"to": "2895", "prefix": "al populationsElderly:Elderly:In the elderly, the dose for ", "from": "2890", "name": "Edluar", "fullId": "http://purl.bioontology.org/ontology/RXNORM/836642", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "Edluar", "suffix": " should be 5 mg [see Warnings and Precautions "}, {"to": "4164", "prefix": ". Dosing with ", "from": "4159", "name": "Edluar", "fullId": "http://purl.bioontology.org/ontology/RXNORM/836642", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "Edluar", "suffix": " should be modified accordingly in patients with hepatic ins"}, {"to": "5906", "prefix": "rent in renally-impaired patients. No dosage adjustment of ", "from": "5901", "name": "Edluar", "fullId": "http://purl.bioontology.org/ontology/RXNORM/836642", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "Edluar", "suffix": " is necessary in patients with compromised renal function. C"}, {"to": "10256", "prefix": "are given together. Patients should be advised that use of ", "from": "10251", "name": "Edluar", "fullId": "http://purl.bioontology.org/ontology/RXNORM/836642", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "Edluar", "suffix": " with ketoconazole may enhance the sedative effects.Other dr"}, {"to": "6679", "prefix": " in single-dose interaction studies for several CNS drugs. ", "from": "6670", "name": "Imipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5691", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "Imipramine", "suffix": " in combination with zolpidem produced no pharmacokinetic in"}, {"to": "6803", "prefix": "ic interaction other than a 20% decrease in peak levels of ", "from": "6794", "name": "Imipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5691", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "imipramine", "suffix": ", but there was an additive effect of decreased alertness. S"}, {"to": "6887", "prefix": " was an additive effect of decreased alertness. Similarly, ", "from": "6874", "name": "Chlorpromazine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2403", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "chlorpromazine", "suffix": " in combination with zolpidem produced no pharmacokinetic in"}, {"to": "7071", "prefix": "ed alertness and psychomotor performance.A study involving ", "from": "7061", "name": "Haloperidol", "fullId": "http://purl.bioontology.org/ontology/MESH/D006220", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "haloperidol", "suffix": " and zolpidem revealed no effect of haloperidol on the pharm"}, {"to": "7118", "prefix": "y involving haloperidol and zolpidem revealed no effect of ", "from": "7108", "name": "Haloperidol", "fullId": "http://purl.bioontology.org/ontology/MESH/D006220", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "haloperidol", "suffix": " on the pharmacokinetics or pharmacodynamics of zolpidem. Th"}, {"to": "7588", "prefix": "gle-dose interaction study with zolpidem tartrate10 mg and ", "from": "7579", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "fluoxetine", "suffix": " 20 mg at steady-state levels in male volunteers did not dem"}, {"to": "7779", "prefix": "odynamic interactions. When multiple doses of zolpidem and ", "from": "7770", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "fluoxetine", "suffix": " at steady state the concentrations were evaluated in health"}, {"to": "8077", "prefix": "ly doses of oral zolpidem tartrate10 mg in the presence of ", "from": "8068", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "sertraline", "suffix": " 50 mg "}, {"to": "8275", "prefix": ". Pharmacokinetics of ", "from": "8266", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "sertraline", "suffix": " and N-desmethylsertraline were unaffected by zolpidem.max w"}, {"to": "8301", "prefix": ". Pharmacokinetics of sertraline and ", "from": "8281", "name": "desmethylsertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/C065162", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "N-desmethylsertraline", "suffix": " were unaffected by zolpidem.max was significantly higher "}, {"to": "8733", "prefix": "ssover interaction study in ten healthy volunteers between ", "from": "8722", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "itraconazole", "suffix": " "}, {"to": "8861", "prefix": " given 5 hours after the last dose of ", "from": "8850", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "itraconazole", "suffix": " resulted in a 34% increase in AUC0-"}, {"to": "9350", "prefix": "hy female subjects between five consecutive daily doses of ", "from": "9343", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "rifampin", "suffix": " "}, {"to": "9453", "prefix": " given 17 hours after the last dose of ", "from": "9446", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "rifampin", "suffix": " showed significant reductions of the AUC "}, {"to": "9818", "prefix": "nistration of a single 5 mg dose of zolpidem tartrate with ", "from": "9807", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "ketoconazole", "suffix": ", a potent CYP3A4 inhibitor, given as 200 mg twice daily for"}, {"to": "10177", "prefix": "ion should be given to using a lower dose of zolpidem when ", "from": "10166", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "ketoconazole", "suffix": " and zolpidem are given together. Patients should be advised"}, {"to": "10274", "prefix": "gether. Patients should be advised that use of Edluar with ", "from": "10263", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "ketoconazole", "suffix": " may enhance the sedative effects.Other drugs with no intera"}, {"to": "10430", "prefix": "drugs with no interactions with zolpidem:A study involving ", "from": "10421", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002927", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "cimetidine", "suffix": ""}, {"to": "10463", "prefix": "zolpidem tartrate and ", "from": "10454", "name": "Ranitidine", "fullId": "http://purl.bioontology.org/ontology/MESH/D011899", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "ranitidine", "suffix": ""}, {"to": "10627", "prefix": "acodynamics of zolpidem.Zolpidem tartrate had no effect on ", "from": "10621", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004077", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "digoxin", "suffix": " pharmacokinetics and did not affect prothrombin time when g"}, {"to": "10675", "prefix": "d no effect on digoxin pharmacokinetics and did not affect ", "from": "10665", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "prothrombin", "suffix": " time when given with warfarin in normal subjects. \n\n\n\n\n"}, {"to": "10705", "prefix": "netics and did not affect prothrombin time when given with ", "from": "10698", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "de965605-268a-4479-86f7-84de949cf36f", "exact": "warfarin", "suffix": " in normal subjects. \n\n\n\n\n"}, {"to": "236", "prefix": "\n                        ", "from": "228", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "Indinavir", "suffix": " is an inhibitor of the cytochrome P450 isoform CYP3A4. Coad"}, {"to": "593", "prefix": ". Based on in vitro data in human liver microsomes, ", "from": "585", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "indinavir", "suffix": " does not inhibit CYP1A2, CYP2C9, CYP2E1 and CYP2B6. However"}, {"to": "664", "prefix": "es not inhibit CYP1A2, CYP2C9, CYP2E1 and CYP2B6. However, ", "from": "656", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "indinavir", "suffix": " may be a weak inhibitor of CYP2D6.\n                        "}, {"to": "733", "prefix": "may be a weak inhibitor of CYP2D6.\n                        ", "from": "725", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "Indinavir", "suffix": " is metabolized by CYP3A4. Drugs that induce CYP3A4 activity"}, {"to": "850", "prefix": "A4 activity would be expected to increase the clearance of ", "from": "842", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "indinavir", "suffix": ", resulting in lowered plasma concentrations of indinavir. C"}, {"to": "907", "prefix": "f indinavir, resulting in lowered plasma concentrations of ", "from": "899", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "indinavir", "suffix": ". Coadministration of CRIXIVAN and other drugs that inhibit "}, {"to": "1013", "prefix": "er drugs that inhibit CYP3A4 may decrease the clearance of ", "from": "1005", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "indinavir", "suffix": " and may result in increased plasma concentrations of indina"}, {"to": "1076", "prefix": "navir and may result in increased plasma concentrations of ", "from": "1068", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "indinavir", "suffix": ".\n                        Drug interaction studies were perf"}, {"to": "1404", "prefix": "effect of other drugs on ", "from": "1396", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "indinavir", "suffix": ""}, {"to": "1438", "prefix": "effect of ", "from": "1430", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "indinavir", "suffix": " on other drugs"}, {"to": "1682", "prefix": "      Delavirdine:  Delavirdine inhibits the metabolism of ", "from": "1674", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "indinavir", "suffix": " such that coadministration of 400-mg or 600-mg indinavir th"}, {"to": "1739", "prefix": "f indinavir such that coadministration of 400-mg or 600-mg ", "from": "1731", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "indinavir", "suffix": " three times daily with 400-mg delavirdine three times daily"}, {"to": "1816", "prefix": "mes daily with 400-mg delavirdine three times daily alters ", "from": "1808", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "indinavir", "suffix": " AUC, Cmax and Cmin "}, {"to": "1860", "prefix": ". ", "from": "1852", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "Indinavir", "suffix": " had no effect on delavirdine pharmacokinetics "}, {"to": "2134", "prefix": "  \n                           Methadone: Administration of ", "from": "2126", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "indinavir", "suffix": " "}, {"to": "2370", "prefix": "rison to historical data, there was little or no change in ", "from": "2362", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "indinavir", "suffix": " AUC.\n                        \n                           Ri"}, {"to": "2501", "prefix": "avir: Compared to historical data in patients who received ", "from": "2493", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "indinavir", "suffix": " 800 mg every 8 hours alone, twice-daily coadministration to"}, {"to": "2585", "prefix": "hours alone, twice-daily coadministration to volunteers of ", "from": "2577", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "indinavir", "suffix": " 800 mg and ritonavir with food for two weeks resulted in a "}, {"to": "2675", "prefix": "with food for two weeks resulted in a 2.7-fold increase of ", "from": "2667", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "indinavir", "suffix": " AUC24h, a 1.6-fold increase in indinavir Cmax, and an 11-fo"}, {"to": "2716", "prefix": "-fold increase of indinavir AUC24h, a 1.6-fold increase in ", "from": "2708", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "indinavir", "suffix": " Cmax, and an 11-fold increase in indinavir Cmin for a 100-m"}, {"to": "2759", "prefix": "old increase in indinavir Cmax, and an 11-fold increase in ", "from": "2751", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "indinavir", "suffix": " Cmin for a 100-mg ritonavir dose and a 3.6-fold increase of"}, {"to": "2829", "prefix": "min for a 100-mg ritonavir dose and a 3.6-fold increase of ", "from": "2821", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "indinavir", "suffix": " AUC24h, a 1.8- fold increase in indinavir Cmax, and a 24-fo"}, {"to": "2871", "prefix": "fold increase of indinavir AUC24h, a 1.8- fold increase in ", "from": "2863", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "indinavir", "suffix": " Cmax, and a 24-fold increase in indinavir Cmin for a 200-mg"}, {"to": "2913", "prefix": "fold increase in indinavir Cmax, and a 24-fold increase in ", "from": "2905", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "indinavir", "suffix": " Cmin for a 200-mg ritonavir dose. In the same study, twice-"}, {"to": "3008", "prefix": "r dose. In the same study, twice-daily coadministration of ", "from": "3000", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "indinavir", "suffix": " "}, {"to": "3313", "prefix": " indicated that coadministration of ", "from": "3305", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "indinavir", "suffix": " "}, {"to": "3448", "prefix": "denafil resulted in an 11% increase in average AUC0-8hr of ", "from": "3440", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "indinavir", "suffix": " and a 48% increase in average indinavir peak concentration "}, {"to": "3488", "prefix": "verage AUC0-8hr of indinavir and a 48% increase in average ", "from": "3480", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "indinavir", "suffix": " peak concentration "}, {"to": "3654", "prefix": "eased by 340% following coadministration of sildenafil and ", "from": "3646", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "indinavir", "suffix": " compared to historical data following administration of sil"}, {"to": "3890", "prefix": "                   \n                           Vardenafil: ", "from": "3882", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114289", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "Indinavir", "suffix": " "}, {"to": "320", "prefix": "of the cytochrome P450 isoform CYP3A4. Coadministration of ", "from": "313", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019469", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "CRIXIVAN", "suffix": " and drugs primarily metabolized by CYP3A4 may result in inc"}, {"to": "937", "prefix": "ed plasma concentrations of indinavir. Coadministration of ", "from": "930", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019469", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "CRIXIVAN", "suffix": " and other drugs that inhibit CYP3A4 may decrease the cleara"}, {"to": "1155", "prefix": "              Drug interaction studies were performed with ", "from": "1148", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019469", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "CRIXIVAN", "suffix": " and other drugs likely to be coadministered and some drugs "}, {"to": "1316", "prefix": "cokinetic interactions. The effects of coadministration of ", "from": "1309", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019469", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "CRIXIVAN", "suffix": " on the AUC, Cmax and Cmin are summarized in Table 2 "}, {"to": "1631", "prefix": "\n\n\n\n                        \n\n\n\n                           ", "from": "1621", "name": "Delavirdine", "fullId": "http://purl.bioontology.org/ontology/MESH/D020008", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "Delavirdine", "suffix": ":  Delavirdine inhibits the metabolism of indinavir such tha"}, {"to": "1645", "prefix": "              \n\n\n\n                           Delavirdine:  ", "from": "1635", "name": "Delavirdine", "fullId": "http://purl.bioontology.org/ontology/MESH/D020008", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "Delavirdine", "suffix": " inhibits the metabolism of indinavir such that coadministra"}, {"to": "1781", "prefix": "f 400-mg or 600-mg indinavir three times daily with 400-mg ", "from": "1771", "name": "Delavirdine", "fullId": "http://purl.bioontology.org/ontology/MESH/D020008", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "delavirdine", "suffix": " three times daily alters indinavir AUC, Cmax and Cmin "}, {"to": "1889", "prefix": ". Indinavir had no effect on ", "from": "1879", "name": "Delavirdine", "fullId": "http://purl.bioontology.org/ontology/MESH/D020008", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "delavirdine", "suffix": " pharmacokinetics "}, {"to": "1971", "prefix": "see DOSAGE AND ADMINISTRATION, Concomitant Therapy, ", "from": "1961", "name": "Delavirdine", "fullId": "http://purl.bioontology.org/ontology/MESH/D020008", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "Delavirdine", "suffix": ""}, {"to": "2021", "prefix": ", based on a comparison to historical ", "from": "2011", "name": "Delavirdine", "fullId": "http://purl.bioontology.org/ontology/MESH/D020008", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "delavirdine", "suffix": " pharmacokinetic data.\n                        \n            "}, {"to": "2105", "prefix": " data.\n                        \n                           ", "from": "2097", "name": "Methadone", "fullId": "http://purl.bioontology.org/ontology/MESH/D008691", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "Methadone", "suffix": ": Administration of indinavir "}, {"to": "2172", "prefix": " with ", "from": "2164", "name": "Methadone", "fullId": "http://purl.bioontology.org/ontology/MESH/D008691", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "methadone", "suffix": " "}, {"to": "2233", "prefix": " for one week in subjects on ", "from": "2225", "name": "Methadone", "fullId": "http://purl.bioontology.org/ontology/MESH/D008691", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "methadone", "suffix": " maintenance resulted in no change in methadone AUC. Based o"}, {"to": "2280", "prefix": "subjects on methadone maintenance resulted in no change in ", "from": "2272", "name": "Methadone", "fullId": "http://purl.bioontology.org/ontology/MESH/D008691", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "methadone", "suffix": " AUC. Based on a comparison to historical data, there was li"}, {"to": "2437", "prefix": "r AUC.\n                        \n                           ", "from": "2429", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "Ritonavir", "suffix": ": Compared to historical data in patients who received indin"}, {"to": "2606", "prefix": "ily coadministration to volunteers of indinavir 800 mg and ", "from": "2598", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "ritonavir", "suffix": " with food for two weeks resulted in a 2.7-fold increase of "}, {"to": "2787", "prefix": "ax, and an 11-fold increase in indinavir Cmin for a 100-mg ", "from": "2779", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "ritonavir", "suffix": " dose and a 3.6-fold increase of indinavir AUC24h, a 1.8- fo"}, {"to": "2941", "prefix": "max, and a 24-fold increase in indinavir Cmin for a 200-mg ", "from": "2933", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "ritonavir", "suffix": " dose. In the same study, twice-daily coadministration of in"}, {"to": "3031", "prefix": " and ", "from": "3023", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "ritonavir", "suffix": " "}, {"to": "3069", "prefix": " resulted in ", "from": "3061", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "ritonavir", "suffix": " AUC24h increases versus the same doses of ritonavir alone "}, {"to": "3121", "prefix": "ted in ritonavir AUC24h increases versus the same doses of ", "from": "3113", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "ritonavir", "suffix": " alone "}, {"to": "3205", "prefix": ".\n                        \n                           ", "from": "3196", "name": "sildenafil", "fullId": "http://purl.bioontology.org/ontology/RXNORM/136411", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "Sildenafil", "suffix": ":  The results of one published study in HIV-infected men "}, {"to": "3387", "prefix": " with a single 25-mg dose of ", "from": "3378", "name": "sildenafil", "fullId": "http://purl.bioontology.org/ontology/RXNORM/136411", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "sildenafil", "suffix": " resulted in an 11% increase in average AUC0-8hr of indinavi"}, {"to": "3573", "prefix": " compared to 800 mg every 8 hours alone. Average ", "from": "3564", "name": "sildenafil", "fullId": "http://purl.bioontology.org/ontology/RXNORM/136411", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "sildenafil", "suffix": " AUC was increased by 340% following coadministration of sil"}, {"to": "3640", "prefix": "il AUC was increased by 340% following coadministration of ", "from": "3631", "name": "sildenafil", "fullId": "http://purl.bioontology.org/ontology/RXNORM/136411", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "sildenafil", "suffix": " and indinavir compared to historical data following adminis"}, {"to": "3721", "prefix": "ir compared to historical data following administration of ", "from": "3712", "name": "sildenafil", "fullId": "http://purl.bioontology.org/ontology/RXNORM/136411", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "sildenafil", "suffix": " alone "}, {"to": "3879", "prefix": ".\n                        \n                           ", "from": "3870", "name": "vardenafil", "fullId": "http://purl.bioontology.org/ontology/MESH/C426063", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "Vardenafil", "suffix": ": Indinavir "}, {"to": "3967", "prefix": " coadministered with a single 10-mg dose of ", "from": "3958", "name": "vardenafil", "fullId": "http://purl.bioontology.org/ontology/MESH/C426063", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "vardenafil", "suffix": " resulted in a 16-fold increase in vardenafil AUC, a 7-fold "}, {"to": "4012", "prefix": "10-mg dose of vardenafil resulted in a 16-fold increase in ", "from": "4003", "name": "vardenafil", "fullId": "http://purl.bioontology.org/ontology/MESH/C426063", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "vardenafil", "suffix": " AUC, a 7-fold increase in vardenafil Cmax, and a 2-fold inc"}, {"to": "4049", "prefix": "a 16-fold increase in vardenafil AUC, a 7-fold increase in ", "from": "4040", "name": "vardenafil", "fullId": "http://purl.bioontology.org/ontology/MESH/C426063", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "vardenafil", "suffix": " Cmax, and a 2-fold increase in vardenafil half-life "}, {"to": "4091", "prefix": "fold increase in vardenafil Cmax, and a 2-fold increase in ", "from": "4082", "name": "vardenafil", "fullId": "http://purl.bioontology.org/ontology/MESH/C426063", "setId": "e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f", "exact": "vardenafil", "suffix": " half-life "}]